Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
METHOD FOR DISTINGUISHING LEUKEMIA SUBTYPES
Document Type and Number:
WIPO Patent Application WO/2005/043161
Kind Code:
A2
Abstract:
Disclosed is a method for distinguishing leukemia subtypes t(15;17), t(8,21), inv(16), inv(3), complex aberrant karyotype (CA), AML-MLL, normal karotype (NK), AML-other (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del(5q), del(9q), t(6;9); del (20q) and del(12p) and trisomy 4), ALL-MLL, ALL Ph+, ALL-t(8, 14), T-ALL, other B-lineage (OBL), CML, normal-BM, and/or CLL in a sample by determining the expression level of markers, as well as a diagnostic kit and an apparatus containing the markers.

Inventors:
HAFERLACH TORSTEN (DE)
DUGAS MARTIN (DE)
KERN WOLFGANG (DE)
KOHLMANN ALEXANDER (DE)
SCHNITTGER SUSANNE (DE)
SCHOCH CLAUDIA (DE)
Application Number:
PCT/EP2004/012463
Publication Date:
May 12, 2005
Filing Date:
November 04, 2004
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ROCHE DIAGNOSTICS GMBH (DE)
HOFFMANN LA ROCHE (CH)
HAFERLACH TORSTEN (DE)
DUGAS MARTIN (DE)
KERN WOLFGANG (DE)
KOHLMANN ALEXANDER (DE)
SCHNITTGER SUSANNE (DE)
SCHOCH CLAUDIA (DE)
International Classes:
C12Q1/68; G01N33/574; (IPC1-7): G01N33/574; C12Q1/68
Domestic Patent References:
WO2003039443A22003-05-15
Foreign References:
EP1043676A22000-10-11
Other References:
SCHOCH CLAUDIA ET AL: "Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 99, no. 15, 23 July 2002 (2002-07-23), pages 10008-10013, XP002215484 ISSN: 0027-8424
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), KOHLMANN ALEXANDER ET AL: "A Gene Expression Study of 59 Acute Myeloid Leukemia (AML) Patients with Recurrent Cytogenetic Abnormalities." XP002269490 Database accession no. PREV200300335805 & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 1205, 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), KOHLMANN ALEXANDER ET AL: "Gene Expression Profiles of t(11q23)/MLL Positive ALL and AML." XP002269818 Database accession no. PREV200300356357 & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 308, 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), KERN WOLFGANG ET AL: "Expression Pattern of Apoptosis-Related Genes in Acute Myeloid Leukemia with Complex Aberrant Karyotype." XP002269819 Database accession no. PREV200300335836 & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 1236, 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), SCHOCH CLAUDIA ET AL: "AML with Complex Aberrant Karyotype Can Be Distinguished from All Other AML Subtypes by Gene Expression Profiles and Are Characterized by Higher Expression of Genes Involved in DNA Repair." XP002269820 Database accession no. PREV200300335804 & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 1204, 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971
KOHLMANN A ET AL: "MOLECULAR CHARACTERIZATION OF ACUTE LEUKEMIAS BY USE OF MICROARRAY TECHNOLOGY" GENES, CHROMOSOMES & CANCER, XX, XX, vol. 37, no. 4, August 2003 (2003-08), pages 396-405, XP008025253
HAFERLACH T ET AL: "The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL" BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), page 139A, XP002263227 ISSN: 0006-4971
GOLUB T R ET AL: "Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 286, no. 5439, 15 October 1999 (1999-10-15), pages 531-537, XP002207658 ISSN: 0036-8075 cited in the application
TIPPING ALEX J ET AL: "Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate." EXPERIMENTAL HEMATOLOGY (NEW YORK), vol. 31, no. 11, November 2003 (2003-11), pages 1073-1080, XP002269821 ISSN: 0301-472X (ISSN print)
DUGAS M ET AL: "A comprehensive leukemia database: integration of cytogenetics, molecular genetics and microarray data with clinical information, cytomorphology and immunophenotyping" LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 15, no. 12, December 2001 (2001-12), pages 1805-1810, XP002263731 ISSN: 0887-6924
DUGAS MARTIN ET AL: "Impact of integrating clinical and genetic information." IN SILICO BIOLOGY, vol. 2, no. 3, 2002, pages 383-391, XP001179418 ISSN: 1386-6338 (ISSN print)
GIESELMANN VOLKMAR ET AL: "Molecular genetics of metachromatic leukodystrophy" HUMAN MUTATION, vol. 4, no. 4, 1994, pages 233-242, XP009025735 ISSN: 1059-7794
ALIZADEH A ET AL: "THE LYMPHOCHIP: A SPECIALIZED CDNA MICROARRAY FOR THE GENOMIC-SCALE ANALYSIS OF GENE EXPRESSION IN NORMAL AND MALIGNANT LYMPHOCYTES" COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, BIOLOGICAL LABORATORY, COLD SPRING HARBOR, NY, US, vol. 64, no. 1, 1999, pages 71-78, XP001099007 ISSN: 0091-7451
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), SCHOCH CLAUDIA ET AL: "AML with recurring chromosome abnormalities as defined in the new WHO-classification: Incidence of subgroups, additional genetic abnormalities, FAB subtype and age distribution in an unselected series of 1897 cytogenetically and moleculargenetically analysed AML" XP002269494 Database accession no. PREV200200241183 & BLOOD, vol. 98, no. 11 Part 1, 16 November 2001 (2001-11-16), pages 457a-458a, 43rd Annual Meeting of the American Society of Hematology, Part 1;Orlando, Florida, USA; December 07-11, 2001 ISSN: 0006-4971
DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2002 (2002-11-16), KOHLMANN ALEXANDER ET AL: "A Simplified and Partially Automated Target Preparation Method for Gene Expression Profiling." XP002269495 Database accession no. PREV200300367771 & BLOOD, vol. 100, no. 11, 16 November 2002 (2002-11-16), page Abstract No. 4287, 44th Annual Meeting of the American Society of Hematology;Philadelphia, PA, USA; December 06-10, 2002 ISSN: 0006-4971
Attorney, Agent or Firm:
ROCHE DIAGNOSTICS GMBH (Alexander Postfach 11 52, Penzberg, DE)
Download PDF:
Claims:
Claims
1. A method for distinguishing leukemia subtypes t (15 ; 17), t (8 ; 21), inv (16), inv (3), complex aberrant karyotype (CA), AMLMLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8 ; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL in a sample, the method comprising determining the expression level of markers selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1 and/or 2, wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1. 1 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.1 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.2 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.2 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.3 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.3 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.4 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.4 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALLt (8 ; 14) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.5 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.5 having a positive fc value, is indicative for the presence AML MLL when AML MLL is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.6 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.6 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.7 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.7 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.8 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1. 8 having a positive fc value, is indicative for the presence AML_komplext when AML leomplext is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.9 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.9 having a positive fc value, is indicative for the presence AMLt (15 ; 17) when AMLt (15 ; 17) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.10 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.10 having a positive fc value, is indicative for the presence AML t ( ; 21) when AML t (8; 21) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.11 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.11 having a positive fc value, is indicative for the presence CLL when CLL is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.12 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.12 having a positive fc value, is indicative for the presence CML when CML is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.13 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.13 having a positive fc value, is indicative for the presence normalBM when normalBM is distinguished from all leukemia subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.1 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.1 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from ALLPh+, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.2 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.2 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from ALL T lineage, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.3 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.3 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from ALL t (8; 14), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.4 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.4 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.5 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.5 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.6 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.6 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.7 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.7 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.8 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.8 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.9 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.9 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.10 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.10 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.11 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.11 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.12 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.12 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.13 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.13 having a positive fc value, is indicative for the presence ALLPh+ when ALL Ph+ is distinguished from ALL T lineage, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.14 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.14 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from ALL t (8; 14), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.15 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.15 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.16 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.16 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.17 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.17 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.18 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.18 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.19 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.19 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AMLt (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.20 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.20 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.21 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.21 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.22 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.22 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.23 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.23 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.24 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.24 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from ALL t (8; 14), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.25 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.25 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.26 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.26 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.27 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.27 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.28 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2. 28 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.29 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.29 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AMLt (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.30 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.30 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.31 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.31 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.32 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.32 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.33 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.33 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.34 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.34 having a positive fc value, is indicative for the presence ALL t ( ; 14) when ALL t (8; 14) distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.35 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.35 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.36 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.36 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.37 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.37 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t ( ; 14) distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.38 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2. 38 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AMLt (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.39 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.39 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t ( ; 14) distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.40 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.40 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.41 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.41 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.42 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.42 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t ( ; 14) distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.43 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.43 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.44 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.44 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.45 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.45 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.46 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.46 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML_t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.47 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.47 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.48 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.48 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.49 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.49 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.50 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.50 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.51 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.51 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.52 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.52 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AML_komplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.53 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.53 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AML_t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.54 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.54 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AML_t (8 ; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.55 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.55 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.56 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.56 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.57 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.57 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.58 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.58 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from AML komplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.59 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.59 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from AMLt (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.60 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.60 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.61 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.61 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.62 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.62 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.63 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.63 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.64 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.64 having a positive fc value, is indicative for the presence AML komplext when AMLkomplext distinguished from AMLt (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.65 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.65 having a positive fc value, is indicative for the presence AMLkomplext when AMLkomplext distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.66 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.66 having a positive fc value, is indicative for the presence AMLkomplext when AMLkomplext distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.67 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.67 having a positive fc value, is indicative for the presence AML komplext when AMLkomplext distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.68 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.68 having a positive fc value, is indicative for the presence AMLkomplext when AMLkomplext distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.69 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.69 having a positive fc value, is indicative for the presence AMLt (15 ; 17) when AMLt (15 ; 17) is distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.70 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.70 having a positive fc value, is indicative for the presence AMLt (15 ; 17) when AMLt (15 ; 17) is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.71 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.71 having a positive fc value, is indicative for the presence AMLt (15 ; 17) when AMLt (15 ; 17) is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.72 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.72 having a positive fc value, is indicative for the presence AMLt (15 ; 17) when AMLt (15 ; 17) is distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.73 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.73 having a positive fc value, is indicative for the presence AML t ( ; 21) when AML t (8; 21) is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.74 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.74 having a positive fc value, is indicative for the presence AML t (8; 21) when AML t (8; 21) is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.75 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.75 having a positive fc value, is indicative for the presence AML t (8; 21) when AML t (8; 21) is distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.76 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.76 having a positive fc value, is indicative for the presence CLL when CLL is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.77 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.77 having a positive fc value, is indicative for the presence CLL when CLL is distinguished from normalBM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2. 78 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.78 having a positive fc value, is indicative for the presence CML when CML is distinguished from normalBM.
2. The method according to claim 1 wherein the polynucleotide is labelled.
3. The method according to claim 1 or 2, wherein the label is a luminescent, preferably a fluorescent label, an enzymatic or a radioactive label.
4. The method according at least one of the claims 13, wherein the expression level of at least two, preferably of at least ten, more preferably of at least 25, most preferably of 50 of the markers of at least one of the Tables 1. 1 2.78 is determined.
5. The method according to at least one of the claims 14, wherein the expression level of markers expressed lower in a first subtype than in at least one second subtype, which differs from the first subtype, is at least 5 %, 10% or 20%, more preferred at least 50% or may even be 75% or 100%, i. e. 2fold lower, preferably at least 10fold, more preferably at least 50 fold, and most preferably at least 100fold lower in the first subtype.
6. The method according to at least one of the claims 14, wherein the expression level of markers expressed higher in a first subtype than in at least one second subtype, which differs from the first subtype, is at least 5 %, 10% or 20%, more preferred at least 50% or may even be 75% or 100%, i. e. 2fold higher, preferably at least 10fold, more preferably at least 50 fold, and most preferably at least 100fold higher in the first subtype.
7. The method according to at least one of the claims 16, wherein the sample is from an individual having leukemia.
8. The method according to at least one of the claims 17, wherein at least one polynucleotide is in the form of a transcribed polynucleotide, or a portion thereof.
9. The method according to claim 8, wherein the transcribed polynucleotide is a mRNA or a cDNA.
10. The method according to claim 8 or 9, wherein the determining of the expression level comprises hybridizing the transcribed polynucleotide to a complementary polynucleotide, or a portion thereof, under stringent hybridization conditions.
11. The method according to at least one of the claims 17, wherein at least one polynucleotide is in the form of a polypeptide, or a portion thereof.
12. The method according to claim 8,9 or 12, wherein the determining of the expression level comprises contacting the polynucleotide or the polypeptide with a compound specifically binding to the polynucleotide or the polypeptide.
13. The method according to claim 12, wherein the compound is an antibody, or a fragment thereof.
14. The method according to at least one of the claims 113, wherein the method is carried out on an array.
15. The method according to at least one of the claims 114, wherein the method is carried out in a robotics system.
16. The method according to at least one of the claims 115, wherein the method is carried out using microfluidics.
17. Use of at least one marker as defined in at least one of the claims 13 for the manufacturing of a diagnostic for distinguishing leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML MLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL.
18. The use according to claim 17 for distinguishing leukemia subtypes t (15 ; 17), t (8 ; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML MLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL in an individual having leukemia.
19. A diagnostic kit containing at least one marker as defined in at least one of the claims 13 for distinguishing leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AMLMLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL, in combination with suitable auxiliaries.
20. The diagnostic kit according to claim 19, wherein the kit contains a reference for the leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AMLMLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL.
21. The diagnostic kit according to claim 20, wherein the reference is a sample or a data bank.
22. An apparatus for distinguishing leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AMLMLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL in a sample containing a reference data bank.
23. The apparatus according to claim 22, wherein the reference data bank is obtainable by comprising (a) compiling a gene expression profile of a patient sample by determining the expression level of at least one marker selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1, and/or 2, and (b) classifying the gene expression profile by means of a machine learning algorithm.
24. The apparatus according to claim 23, wherein the machine learning algorithm is selected from the group consisting of Weighted Voting, K Nearest Neighbors, Decision Tree Induction, Support Vector Machines, and FeedForward Neural Networks, preferably Support Vector Machines.
25. The apparatus according to at least one of the claims 2224, wherein the apparatus contains a control panel and/or a monitor.
26. A reference data bank for distinguishing leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AMLMLL, normal karyotype (NK), AMLother (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALLMLL, ALLPh+, ALLt (8; 14), TALL, other Blineage (OBL), CML, normalBM, and/or CLL obtainable by comprising (a) compiling a gene expression profile of a patient sample by determining the expression level of at least one marker selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1, and/or 2, and (b) classifying the gene expression profile by means of a machine learning algorithm.
27. The reference data bank according to claim 26, wherein the reference data bank is backed up and/or contained in a computational memory chip.
Description:
Method for distinguishing leukemia subtypes The present invention is directed to a method for distinguishing leukemia subtypes, in particular leukemia subtypes AML with t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML-MLL, normal karyotype (NK), AML- other, i. e. trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4, ALL-MLL, ALL-Ph+, ALL-t (8; 14), T-ALL, other B-lineage (OBL), CML, normal-BM (bone marrow), and/or CLL, by determining the expression level of selected marker genes.

Leukemias are classified into four different groups or types: acute myeloid (AML), acute lymphatic (ALL), chronic myeloid (CML) and chronic lymphatic leukemia (CLL). Within these groups, several subcategories can be identified further using a panel of standard techniques as described below. These different subcatgories in leukemias are associated with varying clinical outcome and therefore are the basis for different treatment strategies. The importance of highly specific classification may be illustrated in detail further for the AML as a very heterogeneous group of diseases. Effort is aimed at identifying biological entities and to distinguish and classify subgroups of AML which are associated with a favorable, intermediate or unfavorable prognosis, respectively. In 1976, the FAB classification was proposed by the French-American-British co-operative group which was based on cytomorphology and cytochemistry in order to separate AML subgroups according to the morphological appearance of blasts in the blood and bone marrow. In addition, it was recognized that genetic abnormalities occurring in the leukemic blast had a major impact on the morphological picture and even more on the prognosis. So far, the karyotype of the leukemic blasts is the most important independent prognostic factor regarding response to therapy as well as survival.

Usually, a combination of methods is necessary to obtain the most important information in leukemia diagnostics: Analysis of the morphology and cytochemistry of bone marrow blasts and peripheral blood cells is necessary to establish the diagnosis. In some cases the addition of immunophenotyping is mandatory to separate very undifferentiated AML from acute lymphoblastic leukemia and CLL. Leukemia subtypes investigated can be diagnosed by cytomorphology alone, only if an expert reviews the smears. However, a genetic

analysis based on chromosome analysis, fluorescence in situ hybridization or RT- PCR and immunophenotyping is required in order to assign all cases in to the right category. The aim of these techniques besides diagnosis is mainly to determine the prognosis of the leukemia. A major disadvantage of these methods, however, is that viable cells are necessary as the cells for genetic analysis have to divide in vitro in order to obtain metaphases for the analysis. Another problem is the long time of 72 hours from receipt of the material in the laboratory to obtain the result.

Furthermore, great experience in preparation of chromosomes and even more in analyzing the karyotypes is required to obtain the correct result in at least 90% of cases. Using these techniques in combination, hematological malignancies in a first approach are separated into chronic myeloid leukemia (CML), chronic lymphoid (CLL), acute lymphoblastic (ALL), and acute myeloid leukemia (AML). Within the latter three disease entities several prognostically relevant subtypes have been established. As a second approach this further sub-classification is based mainly on genetic abnormalities of the leukemic blasts and clearly is associated with different prognoses.

The sub-classification of leukemias becomes increasingly important to guide therapy. The development of new, specific drugs and treatment approaches requires the identification of specific subtypes that may benefit from a distinct therapeutic protocol and, thus, can improve outcome of distinct subsets of leukemia. For example, the new therapeutic drug (STI571) inhibits the CML specific chimeric tyrosine kinase BCR-ABL generated from the genetic defect observed in CML, the BCR-ABL-rearrangement due to the translocation between chromosomes 9 and 22 (t (9; 22) (q34; ql 1)). In patients treated with this new drug, the therapy response is dramatically higher as compared to all other drugs that had been used so far.

Another example is the subtype of acute myeloid leukemia AML M3 and its variant M3v both with karyotype t (15 ; 17) (q22; ql l-12). The introduction of a new drug (all-trans retinoic acid-ATRA) has improved the outcome in this subgroup of patient from about 50% to 85 % long-term survivors. As it is mandatory for these patients suffering from these specific leukemia subtypes to be identified as fast as possible so that the best therapy can be applied, diagnostics today must accomplish sub-classification with maximal precision. Not only for these subtypes but also for several other leukemia subtypes different treatment approaches could improve outcome. Therefore, rapid and precise identification of distinct leukemia subtypes is the future goal for diagnostics.

Thus, the technical problem underlying the present invention was to provide means for leukemia diagnostics which overcome at least some of the disadvantages of the prior art diagnostic methods, in particular encompassing the time-consuming and unreliable combination of different methods and which provides a rapid assay to unambigously distinguish one AML subtype from another, e. g. by genetic analysis.

According to Golub et al. (Science, 1999, 286, 531-7), gene expression profiles can be used for class prediction and discriminating AML from ALL samples However, for the analysis of acute leukemias the selection of the two different subgroups was performed using exclusively morphologic-phenotypical criteria. This was only descriptive and does not provide deeper insights into the pathogenesis or the underlying biology of the leukemia. The approach reproduces only very basic knowledge of cytomorphology and intends to differentiate classes. The data is not sufficient to predict prognostically relevant cytogenetic aberrations.

Furthermore, the international application WO-A 03/039443 discloses marker genes the expression levels of which are characteristic for certain leukemia, e. g.

AML subtypes and additionally discloses methods for differentiating between the subtype of AML cells by determining the expression profile of the disclosed marker genes. However, WO-A 03/039443 does not provide guidance which set of distinct genes discriminate between two subtypes and, as such, can be routineously taken in order to distinguish one leukemia subtype from another.

The problem is solved by the present invention, which provides a method for distinguishing leukemia subtypes t (15; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML-MLL, normal karyotype (NK), AML-other (trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4), ALL-MLL, ALL-Ph+, ALL-t (8; 14), T-ALL, other B- lineage (OBL), CML, normal-BM, and/or CLL in a sample, the method comprising determining the expression level of markers selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1 and/or 2, wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.1 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1. 1 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.2 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.2 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.3 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.3 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.4 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.4 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.5 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.5 having a positive fc value, is indicative for the presence AML MLL when AML MLL is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.6 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.6 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.7 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.7 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.8 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1. 8 having a positive fc value, is indicative for the presence AML_komplext when AMLkomplext is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.9 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.9 having a positive fc value,

is indicative for the presence AML-t (15 ; 17) when AMLt (15 ; 17) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.10 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.10 having a positive fc value, is indicative for the presence AML t (8; 21) when AML t (8; 21) is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1. 11 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.11 having a positive fc value, is indicative for the presence CLL when CLL is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.12 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.12 having a positive fc value, is indicative for the presence CML when CML is distinguished from all other subtypes, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.13 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 1.13 having a positive fc value, is indicative for the presence normal-BM when normal-BM is distinguished from all leukemia subtypes, and/or wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.1 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.1 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from ALL Ph+, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.2 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.2 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from ALL T lineage, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.3 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.3 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from ALL t (8; 14), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.4 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.4 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.5 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.5 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML_inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.6 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.6 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.7 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.7 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML komplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.8 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.8 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from AML t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.9 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.9 having a positive fc value,

is indicative for the presence ALL MLL when ALL MLL is distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.10 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.10 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.11 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.11 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.12 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.12 having a positive fc value, is indicative for the presence ALL MLL when ALL MLL is distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.13 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.13 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from ALL T lineage, and/or wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.14 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.14 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from ALL t (8; 14), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.15 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.15 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.16 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.16 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.17 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.17 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.18 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.18 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.19 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.19 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML_t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.20 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.20 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.21 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.21 having a positive fc value, is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.22 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.22 having a positive fc value,

is indicative for the presence ALL Ph+ when ALL Ph+ is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.23 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.23 having a positive fc value, is indicative for the presence ALL Pli+ when ALL Ph+ is distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.24 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.24 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from ALL_t (8; 14), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.25 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.25 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.26 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.26 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML inv (16), and/or wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.27 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.27 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2. 28 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.28 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.29 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.29 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML-t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.30 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.30 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.31 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.31 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.32 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.32 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.33 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.33 having a positive fc value, is indicative for the presence ALL T lineage when ALL T lineage distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.34 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.34 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML MLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.35 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.35 having a positive fc value,

is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.36 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.36 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.37 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.37 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML_komplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.38 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2. 38 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML-t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.39 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.39 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from AML t ( ; 21), and/or wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.40 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.40 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t ( ; 14) distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.41 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.41 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.42 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.42 having a positive fc value, is indicative for the presence ALL t (8; 14) when ALL t (8; 14) distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.43 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.43 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML inv (16), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.44 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.44 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.45 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.45 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.46 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.46 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML-t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.47 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.47 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.48 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.48 having a positive fc value,

is indicative for the presence AML MLL when AML MLL distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.49 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.49 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.50 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.50 having a positive fc value, is indicative for the presence AML MLL when AML MLL distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.51 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.51 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AML_inv (3), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.52 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.52 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AMLjomplext, and/or wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.53 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.53 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AMLt (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.54 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.54 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from AMLt (8 ; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.55 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.55 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.56 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.56 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.57 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.57 having a positive fc value, is indicative for the presence AML inv (16) when AML inv (16) distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.58 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.58 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from AMLkomplext, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.59 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.59 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from AML-t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.60 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.60 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from AML t (8; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.61 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.61 having a positive fc value,

is indicative for the presence AML inv (3) when AML inv (3) distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.62 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.62 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.63 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.63 having a positive fc value, is indicative for the presence AML inv (3) when AML inv (3) distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.64 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.64 having a positive fc value, is indicative for the presence AML_komplext when AMLkomplext distinguished from AML t (15 ; 17), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.65 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.65 having a positive fc value, is indicative for the presence AMLkomplext when AMLkomplext distinguished from AML t (8; 21), and/or wherein

a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.66 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.66 having a positive fc value, is indicative for the presence AML_komplext when AMLkomplext distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.67 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.67 having a positive fc value, is indicative for the presence AMLkomplext when AML_komplext distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.68 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.68 having a positive fc value, is indicative for the presence AML_komplext when AML_komplext distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.69 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.69 having a positive fc value, is indicative for the presence AML-t (15 ; 17) when AML t (15 ; 17) is distinguished from AMLt (8 ; 21), and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2. 70 having a negative fc value, and/or

a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.70 having a positive fc value, is indicative for the presence AMLt (15 ; 17) when AML-t (15 ; 17) is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.71 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.71 having a positive fc value, is indicative for the presence AML-t (15 ; 17) when AML-t (15 ; 17) is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.72 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.72 having a positive fc value, is indicative for the presence AML-t (15 ; 17) when AML-t (15 ; 17) is distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.73 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.73 having a positive fc value, is indicative for the presence AML t (8; 21) when AML-t (8; 21) is distinguished from CLL, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.74 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.74 having a positive fc value,

is indicative for the presence AML t (8; 21) when AML t (8; 21) is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.75 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.75 having a positive fc value, is indicative for the presence AML t (8; 21) when AML t (8; 21) is distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.76 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.76 having a positive fc value, is indicative for the presence CLL when CLL is distinguished from CML, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.77 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.77 having a positive fc value, is indicative for the presence CLL when CLL is distinguished from normal-BM, and/or wherein a lower expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.78 having a negative fc value, and/or a higher expression of at least one polynucleotide defined by at least one of the numbers 1 to 50 of Table 2.78 having a positive fc value, is indicative for the presence CML when CML is distinguished from normal-BM.

As used herein, the following definitions apply to the above abbreviations: t (15 ; 17): AML with t (15 ; 17) translocation t (8; 21) : AML with t (8; 21) translocation inv (16) : AML with inversion 16 inv (3): AML with inversion 3 CA: AML with complex aberrant karyotype AML-MLL: AML with mutations on the mixed lineage leukaemia (MLL) gene normal karyotype (NK) : AML with normal karyotype trisomy 8: AML with trisomy of chromosome 8 trisomy 11: AML with trisomy of chromosome 11 trisomy 13: AML with trisomy of chromosome 13 monosomy 7: AML with monosomy of chromosome 7 del (5q) : AML with 5q deletion del (9q) : AML with 9q deletion t (6; 9): AML with t (6; 9) translocation del (20q) : AML with 20 q deletion del (12p): AML with deletion 12 p deletion trisomy 4: AML with trisomy 4 ALL-MLL: acute lymphoblastic leukaemia with mutations on the mixed lineage leukemia (MLL) gene ALL-Ph+ : acute lymphoblastic leukaemia with genetic aberration on the Philadelphia chromosome ALL-t (8; 14): acute lymphoblastic leukemia with translocation t (8; 21) T-ALL: T cell acute lymphoblastic leukemia other B-lineage (OBL): CML: chronic myeloid leukemia normal-BM : bone marrow from healthy volunteers CLL: chronic lymphatic leukemia

As used herein, "all other subtypes"refer to the subtypes of the present invention, i. e. to all other subtypes except for the one being under investigation According to the present invention, a"sample"means any biological material containing genetic information in the form of nucleic acids or proteins obtainable or obtained from an individual. The sample includes e. g. tissue samples, cell samples, bone marrow and/or body fluids such as blood, saliva, semen. Preferably, the sample is blood or bone marrow, more preferably the sample is bone marrow.

The person skilled in the art is aware of methods, how to isolate nucleic acids and proteins from a sample. A general method for isolating and preparing nucleic acids from a sample is outlined in Example 3.

According to the present invention, the term"lower expression"is generally assigned to all by numbers and Affymetrix Id. definable polynucleotides the t- values and fold change (fc) values of which are negative, as indicated in the Tables.

Accordingly, the term"higher expression"is generally assigned to all by numbers and Affymetrix Id. definable polynucleotides the t-values and fold change (fc) values of which are positive.

According to the present invention, the term"expression"refers to the process by which mRNA or a polypeptide is produced based on the nucleic acid sequence of a gene, i. e."expression"also includes the formation of mRNA upon transcription. In accordance with the present invention, the term,, determining the expression level" preferably refers to the determination of the level of expression, namely of the markers.

Generally, "marker"refers to any genetically controlled difference which can be used in the genetic analysis of a test versus a control sample, for the purpose of assigning the sample to a defined genotype or phenotype. As used herein, "markers"refer to genes which are differentially expressed in, e. g. , different AML subtypes. The markers can be defined by their gene symbol name, their encoded protein name, their transcript identification number (cluster identification number), the data base accession number, public accession number or GenBank identifier or,

as done in the present invention, Affymetrix identification number, chromosomal location, UniGene accession number and cluster type, LocusLink accession number (see Examples and Tables).

The Affymetrix identification number (affy id) is accessible for anyone and the person skilled in the art by entering the"gene expression omnibus"internet page of the National Center for Biotechnology Information (NCBI) (http://www. ncbi. nlm. nih. gov/geo/). In particular, the affy id's of the polynucleotides used for the method of the present invention are derived from the so-called U133 chip. The sequence data of each identification number can be viewed at http://www. ncbi. nlm. nih. gov/geo/query/acc. cgi? acc=GPL96 Generally, the expression level of a marker is determined by the determining the expression of its corresponding"polynucleotide"as described hereinafter.

According to the present invention, the term"polynucleotide"refers, generally, to a DNA, in particular cDNA, or RNA, in particular a cRNA, or a portion thereof or a polypeptide or a portion thereof. In the case of RNA (or cDNA), the polynucleotide is formed upon transcription of a nucleotide sequence which is capable of expression. The polynucleotide fragments refer to fragments preferably of between at least 8, such as 10,12, 15 or 18 nucleotides and at least 50, such as 60,80, 100, 200 or 300 nucleotides in length, or a complementary sequence thereto, representing a consecutive stretch of nucleotides of a gene, cDNA or mRNA. In other terms, polynucleotides include also any fragment (or complementary sequence thereto) of a sequence derived from any of the markers defined above as long as these fragments unambiguously identify the marker.

The determination of the expression level may be effected at the transcriptional or translational level, i. e. at the level of mRNA or at the protein level. Protein fragments such as peptides or polypeptides advantageously comprise between at least 6 and at least 25, such as 30,40, 80,100 or 200 consecutive amino acids representative of the corresponding full length protein. Six amino acids are generally recognized as the lowest peptidic stretch giving rise to a linear epitope recognized by an antibody, fragment or derivative thereof. Alternatively, the

proteins or fragments thereof may be analysed using nucleic acid molecules specifically binding to three-dimensional structures (aptamers).

Depending on the nature of the polynucleotide or polypeptide, the determination of the expression levels may be effected by a variety of methods. For determining and detecting the expression level, it is preferred in the present invention that the polynucleotide, in particular the cRNA, is labelled.

The labelling of the polynucleotide or a polypeptide can occur by a variety of methods known to the skilled artisan. The label can be fluorescent, chemiluminescent, bioluminescent, radioactive (such as 3H or 32p). The labelling compound can be any labelling compound being suitable for the labelling of polynucleotides and/or polypeptides. Examples include fluorescent dyes, such as fluorescein, dichlorofluorescein, hexachlorofluorescein, BODIPY variants, ROX, tetramethylrhodamin, rhodamin X, Cyanine-2, Cyanine-3, Cyanine-5, Cyanine-7, IRD40, FluorX, Oregon Green, Alexa variants (available e. g. from Molecular Probes or Amersham Biosciences) and the like, biotin or biotinylated nucleotides, digoxigenin, radioisotopes, antibodies, enzymes and receptors. Depending on the type of labelling, the detection is done via fluorescence measurements, conjugation to streptavidin and/or avidin, antigen-antibody-and/or antibody-antibody- interactions, radioactivity measurements, as well as catalytic and/or receptor/ligand interactions. Suitable methods include the direct labelling (incorporation) method, the amino-modified (amino-allyl) nucleotide method (available e. g. from Ambion), and the primer tagging method (DNA dendrimer labelling, as kit available e. g. from Genisphere). Particularly preferred for the present invention is the use of biotin or biotinylated nucleotides for labelling, with the latter being directly incorporated into, e. g. the cRNA polynucleotide by in vitro transcription.

If the polynucleotide is mRNA, cDNA may be prepared into which a detectable label, as exemplified above, is incorporated. Said detectably labelled cDNA, in single-stranded form, may then be hybridised, preferably under stringent or highly stringent conditions to a panel of single-stranded oligonucleotides representing different genes and affixed to a solid support such as a chip. Upon applying appropriate washing steps, those cDNAs will be detected or quantitatively detected that have a counterpart in the oligonucleotide panel. Various advantageous embodiments of this general method are feasible. For example, the mRNA or the

cDNA may be amplified e. g. by polymerase chain reaction, wherein it is preferable, for quantitative assessments, that the number of amplified copies corresponds relative to further amplified mRNAs or cDNAs to the number of mRNAs originally present in the cell. In a preferred embodiment of the present in ivention, the cDNAs are transcribed into cRNAs prior to the hybridisation step wherein only in the transcription step a label is incorporated into the nucleic acid and wherein the cRNA is employed for hybridisation. Alternatively, the label may be attached subsequent to the transcription step.

Similarly, proteins from a cell or tissue under investigation may be contacted with a panel of aptamers or of antibodies or fragments or derivatives thereof. The antibodies etc. may be affixed to a solid support such as a chip. Binding of proteins indicative of an AML subtype may be verified by binding to a detectably labelled secondary antibody or aptamer. For the labelling of antibodies, it is referred to Harlow and Lane, "Antibodies, a laboratory manual", CSH Press, 1988, Cold Spring Harbor. Specifically, a minimum set of proteins necessary for diagnosis of all leukemia subtypes may be selected for creation of a protein array system to make diagnosis on a protein lysate of a diagnostic bone marrow sample directly.

Protein Array Systems for the detection of specific protein expression profiles already are available (for example: Bio-Plex, BIORAD, München, Germany). For this application preferably antibodies against the proteins have to be produced and immobilized on a platform e. g. glasslides or microtiterplates. The immobilized antibodies can be labelled with a reactant specific for the certain target proteins as discussed above. The reactants can include enzyme substrates, DNA, receptors, antigens or antibodies to create for example a capture sandwich immunoassay.

For reliably distinguishing Leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML-MLL, normal karyotype (NK), AML- other, i. e. trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4, ALL-MLL, ALL-Ph+, ALL-t (8; 14), T-ALL, other B-lineage (OBL), CML, normal-BM, and/or CLL it is useful that the expression of more than one of the above defined markers. As a criterion for the choice of markers, the statistical significance of markers as expressed in q or p values based on the concept of the false discovery rate is determined. In doing so, a measure of statistical significance called the q value is associated with each tested

feature. The q value is similar to the p value, except it is a measure of significance in terms of the false discovery rate rather than the false positive rate (Storey JD and Tibshirani R. Proc. Natl. Acad. Sci. , 2003, Vol. 100: 9440-5.

In a preferred embodiment of the present invention, markers as defined in Tables 1.1-2. 78 having a q-value of less than 3E-06, more preferred less than 1. 5E-09, most preferred less than 1. 5E-11, less than 1.5E-20, less than 1. 5E-30, are measured.

Of the above defined markers, the expression level of at least two, preferably of at least ten, more preferably of at least 25, most preferably of 50 of at least one of the Tables of the markers is determined.

In another preferred embodiment, the expression level of at least 2, of at least 5, of at least 10 out of the markers having the numbers 1-10,1-20, 1-40,1-50 of at least one of the Tables are measured.

The level of the expression of the, marker", i. e. the expression of the polynucleotide is indicative of the leukemia subtype of a cell or an organism. The level of expression of a marker or group of markers is measured and is compared with the level of expression of the same marker or the same group of markers from other cells or samples. The comparison may be effected in an actual experiment or in silico. When the expression level also referred to as expression pattern or expression signature (expression profile) is measurably different, there is according to the invention a meaningful difference in the level of expression. Preferably the difference at least is 5 %, 10% or 20%, more preferred at least 50% or may even be as high as 75% or 100%. More preferred the difference in the level of expression is at least 200%, i. e. two fold, at least 500%, i. e. five fold, or at least 1000%, i. e. 10 fold.

Accordingly, the expression level of markers expressed lower in a first subtype than in at least one second subtype, which differs from the first subtype, is at least 5 %, 10% or 20%, more preferred at least 50% or may even be 75% or 100%, i. e.

2-fold lower, preferably at least 10-fold, more preferably at least 50-fold, and most preferably at least 100-fold lower in the first subtype. On the other hand, the expression level of markers expressed higher in a first subtype than in at least one

second subtype, which differs from the first subtype, is at least 5 %, 10% or 20%, more preferred at least 50% or may even be 75% or 100%, i. e. 2-fold higher, preferably at least 10-fold, more preferably at least 50-fold, and most preferably at least 100-fold higher in the first subtype.

In another embodiment of the present invention, the sample is derived from an individual having leukemia.

For the method of the present invention it is preferred if the polynucleotide the expression level of which is determined is in form of a transcribed polynucleotide.

A particularly preferred transcribed polynucleotide is an mRNA, a cDNA and/or a cRNA, with the latter being preferred. Transcribed polynucleotides are isolated from a sample, reverse transcribed and/or amplified, and labelled, by employing methods well-known the person skilled in the art (see Example 3). In a preferred embodiment of the methods according to the invention, the step of determining the expression profile further comprises amplifying the transcribed polynucleotide.

In order to determine the expression level of the transcribed polynucleotide by the method of the present invention, it is preferred that the method comprises hybridizing the transcribed polynucleotide to a complementary polynucleotide, or a portion thereof, under stringent hybridization conditions, as described hereinafter.

The term"hybridizing"means hybridization under conventional hybridization conditions, preferably under stringent conditions as described, for example, in Sambrook, J. , et al. , in"Molecular Cloning: A Laboratory Manual" (1989), Eds. J.

Sambrook, E. F. Fritsch and T. Maniatis, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, NY and the further definitions provided above. Such conditions are, for example, hybridization in 6x SSC, pH 7.0/0. 1% SDS at about 45°C for 18-23 hours, followed by a washing step with 2x SSC/0.1% SDS at 50°C.

In order to select the stringency, the salt concentration in the washing step can for example be chosen between 2x SSC/0.1% SDS at room temperature for low stringency and 0.2x SSC/0.1% SDS at 50°C for high stringency. In addition, the temperature of the washing step can be varied between room temperature, ca. 22°C, for low stringency, and 65°C to 70° C for high stringency. Also contemplated are polynucleotides that hybridize at lower stringency hybridization conditions.

Changes in the stringency of hybridization and signal detection are primarily

accomplished through the manipulation, preferably of formamide concentration (lower percentages of formamide result in lowered stringency), salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37°C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl ; 0.2M NaH2PO4 ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 mg/ml salmon sperm blocking DNA, followed by washes at 50°C with 1 X SSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e. g. 5x SSC).

Variations in the above conditions may be accomplished through the inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above, due to problems with compatibility.

"Complementary"and"complementarity", respectively, can be described by the percentage, i. e. proportion, of nucleotides which can form base pairs between two polynucleotide strands or within a specific region or domain of the two strands.

Generally, complementary nucleotides are, according to the base pairing rules, adenine and thymine (or adenine and uracil), and cytosine and guanine.

Complementarity may be partial, in which only some of the nucleic acids'bases are matched according to the base pairing rules. Or, there may be a complete or total complementarity between the nucleic acids. The degree of complementarity between nucleic acid strands has effects on the efficiency and strength of hybridization between nucleic acid strands.

Two nucleic acid strands are considered to be 100% complementary to each other over a defined length if in a defined region all adenines of a first strand can pair with a thymine (or an uracil) of a second strand, all guanines of a first strand can pair with a cytosine of a second strand, all thymine (or uracils) of a first strand can pair with an adenine of a second strand, and all cytosines of a first strand can pair with a guanine of a second strand, and vice versa. According to the present invention, the degree of complementarity is determined over a stretch of 20, preferably 25, nucleotides, i. e. a 60% complementarity means that within a region of 20 nucleotides of two nucleic acid strands 12 nucleotides of the first strand can base pair with 12 nucleotides of the second strand according to the above ruling, either as a stretch of 12 contiguous nucleotides or interspersed by non-pairing nucleotides, when the two strands are attached to each other over said region of 20

nucleotides. The degree of complementarity can range from at least about 50% to full, i. e. 100% complementarity. Two single nucleic acid strands are said to be "substantially complementary"when they are at least about 80% complementary, preferably about 90% or higher. For carrying out the method of the present invention substantial complementarity is preferred.

Preferred methods for detection and quantification of the amount of polynucleotides, i. e. for the methods according to the invention allowing the determination of the level of expression of a marker, are those described by Sambrook et al. (1989) or real time methods known in the art as the TaqMan (g method disclosed in W092/02638 and the corresponding U. S. 5,210, 015, U. S.

5,804, 375, U. S. 5,487, 972. This method exploits the exonuclease activity of a polymerase to generate a signal. In detail, the (at least one) target nucleic acid component is detected by a process comprising contacting the sample with an oligonucleotide containing a sequence complementary to a region of the target nucleic acid component and a labeled oligonucleotide containing a sequence complementary to a second region of the same target nucleic acid component sequence strand, but not including the nucleic acid sequence defined by the first oligonucleotide, to create a mixture of duplexes during hybridization conditions, wherein the duplexes comprise the target nucleic acid annealed to the first oligonucleotide and to the labeled oligonucleotide such that the 3'-end of the first oligonucleotide is adjacent to the 5'-end of the labeled oligonucleotide. Then this mixture is treated with a template-dependent nucleic acid polymerase having a 5' to 3'nuclease activity under conditions sufficient to permit the 5'to 3'nuclease activity of the polymerase to cleave the annealed, labeled oligonucleotide and release labeled fragments. The signal generated by the hydrolysis of the labeled oligonucleotide is detected and/or measured. TaqMang technology eliminates the need for a solid phase bound reaction complex to be formed and made detectable.

Other methods include e. g. fluorescence resoance energy transfer between two adjacenly hybridized probes as used in the LightCycler format described in U. S.

6,174, 670.

A preferred protocol if the marker, i. e. the polynucleotide, is in form of a transcribed nucleotide, is described in Example 3, where total RNA is isolated, cDNA and, subsequently, cRNA is synthesized and biotin is incorporated during the transcription reaction. The purified cRNA is applied to commercially available

arrays which can be obtained e. g. from Affymetrix. The hybridized cRNA is detected according to the methods described in Example 3. The arrays are produced by photolithography or other methods known to experts skilled in the art e. g. from U. S. 5,445, 934, U. S. 5,744, 305, U. S. 5,700, 637, U. S. 5,945, 334 and EP 0 619 321 or EP 0 373 203, or as decribed hereinafter in greater detail.

In another embodiment of the present invention, the polynucleotide or at least one of the polynucleotides is in form of a polypeptide. In another preferred embodiment, the expression level of the polynucleotides or polypeptides is detected using a compound which specifically binds to the polynucleotide of the polypeptide of the present invention.

As used herein, "specifically binding"means that the compound is capable of discriminating between two or more polynucleotides or polypeptides, i. e. it binds to the desired polynucleotide or polypeptide, but essentially does not bind unspecifically to a different polynucleotide or polypeptide.

The compound can be an antibody, or a fragment thereof, an enzyme, a so-called small molecule compound, a protein-scaffold, preferably an anticalin. In a preferred embodiment, the compound specifically binding to the polynucleotide or polypeptide is an antibody, or a fragment thereof.

As used herein, an"antibody"comprises monoclonal antibodies as first described by Kohler and Milstein in Nature 278 (1975), 495-497 as well as polyclonal antibodies, i. e. entibodies contained in a polyclonal antiserum. Monoclonal antibodies include those produced by transgenic mice. Fragments of antibodies include F (ab') 2, Fab and Fv fragments. Derivatives of antibodies include scFvs, chimeric and humanized antibodies. See, for example Harlow and Lane, loc. cit.

For the detection of polypeptides using antibodies or fragments thereof, the person skilled in the art is aware of a variety of methods, all of which are included in the present invention. Examples include immunoprecipitation, Western blotting, Enzyme-linked immuno sorbent assay (ELISA), Enzyme-linked immuno sorbent assay (RIA), dissociation-enhanced lanthanide fluoro immuno assay (DELFIA), scintillation proximity assay (SPA). For detection, it is desirable if the antibody is labelled by one of the labelling compounds and methods described supra.

In another preferred embodiment of the present invention, the method for distinguishing leukemia subtypes is carried out on an array.

In general, an"array"or"microarray"refers to a linear or two-or three dimensional arrangement of preferably discrete nucleic acid or polypeptide probes which comprises an intentionally created collection of nucleic acid or polypeptide probes of any length spotted onto a substrate/solid support. The person skilled in the art knows a collection of nucleic acids or polypeptide spotted onto a substrate/solid support also under the term"array". As known to the person skilled in the art, a microarray usually refers to a miniaturised array arrangement, with the probes being attached to a density of at least about 10,20, 50,100 nucleic acid molecules referring to different or the same genes per cm2. Furthermore, where appropriate an array can be referred to as"gene chip". The array itself can have different formats, e. g. libraries of soluble probes or libraries of probes tethered to resin beads, silica chips, or other solid supports.

The process of array fabrication is well-known to the person skilled in the art. In the following, the process for preparing a nucleic acid array is described.

Commonly, the process comprises preparing a glass (or other) slide (e. g. chemical treatment of the glass to enhance binding of the nucleic acid probes to the glass surface), obtaining DNA sequences representing genes of a genome of interest, and spotting sequences these sequences of interest onto glass slide. Sequences of interest can be obtained via creating a cDNA library from an mRNA source or by using publicly available databases, such as GeneBank, to annotate the sequence information of custom cDNA libraries or to identify cDNA clones from previously prepared libraries. Generally, it is recommendable to amplify obtained sequences by PCR in order to have sufficient amounts of DNA to print on the array. The liquid containing the amplified probes can be deposited on the array by using a set of microspotting pins. Ideally, the amount deposited should be uniform. The process can further include UV-crosslinking in order to enhance immobilization of the probes on the array.

In a preferred embodiment, the array is a high density oligonucleotide (oligo) array using a light-directed chemical synthesis process, employing the so-called photolithography technology. Unlike common cDNA arrays, oligo arrays (according to the Affymetrix technology) use a single-dye technology. Given the

sequence information of the markers, the sequence can be synthesized directly onto the array, thus, bypassing the need for physical intermediates, such as PCR products, required for making cDNA arrays. For this purpose, the marker, or partial sequences thereof, can be represented by 14 to 20 features, preferably by less than 14 features, more preferably less than 10 features, even more preferably by 6 features or less, with each feature being a short sequence of nucleotides (oligonucleotide), which is a perfect match (PM) to a segment of the respective gene. The PM oligonucleotide are paired with mismatch (MM) oligonucleotides which have a single mismatch at the central base of the nucleotide and are used as "controls". The chip exposure sites are defined by masks and are deprotected by the use of light, followed by a chemical coupling step resulting in the synthesis of one nucleotide. The masking, light deprotection, and coupling process can then be repeated to synthesize the next nucleotide, until the nucleotide chain is of the specified length.

Advantageously, the method of the present invention is carried out in a robotics system including robotic plating and a robotic liquid transfer system, e. g. using microfluidics, i. e. channelled structured.

A particular preferred method according to the present invention is as follows: 1. Obtaining a sample, e. g. bone marrow or peripheral blood aliquots, from a patient having leukemia 2. Extracting RNA, preferably mRNA, from the sample 3. Reverse transcribing the RNA into cDNA 4. In vitro transcribing the cDNA into cRNA 5. Fragmenting the cRNA 6. Hybridizing the fragmented cRNA on standard microarrays 7. Determining hybridization In another embodiment, the present invention is directed to the use of at least one marker selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1, and/or 2 for the manufacturing of a diagnostic for distinguishing Leukemia subtypes. The use of the present invention is particularly advantageous for distinguishing leukemia subtypes in an individual having leukemia. The use of said markers for diagnosis of leukemia subtypes, preferably based on microarray technology, offers the following advantages: (1) more rapid and more precise diagnosis, (2) easy to use in laboratories without

specialized experience, (3) abolishes the requirement for analyzing viable cells for chromosome analysis (transport problem), and (4) very experienced hematologists for cytomorphology and cytochemistry, immunophenotyping as well as cytogeneticists and molecularbiologists are no longer required.

Accordingly, the present invention refers to a diagnostic kit containing at least one marker selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1, and/or 2 for distinguishing leukemia subtypes, in combination with suitable auxiliaries. Suitable auxiliaries, as used herein, include buffers, enzymes, labelling compounds, and the like. In a preferred embodiment, the marker contained in the kit is a nucleic acid molecule which is capable of hybridizing to the mRNA corresponding to at least one marker of the present invention. Preferably, the at least one nucleic acid molecule is attached to a solid support, e. g. a polystyrene microtiter dish, nitrocellulose membrane, glass surface or to non-immobilized particles in solution.

In another preferred embodiment, the diagnostic kit contains at least one reference for a t (15 ; 17), t (8 ; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML- MLL, normal karyotype (NK), AML-other, i. e. trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4, ALL- MLL, ALL-Ph+, ALL-t (8; 14), T-ALL, other B-lineage (OBL), CML, normal-BM, and/or CLL leukemia subtype. As used herein, the reference can be a sample or a data bank.

In another embodiment, the present invention is directed to an apparatus for distinguishing leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML-MLL, normal karyotype (NK), AML-other, i. e. trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4, ALL-MLL, ALL-Ph+, ALL-t (8; 14), T-ALL, other B- lineage (OBL), CML, normal-BM, and/or CLL in a sample, containing a reference data bank obtainable by comprising (a) compiling a gene expression profile of a patient sample by determining the expression level at least one marker selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1, and/or 2, and (b) classifying the gene expression profile by means of a machine learning algorithm.

According to the present invention, the"machine learning algorithm"is a computational-based prediction methodology, also known to the person skilled in the art as"classifier", employed for characterizing a gene expression profile. The signals corresponding to a certain expression level which are obtained by the microarray hybridization are subjected to the algorithm in order to classify the expression profile. Supervised learning involves"training"a classifier to recognize the distinctions among classes and then"testing"the accuracy of the classifier on an independent test set. For new, unknown sample the classifier shall predict into which class the sample belongs.

Preferably, the machine learning algorithm is selected from the group consisting of Weighted Voting, K-Nearest Neighbors, Decision Tree Induction, Support Vector Machines (SVM), and Feed-Forward Neural Networks. Most preferably, the machine learning algorithm is Support Vector Machine, such as polynomial kernel and Gaussian Radial Basis Function-kernel SVM models.

The classification accuracy of a given gene list for a set of microarray experiments is preferably estimated using Support Vector Machines (SVM), because there is evidence that SVM-based prediction slightly outperforms other classification techniques like k-Nearest Neighbors (k-NN). The LIBSVM software package version 2.36 was used (SVM-type: C-SVC, linear kernel (http://www. csie. ntu. edu. tw/-cjlin/libsvm/)). The skilled artisan is furthermore referred to Brown et al. , Proc. Natl. Acad. Sci. , 2000; 97: 262-267, Furey et al., Bioinformatics. 2000; 16: 906-914, and Vapnik V. Statistical Learning Theory.

New York: Wiley, 1998.

In detail, the classification accuracy of a given gene list for a set of microarray experiments can be estimated using Support Vector Machines (SVM) as supervised learning technique. Generally, SVMs are trained using differentially expressed genes which were identified on a subset of the data and then this trained model is employed to assign new samples to those trained groups from a second and different data set. Differentially expressed genes were identified applying ANOVA and t-test-statistics (Welch t-test). Based on identified distinct gene expression signatures respective training sets consisting of 2/3 of cases and test sets with 1/3 of cases to assess classification accuracies are designated. Assignment of cases to

training and test set is randomized and balanced by diagnosis. Based on the training set a Support Vector Machine (SVM) model is built.

According to the present invention, the apparent accuracy, i. e. the overall rate of correct predictions of the complete data set was estimated by 10fold cross validation. This means that the data set was divided into 10 approximately equally sized subsets, an SVM-model was trained for 9 subsets and predictions were generated for the remaining subset. This training and prediction process was repeated 10 times to include predictions for each subset. Subsequently the data set was split into a training set, consisting of two thirds of the samples, and a test set with the remaining one third. Apparent accuracy for the training set was estimated by 10fold cross validation (analogous to apparent accuracy for complete set). A SVM-model of the training set was built to predict diagnosis in the independent test set, thereby estimating true accuracy of the prediction model. This prediction approach was applied both for overall classification (multi-class) and binary classification (diagnosis X => yes or no). For the latter, sensitivity and specificity were calculated: Sensitivity = (number of positive samples predicted)/ (number of true positives) Specificity = (number of negative samples predicted)/ (number of true negatives) In a preferred embodiment, the reference data bank is backed up on a computational data memory chip which can be inserted in as well as removed from the apparatus of the present invention, e. g. like an interchangeable module, in order to use another data memory chip containing a different reference data bank.

The apparatus of the present invention containing a desired reference data bank can be used in a way such that an unknown sample is, first, subjected to gene expression profiling, e. g. by microarray analysis in a manner as described supra or in the art, and the expression level data obtained by the analysis are, second, fed into the apparatus and compared with the data of the reference data bank obtainable by the above method. For this purpose, the apparatus suitably contains a device for entering the expression level of the data, for example a control panel such as a keyboard. The results, whether and how the data of the unknown sample fit into the reference data bank can be made visible on a provided monitor or display screen and, if desired, printed out on an incorporated of connected printer.

Alternatively, the apparatus of the present invention is equipped with particular appliances suitable for detecting and measuring the expression profile data and, subsequently, proceeding with the comparison with the reference data bank. In this embodiment, the apparatus of the present invention can contain a gripper arm and/or a tray which takes up the microarray containing the hybridized nucleic acids.

In another embodiment, the present invention refers to a reference data bank for distinguishing leukemia subtypes t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML-MLL, normal karyotype (NK), AML-other, i. e. trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (5q), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4, ALL-MLL, ALL-Ph+, ALL-t (8; 14), T-ALL, other B- lineage (OBL), CML, normal-BM, and/or CLL in a sample obtainable by comprising (a) compiling a gene expression profile of a patient sample by determining the expression level of at least one marker selected from the markers identifiable by their Affymetrix Identification Numbers (affy id) as defined in Tables 1, and/or 7, and (b) classifying the gene expression profile by means of a machine learning algorithm.

Preferably, the reference data bank is backed up and/or contained in a computational memory data chip.

The invention is further illustrated in the following Table and Examples, without limiting the scope of the invention: TABLES 1. 1 to 2. 78 Tables 1.1 to 2.78 show leukemia subtype analysis of t (15 ; 17), t (8; 21), inv (16), inv (3), complex aberrant karyotype (CA), AML-MLL, normal karyotype (NK), AML-other, i. e. trisomy 8, trisomy 11, trisomy 13, monosomy 7, del (Sq), del (9q), t (6; 9); del (20q) and del (12p) and trisomy 4, ALL-MLL, ALL-Ph+, ALL-t (8; 14), T- ALL, other B-lineage (OBL), CML, normal-BM, and/or CLL. The analysed markers are ordered according to their q-values, beginning with the lowest q- values.

For convenience and a better understanding, Tables 1.1 to 2.78 are accompanied with explanatory tables (Table l. lA to 2.78A) where the numbering and the Affymetrix Id are further defined by other parameters, e. g. gene bank accession number EXAMPLES Example 1: General experimental design of the invention and results So far comprehensive diagnosis of leukemia requires a combination of cytomorphology, immunophenotyping, and genetic methods. We aimed at developing a diagnostic tool based only on gene expression profiling to accurately predict all clinically relevant subtypes of leukemia. Therefore, we analyzed samples from 540 patients at diagnosis using oligonucleotide microarrays representing 33,000 different genes (U133 set, Affymetrix). The following leukemia subtypes were included in this study: 367 AML (20 t (15 ; 17); 25 t (8; 21); 25 inv (16) ; 18 inv (3); 34 complex aberrant karyotype (CA); 30 AML-MLL; 158 normal karyotype (NK); 57 AML-other, i. e. trisomy 8 (n=12), trisomy 11 (n=7), trisomy 13 (n=7), monosomy 7 (n=9), del (5q) (n=7), del (9q) (n=9), t (6; 9) (n=3) ; del (20q) and del (12p) and trisomy 4 one case each); 85 ALL (17 ALL-MLL; 21 ALL-Ph+; 12 ALL-t (8; 14) ; 23 T-ALL; 12 other B-lineage (OBL) ), 46 CML, 34 CLL, and 8 bone marrows from healthy volunteers (n-BM). To identify differentially expressed genes we applied ANOVA and t-test-statistics (Welch t- test). To assess the false discovery rate we calculated q values according to Storey et al. (PNAS, 2003). To estimate diagnostic accuracy based on gene expression signatures, we designated a training set consisting of 2/3 of cases and a test set with 1/3 of cases. Assignment of cases to training and test set was randomized and

balanced by diagnosis. Based on the training set we built Support Vector Machine (SVM) models. Classification accuracy was assessed in the independent test set. In the first analysis five main categories AML, ALL, CML, CLL, and n-BM were distinguished in the test set with an accuracy of 96% (177/184 correctly assigned).

In a second analysis the following 13 subtypes were included: ALL-MLL, ALL- Ph+, T-ALL, ALL-t (8 ; 14), AML-t (8; 21), AML-inv (16), AML-t (15; 17), AML- MLL, AML-inv (3), AML-CA, AML-NK, CLL, and CML. 151/154 cases of the test set were correctly assigned (98%). Only two cases with AML-CA and one case with AML-NK were misclassified. In a third analysis n-BM, AML-other and ALL- OBL were added to the 13 subtypes. The accuracy was reduced to 88% (159/180).

Categories with 100% sensitivity and specificity each were: n-BM, CLL, CML, ALL-MLL, ALL-t (8; 14), AML-t (15 ; 17), and AML-inv (16). AML-other and ALL- OBL, respectively, are considered genetically heterogeneous diseases and are not characterized by a specific gene expression profile. This may have caused the reduced accuracy in the latter SVM analysis. In conclusion, we were able to identify distinct expression profiles for all clinically and prognostically relevant leukemia subtypes based on gene expression data. Sensitivity and specificity were very high when specific leukemia subtypes were included into the analysis. Even the subgroup AML-NK was predicted with high accuracy. Using gene expression profiling as a robust diagnostic tool to correctly subclassify leukemias is a realistic goal and may guide relevant therapeutic consequences in the near future.

Example 2: General materials, methods and definitions of functional annotations The methods section contains both information on statistical analyses used for identification of differentially expressed genes and detailed annotation data of identified microarray probesets.

Affymetrix Probeset Annotation All annotation data of GeneChip arrays are extracted from the NetASx Analysis Center (internet website: www. affymetrix. com). Files for U133 set arrays, including U133A and U133B microarrays are derived from the June 2003 release.

The original publication refers to: Liu G, Loraine AE, Shigeta R, Cline M, Cheng J, Valmeekam V, Sun S, Kulp D, Siani-Rose MA. NetAffx: Affymetrix probesets and annotations. Nucleic Acids Res. 2003 ; 31 (1): 82-6.

The sequence data are omitted due to their large size, and because they do not change, whereas the annotation data are updated periodically, for example new information on chromomal location and functional annotation of the respective gene products. Sequence data are available for download in the NetAffx Download Center (www. affymetrix. com) Data fields: In the following section, the content of each field of the data files are described.

Microarray probesets, for example found to be differentially expressed between different types of leukemia samples are further described by additional information.

The fields are of the following types: 1. GeneChip Array Information 2. Probe Design Information 3. Public Domain and Genomic References 1. GeneChip Array Information HG-U133 ProbeSet ID : HG-U133 ProbeSetID describes the probe set identifier. Examples are: 200007at, 20001 lsat, 200012xat.

GeneChip: The description of the GeneChip probe array name where the respective probeset is represented. Examples are: Affymetrix Human Genome U133A Array or Affymetrix Human Genome U133B Array.

2. Probe Design Information Sequence Type: The Sequence Type indicates whether the sequence is an Exemplar, Consensus or Control sequence. An Exemplar is a single nucleotide sequence taken directly from a public database. This sequence could be an mRNA or EST. A Consensus sequence, is a nucleotide sequence assembled by Affymetrix, based on one or more sequence taken from a public database.

Transcript ID : The cluster identification number with a sub-cluster identifier appended.

Sequence Derived From: The accession number of the single sequence, or representative sequence on which the probe set is based. Refer to the"Sequence Source"field to determine the database used.

Sequence ID: For Exemplar sequences: Public accession number or GenBank identifier. For Consensus sequences: Affymetrix identification number or public accession number.

Sequence Source: The database from which the sequence used to design this probe set was taken.

Examples are: GenBankg, RefSeq, UniGene, TIGR (annotations from The Institute for Genomic Research).

3. Public Domain and Genomic References Most of the data in this section come from LocusLink and UniGene databases, and are annotations of the reference sequence on which the probe set is modeled.

Gene Symbol and Title: A gene symbol and a short title, when one is available. Such symbols are assigned by different organizations for different species. Affymetrix annotational data come from the UniGene record. There is no indication which species-specific databank was used, but some of the possibilities include for example HUGO: The Human Genome Organization.

MapLocation: The map location describes the chromosomal location when one is available.

Unigene-Accession : UniGene accession number and cluster type. Cluster type can be"full length"or "est", or"---"if unknown.

LocusLink: This information represents the LocusLink accession number.

Full Length Ref. Sequences: Indicates the references to multiple sequences in RefSeq. The field contains the ID and description for each entry, and there can be multiple entries per probeSet.

Example 3: Sample preparation, processing and data analysis Method 1 : Microarray analyses were performed utilizing the GeneChip° System (Affymetrix, Santa Clara, USA). Hybridization target preparations were performed according to recommended protocols (Affymetrix Technical Manual). In detail, at time of diagnosis, mononuclear cells were purified by Ficoll-Hypaque density centrifugation. They had been lysed immediately in RLT buffer (Qiagen, Hilden, Germany), frozen, and stored at-80°C from 1 week to 38 months. For gene expression profiling cell lysates of the leukemia samples were thawed, homogenized (QIAshredder, Qiagen), and total RNA was extracted (RNeasy Mini Kit, Qiagen). Subsequently, 5-10 ug total RNA isolated from 1 x 107 cells was used as starting material for cDNA synthesis with oligo [ (dT) 24T7promotor] 65 primer (cDNA Synthesis System, Roche Applied Science, Mannheim, Germany). cDNA products were purified by phenol/chlorophorm/IAA extraction (Ambion, Austin, USA) and acetate/ethanol-precipitated overnight. For detection of the hybridized target nucleic acid biotin-labeled ribonucleotides were incorporated during the following in vitro transcription reaction (Enzo BioArray HighYield RNA Transcript Labeling Kit, Enzo Diagnostics). After quantification by spectrophotometric measurements and 260/280 absorbance values assessment for quality control of the purified cRNA (RNeasy Mini Kit, Qiagen), 15 ug cRNA was fragmented by alkaline treatment (200 mM Tris-acetate, pH 8.2/500 mM potassium acetate/150 mM magnesium acetate) and added to the hybridization cocktail sufficient for five hybridizations on standard GeneChip microarrays (300 ul final volume). Washing and staining of the probe arrays was performed according to the recommended Fluidics Station protocol (EukGE-WS2v4). Affymetrix Microarray Suite software (version 5.0. 1) extracted fluorescence signal intensities from each feature on the microarrays as detected by confocal laser scanning according to the manufacturer's recommendations.

Expression analysis quality assessment parameters included visiual array inspection of the scanned image for the presence of image artifacts and correct grid alignment for the identification of distinct probe cells as well as both low 3'/5' ratio of housekeeping controls (mean: 1.90 for GAPDH) and high percentage of detection calls (mean: 46.3% present called genes). The 3'to 5'ratio of GAPDH probesets can be used to assess RNA sample and assay quality. Signal values of the 3'probe sets for GAPDH are compared to the Signal values of the corresponding 5'probe set. The ratio of the 3'probe set to the 5'probe set is generally no more than 3.0. A high 3'to 5'ratio may indicate degraded RNA or inefficient synthesis of ds cDNA or biotinylated cRNA (GeneChip'» Expression Analysis Technical Manual, www. affymetrix. com). Detection calls are used to determine whether the transcript of a gene is detected (present) or undetected (absent) and were calculated using default parameters of the Microarray Analysis Suite MAS 5.0 software package.

Method 2: Bone marrow (BM) aspirates are taken at the time of the initial diagnostic biopsy and remaining material is immediately lysed in RLT buffer (Qiagen), frozen and stored at-80 C until preparation for gene expression analysis. For microarray analysis the GeneChip System (Affymetrix, Santa Clara, CA, USA) is used. The targets for GeneChip analysis are prepared according to the current Expression Analysis. Briefly, frozen lysates of the leukemia samples are thawed, homogenized (QIAshredder, Qiagen) and total RNA extracted (RNeasy Mini Kit, Qiagen). Normally 10 ug total RNA isolated from 1 x 107 cells is used as starting material in the subsequent cDNA-Synthesis using Oligo-dT-T7-Promotor Primer (cDNA synthesis Kit, Roche Molecular Biochemicals). The cDNA is purified by phenol-chlorophorm extraction and precipitated with 100% Ethanol over night. For detection of the hybridized target nucleic acid biotin-labeled ribonucleotides are incorporated during the in vitro transcription reaction (Enzo BioA-rrayTm HighYieldTM RNA Transcript Labeling Kit, ENZO). After quantification of the purified cRNA (RNeasy Mini Kit, Qiagen), 15 ug are fragmented by alkaline treatment (200 mM Tris-acetate, pH 8.2, 500 mM potassium acetate, 150 mM magnesium acetate) and added to the hybridization cocktail sufficient for 5 hybridizations on standard GeneChip microarrays. Before expression profiling Test3 Probe Arrays (Affymetrix) are chosen for monitoring of the integrity of the

cRNA. Only labeled cRNA-cocktails which showed a ratio of the messured intensity of the 3'to the 5'end of the GAPDH gene less than 3.0 are selected for subsequent hybridization on HG-U133 probe arrays (Affymetrix). Washing and staining the Probe arrays is performed as described (siehe Affymetrix-Original- Literatur (LOCKHART und LIPSHUTZ). The Affymetrix software (Microarray Suite, Version 4.0. 1) extracted fluorescence intensities from each element on the arrays as detected by confocal laser scanning according to the manufacturers recommendations.

Table 1 1. One-Versus-All (OVA) 1.1 ALL MLL versus rest # affy id HUGO name fc stn t Map Location 1 200871_s_at PSAP -4.69 1. 31E-45 4. 49E-42-1. 44-23. 93 10q21-q22 2 204949_at ICAM3 -8.98 8. OOE-66 2. 29E-61-1. 33-23. 5719p13. 3-p13. 2 3 217800_s_at NDFIP1 -7.80 2. 52E-40 3.60E-37-1. 40-22. 79 5q31. 3 4 202382 s at GNPI-10. 47 1. 41 E-45 4. 49E-42-1.30-21. 95 5q21 5 227353_at EVER2 -3.80 4. 54E-29 1.43E-26-1. 30-20. 02 17q25. 3 6 224918_x_at MGST1 -26.96 5.22E-54 7.46E-50-1. 06-18. 96 12p12. 3-p12. 1 7 204852 s at PTPN7-3. 58 2.48E-24 4. 41 E-22-1. 29-18. 96 1q32. 1 8218486at-13. 86 2.02E-53 1.92E-49-1. 04-18.71 9 218942_at FLJ22055 -6. 87 3. 54E-28 9.74E-26-1. 20-18. 65 12q13. 13 10 202853 s at RYK-4. 84 1.07E-23 1.76E-21-1. 27-18. 60 3q22 11 218831 s at FCGRT-8. 33 3. 72E-35 2.73E-32-1. 11-18. 40 19q13. 3 12 225782_at LOC253827 -20.15 3.28E-52 2.34E-48-1. 02-18. 40 12q14. 1 13 231736_x_at MGST1 -21.12 2.30E-50 1.32E-46-1. 00-18.01 12p12. 3-p12. 1 14 200866satPSAP-4. 22 1. 41E-39 1.83E-36-1. 05-17. 99 10q21-q22 15 200953_s_at CCND2 -4.80 8. 21E-46 3.35E-42-1. 00-17. 72 12p13 16 217967_s_at C1orf24 -6. 05 3.14E-43 6.92E-40-1. 01-17.70 1 q25 17 210024_s_at UBE2E3 -5.80 7. 63E-23 1. 14E-20-1. 20-17. 62 2q32.1 18 202788_at MAPKAPK3 -2. 77 1.09E-31 4.97E-29-1. 08-17. 56 3p21. 3 19 225789_at CENTG3 -4.34 3. 82E-20 4. 12E-18-1. 24-17.32 7q36.1 20 201494 at PRCP-2. 83 4.16E-31 1. 80E-28-1. 06-17. 27 11q14 21 219013_at GALNT11-4. 85 4. 62E-28 1. 23E-25-1. 09-17.24 7q34-q36 22 225637_at FLJ20186 -8.53 6.63E-44 1. 58E-40-0. 97-17. 10 16q24. 3 23 225790_at LOC253827 -20.03 4. 39E-47 2. 09E-43-0. 95-17. 1012q14. 1 24 204446_s_at ALOX5 -7.63 7.02E-42 1. 34E-38-0.97-17. 04 10q11. 2 25 204563_at SELL -6.10 8. 12E-41 1.22E-37-0. 96-16. 751q23-q25 26 203591_s_at CSF3R -7.86 2.25E-44 5. 86E-41-0. 93-16. 681p35-p34. 3 27 203949 at MPO-10. 32 5. 42E-41 9. 11 E-38-0. 95-16. 62 17q23. 1 28 203948_s_at MPO-18. 0a 1.19E-44 3.39E-41-0. 91-16. 47 17q23. 1 29 213116atNEK3-4. 07 5.46E-24 9.30E-22-1. 07-16. 37 13q14. 13 30 203973_s_at CEBPD -6.99 4. 38E-33 2. 41 E-30-0. 95-16.12 8p11. 2-p11. 1 31 200602atAPP-10. 63 2. 84E-42 5.80E-39-0. 89-16. 01 21q21. 3 32 204214_s_at RAB32 -4. 61 1. 16E-29 3. 89E-27-0. 96-15. 91 6q24.2 33 224448_s_at MGC14833 -3. 23 2. 47E-30 9.96E-28-0. 95-15. 76 6p21. 31 34 206120atCD33-27. 98 1. 99E-41 3.56E-38-0. 88-15. 73 19q13. 3 35 219191 s at BIN2-7. 62 2. 60E-29 8. 46E-27-0. 95-15. 6912q13 36 220307atCD244-5. 49 3. 28E-35 2. 47E-32 -0.90 -15.64 1q23. 1 37 201425 at ALDH2-5. 98 9. 46E-39 1.18E-35-0. 88-15. 6412q24. 2 38 204487_s_at KCNQ1 -15. 82 1. 56E-36 1. 54E-33-0. 89-15. 5811p15. 5 39 205639_at AOAH -10. 01 2. 09E-38I 2. 49E-35-0. 88 -15. 56 7p14-p12 Table 1 40 210424_s_at GOLGIN-67 -5. 32 1. 22E-32 6.25E-30-0. 91-15. 5415q11. 2 41 223046_at EGLN1 -4. 24 1. 81E-24 3. 23E-22 -0.99 -15.53 1q42. 1 42 212593_s_at PDCD4 -3. 26 3. 68E-25 7. 26E-23-0.98-15. 5210q24 43 201462_at KIAA0193 -10. 60 6.89E-41 1. 09E-37-0. 86-15.51 7p14. 3-p14. 1 44 228058_at LOC124220-8. 52 4. 68E-38 5. 35E-35-0. 88-15. 50 16p13. 3 45 218910_at FLJ10375 -10. 04 7. 34E-40 9.99E-37-0. 85-15. 28 3p21. 32 46 214181_x at LST1-5. 17 3.49E-34 2.27E-31-0. 88-15.27 6p21. 3 47 204661_at CDW52 -9. 95 2. 32E-36 2.07E-33-0. 86-15. 14 lu36 48 227001_at -3. 56 7.90E-22 1. 03E-19-1. 00-15.13 49 204122_at TYROBP -5.71 1. 11E-37 1. 17E-34-0. 85-15. 11 19q13. 1 50 214172 x at RYK-3. 21 7. 53E-16 4. 77E-14-1. 17-15.05 3q22 1.2 ALL Ph+ versus rest # affy id HUGO name fc p q stn t Map Location 1 234107_s_at HARS2 -3.71 2. 79E-39 8. 04E-35-1.09-18. 35 20p11. 23 2205020satARL4-3. 73 7. 65E-26 1.96E-22-0. 88-14.28 7p21-p15. 3 3 201462_at KIAA0193 -8.11 2. 94E-35 4. 24E-31-0.80-14. 27 7p14. 3-p14. 1 4 218404_at SNX10 -4. 49 1. 18E-26 3.77E-23-0. 87-14.18 7p15. 2 5 224839_s_at GPT2 -11. 60 1. 24E-34 1. 19E-30-0. 78-13. 92 16q12. 1 6 218718_at PDGFC -7. 17 6. 00E-34 4.32E-30-0. 76-13.69 4q32 7 203955_at KIAA0649 -5. 68 7. 28E-32 4. 20E-28-0. 78-13.68 9q34. 3 8 204362_at SCAP2 -4. 98 1. 11E-27 4.57E-24-0. 81-13.61 7p21-p15 9 224918_x_at MGST1 -6. 75 4.62E-24 7. 00E-21-0. 79-12. 92 12p12. 3-p12. 1 10 231736 x_at MGST1-6. 49 1. 29E-25 2.85E-22-0. 77-12. 8912p12. 3-p12. 1 11 219452 at LOC64174-10. 71 1. 02E-29 4.91E-26 -0. 71-12. 69 16q22. 1 12 225639 at SCAP2-4. 73 1. 03E-23 1.35E-20-0. 76-12.56 7p21-p15 13 226794_at STXBP5 -4.21 1.53E-24 2. 45E-21-0. 74-12. 44 6q24. 3 14 216899_s_at SCAP2 -4. 04 3. 41 E-27 1.23E-23-0. 71-12.37 7p21-p15 15 204214_s_at RAB32 -3. 56 2. 08E-19 1. 28E-16-0.81-12. 37 6q24.2 16 204072_s_at 13CDNA73 -4.51 8. 15E-26 1.96E-22-0. 71-12.26 13q12. 3 17 228642 at-3. 46 9. 77E-25 1.66E-21-0. 72-12.25 18 219229 at SLC21A11-4. 83 3. 25E-18 1.54E-15-0. 81-12. 09 15q26 19 227266sat-4. 00 4. 32E-23 5. 41 E-20-0. 72-11.99 20 221080satFLJ22757-1. 81 1.78E-14 4. 04E-12-0. 94-11. 96 19p13. 3 21 204361satSCAP2-4. 95 3.53E-21 2.99E-18-0. 74-11.93 7p21-p15 22 205645_at REPS2 -5. 66 1.79E-25 3.53E-22-0. 68-11. 93 Xp22. 22 23 202295_s_at CTSH -4. 50 3. 24E-26 9.35E-23-0. 67-11. 90 15q24-q25 24 223501_at -3. 87 1.44E-21 1. 38E-18-0. 72-11. 82 25 203373 at SOCS2 4. 48 3. 39E-12 3.73E-10 1.18 11.81 12q 26 223703 at CDA017-3. 03 1.40E-21 1.38E-18-0. 72 -11.79 10q23. 1 27 202746_at ITM2A -4. 64 8.63E-25 1.55E-21-0. 68-11. 78 Xq13. 3-Xq21. 2 28 208702_x_at APLP2 -3.52 5. 19E-19 2. 88E-16-0. 75-11. 7511q24 29 214875_x at APLP2-3. 52 1. 55E-20 1. 18E-17-0. 72-11. 67 11 q24 Table 1 30 223502_s_at TNFSF13B -3. 75 8. 19E-20 5.49E-17-0. 73-11. 62 13q32-34 31 211404_s_at APLP2 -3.26 3. 96E-18 1. 84E-15 -0. 75-11. 54 11q24 32"204167at BID-4. 32 6.90E-21 5. 52E-18 -0.70 -11.50 3p25 33 201384_s_at M17S2 -2.20 6. 75E-17 2.56E-14-0. 77-11. 4017q21. 1 34 219919_s_at SSH-3 -5. 41 1.84E-25 3.53E-22-0. 63-11. 3811q13. 1 35 227947 at-4. 28 2.51 E-19 1. 45E-16-0. 71-11.33 36 242282_at-2. 01 1. 78E-20 1.31 E-17-0. 68-11. 26 37 202747 s at ITM2A-4. 80 6. 39E-23 7. 67E-20-0. 65-11. 25 Xq13.3-Xq21. 2 38 217963 s at NGFRAP1-6. 85 6.66E-24 9.60E-21-0. 63-11. 18 Xq22. 1 39 220326_s_at FLJ10357 -2. 94 7.85E-21 6. 12E-18-0. 67-11. 1814q11. 1 40 211795_s_at FYB -3.85 3. 41 E-21 2. 98E-18-0. 65-11. 07 5p13. 1 41 51192_at SSH-3 -2. 73 2.19E-14 4.86E-12-0. 81-11. 02 11q13. 1 42 239135_at -4.00 1.59E-21 1. 48E-18-0. 64-11.01 43 225782 at LOC253827-7. 35 4. 09E-16 1. 36E-13-0. 74-10. 99 12q14. 1 44 228970 at-1. 69 9.77E-17 3.66E-14-0. 72-10.98 45 212934 at LOC137886-2. 55 3. 09E-16 1. 05E-13-0. 74-10. 96 8q11. 23 46 227230_s_at KIAA1211 -6. 11 8.66E-24 1. 19E-20-0. 61-10.91 4q12 47 227425at-2. 44 1. 38E-19 8. 86E-17-0. 66-10. 90 48 218094_s_at C20orf35 -2.93 2. 50E-18 1. 21E-15-0. 68-10. 87 20q13. 11 49 225386_s_at LOC92906 -6.39 2. 41 E-17 9. 93E-15-0. 69-10. 84 2p22.2 50 223635_s_at SSBP3 -2.05 4.42E-21 3. 64E-18-0. 63-10.83 1p32. 3 1.3 ALL_T-lineage versus rest # affy id HUGO name fc p q stn t Map Location 1200742satCLN2-4. 55 6. 96E-44 2.18E-40-1. 22-20.51 11 p15 2 203555 at PTPN18-4. 79 1.52E-41 2. 78E-38-1. 19-19.93 2q21. 1 3 210982_s_at HLA-DRA -13. 87 1. 28E-52 1. 41 E-48-1. 05-18. 75 6p21.3 4213521at-3. 46 9.17E-34 4. 38E-31-1. 16-18.64 5 208894_at HLA-DRA -13.65 1. 17E-52 1. 41 E-48-1. 04-18. 62 6p21. 3 6 217478_s_at HLA-DMA -7.59 3. 21E-48 2.35E-44-1. 02-18.08 6p21. 3 7200696satGSN-5. 91 3. 22E-39 3. 08E-36-1. 03-17.51 9q33 8 202241_at C8FW -6.10 2. 14E-40 2.46E-37-1. 02-17. 45 8q24. 13 9 203799 at BIMLEC-7. 89 3.55E-41 5. 56E-38-1. 01-17. 45 2q24. 2 10 226459_at FLJ35564-4. 25 3. 03E-29 7. 74E-27-1. 11-17. 43 10q23. 33 11 205640 at ALDH3B1-9. 58 9. 29E-42 2. 04E-38-1. 00-17. 31 11q13 12 215193_x_at HLA-DRB1 -9. 23 3. 55E-44 1. 30E-40-0. 98-17.28 6p21. 3 13 211991_s_at HLA-DPA1 -13. 54 1. 96E-46 1.08E-42-0. 95-17.10 6p21. 3 14 223696 at-9. 13 2.44E-41 4. 12E-38-0. 98-17. 07 15 200743 s at CLN2-3.26 2.64E-22 2. 14E-20-1. 21-17. 00 11 p15 16 216041_x_at GRN -5. 97 7. 12E-39 6. 51E-36 -0.98 -16.87 17q21. 32 17 223703atCDA017-4. 50 1.33E-45 5.83E-42-0. 94-16.86 10q23. 1 18 217984_at RNASE6PL-2. 56 1.85E-25 2. 47E-23-1. 12-16.80 6q27 19 200678_x_at GRN -5.60 7. 23E-36 4. 18E-33 -0.98 -16.64 17q21. 32 Table 1 20 203949_at MPO-9. 73 1. 21 E-41 2.41 E-38-0. 93-16. 48 17q23. 1 21 204122_at TYROBP-8. 1 r 2. 33E-43 6. 41 E-40-0. 91-16.37 19q13. 1 22 212335_at GNS-3. 95 9. 33E-38 7. 07E-35-0. 95-16. 3412q14 23 207571_x_at C1orf38 -6. 10 3.38E-28 7.29E-26-1. 02-16. 15 1 p35. 2 24 211284_s_at GRN -6. 27 2. 70E-38 2.20E-35-0. 93-16. 12 17q21. 32 25 222698_s_at IMPACT -3.52 3. OOE-23 2.70E-21-1. 09-16. 09 18q11.2-q12. 1 26 223553_s_at FLJ22570-4. 19 2. 69E-35 1.48E-32-0. 93-15. 94 5q35. 3 27 200808_s_at ZYX -3. 97 3. 41 E-32 1. 21 E-29-0. 96-15. 93 7q32 28 214196satCLN2-4. 56 5. 40E-33 2. 26E-30-0. 95-15. 92 11p15 29 203028_s_at CYBA -4.34 3. 76E-33 1. 62E-30-0. 95-15. 90 16q24 30 203948_s_at MPO -15. 53 4.97E-42 1. 21 E-38-0. 88-15.88 17q23.1 31 204670_x_at HLA-DRB5 -5.65 7. 92E-30 2.26E-27-0. 97-15 : 86 6p21. 3 32 211990atHLA-DPA1-5. 63 2. 63E-23 2.39E-21-1. 07-15. 85 6p21. 3 33 208306xatHLA-DRB4-6. 80 6. 10E-31 1. 97E-28-0. 96-15. 85 6p21. 3 34 218217_at RISC -5.85 5.61 E-41 7.71 E-38-0. 88-15. 80 17q23.1 35 231736_x_at MGST1 -11.45 5. 62E-40 5.88E-37-0. 89-15. 76 12p12. 3-p12. 1 36 224918 x at MGST1-11. 37 4.15E-37 2.85E-34-0. 90-15. 67 12p12. 3-p12. 1 37 206111_at RNASE2 -5.92 1. 09E-32 4. 26E-30-0. 93-15. 6214q24-q31 38 201137_s_at HLA-DPB1-6. 9 2.04E-34 1.04E-31-0. 91-15.61 6p21. 3 39 209166 s at MAN2B1-2. 50 7.07E-27 1. 20E-24-0. 99-15. 60 19cen-ql3. 1 40 201887_at IL13RA1 -6. 31 2. 24E-40 2.46E-37-0. 87-15. 60 Xq24 41 209473_at ENTPD1 -4.99 4.42E-41 6. 48E-38-0. 87-15. 59 10q24 42 225059_at AGTRAP-7. 6 2. 29E-39 2.29E-36 -0.88 -15.56 1p36. 21 43 225286 at-5. 12 3.13E-27 5. 79E-25-0. 97-15.51 44 226190_at-4. 0 4.31 E-35 2. 25E-32-0. 90-15.51 45 209312_x_at HLA-DRB1 -5.99 1.33E-28 3. 08E-26-0. 96-15. 49 6p21. 3 46 214575satAZU1-23. 06 1. 08E-40 1.32E-37-0. 86-15. 48 19p13. 3 47 219013_at GALNT11 -4. 31 4. 31 E-25 5. 29E-23-1. 00-15. 48 7q34-q36 48 220416_at KIAA1939 -13.11 8. 28E-41 1. 07E-37 -0.86 -15.48 15q15. 3 49 223158_s_at NEK6 -3.93 1. 75E-25 2. 35E-23-0. 99-15. 43 9q33. 3-q34. 11 50 210613_s_at SYNGR1 -5.84 1. 10E-26 1. 81E-24-0. 97-15. 35 22q13. 1 1. 4 ALL t (8; 14) versus rest # affy id HUGO name fc p q stn t Map Location 1231982at-15. 62 1. 24E-43 2.48E-39-0. 97-17.11 2211709satSCGF-7. 06 1. 69E-29 5. 62E-26-0. 96-16. 01 19q13. 3 3226869at-9. 09 2. 77E-13 5. 47E-11-1. 08-13. 91 4 215111 s at TSC22-4. 58 8. 80E-30 3. 52E-26-0. 79-13. 6913q14 5 206674 at FLT3-11. 37 9. 71 E-32 9. 70E-28 -0.73 -13.15 13q12 6 225537_x_at DDAH2 -4.90 2. 43E-17 1.24E-14-0. 87-13. 09 6p21. 3 7 209160_at AKR1C3 -7. 74 3. 88E-30 1.94E-26-0. 73-13. 0410p15-p14 8 213589_s_at LOC284208 -12.10 1. 69E-30 1. 13E-26-0. 71-12. 77 17q25. 3 9201028satCD99-3. 71 4. 52E-25 8. 22E-22-0. 75-12. 74 Xp22. 32 Table 1 10 201029sat CD99-3.03 1. 81 E-13 3. 73E-11-0. 92-12. 51 Xp22. 32 11 215116 s at DNM1-6. 08 1. 15E-28 3. 29E-25-0. 70-12. 44 9q34 12 225306_s_at C14orf69 -4.39 3. 84E-15 1. 13E-12-0. 85-12. 40 14q32. 32 13 205131_x_at SCGF -10.46 9. 49E-28 2. 11E-24 -0.70 -12.39 19q13. 3 14 201825_s_at CGI-49 -2.62 3.68E-17 1.75E-14-0. 80-12. 29 1q44 15 209199_s_at MEF2C -5.89 5. 11 E-28 1.28E-24-0. 69-12. 29 5q14 16 202747satJTM2A16*89 1.43E-23 2. 19E-20-0. 72-12.26 Xq13. 3-Xq21. 2 17 204798 at MYB-3. 63 3.51 E-13 6. 85E-11-0. 90-12. 21 6q22-q23 18 202768_at FOSB -4. 53 1. 84E-17 9.92E-15-0. 78-12. 15 19q13. 32 19 219654_at PTPLA -5. 46 9.69E-26 1. 94E-22-0. 69-12. 04 10p14-p13 20 214909_s_at DDAH2 -3.39 5.58E-17 2. 53E-14-0. 78-12. 00 6p21. 3 21 230127 at-5. 50 2. 49E-18 1. 66E-15-0. 74-11.87 22 202708_s_at HIST2H2BE -3. 37 1. 47E-19 1. 54E-16-0. 73-11. 86 1q21-q23 23 213541 s at ERG-4. 13 8. 42E-18 4. 95E-15 -0.75 -11.85 21q22. 3 24 209360_s_at RUNX1 -5.43 4.57E-14 1.13E-11-0. 82-11.77 21q22. 3 25 212442satLOC253782-3. 65 1. 36E-11 2. 08E-09-0. 91-11. 65 2q31. 1 26 229307_at -3. 94 6. 06E-15 1. 70E-12-0. 78-11. 61 27 201162_at IGFBP7 -5.69 2. 37E-16 8.95E-14-0. 74-11.51 4q12 28 219201satTWSG130 2. 95E-19 2. 56E-16-0. 70-11. 4918p11. 3 29 202262 x at DDAH2-3. 71 1. 52E-11 2. 28E-09-0. 86-11. 26 6p21. 3 30 201564 s at FSCN1-7. 38 2. 93E-22 3. 90E-19-0. 64-11. 16 7p22 31 219871_at FLJ3197 -4. 24 9.23E-17 4. 01E-14 -0.70 -11.12 4p14 32 201826_s_at CGI-49 -2.15 1. 68E-15 5. 50E-13-0. 71-11. 04 1q44 33 201324 at EMP1-9. 80 3.92E-24 6.53E-21-0. 61-11. 02 12p12. 3 34 200665_s_at SPARC -6.99 1. 13E-18 8. 36E-16-0. 66-10. 93 5q31. 3-q32 35 224710atRAB34-4. 78 2. 37E-11 3. 44E-09-0. 82-10. 8017q11. 1 36 224851at-3. 95 1.66E-19 1. 66E-16-0. 63-10. 72 37 208634 s at MACF1-2. 82 8. 77E-13 1.54E-10 -0.75 -10.72 1p32-p31 38 210612satSYNJ2-4. 93 2.69E-16 9.96E-14-0. 67-10. 70 6q25. 3 39 201325 s at EMP1-15. 76 2. 03E-22 2. 90E-19-0. 58-10. 51 12p12. 3 40 219634_at C4ST -2.98 1. 11E-10 1.35E-08-0. 82-10. 50 12q 41 206067_s_at WT1 -30. 72 3.83E-22 4.78E-19-0. 58 -10.45 11p13 42 209530_at CACNB3 -2.66 2. 18E-15 7. 01E-13-0. 66-10. 3812q13 43 202746 at ITM2A-4. 18 4. 20E-16 1. 50E-13-0 64-10.37 Xq13. 3-Xq21. 2 44 209267_s_at BIGM103 -2.68 1.61E-11 2.40E-09-0. 74-10.26 4q22-q24 45 243000at-5. 18 2. 89E-19 2. 56E-16-0. 59-10. 24 46 225962_at NIN283 -10.30 3.60E-21 4. 22E-18-0. 57-10. 21 16q22.3 47 223383_at NIN283 -4. 91 1. 23E-11 1. 91 E-09-0. 73-10. 21 16q22.3 48 210613_s_at SYNGR1 -3.96 3. 86E-10 4. 36E-08-0. 80-10. 13 22q13. 1 49 210298 x at FHL1-6. 53 3.66E-19 3.05E-16-0. 58-10. 13 Xq26 50 212959_s_at MGC4170 -2.69 4. 27E-11 6. 00E-09 -0. 73 -10.02 12q23. 3 1.5 AML MLL versus rest Table 1 # affy id HUGO name fc stn t Map Location 1 204951_at ARHH -5.93 3.09E-38 4.88E-34-0. 85-15. 16 4p13 2 233849_s_at ARHGAP5 -7.32 1. 26E-31 3. 18E-28-0. 84-14. 36 14q12 3 226517_at BCAT1 -7.88 9.15E-36 7.24E-32-0. 79-14. 24 12pter-q12 4 220306 at FLJ20202-3. 90 1. 41E-31 3. 18E-28 -0. 82-14. 101p11. 1 5 214022_s_at MGC27165 -3. 88 3. 34E-30 5. 86E-27-0. 79-13. 6014 6208650satCD24-10. 89 1. 93E-33 1.02E-29-0. 75-13. 55 6q21 7 202746_at ITM2A -7.35 2.15E-32 6. 81E-29-0. 76-13.55 Xq13. 3-Xq21. 2 8 266_s_at CD24 -7.99 1.88E-32 6.81 E-29-0. 74-13. 33 6q21 9 216379_x_at KIAA1919 -6. 33 9. 18E-31 1.82E-27-0. 75-13.27 6q22 10 203544_s_at STAM -3.00 8. 34E-25 4. 00E-22 -0. 81-13. 0810p14-p13 11 200602_at APP-7. 59 1. 15E-27 8. 66E-25 -0.76 -13.04 21q21. 3 12 215785_s_at CYFIP2 -4. 43 1. 13E-25 6.64E-23-0. 78-12.96 5q34 13 209771_x_at CD24 -5. 70 2.28E-28 2.52E-25-0. 74-12. 88 6q21 14"214651satHOXA96*94 4.74E-15 2. 52E-13 1.32 12. 84 7p15-p14 15 202747_s_at ITM2A -7. 69 3. 61E-29 5.19E-26-0. 72-12.76 Xq13. 3-Xq21. 2 16 236198 at-7. 42 9.78E-30 1.55E-26-0. 71-12.64 17 207734_at LAX -2. 48 2.39E-28 2. 52E-25-0.72-12. 61 1q32. 1 18 212758_s_at TCF8 -4. 36 2.82E-27 2. 03E-24 -0.72 -12. 53 10p11. 2 19 201601_x_at MGC27165 -4.36 2.34E-28 2. 52E-25-0. 70-12. 43 14 20 228029_at KIAA1982-5. 37 2.03E-28 2.52E-25-0. 70-12.43 4p16. 3 21 21137_s_at ATP2C1 -1. 97 5.29E-27 3.64E-24-0. 71-12. 42 3q21-q24 22 208657_s_at MSF -3. 27 2.78E-28 2. 75E-25-0.70-12. 40 17q25 23 212764 at TCF8-5. 40 3.16E-28 2. 94E-25-0. 69-12. 33 10p11. 2 24 215082_at-2. 00 9. 82E-28 7.77E-25-0. 70-12.31 25 214643_x_at BIN1 -3. 31 1. 11E-22 3.32E-20-0. 76-12.31 2q14 26 217936_at -3. 36 2.33E-22 6.14E-20-0. 77-12.27 27204881_s_at UGCG -3. 94 1.06E-26 6.97E-24-0. 70-12.21 9q31 28 214439_x_at BIN1 -3. 05 3.84E-22 9. 80E-20-0.76-12. 17 2q14 29 200965 s at ABLIM1-5. 65 3.90E-28 3. 43E-25-0.67-12. 12 10q25 30 206761_at TACTILE-9. 25 7. 09E-28 5.90E-25-0. 68-12. 103q13. 13 31 210875 s at TCF8-4. 53 2.24E-25 1. 18E-22-0. 70-12. 0810p11. 2 32 213737_x_at 2.27 6.42E-15 3.26E-13 1.08 12.01 33 220104_at ZAP -2. 64 3.06E-23 1. 01 E-20-0. 72-11. 96 7q34 34 213549_at PRO2730 -3. 07 7.54E-26 4. 59E-23-0. 67-11. 85 3p21. 31 35 220999_s_at PRO1331 -3. 76 1. 10E-26 6.97E-24-0. 66-11.78 5q33.3 36 226765_at SPTBN1 -2.35 1.14E-19 1. 76E-17-0. 76-11. 67 2p21 37 212912 at-3. 62 4.13E-24 1. 72E-21-0. 68-11. 65 38 210201_x_at BIN1 -2. 55 2.83E-21 5. 81E-19-0. 72-11.63 2q14 39 214953 s at APP-4. 76 3.77E-21 7.36E-19-0. 72-11.61 21q21. 3 40 209447_at SYNE1 -3. 88 1. 86E-25 1. 01E-22 -0. 65-11. 51 6q25 41 243888_at -3.20 2.95E-24 1. 29E-21-0. 66-11.51 42 230006satDKFZp313A2432-3. 00 5.75E-23 1. 82E-20-0.68-11. 49 11p14. 2 43 225706 atGLCC11-2. 98 6.28E-24 2.42E-21-0. 66-11. 47 7p22.1 44 225285_at-6. 18 1.52E-22 4. 35E-20-0.68-11. 44 45 225912_at TP531NP1-3. 74 9. 49E-25 4. 41 E-22-0. 65 11 42 8q22 i adie 1 46 214390sat BCAT1-5. 87 1. 15E-24 5.18E-22-0. 65-11.42 12pter-q12 47 212071_s_at SPTBN1 -2.69 5. 08E-18 5. 66E-16-0. 77-11.41 2p21 48 236293_at -4. 77 1. 85E-25 1. 01 E-22-0. 63-11.38 49 209772_s_at CD24 -12. 97 2. 42E-25 1.24E-22-0. 63-11. 38 6q21 50 201906_s_at HYA22 -3.93 3.02E-24 1.29E-21-0. 65-11. 36 3p21. 3 1.6 AML_inv(16) versus rest # affy id HUGO name fc p q stn t Map Location 1 202370_s_at CBFB -2.62 6.35E-36 1.93E-32-1. 18 -19.07 16q22. 1 2 223471_at RAB3IP -3. 77 3.17E-31 2.89E-28-1. 06-17.08 3212463at-5. 74 4.28E-45 7.79E-41-0. 95-16.98 4201669satMARCKS-12. 31 4. 26E-43 3. 88E-39-0. 89-16. 07 6q22.2 5 218414_s_at NUDE1 -2.28 5.37E-27 2.58E-24-1. 03-16. 00 16p13. 11 6 200985_s_at CD59 -8.79 3. 32E-40 2. 02E-36-0. 87-15. 58 11 p13 7 204198_s_at RUNX3 -5. 12 3.13E-31 2.89E-28-0. 93-15. 47 1p36 8227567at-4. 69 1.23E-34 2.49E-31-0. 89-15. 31 9 201811_x_at SH3BP5 -5.39 3.34E-34 5.53E-31-0. 87-15. 09 3p24. 3 10 204197_s_at RUNX3 -3. 47 5.77E-35 1.50E-31-0. 87-15. 04 1 p36 11 222786atC4S-2-2. 85 2. 80E-32 3. 19E-29-0. 88-14. 91 7p22 12 201810_s_at SH3BP5-4. 01 5.48E-37 2. 49E-33-0. 82-14.67 3p24.3 13 200984_s_at CD59 -3.96 1.61E-34 2.93E-31-0. 82 -14.40 11p13 14 228497_at FLIPT1 -5.80 5. 09E-36 1. 85E-32 -0.79 -14.24 1p13. 1 15 213002atMARCKS-3. 35 1. OOE-34 2. 28E-31-0. 79-14. 09 6q22.2 16 225706 at GLCCI1-4. 09 4. 30E-33 5. 60E-30-0. 80-14. 07 7p22.1 17 225055_at DKFZp667M241-4. 3 2.47E-30 1. 96E-27-0. 82-14. 06 17q11. 2 18 227856atFLJ39370-5. 51 1. 89E-29 1. 28E-26-0. 82-13. 96 4q25 19 201670_s_at MARCKS -15.19 4.62E-34 7. 01E-31 -0.76 -13. 75 6q22.2 20 232611_at LOC92497 -6. 81 6.29E-34 8.82E-31-0. 76-13.71 12q23.2 21 218795_at ACP6 -3.80 3. 96E-26 1. 44E-23-0. 83-13. 60 1q21 22 224952-at DKFZP564Dl66-3. 75 2. 72E-23 7.29E-21-0. 86-13. 55 17q23. 3 23 213353_at ABCA5-3. 9a 4.60E-28 2. 62E-25-0. 79-13. 42 17q24. 3 24 225897_at -6. 97 1.48E-32 1. 80E-29-0. 74-13.33 25 201690_s_at TPD52 -5.18 1.57E-31 1. 66E-28-0. 74-13.26 8q21 26 226352_at -5. 57 1.64E-31 1. 66E-28-0. 74-13. 25 27 200983_x_at CD59 -6.80 3.43E-31 2. 98E-28-0. 72-13. 01 11p13 28 218456_at EEG1 -3.46 1. 29E-29 9.01 E-27-0.74-12. 98 12p11 29 205760_s_at OGG1 -2.60 4.51E-23 1.11E-20 -0. 81-12.97 3p26.2 30 235165_at-6. 66 1. 50E-22 3. 38E-20-0. 80-12. 77 31 213241_at -5.89 1.73E-30 1.43E-27-0. 71-12.77 32 210425_x_at GOLGIN-67 -3.54 6.91E-29 4.20E-26-0. 72-12. 67 15q11. 2 33 228155 at MGC4248-4. 09 4. 62E-30 3. 51E-27 -0.70 -12.65 10q22. 3 34 202085_at TJP2-4. 52 5.72E-28 3.16E-25-0. 72-12.61 9q13-q21 35 226884_at KIAA1497 -9.67 8. 52E-30 6. 21 E-27-0. 70-12. 58 3p26. 2 Table 1 36 213908at-5. 40 4. OOE-29 2. 52E-26-0. 70-12. 53 37 218477 at PTD011-2. 60 8. 52E-22 1. 71 E-19-0. 78-12. 50 6p12. 1 38 209406_at BAG2 -3. 44 7.67E-27 3. 41 E-24-0. 72-12.50 6p12.3-p11. 2 39 204160_s_at ENPP4 -7.47 3.92E-29 2.52E-26 -0.70 -12.49 6p12. 3 40 229202-at-4-58 2. 03E-28 1. 19E-25-0. 69-12. 38 41 218872_at TSC -3.50 2.99E-26 1. 14E-23-0. 71-12. 3512q24. 22 42 218927satC4S-2-4. 35 2.21 E-22 4.75E-20-0. 76-12. 34 7p22 43 203973_s_at CEBPD 2.63 1. 67E-13 7. 18E-12 1.13 12.23 8p11.2-p11. 1 44 230894-s-at-8. 50 2. 09E-27 1. 11 E-24-0. 69-12. 22 45 223044_at SLC11A3 -7. 41 3.54E-27 1.79E-24-0. 69-12. 21 2q32 46 209447 at SYNE1-4. 96 1. 05E-26 4.55E-24-0. 69-12. 19 6q25 47 201689_s_at TPD52 -5.86 1.82E-26 7.52E-24-0. 69-12. 16 8q21 48 200665_s_at SPARC 4.91 3.73E-12 1. 15E-10 1. 48 12.11 5q31. 3-q32 49 215785 s at CYFIP2-3. 50 1. 38E-22 3. 14E-20-0. 73-12. 07 5q34 50 227525_at GLCCI1-4. 8 2.80E-26 1. 11E-23 -0.69 -12. 07 7p22. 1 1.7 WML_inv (3) versus rest # affy id HUGO name fc p q stn t Map Location 1 210115_at RPL39L -7.48 1.35E-41 2.92E-37-0. 87-15. 68 3q27 2 212318_at TRN-SR-2. 4 2. 80E-19 3. 77E-16-1. 06-15. 18 7q32.2 3 226123_at LOC286180-4. 56 1.13E-25 4. 08E-22 -0.92 -14.88 8q12.1 4 218829_s_at KIAA1416 -3.06 1.78E-27 7.68E-24-0. 90-14. 76 8q12. 1 5 204921_AT GAS8 -2.81 4.43E-29 2. 39E-25-0. 85 -14.36 16q24. 3 6 204301 at KIAA0711-6. 66 2. 01 E-34 2. 16E-30-0. 78-13. 99 8p23.2 7 203421_at PIG11 -5.39 3. 01E-34 2. 16E-30-0. 78-13. 9411p11. 2 8 226685_at -2.28 2.20E-24 6.80E-21-0. 70-12. 02 9 244166 at-5. 32 8.66E-24 2. 34E-20-0. 70-11. 97 10 205248_at C21orf5 -2.07 2. 54E-17 2. 11E-14 -0.78 -11. 82 21q22. 2 11 214141_x_at SFRS7 -1.64 1. 51 E-14 4. 18E-12-0. 81-11.37 2p22.1 12 230044_at 2.85 1.66E-13 3. 35E-11-0. 83-11. 23 13 226789 at-2. 63 2. 65E-17 2.12E-14-0. 71-11. 13 14 203467_at PMM1 -3.02 2.57E-14 6. 59E-12-0. 76-10. 94 22q13. 2 15 227172_at LOC89894 -1.64 2.96E-15 1. 10E-12 -0.73 -10.92 12q24.13 16 203746_s_at HCCS -1.45 4. 89E-19 6. 21E-16 -0.65 -10.80 Xp22.3 17 227929_at -7.69 1.53E-22 3.31 E-19-0. 60-10. 73 18 203046_s_at TIMELESS -2.22 2.90E-14 7. 27E-12-0. 74-10. 70 12q12-q13 19 214475_x_at CAPN3 -8.27 1.29E-21 2. 54E-18 -0.60 -10.60 15q15.1-q21.1 20 221558_s_at LEF1 -7.94 1.09E-22 2. 62E-19-0. 59-10. 59 4q23-q25 21 225619_at FLJ30046 -4.32 1.33E-18 1. 43E-15-0. 64-10. 58 13q21. 33 22 204174 at ALOX5AP-3. 76 2.38E-18 2. 45E-15-0. 64-10. 5713q12 23 202759_s_at AKAP2 -3.59 5.54E-14 1. 26E-11-0. 72-10. 50 9q31-q33 24 227429atMGC45840-2. 46 1. 48E-15 6. 02E-13 -0. 68-10. 43 11 p15. 5 25 202954_at UBE2C-2. 2 8. 59E-15 2. 73E-12 -0.69 -10.41 20q13. 11 Table 1 26 211984_at -1.94 3.95E-14 9.48E-12-0. 71-10. 40 27 243819 at-2. 71 9. 01 E-15 2.82E-12-0. 69-10. 38 28 200700_s_at KDELR2 -2. 26 6. 06E-13 1. 06E-10-0. 75-10.36 7p22.2 29 213292_s_at SNX13 -1.82 1. 39E-11 1. 64E-09-0. 81-10. 26 7p21. 1 30 228252_at PIF1 -2. 22 1. 36E-12 2. 14E-10 -0.75 -10.25 15q22.1 31 21040_at CST7 -3.36 5. 64E-18 5. 07E-15 -0. 61-10. 2220p11. 21 32 223609 at ASP-2. 70 4.72E-18 4. 43E-15-0. 61-10.22 2p11. 2 33 202022_at ALDOC-2. 46 1.70E-14 4.64E-12-0. 67-10. 1517cen-q12 34 214084_x_at NCF1 -4.30 3. 48E-20 6. 27E-17-0. 57-10. 10 7q11. 23 35 243134_at-2. 26 7. 64E-14 1. 67E-11-0. 66-9.90 36 207100_s_at VAMP1 -2.75 1. 44E-11 1.69E-09-0. 75-9. 86 12p 37 240093_x_at -5.29 4. 55E-20 7.56E-17-0. 55-9.84 38 219588_s_at FLJ20311 -2. 34 1. 49E-13 3. 09E-11-0. 66-9. 83 7q36. 3 39 218865_at FLJ22390 -6.91 5. 25E-20 8. 09E-17-0. 54-9. 81 1q42. 11 40 206440_at LIN7A -5.59 6. 36E-16 2. 99E-13-0. 60-9. 75 12q21 41 235495_at MGC20255 -2. 67 4. 04E-18 3. 97E-15-0. 57-9. 7519q13. 13 42 202760_s_at AKAP2 -4.76 4.88E-14 1. 13E-11-0. 64-9. 72 9q31-q33 43 240027 at-4. 59 8. 38E-19 9. 52E-16-0. 55-9. 68 44 211213_at ORC5L -4. 64 6. 37E-19 7. 64E-16-0. 55-9. 67 7q22. 1 45 227165 at C13orf3-1. 83 2.73E-12 3. 82E-10-0. 69-9. 66 13q11 46 229116_at -5.89 1. 74E-19 2.51 E-16-0. 54-9.64 47 205716_at MCFP -2. 24 4. 17E-15 1. 50E-12-0. 60-9. 647q21. 12 48 221340_at CDX4 -2.64 2. 34E-16 1. 37E-13-0. 58-9. 64Xq13. 2 49 230480 at HIW 12-2. 75 5.45E-17 4.06E-14-0. 57-9. 60 11q21 50 208795_s_at MCM7 -2. 13 8. 49E-13 1. 42E-10-0. 66-9. 59 7q21. 3-q22.1 1.8 AML komplext versus rest # affy id HUGO name fc p q stn t Map Location 1 223318_s_at MGC10974 -2. 61 6. 85E-20 1. 15E-15-0. 73-11. 50 19pu 3. 3 2 227056_at -2.15 4. 13E-16 1. 39E-12-0. 76-10.79 3222229xat-1. 38 8.42E-13 7. 88E-10-0. 93-10.20 4235502atPPP2CA-2. 66 8. 78E-18 3.69E-14-0. 62-10. 05 5q23-q31 5 208645_s_at RPS14 -1.31 9. 83E-13 8. 67E-10-0. 88-10. 01 5q31-q33 6 226694_at AKAP2 -3.43 2. 06E-19 1.74E-15-0. 57-9. 89 9q31-q33 7 244166_at -3. 44 4. 34E-18 2. 44E-14-0. 57-9. 68 8 200608 s at RAD21 1. 55 6.51 E-12 3.37E-09 0. 85 9.45 8q24 9 218600 at MGC10986-1. 99 6.48E-14 9. 88E-11-0. 62-9. 20 17q24. 1 10 217729_s_at AES -1.92 2. 92E-15 7.03E-12-0. 57-9. 17 19p13. 3 11 231840 x_at LOC90624-1. 91 7. 04E-14 9. 88E-11-0. 61-9. 07 5q31.1 12 200620atC1orf81. 54 6. 14E-11 2. 23E-08 0. 85 8. 90 1 p36-p31 13 208646atRPS14-1. 98 4.42E-12 2. 66E-09-0. 68-8. 89 5q31-q33 14 203079_s_at CUL2 1.99 8. 73E-11 2. 88E-08 0. 87 8.84 10p11. 21 15 202659 at PSMB10-2. 16 1. 10E-11 5. 02E-09 -0.66 -8.62 16q22. 1 Table 1 16 225763at MGC21854-2.03 4. 09E-13 4.43E-10-0. 56-8. 57 1 q22-q24 17 201807_at VPS26 1.71 2.04E-10 6.04E-08 0. 84 8.56 10q21.1 18 209190_s_at DIAPH1 -1. 69 1.80E-12 1.32E-09-0. 57-8.42 5q31 19 211746_x_at PSMA1 1.46 3. 20E-10 8.68E-08 0. 82 8. 4011p15. 1 20 224368_s_at NDRG3 -1. 91 1. 67E-11 7.04E-09-0. 62-8. 38 20q11. 21- q11. 23 21 206398sat CD19-4. 51 2. 86E-15 7. 03E-12-0. 47 -8.36 16p11. 2 22 213514_s_at DIAPH1 -1.84 1. 03E-12 8.67E-10-0. 54-8.29 5q31 23 201920_at SLC20A1 1.95 6. 19E-10 1. 41 E-07 0. 83 8. 23 2q11-q14 24 224481_s_at HECTD1 1.51 5. 66E-10 1.32E-07 0. 77 8. 14 14q12 25 201676_x_at PSMA1 1.47 6. 89E-10 1. 51E-07 0.79 8.14 11p15. 1 26 209523 at TAF2 1. 97 1.25E-09 2.50E-07 0. 85 8. 07 8q24. 12 27 201377_at NICE-4 1. 72 7. 84E-10 1.69E-07 0. 77 8. 061q21. 3 28 224875_at-1. 8C 2. 16E-12 1.46E-09-0. 51-8.01 29 222983 s at PAIP2-1. 45 2. 29E-10 6.53E-08-0. 65-8. 01 5q31. 3 30 221969_at PAX5 -5. 22 2.95E-14 6. 21 E-11-0. 44-7.96 9p13 31 201263atTARS1. 87 1. 47E-09 2.76E-07 0. 78 7. 91 5p13 2 32 201699_at PSMC6 1. 68 1.64E-09 2.94E-07 0. 79 7.89 14q22.1 33 228737 at C20orf100-7. 15 4.68E-14 8. 74E-11-0. 44-7. 89 20q13. 11 34 228664at-2. 37 4. 48E-13 4.43E-10-0. 47-7. 89 35 222902_s_at FLJ21144 1.57 6.41 E-10 1.44E-07 0. 68 7.88 1p34. 1 36 213622 at COL9A2-2. 13 1. 63E-13 1.96E-10-0. 45-7. 87 1 p33-p32 37 226781 at-4. 09 5.49E-14 9. 25E-11-0. 44-7.87 38 212491_s_at DNAJC8 1.49 1.49E-09 2.76E-07 0. 76 7. 86 1 p35. 2 39 212397_at RDX 2.17 2. 65E-09 4.37E-07 0. 84 7. 83 11 q23 40 225635sat-1. 92 4.34E-13 4.43E-10-0. 46-7. 83 41 201994_at MORF4L2 1.41 1.29E-09 2.56E-07 0. 71 7. 78 Xq22 42 227203_at 1. 7c 7. 62E-11 2.62E-08-0. 55-7.76 43 214700 x at DKFZP434D193 2. 21 3.74E-09 5.73E-07 0. 86 7. 76 2q23.3 44 201792_at AEBP1 -3. 92 1.18E-13 1.53E-10-0. 43-7.75 7p13 45 202413_s_at USP1 1.56 7. 97E-10 1.70E-07 0. 64 7.72 1p32.1-p31. 3 46 225223at-1. 88 2. 77E-11 1. 11 E-08-0. 51-7. 70 47 201548_s_at PLU-1 1.70 1.78E-09 3. 15E-07 0.67 7.62 1q32. 1 48 228788_at PPIL2 -2. 36 1.64E-12 1.26E-09-0. 45-7. 62 22q11.21 49 208872satDP1-1. 83 6. 99E-11 2.45E-08-0. 51-7. 59 5q22-q23 50 212058_at SR140 1.55 5.02E-09 7.35E-07 0. 80 7. 59 3q23 1. 9 AML_t(15 ; 17) versus rest # affy id HUGO name fc p q stn t Map Location 1 204425 at ARHGAP4-18. 20 9.73E-84 1.46E-79-1. 51-27. 05 Xq28 2209732atCLECSF2-26. 43 1.38E-79 1.03E-75-1. 43-25. 70 12p13-p12 3 211990_at HLA-DPA1 -9.05 7.33E-58 3.66E-54-1. 34-23. 26 6p21. 3 4 205771_s_at AKAP7 -8.69 8.46E-53 2. 53E-49-1. 32-22. 67 6q23 Table 1 5 213587 s at LOC155066 -6.05 6.13E-57 2.30E-53-1. 10-19. 73 7q36.1 6 227353_at EVER2 -4.23 2.89E-26 2.47E-24-1. 31-19. 28 17q25. 3 7 238949_at FLJ31951 -9.28 3.35E-46 3.14E-43-1. 09-18. 90 5q33.3 8 201753_s_at ADD3 -6.13 6.89E-37 2. 29E-34-1. 14-18. 85 10q24. 2-q24.3 9 226077_at FLJ31951 -6. 11 5.44E-39 2. 91E-36 -1.11 -18.66 5q33.3 10 201923atPRDX4-5. 58 5.55E-33 1.03E-30-1. 15-18. 51 Xp22. 13 11 201137_s_at HLA-DPB1 -9.44 1.98E-51 4. 94E-48-1. 03-18. 44 6p21. 3 12 232617 at CTSS-5. 47 2.85E-49 6. 10E-46 -1. 02-18. 13 1q21 13 236322_at-7. 03 4.86E-37 1.73E-34-1. 07-17.99 14 213106_at -6. 62 1. 18E-42 8.07E-40-1. 03-17.88 15 227598 at LOC113763-5. 31 1.40E-45 1. 17E-42-1. 01-17.84 7q35 16 201534_s_at UBL3 -4. 67 2.32E-42 1. 51 E-39-1. 03-17. 82 13q12-q13 17 201034_at ADD3 -4.85 5.27E-27 4.87E-25 -1.15 -17.71 10q24.2-q24.3 18 204362_at SCAP2 -11.44 4.38E-46 3.86E-43 -1.00 -17.65 7p21-p15 19 201669 s at MARCKS-35. 36 1.65E-48 3.08E-45-0. 99-17. 62 6q22. 2 20 207697_x_at LILRB2 -11.15 3.06E-47 4.17E-44-0. 99-17. 60 19q13. 4 21 201752_s_at ADD3-4. 42 4.34E-34 9.41 E-32-1.06-17. 57 1 ou24. 2-q24.3 22 226106_at ZFP26 -4.23 1. 54E-33 3.09E-31-1. 06-17. 4911p15. 3 23 225386_s at LOC92906-23. 92 3. 00E-48 5. 00E-45-0. 97-17.41 2p22.2 24 211991_s_at HLA-DPA1 -14.34 7.22E-48 1.08E-44 -0.97 -17.38 6p21.3 25 236554_x_at EVER2 -3.68 5.25E-25 3.75E-23 -1.15 -17.25 17q25.3 26 205882_x_at ADD3 -4.17 2.22E-31 3.17E-29 -1.06 -17.20 10q24.2-q24.3 27 204661_at CDW52 -19.50 3.88E-47 4.84E-44 -0.95 -17.14 1p36 28 203948 s at MPO 3. 37 1.17E-16 2. 76E-15 1.47 17.11 17q23.1 29 202901xatCTSS-6. 41 1. 12E-44 8.42E-42-0. 96-17. 031q21 30 210146_x_at LILRB2 -14.78 1.63E-46 1.75E-43-0. 95-17. 00 19q13. 4 31 34210atCDW52-25. 10 1.06E-46 1.22E-43-0. 94-16. 991p36 32"'229041sat-26. 16 2.90E-46 2.90E-43-0. 95-16. 98 33 205382 s at DF 5. 60 3.76E-14 6.09E-13 1.87 16. 90 19p13. 3 34 200931_s_at VCL -4. 01 6.04E-34 1.29E-31-1. 01-16. 85 10q22. 1-q23 35 228370atSNURF-9. 14 5.49E-40 3.16E-37-0. 97-16.81 15q12 36 212953 x at CALR 3. 75 3. 41 E-13 4.83E-12 2. 39 16. 77 19p13. 3-p13. 2 37 214450 at CTSW 10. 82 5. 73E-13 7.84E-12 2. 70 16.71 11q13. 1 38 219593 at PHT2-24. 20 5. 21 E-45 4. 11 E-42-0. 94-16. 6811q12. 1 39 204563 at SELL-6. 14 1.67E-39 9.24E-37-0. 95-16. 501q23-q25 40 226117_at T2BP-3. 5g 9.63E-37 3. 07E-34-0. 96-16. 46 4q25 41 201719 s at EPB41 L2-10. 87 2. 47E-44 1. 76E-41-0. 91-16. 45 6q23 42 38487 at STAB1 13. 57 1.06E-12 1. 38E-11 2. 69 16. 20 3p21. 31 43 203535_at S100A9 -7.49 1.93E-30 2. 52E-28 -0.99 -16.18 1q21 44 221004_s_at ITM2C 6.00 4. 41E-13 6. 14E-12 2.10 16.12 2q37 45 209448_at HTATIP2 -5. 63 5.56E-37 1.94E-34-0. 93-16. 06 11p15. 1 46 217478_s_at HLA-DMA -5. 54 1.02E-36 3.18E-34-0. 93-16. 01 6p21. 3 47 225639_at SCAP2 -9.95 1. 15E-36 3. 51 E-34-0. 92-15. 98 7p21-p15 48 209606atPSCDBP-4. 82 1.75E-29 2.04E-27-0. 98-15. 97 2q11. 2 49 208771_s_at LTA4H -3. 03 6.08E-37 2.07E-34-0. 92-15. 96 12q22 50 223663atFLJ37970-6. 25 7. 79E-22 3.58E-20 -1.09 -15.94 11q12. 3 Table 1 1.10 AMLt (8 ; 21) versus rest # affy id HUGO name fc p q stn t Map Location 1 224764 at ARHGAP10-7. 14 6. 90E-47 1.49E-42-0. 96-17. 27 10 2 221581_s_at WBSCR5 -6. 35 3.33E-44 3.59E-40-0. 94-16. 74 7q11. 23 3 201811_x_at SH3BP5 -6. 29 3.63E-42 2. 61 E-38-0. 94-16.56 3p24.3 4 218236_s_at PRKCN -5. 63 4.73E-34 1. 70E-30-0. 89-15. 23 2p21 5 215087_at -3. 11 3.30E-35 1.52E-31-0. 85-14. 83 6 220066_at CARD15-6. 95 9.26E-34 2.85E-30-0. 82-14. 3916p12-q21 7 203741_s_at ADCY7 -4. 13 2.45E-26 2.20E-23-0. 89-14. 3616q12-q13 8212828atSYNJ2-3. 04 1.57E-27 1.99E-24-0. 87-14.34 6q25.3 9 211084_x_at PRKCN -4. 49 7.08E-22 2. 46E-19-0. 95-14.17 2p21 10 208146 s at CPVL-9. 12 3.53E-35 1. 52E-31-0. 78-14. 08 7p15-p14 11 238012_at -2. 54 5.42E-27 6.47E-24-0. 85-13. 99 12 233849_s_at ARHGAP5 -5. 33 3. 63E-29 6. 00E-26 -0. 80-13. 68 14q12 13 201850 at CAPG-4. 26 7. 07E-31 1.52E-27-0. 77-13.52 2cen-q24 14 201810_s_at SH3BP5 -4. 21 3. 42E-29 6. 00E-26 -0. 79-13.51 3p24.3 15 201425_at ALDH2-6. 8C 2. 07E-25 1.35E-22-0. 82-13. 4912q24. 2 16 212895 s at ABR-2. 97 8. 06E-26 5.98E-23-0. 81-13.41 17p13. 3 17 225615_at LOC126917-4. 25 6.69E-29 1.03E-25-0. 77-13. 32 1 p36. 13 18 217963satNGFRAP1-14. 13 1. 91 E-32 5.13E-29-0. 74-13. 30Xq22. 1 19 203521satZFP318-2. 30 1.79E-31 4. 29E-28-0. 74 -13. 27 6pter-p12. 1 20 204494_s_at DKFZP434H132 -2. 62 1. 39E-26 1.57E-23-0. 78-13. 1915q22. 33 21238790at-4. 46 1.23E-21 4. 01E-19 -0.83 -12.94 22 204495_s_at DKFZP434H132 -2. 72 1. 57E-28 2. 25E-25-0. 74-12. 91 15q22.33 23 210612satSYNJ2-6. 96 2. 80E-28 3.77E-25-0. 74-12. 86 6q25.3 24 213908at-5. 60 1. 77E-30 3.47E-27-0. 71-12. 83 25 211962satZFP36L1-3. 68 3. 55E-22 1.36E-19-0. 79-12. 6814q22-q24 26 225786_at LOC284702 -3. 39 1.85E-26 1.73E-23-0. 72-12. 48 1q44 27 38269 at PRKD2-2. 25 1.02E-24 5. 21E-22 -0. 72-12. 23 19q13. 2 28 218474_s_at FLJ20040 -2.60 6. 86E-19 1.33E-16-0. 81-12. 18 16p13. 3 29 225227_at -3. 64 1. 48E-26 1.59E-23-0. 69-12. 12 30 211965atZFP36L1-3. 73 2. 58E-25 1.54E-22-0. 70-12. 05 14q22-q24 31 207124_s_at GNB5 -6. 61 6. 03E-26 4.64E-23-0. 69-12. 0215q15. 3 32 204000atGNB5-3. 27 2. 22E-25 1.39E-22-0. 68-11. 89 15q15. 3 33 226206 at FLJ32205-2. 11 9. 03E-19 1. 70E-16-0.78-11. 85 7p22. 3 34 203232satSCA1-6. 99 4. 12E-25 2.28E-22-0. 68-11. 85 6p23 35 212423atFLJ90798-3. 30 2.71 E-19 5.94E-17 -0.76 -11.84 10q22. 3 36 218608atHSA9947-5. 77 7.54E-21 2. 22E-18-0. 73-11. 7 1 p36 37 203505atABCA1-5. 91 1. 66E-26 1, 62E-23-0. 66-11. 75 9q31. 1 38 226865_at-3. 93 3. 42E-26 2.94E-23-0. 66-11.74 39 204057 at ICSBP1-3. 98 1. 58E-26 1. 62E-23 -0.65 -11.70 16q24. 1 40 226134-s-at-4. 14 5. 28E-26 4.21 E-23-0. 65-11. 67 Table 1 41 226673 at SH2D3C-4. 13 1. 71 E-21 5.50E-19-0. 71-11. 65 9q34. 12 42 208091_s_at DKFZP564K0822 -10. 61 4. 11 E-26 3.40E-23-0. 64-11.58 7p14. 1 43 202732 at PKIG-2. 61 3.99E-25 2.26E-22-0. 65-11.55 20q12-q13. 1 44 207104_x_at LILRB1 -5. 88 2.26E-25 1.39E-22-0. 65-11. 54 19q13. 4 45 221866atTFEB-3. 05 1.30E-23 5.81 E-21-0. 67-11. 52 6p21 46 202887_s_at RTP801 -3. 16 2.03E-22 7.95E-20-0. 67-11. 43 1 Opter-q26. 12 47 225240sat-3. 79 2.87E-25 1.67E-22-0. 64-11.43 48 207839_s_at LOC51754 -2. 63 5.78E-14 3. 62E-12-0. 92-11. 42 9p13. 1 49 230894sat-5. 79 8.42E-25 4.53E-22-0. 64-11.42 50 240572_s_at -6.74 1. 44E-25 1.03E-22-0. 63-11. 41 1.11 CLL versus rest # affy id HUGO name fc stn t Map Location 1 202503_s_at KIAA0101 -25.91 2. 26E-106 3. 53E-102-1.97-34. 65 15q22. 1 2 202589_at TYMS-30. 97 1. 83E-102 1.43E-98-1. 90-33. 46 18p11. 32 3226936at-10. 02 8.08E-91 4.21 E-87-1.60-28. 76 4208864satTXN-5. 34 6. 51 E-69 4. 24E-66-1. 69-28. 76 9q31 5 204798_at MYB -19. 19 9. 25E-90 3. 61E-86 -1.58 -28.50 6q22-q23 6 203675_at NUCB2 -24. 32 4. 98E-83 1. 56E-79-1. 52-27. 0611p15. 1-p14 7 224838_at FOXP1 4.85 3. 06E-26 5. 45E-25 2. 85 26. 63 3p14. 1 8 218883_s_at FLJ23468 -6.06 2. 10E-82 5. 47E-79-1. 47-26. 39 4q35.1 9 226546_at -10. 03 4. 52E-80 1. 01 E-76-1. 47-26. 15 10 207168_s_at H2AFY -2. 84 1. 66E-37 6. 99E-36-1. 82-26. 06 5q31. 3-q32 11 232232_s_at CT2 -13. 61 2. 64E-79 5.16E-76-1. 42-25.52 6q22.1 12 210613_s_at SYNGR1 -21. 84 1.57E-78 2.73E-75-1. 42-25. 43 22q13. 1 13 219076_s_at PXMP2 -5. 82 5.57E-75 6. 69E-72-1. 43-25. 3912q24. 33 14 201163_s_at IGFBP7 -21. 77 1.55E-76 2.20E-73-1. 40-25. 04 4q12 15 219869_s_at BIGM103 -6. 10 2.18E-77 3. 41E-74 -1.39 -24.97 4q22-q24 16 211626xatERG-7. 75 1.80E-72 1. 65E-69-1. 39-24. 79 21q22. 3 17 228249_at LOC119710 -7. 34 7.52E-75 8. 40E-72-1. 36-24. 52 11p12 18 202441-at'KE04-6. 88 1.22E-75 1.58E-72-1. 36-24. 5010q21-q22 19 213911_s_at H2AFZ -2. 23 1.73E-45 1. 33E-43-1. 55-24. 47 4q24 20 202580xatFOXM1-15. 48 3.70E-73 3. 62E-70-1. 35 -24.12 12p13 21 222036_s_at MCM4 -5. 94 1.16E-73 1. 21E-70 -1. 33-23.97 8q12-q 13 22 202338_at TK1 -4.90 2.05E-69 1. 45E-66-1. 33-23. 70 17q23. 2-q25.3 23 212141_at MCM4 -11. 25 3.83E-72 3. 32E-69-1. 32-23. 66 8q12-q13 24 210052_s_at C20orf1 -11. 05 1. 10E-70 9.05E-68-1. 30-23. 30 20q11. 2 25 222680satRAMP-5. 73 1.86E-70 1. 45E-67-1. 30-23. 30 26 211709satSCGF-26. 57 1. 91E-68 1. 10E-65-1. 33-23. 2719q13. 3 27 206111_at RNASE2 -24. 48 5. 11 E-70 3.80E-67-1. 30-23. 22 14q24.-q31 28 228868xatCDT1-6. 30 9.98E-69 6. 24E-66-1. 29-23. 13 16q24. 3 29 201231_s_at ENO1 -3.30 5.55E-49 5.22E-47-1. 40-23. 02 1 p36. 3-p36.2 30 224428_s_at CDCA7 -13. 78 3.53E-69 2.40E-66-1. 28-22. 99 2q31 31 214501satH2AFY-4. 65 1.53E-56 2. 75E-54-1. 33 -22. 88 5q31. 3-q32 Table 1 32 201310_s_at C5orf13 -16. 96 1. 07E-68 6. 41E-66 -1. 26-22. 74 5q22. 1 33 201200_at CREG -5.23 2.53E-51 3.14E-49-1. 35-22. 651q24 34 213008_at FLJ10719 -11.05 1.32E-67 7. 39E-65-1. 24-22. 3915q25-q26 35 200896_x_at HDGF -2.86 1.53E-50 1. 69E-48-1. 33-22.33 Xq25 36 AFFX-GAPD-2.28 9.68E-30 2.34E-28-1. 68-22. 31 12p13 HUMGAPDH/M33 197 3 at-HG- U133B 37 209267-s-at BIGM103-6. 31 4.25E-67 2. 21E-64 -1. 24-22. 30 4q22-q24 38 228273_at -9. 83 2.72E-67 1.47E-64-1. 24-22. 29 39 229838_at NUCB2 -14. 94 1. 30E-66 6.55E-64-1. 24-22. 2511p15. 1-p14 40 202705_at CCNB2 -12. 73 5. 05E-65 2.47E-62-1. 25-22. 14 15q21. 2 41 210046_s_at IDH2 -4. 52 2. 28E-64 9. 88E-62-1. 23-22. 0715q26. 1 42 202487_s_at H2AV -2.78 7. 25E-56 1. 23E-53-1. 27-21. 93 7p13 43 225927 at 4. 05 1. 40E-23 2. OOE-22 2.24 21.92 44 204026_s_at ZWINT -6.40 8. 17E-65 3. 76E-62-1. 22-21. 8910q21-q22 45 201829_at NET1 -8.70 7. OOE-65 3.32E-62-1. 21 -21.76 10p15 46 229307 at-14. 20 2. 01 E-64 8.97E-62-1. 21 -21.73 47 224578_at TD-60 -2. 36 1. 64E-50 1. 80E-48-1. 28-21. 59 1 p36. 13 48 211714_x_at OK/SW-cl.56 -3. 96 4.58E-61 1. 46E-58-1. 21-21. 55 6p21. 31 49 232233_at CT2 -4.02 1.10E-62 3.99E-60 -1.20 -21.45 6q22.1 50 203949_at MPO -93.51 1.21E-61 3.95E-59 -1.24 -21.42 17q23.1 1. 12 CML versus rest # affy id HUGO name fc p q stn t Map Location 1 205557_at BPI 6.20 2. 63E-34 1. 13E-31 1.97 24.77 20q11. 23-q12 2 212531_at LCN2 7. 09 8. 58E-33 2. 86E-30 1.87 23.37 9q34 3 206676_at CEACAM8 6.91 2. 56E-32 7. 79E-30 1.83 22. 93 19q13. 2 4 201029_s_at CD99 -4. 01 1. 15E-68 2. 04E-64-1. 26-22. 73 Xp22. 32 5 210254_at MS4A3 3.69 1. 18E-34 5. 48E-32 1.46 20. 88 11q12 6 211657_at CEACAM6 5.81 8. 77E-30 1. 64E-27 1. 63 20. 5219q13. 2 7 212268_at SERPINB1 2. 48 1. 18E-36 7. 72E-34 1. 36 20. 37 6p25 8 203757_s_at CEACAM6 7. 19 3. 85E-28 5. 49E-26 1. 70 20. 18 19q13. 2 9 209771 x_at CD24 3. 56 7. 72E-32 1. 92E-29 1. 40 19.57 6q21 10 207269 at DEFA4 4. 93 1. 43E-29 2. 57E-27 1. 46 19.31 8p23 11 202018_s_at LTF 3. 89 1. 48E-30 3. 08E-28 1. 40 19. 19 3q21-q23 12 216379_x_at KIAA1919 3. 71 1. 52E-30 3. 12E-28 1. 39 19. 13 6q22 13 206871_at ELA2 3. 04 7. 21 E-36 4. 10E-33 1. 20 18. 69 19p13. 3 14 203021_at SLPI 5. 34 2. 73E-27 3.44E-25 1.50 18.69 20q 12 15 200858_s_at RPS8-1. 42 4. 80E-37 3. 53E-34-1. 18-18. 681p34. 1-p32 16 210244 at CAMP 11. 41 4. 66E-25 4. 11 E-23 1. 71 18.48 3p21. 3 17 207802_at SGP28 16. 56 1. 44E-24 1. 19E-22 1. 80 18. 48 6p12. 3 18 205513_at TCN1 6. 33 4. 06E-26 4. 24E-24 1.51 18. 2011q11-q12 19 201061_s_at STOM 3.31 3.22E-28 4.66E-26 1.37 18.19 9q34. 1 20 223423_at GPCR1 4.04 5.53E-26 5.67E-24 1.49 18. 03 3q26. 2-q27 Table 1 21 211275_s_at GYG 2. 95 1.84E-27 2. 43E-25 1.38 18.02 3q24-q25.1 22 205863_at S100A12 4.51 2.78E-26 2. 98E-24 1.45 17.94 1q21 23 203936_s_at MMP9 9.25 5.78E-24 4.27E-22 1.73 17.87 20q11. 2-q13. 1 24 201554_x_at GYG 3.38 2.69E-27 3.42E-25 1.36 17.78 3q24-q25.1 25 205653_at CTSG 4.71 2. 41E-26 2. 63E-24 1. 38 17. 59 14q11. 2 26 225958_at M6PR-1. 94 1.20E-40 2.12E-37-1. 03-17. 46 12p13 27"225386satLOC92906353 6.92E-28 9. 32E-26 1.28 17.46 2p22. 2 28 208700_s_at TKT 2.44 7. 51E-27 8.77E-25 1.33 17.43 3p14. 3 29 213503_x_at ANXA2 -3. 61 2.90E-48 2.56E-44-0. 96-17. 3915q21-q22 30 219281 at MSRA 3. 07 4.43E-24 3.36E-22 1.55 17.35 8p23.1 31 221952_x_at KIAA1393 1. 84 1.03E-26 1. 18E-24 1.32 17.31 14q23.1 32 204174 at ALOX5AP 3. 92 2.96E-25 2. 72E-23 1. 41 17. 29 13q12 33 213572_s_at SERPINB1 2.17 8.70E-30 1.64E-27 1.17 17. 15 6p25 34 201590xatANXA2-3. 39 4.56E-47 2.68E-43-0. 95-17. 09 15q21-q22 35 202332atCSNK1E-2. 78 3.77E-42 1. 11 E-38-0. 98-16.99 22q13. 1 36 214575_s_at AZU1 3.89 7. 79E-27 9. 04E-25 1. 24 16. 82 19p13. 3 37 205786_s_at ITGAM 4.05 2.81 E-24 2.24E-22 1.38 16. 70 16p11. 2 38 204351 at S100P 3. 65 2.82E-25 2.61 E-23 1.30 16. 67 4p16 39 208308_s_at GPI 2.47 1.88E-26 2. 10E-24 1.23 16. 64 19q13. 1 40 209772_s_at CD24 6.72 1.58E-23 1.07E-21 1.45 16.63 6q21 41 208699_x_at TKT 2.71 5. 78E-25 4. 97E-23 1. 29 16.51 3p14. 3 42 208650 s at CD24 4. 58 3.75E-24 2. 90E-22 1. 33 16.37 6q21 43 231688 at 5. 26 4.44E-24 3.36E-22 1.33 16.32 44 210427_x_at ANXA2 -3.28 6.56E-44 2. 89E-40-0. 91-16.31 15q21-q22 45 212414 s at SEPT6-3. 01 2.06E-43 7.26E-40-0. 90-16. 22 Xq24 46 200654_at P4HB 1.99 6.47E-32 1. 63E-29 1. 03 16. 22 17q25 47 209369_at ANXA3 7.49 2.22E-22 1.25E-20 1.48 16.11 4q13-q22 48 204670_x_at HLA-DRB5 -3.73 6.06E-42 1.53E-38-0. 90-16.06 6p21. 3 49 206851 atRNASE34. 56 4.62E-23 2. 93E-21 1. 33 15. 8714q24-q31 50 266_s_at CD24 4.21 1.88E-23 1.26E-21 1.28 15. 83 6q21 1.13 normalBM versus rest # affy id HUGO name fc stn t Map Location 1 204285_s_at PMAIP1-6. 31 1.56E-33 1. 36E-29-1. 16-19. 31 18q21. 31 2 204286_s_at PMAIP1 -9. 67 1.96E-44 3.40E-40-0. 95-16. 96 18q21. 31 3 208690_s_at PDLIM1 -3.65 1.76E-25 2.04E-22-0. 96-15. 80 10q22-q26. 3 4 209806_at HIST1H2BK -2.86 7. 39E-20 3.21 E-17-1. 01-15. 67 6p21. 33 5 224767_at -4.72 2.78E-24 2.32E-21-0. 95-15.57 6 217988 at HE110-2. 28 1. 52E-16 3.89E-14-1. 03-15. 24 14q11. 1 7 201595_s_at HT010 -1. 73 2. 11E-16 5. 31 E-14-1. 03-15.23 2q32.1 8 208549_x_at LOC51685 -2.10 8.24E-14 1. 33E-11-1. 08-15. 0014 9 210281_S_AT znf198 -2.92 5. 24E-15 1.05E-12-1. 03-14. 88 13q11-q12 10 238389_s_at -3.25 1.32E-14 2.38E-12 -0. 97-14.12 Table 1 11 210396sat-2. 05 1. 91 E-14 3.35E-12-0. 98-14. 10 12 200631_s_at SET -1.59 2. 03E-10 1. 53E-08-1.14-13. 94 9q34 13 40189_at SET -1.68 3.15E-11 2.94E-09-1. 08-13. 93 9q34 14 36711_at MAFF-6 9c 7.05E-28 1. 11 E-24-0. 81-13.90 22q13. 1 15 202722_s_at GFPT1 -1.67 9.68E-18 3.12E-15-0. 89-13. 83 2p13 16 214455 at HIST1 H2BC-7. 59 6. 41 E-24 5. 06E-21-0. 83-13. 81 6p21. 3 17 242832_at PER1 -8.79 5. 00E-30 1. 45E-26-0. 78-13. 71 17p13. 1-17p12 18 212099_at -3.38 1. 01 E-26 1.46E-23-0. 80-13. 64 19 202018_s_at LTF 3.03 2.20E-08 9.51 E-07 1. 37 13.56 3q21-q23 20 208754_s_at NAP1L1 -2.09 3.81E-13 5.06E-11 -0.96 -13.54 12q21.1 21 215111_s_at TSC22 -3.87 1.40E-30 5.66E-27 -0.77 -13.50 13q14 22 201830 s at NET1-3. 38 1.44E-28 2.78E-25-0. 77-13. 3610p15 23 201015_s_at JUP -10. 37 1.63E-30 5.66E-27-0. 75-13. 25 17q21 24 226608_at SAS10 -2. 32 5.03E-15 1.03E-12-0. 88-13. 20 4q13. 3 25 204900xatSAP30-3. 87 2.80E-24 2.32E-21-0. 78-13. 17 4q34.1 26"222067xatH) ST1H2BD-3. 92 1.25E-29 3.09E-26-0. 74-13.12 6p21. 3 27 201416_at SOX4 -4.96 3.25E-31 1.88E-27-0. 72-13. 03 6p22.3 28 204011_at SPRY2-5. 45 1. 61 E-24 1.47E-21-0. 76-13. 01 13q22.1 29 201417-at-3. 15 2.06E-23 1.56E-20-0. 76-12.89 30 212241_at GGRINL1A -1.75 6.17E-12 6. 54E-10-0. 94-12. 8415q22. 1 31 224763_at MAPK81P2 -2. 24 1. 04E-22 7. 25E-20-0. 76-12. 80 22Q13. 33 32 218224_at PNMA1-2. 5E 1.38E-22 9.24E-20-0. 76-12. 7514q24. 1 33 238333_s_at LOC92170 -3. 32 6.53E-25 6.31 E-22-0.74-12. 71 10q26. 3 34 218247_s_at LOC51320 -2. 94 8.59E-14 1. 37E-11 -0.86 -12.68 18q21.1 35 204805_s_at TGM2 -2. 83 2. 07E-10 1.56E-08-0. 99-12.67 20q12 36 209398_at HIST1H1C -5. 05 5. 30E-29 1. 15E-25-0. 71-12.61 6p21. 3 37 232322xatSTARD10-3. 45 3.06E-26 3.80E-23-0. 72-12. 60 11q13 38 208546_x_at HIST1H2BH -4.13 2. 97E-15 6. 37E-13-0. 83-12.60 6p21. 3 39 230894_s_at -7.50 6. OOE-28 1. 04E-24-0. 71-12.52 40 215411 s at C6orf4-2. 68 6. 95E-13 8. 82E-11-0. 87-12. 44 6q21 41 207121_s_at MAPK6 -1.96 8. 17E-17 2. 29E-14 -0.79 -12.44 15q21 42 201917_s_at FLJ10618 -2. 67 4. 14E-09 2.26E-07-1. 07-12.41 3q23 43 221517_s_at CRSP6 -3. 14 2*15E-12 2. 49E-10-0. 88-12. 4011q14 44 234875_at -1. 61 4. 57E-11 4. 08E-09 -0.93 -12.39 45 212420atELF1-2. 48 3. 25E-11 3. 02E-09 -0.92 -12.37 13q13 46 222594_s_at FLJ13117 -4.38 1.59E-26 2.12E-23-0. 70-12. 31 12q13. 12 47 222669_s_at SBDS -2.30 3. 39E-13 4. 60E-11-0. 84-12. 26 7q11. 21 48 236193_at HIST1H2BC -5.21 2. 44E-16 6. 06E-14-0. 78 -12. 22 6p21. 3 49 217722_s_at NEUGRIN -1. 82 2.86E-21 1. 65E-18-0. 72-12. 14 15q26. 1 50 204203atCEBPG-2. 10 6. 92E-11 5. 81 E-09-0. 91-12. 13 19q13. 11 Table 2 2. All-Pairs (AP) 2.1 ALL MLL versus ALL Ph+ # affy id HUGO name fc p q stn t Map Location 1 204069_at MEIS1 40. 29 5.62E-09 1. 88E-05 2. 62 11. 17 2p14-p13 2 225637_at FLJ20186 -5. 19 1. 98E-11 6.45E-07-1. 66-10. 17 16q24. 3 3 225563_at LOC255967 3.83 3.77E-09 1. 61E-05 1.88 10.11 13q12. 13 4 201874_at MPZL1 2.42 1.23E-09 9. 99E-06 1.79 10.11 1q23. 2 5 34210_at CDW52 -12.07 6.62E-10 7.19E-06-1. 74-9. 751p36 6 227353 at EVER2-3. 59 2. 04E-10 3. 32E-06-1. 61-9.61 17q25. 3 7 219463_at C20orf103 38. 91 3.65E-08 5. 66E-05 2. 00 9. 54 20p12 8 205055_at ITGAE 2. 37 1.76E-09 1. 08E-05 1.64 9.49 17p13 9 242414_at 5.63 4.41 E-08 6. 38E-05 1. 90 9. 31 10204661atCDW52-12. 08 3.94E-09 1. 61E-05 -1. 62-8. 97 1p36 11 219033_at FLJ21308 3.85 3.18E-08 5. 45E-05 1.57 8. 64 5q11.1 12 223046_at EGLN1-5. 85 5.78E-09 1. 88E-05-1. 52-8. 64 1q42. 1 13 221969_at PAX5 3. 91 5. 91 E-08 7.70E-05 1.61 8.58 9p13 14 231887_s_at KIAA1274 -3.44 1.99E-09 1. 08E-05 -1.41 -8.50 10q22. 1 15 233500_x_at LLT1 7. 57 1.20E-07 1. 13E-04 1.65 8.44 12p13 16 200871_s_at PSAP -3. 70 1.12E-08 2.61 E-05-1. 43-8. 25 10q21-q22 17 208146 s at CPVL-5. 60 1.22E-08 2.66E-05-1. 35-7. 97 7p 15-p14 18 230643_at -5. 24 8.72E-09 2. 23E-05-1. 32-7.94 19 209822_s at VLDLR 9. 55 4.67E-07 2. 46E-04 1. 63 7. 90 9p24 20 228083_at CACNA2D4 9.51 1. 75E-07 1. 50E-04 1.44 7.85 12p13. 33 21 202853_s at RYK-4. 11 1.32E-08 2. 68E-05-1. 29-7.78 3q22 22238021sat5. 82 2.18E-07 1. 69E-04 1. 43 7. 76 23 239214 at 5. 58 3.74E-07 2. 20E-04 1. 47 7. 69 24204328atEVER1-2. 28 7.40E-09 2. 19E-05-1. 22-7. 6017q25. 3 25 227584_at -3.91 1.87E-08 3. 57E-05-1. 24-7.53 26 225703 at KIAA1545 2. 14 4.69E-08 6. 38E-05 1.26 7.53 12q24. 33 27 218966_at MY05C-4. 31 1.19E-07 1.13E-04-1. 37-7. 48 15q21 28 224252_s_at FXYD5 -1. 83 8.90E-09 2. 23E-05-1. 19-7. 44 19q12-q13.1 29 225912_at TP53INP1 -9.01 1. 44E-07 1.27E-04-1. 37-7.42 8q22 30 243756_at 2.99 6.31 E-08 7.81 E-05 1.22 7.35 31 238022 at 4. 46 3.45E-07 2. 11 E-04 1. 32 7. 34 32201105atLGALS16. 98 3.78E-07 2. 20E-04 1. 31 7. 30 22q13. 1 33 204044_at QPRT 6. 09 1.55E-06 5. 00E-04 1.53 7.25 16p12. 1 34 217967_s_at C1 orf24-3. 77 7.57E-08 8. 51 E-05-1. 22-7. 241q25 35 200953_s_at CCND2 -7. 08 3.07E-07 1.96E-04-1. 38-7. 17 12p13 36 228046_at LOC152485 -4. 47 6.47E-08 7. 81 E-05-1. 19-7. 16 4q31.1 37 222868_s_at IL18BP -2. 33 1.09E-07 1. 11E-04 -1. 21-7. 14 11q13 38 224772_at NAV1 -4. 63 1.26E-07 1. 14E-04-1. 23-7.14 39 201875 s at FLJ21047 1. 98 3. 06E-08 5. 45E-05 1.14 7.13 1q23. 2 40 221497_x_at EGLN1 -4.07 1.02E-07 1.07E-04 -1.19 -7.09 1q42.1 Table 2. 1-2.78 41 209170sat GPM6B 12.86 2. 25E-06 6. 47E-04 1.51 7. 07 Xp22. 2 42 215925_s_at CD72 6.14 1. 06E-06 4.06E-04 1. 31 7.03 9p13. 1 43 219686_at HSA250839 -20. 05 4.36E-07 2. 45E-04-1. 36-7. 02 4p16. 2 44 242172 at 8. 83 2. 56E-06 6. 89E-04 1. 52 7. 02 45 214022_s_at MGC27165 -4.60 2.08E-07 1.69E-04-1. 22-7.01 14 46 206099_at PRKCH-2. 92 8. 45E-08 9. 17E-05-1. 15-6. 9914q22-q23 47 202052_s_at RAI14 -9. 02 2.98E-07 1. 96E-04 -1.24 -6.97 5p13.3-p13. 2 48 229390_at -3.38 4. 70E-08 6. 38E-05-1. 11-6.94 49 243618 s at LOC152485-13. 40 5.38E-07 2.73E-04-1. 33-6. 91 4q31. 1 50 205672_at XPA -2. 67 3. 58E-08 5. 66E-05-1. 09-6. 88 9q22.3 2. 2 ALL MLL versus ALL T-lineage # affy id HUGO name fc stn t Map Location 1 213539_at CD3D -31.00 1.82E-12 3. 82E-08-2. 63-13. 771') q23 2 226496 at FLJ22611 14. 40 1. 35E-10 6. 46E-07 2. 77 13.62 9p12 3 225314 at MGC45416-7. 94 5. 21E-12 4. 36E-08-2. 32-12. 70 4p11 4 221969_at PAX5 28.36 2. 90E-09 3.24E-06 2.56 11. 58 9p13 5 231902_at LOC152485 -3.59 3. 71E-12 4. 14E-08-1. 78-10. 87 4q31. 1 6 204069_at MEIS1 20. 91 6. 05E-09 5. 47E-06 2.27 10.80 2p14-p13 7 202789 at-4. 91 2. 28E-12 3. 82E-08-1. 74-10. 75 8 226878_at 4. 57 1. 54E-09 2. 14E-06 1. 97 10.63 9 244876_at 4.11 6. 86E-10 1. 35E-06 1.89 10.60 10 228046 at LOC152485-13. 63 2. 82E-10 9.53E-07-1. 95-10. 50 4q31. 1 11 226764_at LOC152485 -40.14 5.60E-10 1.17E-06 -2.13 -10.42 4q31.1 12 225563_at LOC255967 3.91 3.16E-09 3.35E-06 1.88 10.16 13q12.13 13 226459_at FLJ35564 9. 08 1. 61E-08 1. 02E-05 2. 06 10. 02 10q23. 33 14 212827 at IGHM 8. 78 7. 57E-09 6. 29E-06 1.81 9.73 14q32. 33 15 219463_at C20orf103 47.99 4. 07E-08 1. 97E-05 2.18 9.66 20p12 16 222895_s_at BCL11B -18.24 1.05E-09 1. 67E-06-1. 75-9. 66 14q32.31 17 217800_s_at NDFIP1 -8. 14 8. 87E-10 1. 48E-06-1. 68-9. 54 5q31. 3 18 209619_at CD74 5.84 3. 85E-10 9.53E-07 1. 58 9.51 5q32 19 201029_s_at CD99 -2.02 2. 02E-11 1.35E-07-1. 48-9. 37 Xp22. 32 20 225703_at KIAA1545 2.80 1.39E-09 2. 02E-06 1. 58 9. 31 12q24.33 21 219033_at FLJ21308 4.97 8. 32E-09 6. 47E-06 1.67 9.28 5q11. 1 22 222422_s_at NDFIP1 -5. 31 5. 36E-11 2.99E-07-1. 48-9. 26 5q31. 3 23 239214-at 21. 85 6. 68E-08 2. 79E-05 1. 96 9. 19 24 217478_s_at HLA-DMA 6.60 2. 87E-08 1. 67E-05 1.76 9.18 6p21. 3 25 201720_s_at LAPTM5 3.09 3. 49E-10 9. 53E-071'509. 181p34 26228007at-5. 15 3. 99E-10 9.53E-07-1. 52-9. 18 27 233500_x_at LLT1 13.73 6. 23E-08 2.71 E-05 1. 92 9. 17 12p13 28 244189_at -2. 57 4. 96E-10 1. 11E-06 -1. 53-9. 16 29 204949 at ICAM3-5. 90 1. 96E-09 2. 52E-06-1. 60-9. 1319p13. 3-p13. 2 30 208788_at HELO1 -3. 24 3. 86E-10 9. 53E-07 -1.50 -9.10 6p21.1-p12. 1 31 218205_s_at MKNK2 3.26 2. 72E-08 1. 62E-05 1.72 9.09 19p13. 3 Table 2. 1-2. 78 32 211990_at HLA-DPA1 5. 15 2.17E-09 2. 69E-06 1. 51 8. 98 6p21. 3 33 214172 x at RYK-3. 93 8.55E-10 1. 48E-06-1. 49-8.93 3q22 34 225637 at FLJ20186-4. 42 2.92E-10 9.53E-07-1. 44-8. 92 16q24. 3 35 209374 s at IGHM 9. 33 2.94E-08 1. 67E-05 1.65 8.89 14q32. 33 36 217979 at NET-6 5. 71 1. 13E-08 8. 02E-06 1. 57 8. 89 7p21. 1 37 227353_at EVER2 -4. 33 3.30E-09 3. 35E-06-1. 55-8. 86 17q25. 3 38 207697_x_at LILRB2 5. 39 8.94E-09 6. 80E-06 1.54 8.83 19q13. 4 39 227247-at-3. 82 1.34E-09 2. 02E-06-1. 48-8.81 40 205689_at KIAA0435 -5. 41 2. 10E-10 8.78E-07-1. 41-8.81 1q42. 2 41 243756 at 4. 17 5. 86E-09 5. 45E-06 1. 50 8. 76 42215925satCD7269. 67 1.93E-07 5. 71E-05 2.03 8.66 9p13. 1 43 206804 at CD3G-26. 40 1.48E-08 9. 88E-06-1. 70-8. 64 11 q23 44 209536_s_at EHD4 3. 82 4.72E-08 2. 16E-05 1.60 8.62 15q11. 1 45 218764_at PRKCH -5. 38 2.38E-09 2.74E-06-1. 44 -8.59 14q22-q23 46218942atFLJ22055-5. 52 1.65E-09 2. 21E-06 -1. 41-8. 5212q13. 13 47 224710 at RAB34 5. 30 3.28E-09 3. 35E-06 1.41 8.50 17q11. 1 48 241871_at -12. 12 1.62E-08 1.02E-05-1. 57-8. 45 49 202853_s_at RYK -5.98 8.11E-09 6. 46E-06-1. 48-8. 44 3q22 50 244261_at IL28RA 20. 36 2. 00E-07 5. 79E-05 1.75 8.42 1p36.11 2.3 ALL_MLL versus ALL_t(8; 14) # affy id HUGO name fc p q stn t Map Location 1 225563_at LOC255967 8. 73 6.43E-10 2. 51E-06 2.76 12.61 13q12. 13 2 204798_at MYB 7.19 8.01 E-11 9.21 E-07 2. 42 12. 36 6q22-q23 3 203373_at SOCS2 34. 53 1.89E-09 3. 78E-06 2.66 11.88 12q 4 215537_x_at DDAH2 9.01 4.55E-10 2. 23E-06 2. 30 11. 56 6p21. 3 5 212207_at KIAA1025 4.99 1. 12E-10 9. 21E-07 2.21 11.52 12q24. 22 6 204069_at MEIS1 25. 72 6.19E-09 1.01 E-05 2.47 10.97 2p14-p13 7 212481_s_at TPM4 4.25 2.13E-09 3. 78E-06 2.20 10.84 19p13. 1 8 214909 s at DDAH2 6. 07 1.77E-09 3. 78E-06 2. 16 10. 78 6p21. 3 9 226496 at FLJ22611 5. 39 1. 41 E-10 9. 21 E-07 2. 00 10. 69 9p12 10 242414 at 11. 83 9.79E-09 1. 25E-05 2.23 10.38 11 204446_s_at ALOX5 -9. 94 1.52E-07 6. 31E-05-2. 33-10. 1510q11. 2 12 224710 at RAB34 8. 55 1.65E-09 3. 78E-06 1.94 10.08 17q11. 1 13 201417 at 5. 18 1.99E-09 3. 78E-06 1. 89 9. 84 14 214623_at FBXW3 6. 32 8.93E-10 2.91 E-06 1.84 9.79 22q11 15 202853 s at RYK-4. 14 1.40E-08 1.44E-05-1. 86-9.51 3q22 16 225314_at MGC45416 -4.42 1.90E-07 7.01E-05 -2.05 -9.45 4p11 17 201015_s_at JUP 12.01 1.09E-08 1.25E-05 1.85 9.39 17q21 18 217168 s at HERPUD1 -3. 41 1. 98E-08 1. 84E-05-1. 83-9. 3616q12. 2-q13 19 219033_at FLJ21308 4.85 1.24E-08 1. 35E-05 1.85 9.35 5q11. 1 20 202262 x at DDAH2 6. 26 9.29E-09 1. 25E-05 1.82 9.31 6p21. 3 21 217979_at NET-6 6.04 1.52E-08 1. 48E-05 1.84 9.26 7p21. 1 22 211671_s_at NR3C1 5.47 7.11E-08 3. 97E-05 1.93 9.02 5q31 Table 2. 1-2. 78 23 223276_at NID67 8.58 2.52E-08 2.14E-05 1.76 8.93 5q33.1 24 238750_at 7.48 4.85E-08 3.49E-05 1.80 8.86 25 228083 at CACNA2D4 19. 61 1.53E-07 6. 31E-05 1.99 8.76 12p13. 33 26 204759 at CHC1L 4. 46 1. 08E-08 1. 25E-05 1.64 8.69 13q14. 3 27 202887_s_at RTP801 4.51 5. 72E-08 3.50E-05 1. 73 8. 6410pter-q26. 12 28 231982_at 27.52 1.75E-07 6.57E-05 1.92 8.62 29 201540_at FHL1 10. 02 1. 58E-07 6. 32E-05 1. 83 8. 54 Xq26 30 213792_s_at INSR 12. 42 1. 55E-07 6. 31 E-05 1. 81 8. 51 19p13. 3-p13. 2 31 221581_s_at WBSCR5 5.53 7.81 E-08 4.12E-05 1. 71 8.50 7q11. 23 32 212208 at KIAA1025 4. 42 7. 34E-08 3. 98E-05 1.68 8.44 12q24. 22 33 201416_at SOX4 6.00 2. 82E-08 2. 30E-05 1. 62 8. 43 6p22.3 34 203796_s_at BCL7A 3.98 5. 77E-08 3. 50E-05 1.66 8.43 12q24. 13 35 224681 at GNA12 6. 23 1. 31 E-07 5. 69E-05 1. 69 8. 31 7p22-p21 36 203372_s_at SOCS2 48. 70 3. 33E-07 1. 10E-04 1.94 8.30 12q 37 226668_at FLJ36175 3.85 5. OOE-08 3. 49E-05 1.57 8.18 2q24.2 38 201865_x_at NR3C1 4.48 1.97E-07 7. 14E-05 1.66 8.11 5q31 39 225592_at NRM 2. 57 5. 33E-08 3. 50E-05 1. 54 8. 06 6p21. 31 40 209267_s_at BIGM103 5.79 2.66E-07 9. 12E-05 1.68 8.06 4q22-q24 41 226043_at AGS3 5. 84 1.12E-07 5. 62E-05 1.58 8.05 9q34.3 42212509sat15. 08 4.62E-07 1. 33E-04 1. 81 8. 04 43 239214 at 6. 87 2.21 E-07 7. 70E-05 1.64 8.03 44 226528 at-4. 18 7.47E-07 1.87E-04-1. 67-8.02 45 209822 s at VLDLR 10. 39 4.48E-07 1. 31 E-04 1. 78 8. 02 9p24 46 205055_at ITGAE 2.35 1.01 E-08 1. 25E-051*468'01 17p13 47 204044 at QPRT 12. 88 4.33E-07 1. 31E-04 1.76 8.01 16p12. 1 48 202481_at SDR1 5.94 5. 80E-08 3. 50E-05 1.53 8.00 1p36. 1 49 220987_s_at SNARK -2.88 3.88E-07 1. 24E-04-1. 59-7. 95 1q32. 1 50 209112_at CDKN1B 2.57 4. 93E-08 3. 49E-05 1.47 7.82 12p13.1-p12 2.4 ALL_MLL versus AML MLL # affy id HUGO name fc stn t Map Location 1211404satAPLP2-5. 96 6. 57E-19 1. 69E-14-2.16-15. 05 11q24 2208702xatAPLP2-8. 08 2. 12E-16 1.95E-12-2. 22 -14.46 11 q24 3 214875_x_at APLP2 -7.65 5. 77E-15 2. 41E-11 -2.10 -13.30 11q24 4200742satCLN2-4. 08 2. 28E-16 1. 95E-12 -1.85 -12.86 11p15 5 201858_s_at PRG1 -2.96 1. 90E-14 6. 10E-11-1. 75-12. 01 10q22. 1 6 217800_s_at NDFIP1 -11.20 5.64E-14 1. 61E-10 -1. 84-12. 00 5q31. 3 7 204122_at TYPOBP -9.13 9. 55E-14 2. 04E-10-1. 87-11. 97 19q13. 1 8 41220_at MSF 2. 81 1. 96E-11 8. 54E-09 1.93 11.95 17q25 226496_at FLJ22611 7. 7 2. 98E-11 1. 09E-08 1.90 11.73 9p12 10 225703 at KIAA1545 3. 89 4. 55E-10 9. 83E-08 2. 10 11. 6912q24. 33 11 225775_at 3.93 6. 11 E-12 3. 74E-09 1. 80 11. 60 12 206111_at RNASE2 -5. 21 1. 85E-15 1. 19E-11-1. 63-11. 5514q24-q31 13 244876_at 4. 6E 9. 76E-10 1. 78E-07 2.13 11.48 Table 2. 1-2.78 14 221969 at PAX5 22. 69 3.24E-09 4.54E-07 2.47 11. 47 9p 13 15 200743_s_at CLN2 -2.86 6. 58E-15 2. 41E-11 -1.61 -11.36 11p15 16 212207 at KIAA1025 3. 98 9.91 E-10 1. 78E-07 2. 08 11. 35 12q24. 22 17 219013_at GALNT11-6. 74 1. 33E-13 2. 45E-10-1. 68-11. 277q34-q36 18 227853_at -5. 79 6. 43E-15 2. 41E-11 -1.59 -11. 23 19 223120_at MGC1314 -3. 91 7.16E-14 1. 67E-10-1. 64-11. 20 6q24 20 205639_at AOAH -21.77 8.63E-13 9. 23E-10-1. 80-11. 19 7p14-p12 21 229215_at ASCL2-9. 01 3.50E-13 5.00E-10 -1. 66-11. 0211p15. 5 22213116atNEK3-5. 48 1.86E-13 3. 18E-10-1. 62-10. 96 13q14. 13 23 203799_at BIMLEC -5. 01 2. 27E-13 3. 44E-10-1. 58-10.76 2q24.2 24 222422 s_at NDFIP1-9 9E 5. 33E-13 6. 85E-10-1. 59-10. 70 5q31. 3 25 214181_x_at LST1 -7. 23 1.30E-12 1.24E-09-1. 63-10. 66 6p21. 3 26 230015_at 9.33 6.50E-09 7. 52E-07 2. 10 10. 61 27 210314_x_at TNFSF13 -6.33 1.19E-13 2. 34E-10-1. 52-10. 60 17p13. 1 28 211581_x_at LST1 -5. 45 4. 96E-13 6. 71E-10 -1. 56-10.60 6p21. 3 29 225563_at LOC255967 4. 40 1. 81 E-09 2.93E-07 1. 87 10. 59 13q12. 13 30209500xatTNFSF13-5. 42 5.69E-13 6. 96E-10-1. 55-10. 52 17p13. 1 31 211474_s_at SERPINB6 -5. 31 9.80E-13 9. 68E-10-1. 56-10. 49 6p25 32 200975 at PPT1-3. 28 7.16E-14 1. 67E-10-1. 49-10. 47 1p32 33 217979_at NET-6 10.43 8. 86E-09 9. 81E-07 2.07 10.42 7p21.1 34 218942_at FLJ22055-6. 32 2. 24E-13 3. 44E-10-1. 50-10.41 12q13. 13 35 211582_x_at LST1 -6. 14 1.45E-12 1. 28E-09-1. 56-10.40 6p21. 3 36 200871_s_at PSAP -5. 81 4.34E-12 2. 86E-09-1. 60-10.32 10q21-q22 37 202788_at MAPKAPK3-2. 80 7. 60E-13 8. 48E-10-1. 51-10.30 3p21. 3 38 215633_x_at LST1 -6.86 5. 11 E-12 3. 28E-09 -1. 59-10.26 6p21. 3 39 243756 at 5. 45 6.16E-09 7. 27E-07 1. 89 10. 22 40 214574 x_at LST1-5. 95 3.56E-12 2. 54E-09-1. 55-10. 19 6p21. 3 41 210629_x_at LST1 -4. 83 2.78E-12 2. 16E-09-1. 50-10.07 6p21. 3 42 235033_at -3. 62 1.76E-12 1. 50E-09-1. 48-10.07 43 223168_at ARHU -8. 52 1. 23E-11 6. 08E-09-1. 58-10. 01 1q42. 11-q42.3 44 222764 at ASRGL1-13. 69 1. 06E-11 5.50E-09 -1.55 -9.99 11q12. 2 45 216041_x_at GRN -7.06 6. 60E-12 3.85E-09 -1. 51-9. 9817q21. 32 46 204971_at CSTA -6. 40 2.95E-12 2. 18E-09-1. 46-9.92 3q21 47 203796_s_at BCL7A 6.49 1.68E-08 1. 63E-06 1.95 9.92 12q24. 13 48 202382_s_at GNPI -13. 15 1. 28E-11 6. 21 E-09-1. 54-9.90 5q21 49 203041_s_at LAMP2 -4. 02 2.35E-12 1. 89E-09-1. 45-9.89 Xq24 50200661atPPGB-6. 06 4. 07E-12 2. 75E-09-1. 46 -9.86 20q13. 1 2. 5 ALL MLL versus AML inv (16) # affiy id HUGO name fc p q stn t Map Location 1 203949_at MPO-16. 62 1. 02E-25 2.78E-21 -4. 54-28. 7517q23. 1 2 203948_s_at MPO -27.99 1. 12E-18 7. 64E-15-3. 97-22. 74 17q23.1 3 203973_s at CEBPD-15. 58 1.92E-17 8. 71E-14-3. 22-19.06 8p11. 2-p11. 1 4 203585_at ZNF185 -5.46 3.42E-19 3. 11E-15-2. 92-18.38 Xq28 Table 2. 1-2.78 5 208702xat APLP2-6. 85 1.54E-16 5.99E-13-2. 78-16. 83 11q24 6 200953_s_at CCND2 -7.78 1. 62E-15 4.03E-12-2. 88-16. 66 12p13 7 208248_x_at APLP2 -5.07 3. 26E-19 3. 11E-15 -2. 56-16.51 11q24 8 225789_at CENTG3 -6.00 5. 47E-18 2. 98E-14-2. 51-16.01 7q36.1 9 204949_at ICAM3-8. 53 1. 08E-15 2.95E-12-2. 67-15. 9919p13. 3-p13. 2 10 224918_x_at MGST1 -41. 86 1.10E-13 1. 11E-10 -2. 84-14. 9012p12. 3-p12. 1 11 204661_at CDW52 -17. 50 2.69E-14 3. 19E-11-2. 53-14. 71 1p36 12 231310 at-7. 69 1.14E-14 1. 94E-11-2. 38-14.35 13 205382 s at DF-21. 30 2.28E-14 2. 83E-11-2. 37-14. 19 19p13. 3 14 200951_s_at CCND2 -19. 84 3. 59E-13 2. 88E-10-2. 59-13. 98 12p13 15 226496_at FLJ22611 16. 06 1. 68E-10 3. 52E-08 2.95 13.85 9p12 16 200665_s_at SPARC -10. 29 2.78E-13 2. 45E-10-2. 46-13.81 5q31. 3-q32 17 34210_at CDW52 -16. 29 1.46E-13 1. 38E-10-2. 34-13. 65 1p36 18 231736 x at MGST1-33. 49 1.22E-12 7. 10E-10-2. 55-13.34 12p12. 3-p12. 1 19 200661_at PPGB -5. 09 6. 64E-16 2.26E-12-2. 07-13.32 20qu3. 1 20 204214 s at RAB32-5. 51 1.38E-14 2. 09E-11-2. 12-13.22 6q24.2 21 228058_at LOC124220 -16. 46 6.53E-13 4. 21 E-10-2. 34-13. 22 16p13. 3 22201012atANXA1-3. 30 7.47E-16 2.27E-12-2. 04-13. 19 9q12-q21. 2 23214875xatAPLP2-7. 18 8. 07E-13 5. 01E-10-2. 32-13. 1011q24 24 201605_x_at CNN2 -2. 56 4.75E-14 5. 40E-11-2. 09-13. 08 21q11. 1 25 211404_s_at APLP2 -5. 52 1.57E-14 2. 26E-11 -2.09 -1307 11q24 26 204563 at SELL-9. 20 6.05E-13 4. 07E-10-2.24-12. 97 1q23-q25 27 223120_at MGC1314 -3. 25 4. 49E-15 1. 02E-11 -1. 99-12.74 6q24 28 204122_at TYROBP -9. 86 1. 51 E-12 8. 26E-10-2. 26-12. 73 19q13. 1 29 38487_at STAB1 -5. 69 2. 17E-14 2. 82E-11-2. 02-12. 71 3p21. 31 30208704xatAPLP2-4. 72 9.68E-15 1. 76E-11 -2.00 -12.69 11q24 31 224391_s_at CSE-C -4. 15 2. 34E-13 2.13E-10-2. 09-12. 65 11q24 32 224583 at COTL1-6. 46 5. 37E-13 3.75E-10-2. 10-12. 53 16q23. 3 33 233177 s at MR-1-2. 65 8. 00E-15 1. 68e-11 -1. 95-12. 49 2q35 34 97 4.55E-13 3.34E-10-2. 00-12. 3715q26 229776_at SLC21A11 -3. 62 9. 90E-14 1. 04E-10-1. 98-12. 32 35 208683_at CAPN2 -6. 1q41-q42 24 4.67E-12 1.99E-09-2. 23-12. 36 217849_s_at CDC42BPB -19. 3 37 224252_s at FXYD5-2. 41 8. 65E-15 1. 69E-11-1. 89-12. 1819q12-q13. 1 38 225602 at C9orf19-4. 46 3. 45E-13 2.85E-10-1. 98-12. 15 9p13-p12 39 201360_at CST3-47. 02 9.47E-12 3.69E-09-2. 37-12. 15 20p11. 21 40 200871 s at PSAP-5. 68 2. 28 14q32. 1.24E-09-2. 07-12. 0610q21-q22 51E-12 19 2. 54E-12 1.24E-09-2. 03-11. 931q25 42 225563 at LOC255967 6. 31 1.13E-09 1. 41 217967_s_at C1orf24 -7. 13 60E-07 2.41 11.91 13q12. 02 4. 28E-13 3. 43 225510_at -7. 30E-10 -1. 92-11.85 44 217989_at RetSDR2 -2. 51 1. 31 E-14 2. 09E-11-1. 83-11.84 4q21. 3 45 203373_at SOCS2 27. 97 2.02E-09 2.51 E-07 2. 53 11. 78 12q 46 200975 at PPT1-2. 91 2. 01 E-14 2. 74E-11-1. 82-11.76 1 p32 47 208891_at DUSP6 -5. 31 1.24E-13 1. 21E-10 -1.86 -11.75 12q22-q23 48 221059_s_at CHST6 -5. 45 3. 03E-12 1.45E-09-1. 98-11. 72 16q22 49 215706_x at ZYX-3. 63 5.65E-14 6. 17E-11-1. 82-11. 65 7q32 50 221969_at PAX5 30.98 3.01 E-09 3. 44E-07 2.68 11. 65 9p13 Table 2. 1-2. 78 2.6 ALL_MLL versus AML inv (3) # affy id HUGO name fc p q stn t Map Location 1 204949_at ICAM3 -8. 93 1. 24E-10 1.20E-06-2. 52-12. 6919p13. 3-p13. 2 2 226496_at FLJ22611 7. 58 9. 89E-11 1. 20E-06 2. 28 12. 14 9p12 3 221969_at PAX5 22. 08 3. 48E-09 4. 28E-06 2. 59 11. 47 9p13 4210024satUBE2E3-9. 74 6. 65E-10 2. 19E-06-2.16-11. 16 2q32. 1 5244876at4. 15 1. 83E-09 3. 78E-06 2. 22 11. 11 6 227353_at EVER2 -4. 65 6. 76E-10 2. 19E-06-2.07-10. 90 17q25. 3 7 225563_at LOC255967 4.55 2. 41 E-09 4. 25E-06 2. 16 10. 8813q12. 13 8 204214_s_at RAB32 -3. 49 2. 09E-11 6.31 E-07-1. 77-10. 35 6q24. 2 9 202888_s_at ANPEP -7.88 3. 17E-09 4.28E-06-1. 93-10. 06 15q25-q26 10 219033_at FLJ21308 5.51 1.02E-08 8.09E-06 1.94 9.83 5q11. 1 11 219463 at C20orf103 143. 42 3. 52E-08 1. 71 E-05 2. 36 9. 82 20p12 12217963satNGFRAP1-31. 63 1. 87E-08 1. 15E-05-2. 17-9.81 Xq22.1 13 222422_s_at LOC124220 -7. 63 3. 69E-09 4. 28E-06-1. 85-9.81 16p13. 3 14 203725_at GADD45A -3. 72 5. 62E-10 2.19E-06-1. 72-9. 72 1 p31. 2-p31. 1 15 218942_at FLJ22055-6. 70 1. 88E-09 3. 78E-06-1. 78-9. 71 12q13. 13 16221752atSSH1-2. 81 2.56E-10 1. 54E-06-1. 69-9. 6912q24. 12 17 225799_at MGC4677-5. 22 3. 38E-09 4. 28E-06-1. 80-9. 67 2p11. 1 18 222422_s_at NDFIP1 -6. 31 7. 25E-10 2.19E-06-1. 70-9. 58 5q31. 3 19 201462_at KIAA0193 -12. 42 2. 20E-08 1.27E-05-2. 01-9.55 7p14. 3-p14. 1 20 242414 at 6. 69 2. 33E-08 1. 32E-05 1. 94 9. 55 21 213716_s_at SECTM1 -5. 49 3. 36E-09 4.28E-06-1. 76-9.54 17q25 22 201494_at PRCP -2. 66 2.61 E-09 4.25E-06-1. 73-9. 49 11a14 23 60471_at RIN3 -3.71 1.59E-10 1.20E-06-1. 62-9. 48 14q32. 13 24 243756_at 5. 16 2. 68E-09 4. 25E-06 1. 72 9. 48 25 201200_at CREG -2. 79 3. 09E-10 1.55E-06-1. 64-9. 48 1 q24 26 223136_at AIG-1 -7. 89 1. 15E-08 8.54E-06-1. 80-9. 36 6q24. 1 27 233500_x_at LLT1 15. 40 6. 10E-08 2. 40E-05 2.04 9.30 12P13 28 211581_x_at LST1 -4. 32 3.96E-09 4. 42E-06-1. 68-9. 24 6p21. 3 29 214574_x_at LST1 -4. 55 9. 33E-09 7.61 E-06-1. 72-9. 19 6p21. 3 30 224910_at 2.78 1. 69E-08 1. 11E-05 1.75 9.18 31 224910_at 3. 87 2. 11E-08 1.25E-05 1.76 9.14 32 239214_at 17. 95 8. 48E-08 2. 88E-05 2.05 9.14 33 219457_s_at RIN3 -5.12 3. 31 E-09 4. 28E-06-1. 64 -9.12 14q32. 13 34 203796_s_at BCL7A 5.08 1. 83E-08 1. 15E-05 1.71 9.05 12q24. 13 35 215051_x_at AIF1 -3. 74 2. 34E-09 4.25E-06-1. 60-9.03 6p21. 3 36 203373 at SOCS2 5. 06 7. 21E-09 6. 80E-06 1. 64 9. 00 12q 37 200953_s_at CCND2 -5. 89 4.70E-08 2.17E-05-1. 85-8. 98-12p13 38 211582_x_at LST1-4. 43 9. 19E-09 7.61 E-06-1.64-8. 92 6p21. 3 39 220951_s_at CCND2 -14. 09 7.37E-08 2. 73E-05 -1. 93-8. 89 12p13 40 201243_s_at ATP1B1 -13.89 7.41 E-08 2.73E-05-1. 92-8. 87 1q22-q25 41 217800_s_at NDFIP1-11. 26 6. 03E-08 2. 40E-05-1 82-8. 84 5q31. 3 Table 2.1-2. 78 42 200602at APP-15.46 8.23E-08 2. 88E-05-1. 87-8. 77 21q21. 3 43 214181_x_at LST1 -5. 80 4.13E-08 1. 98E-05-1. 70-8.73 6p21. 3 44 244261_at IL28RA 36. 41 1.77E-07 4. 89E-05 2.02 8.70 1p36. 11 45 225592_at NRM 2.63 6. 93E-08 2. 64E-05 1.71 8. 66 6p21. 31 46 201829_at NET1 -3. 62 2. 53E-08 1. 39E-05-1. 60-8. 59 10p15 47 215925_s_at CD72 45. 33 2.13E-07 5. 47E-05 2.00 8.59 9p13. 1 48 218818_at FHL3 -2. 20 9. 56E-10 2. 62E-06-1. 46-8. 58 1p34 49 225314-at MGC45416-4. 69 6. 16E-08 2. 40E-05-1. 69-8.57 4p11 50 215633 x at LST1-4. 80 5. 47E-08 2. 29E-05-1. 66-8. 54 6p21. 3 2.7 ALL MLL versus AML komplext affy id HUGO name fc p q stn t Map Location 1 226496_at FLJ22611 12. 38 1. 42E-10 4.01 E-08 2.58 13. 41 9p12 2 202788_at MAPKAPK3-2. 62 1.05E-15 2. 08E-11 -1.69 -11.93 3p21. 3 3204852satPTPN7-4. 33 7.05E-15 4. 65E-11-1. 70-11.81 1q32. 1 4 202853 s at RYK-5. 62 5.68E-15 4. 65E-11-1. 67-11. 69 3q22 5 200871_s_at PSAP -5. 54 1.09E-13 2. 39E-10-1. 73-11. 4910q21-q22 6 221969_at PAX5 22. 70 3.20E-09 3. 37E-07 2.45 11.46 9p13 7 203373_at SOCS2 11. 61 3.68E-09 3. 62E-07 2. 22 11. 0912q 8201200atCREG-2. 86 1.99E-14 9. 84E-11-1. 50-10.71 1q24 9 200975_at PPT1 -3. 48 4.84E-14 1. 60E-10-1. 49-10. 60 1p32 10 227353 at EVER2-4. 12 3.12E-13 6. 16E-10-1. 54-10. 59 17q25. 3 11 215051_x_at AIF1 -3. 63 4.64E-14 1.60E-10-1. 47-10.46 6p21. 3 12 217967 s at C10rf24-11. 05 3.56E-12 3. 52E-09-1. 65-10. 44 1q25 13 214172_x_at RYK-3. 68 8.78E-14 2. 17E-10-1. 47-10.40 3q22 14 200620_at C1orf8 -1. 93 6. 11E-14 1. 73E-10-1. 45-10. 36 1 p36-p31 15 210024_s_at UBE2E3 -8. 50 4. 10E-12 3. 65E-09-1. 48-9. 94 2q32.1 16 225563 at LOC255967 3. 91 1. 93E-09 2. 35E-07 1.66 9.93 13q12. 13 17 213095 x at AIF1-4. 10 8. 71E-13 1. 44E-09-1. 42-9.92 6p21. 3 18 204949_at ICAM3 -9. 71 1. 28E-11 7. 18E-09-1. 55-9. 89 19p13. 3-p13. 2 19 225613_at KIAA0303 -5. 43 2.14E-12 2. 35E-09-1. 43-9.88 5q12. 3 20 219615 s_at KCNK5-3. 25 1. 03E-11 6. 81 E-09-1. 48-9.77 6p21 21 208864_s_at TXN -2.29 1.24E-12 1.75E-09 -1. 39-9.75 9q31 22 203139_at DAPK1-7. 50 1.17E-11 7. 06E-09-1. 47-9.71 9q34.1 23225782atLOC253827-30. 69 3. 07E-11 1. 38E-08-1. 58-9. 70 12q14. 1 24 219463_at C20orf103 53. 28 3.93E-08 2. 08E-06 2.14 9.68 20p12 25 207654_x_at DR1 -2.28 6.56E-13 1. 18E-09-1. 36-9. 67 1p22. 1 26218942atFLJ22055-8. 10 6.90E-12 4. 87E-09-1. 42-9. 67 12q13. 13 27 225789_at CENTG3 -5. 25 3.93E-12 3.65E-09-1. 40-9.66 7q36. 1 28 202381_at ADAM9-7. 23 4.50E-12 3. 71 E-09-1. 40-9. 66 8p11. 21 29 217800_s_at NDFIP1 -8. 26 1.15E-11 7. 06E-09-1. 45-9.66 5q31. 3 30 209188_x_at DR1 -2. 33 1. 44E-12 1.89E-09-1. 36-9.61 1p22. 1 31 201201_at CSTB-3. 93 9.96E-13 1.51 E-09-1. 35-9. 60 21q22. 3 32 203796_s_at BCL7A 5.24 2.90E-08 1.67E-06 1.80 9.43 12q24. 13 Table 2. 1-2.78 33 235033at-2. 57 1. 60E-12 1. 97E-09-1.32-9. 41 34 204328_at EVER1 -2. 63 2. OOE-12 2.33E-09-1. 32-9. 40 17q25. 3 35 203725_at GADD45A -5. 24 1. 79E-11 9. 32E-09-1. 39 -9.39 1p31.2-p31. 1 36 209804 at DCLRE1A-6. 74 5.90E-12 4.32E-09-1. 34-9. 38 10q25. 1 37 218168_s_at CABC1 -2. 78 2. 26E-12 2. 36E-09-1. 32-9. 371q42. 13 38 209340_at UAP1 -2.86 4.24E-12 3. 65E-09-1. 32-9. 33 lq23. 1 39 239214_at 23. 92 6. 77E-08 3. 06E-06 1. 99 9. 26 40 232543_x_at ARHGAP9 -3. 36 3. 22E-11 1.38E-08-1. 38-9. 23 12q14 41 218910 at FLJ10375-8. 54 6. 45E-11 2.28E-08-1. 40-9. 163p21. 32 42225790atLOC253827-25. 47 1. 44E-10 4.01E-08 -1.48 -9.10 12q14. 1 43216652sat-2. 26 5. 44E-12 4. 14E-09-1. 28-9. 09 44 201012_at ANXA1-2. 98 4.78E-12 3.78E-09-1. 27-9. 06 9q12-q21. 2 45 227481_at FLJ31349-5. 41 3. 14E-11 1. 38E-08-1.32-9. 05 6q25.2 46217963satNGFRAP1-26. 34 1. 68E-10 4.50E-08-1. 47-9. 04 Xq22. 1 47 208891_at DUSP6 -4. 61 1. 31 E-11 7. 18E-09-1. 29-9. 03 12q22-q23 48 244741_s_at -8. 46 9. 58E-11 3.05E-08-1. 38-9. 02 49 203973_s_at CEBPD -8. 76 7. 34E-11 2. 46E-08-1. 36-9. 02 8p11. 2-p11. 1 50 209901_x_at AIF1 -4. 78 2. 73E-11 1. 28E-08-1. 30-8. 98 6p21. 3 2.8 ALL_MLL versus AML_t (15; 17) affy id HUGO name fc p q stn t Map Location 1 203949 at MPO-21. 90 2. 92E-20 6. 32E-16-5. 21-29. 2517q23. 1 2 203948_s_at MPO -50. 34 9.06E-17 3. 27E-13-5. 30-26. 30 17q23. 1 3 224918 x at MGST1-76. 09 1. 51E-15 4.07E-12-5. 01-23. 47 12p12. 3-p12. 1 4 231736_x_at MGST1 -63. 73 1.33E-14 2. 06E-11 -4.47 -20.87 12p12.3-p12. 1 5 206871_at ELA2 -14. 24 6. 78E-17 3. 10E-13-3. 65-20. 60 19p13. 3 6205382satDF-45. 39 4. 08E-15 9. 81E-12 -3. 97-20. 54 19p13. 3 7 200654_at P4HB -4. 60 5. 91E-19 6. 39E-15-3. 43-20. 35 17q25 8 212953_x_at CALR -5. 70 8. 58E-15 1. 55E-11-3. 39-18. 36 19p13. 3-p13. 2 9 214450_at CTSW -18. 36 1. 32E-13 1. 43E-10-3. 32-17. 18 11q13. 1 10 38487_at STAB1 -45. 09 4. 47E-13 4. 20E-10-3. 63-17. 14 3p21. 31 11 208689_s_at RPN2 -3. 32 1.08E-17 7. 78E-14-2. 67-16. 19 20q12-q13. 1 12 214575_s_at AZU1 -29. 25 9. 85E-13 7. 75E-10-3. 22-16.01 19p13. 3 13 221739_at IL27w -2. 49 7. 17E-17 3. 10E-13-2. 64-15. 8619p13. 3 14 200953_s at CCND2-11. 41 2.59E-12 1. 81 E-09-3. 06-15. 18 12p13 15 205624_at CPA3-94. 78 5. 09E-12 3. 34E-09-3. 29-15. 05 3q21-q25 16 221004_s_at ITM2C -6. 12 9. 69E-15 1. 61 E-11-2. 47-14.53 2q37 17 206111_at RNASE2 -5. 26 5. 18E-16 1.60E-12-2. 33-14. 14 14q24-q31 18 210788 s at retSDR4-3. 66 1. 00E-12 7. 75E-10-2. 54-14.01 14q22.3 19 226496_at FLJ22611 18. 36 1.43E-10 5. 03E-08 2. 99 13. 95 9p12 20 208675_s_at DDOST -3. 42 5. 20E-15 1. 06E-11-2. 23-13. 47 1p36. 1 21201012atANXA1-3. 29 5. 40E-15 1. 06E-11-2. 15-13. 08 9q12-q21. 2 22217716satSEC61A1-2. 79 1.86E-14 2. 68E-11-2. 17-13.04 3q21. 3 23 200951_s_at CCND2 -27.01 7. 18E-11 2.88E-08-2. 71-12. 85 12p13 Table 2. 1-2.78 24 218910_at FLJ10375 -12. 12 3. 53E-11 1. 82E-08-2. 45-12. 72 3p21. 32 25 233072_at KIAA1857 -16. 57 6. 50E-11 2.79E-08-2. 56-12. 69 9q34 26 203591_s_at CSF3R -13. 93 6. 40E-11 2.79E-08-2. 53-12. 64 1 p35-p34. 3 27208852satCANX-3. 44 4. 06E-13 3. 99E-10-2. 13-12. 52 5q35 28210024satUBE2E3-4. 90 2. 50E-14 3.38E-11 -2. 04-12.40 2q32.1 29 201494_at PRCP -4.27 3. 05E-11 1. 61E-08-2. 31-12. 37 11q14 30201360atCST3-37. 70 1.80E-10 5. 91 E-08-2. 65-12. 24 20p11. 21 31 208612_at GRP58 -2. 55 6.35E-14 7. 81E-11 -2.01 -12.20 15q15 32 201666 at TIMP1-7. 00 8.72E-12 5.55E-09-2. 16-12. 17 Xp11. 3-p11. 23 33 200068 s at-CANX-1. 98 6.50E-14 7. 81E-11 -2.00 -12. 14 5q35 HG-U 133B 34 204150at STAB1-51. 98 2.57E-10 7.45E-08-2. 59-11. 9E 3p21. 31 35 218084_x_at FXYD5 -2. 39 1. 29E-13 1.43E-10-1. 97-11. 9319q12-q13. 1 36 221969_at PAX5 67.66 2.38E-09 4. 40E-07 2.81 11.87 9p13 37 226878_at 6.53 9.29E-10 2. 12E-07 2. 40 11. 87 38 204347_at AK3 -11. 28 2. 31E-12 1.67E-09-2. 03-11. 85 1p31. 3 39 203373_at SOCS2 26.52 2.15E-09 4. 20E-07 2.58 11.77 12q 40201596xatKRT18-26. 67 3.37E-10 9.34E-08-2. 48-11. 74 12a13 41 200663_at CD63 -2.83 1. 42E-13 1.47E-10-1. 93-11. 7012q12-q13 42 225563_at LOC255967 5.97 1.02E-09 2. 27E-072*3311. 6713q12. 13 43 214315_x_at CALR -3. 37 1. 55E-11 9.29E-09-2. 05-11. 6519p13. 3-p13. 2 44 205663_at PCBP3 -3.96 6. 59E-11 2. 79E-08 -2.09 -11.48 21a22. 3 45 225790_at LOC253827 -37.66 5.83E-10 1.50E-07-2. 40-11. 3712q14. 1 46 41220 at MSF 2. 59 5. 72E-11 2. 63E-08 1. 99 11. 30 17q25 47 200986_at SERPING1 -25.55 7. 33E-10 1.78E-07-2. 44-11. 2611q12-q13. 1 48 200656 s_at P4HB-7. 49 3. 78E-10 1.02E-07-2. 18-11. 22 17q25 49 204069_at MEIS1 45.29 5. 38E-09 8. 15E-07 2. 62 11. 21 2p14-p13 50238365sat-5. 93 2. 58E-1 7. 45E-08-2.12-11. 19 2.9 ALL_MLL versus AML-t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 203949 at MPO-20. 09 2. 74E-18 7. 56E-14-3. 49-20. 62 17q23. 1 2 203948_s_at MPO -36.79 3. 12E-14 2. 86E-10 -3.89 -15.59 17q23.1 3 202853_s_at RYK -4.88 3. 51E-16 4.83E-12-2. 11-13. 56 3q22 4 226496_at FLJ22611 9.79 2. 84E-10 1. 82E-07 2. 74 13. 21 9p12 5 228058_at LOC124220 -19. 36 1. 41E-12 3. 00E-09-2. 33-12. 93 16p13. 3 6 202788_aT MAPKAPK3 -4. 21 5. 45E-13 2.14E-09 -2.18 -12.79 3p21. 3 7 200953_s_at CCND2 -4.13 1. 84E-13 1. 02E-09-2. 03-12. 44 12p13 225563_at LOC255967 6. 64 9.91 E-10 4.71 E-07 2.44 12.02 13q12. 13 9 224918_x_at MGST1 -39. 17 1. 66E-11 2.70E-08-2. 27-11. 8012p12. 3-p12. 1 10 204852_s_at PTPN7 -4.25 8.91 E-13 2. 49E-09-1. 89-11. 61 1q32. 1 11 202382_s_at GNP1 -14.60 9. 69E-12 1. 78E-08-2. 01-11. 53 5q21 12 217800 s at NDFIP1-6. 66 8. 31E-13 2. 49E-09-1. 86-11. 53 5q31. 3 13 238790_at 7.07 2. 62E-10 1. 72E-07 2.00 11.28 Table 2. 1-2.78 14 221969_AT PAX5 14.73 4. 88E-09 1. 24E-06 2. 49 11. 20 9p13 15 204069_at MEIS1 43. 24 5.48E-09 1. 35E-06 2. 62 11. 19 2p14-p13 16 244876 at 4. 32 9. 70E-10 4.71 E-07 2. 04 11. 07 17 210024 s at UBE2E3-6. 20 9. 93E-13 2. 49E-09-1. 75-11. 03 2q32. 1 18 208248_x_at APLP2-3. 68 1.82E-13 1. 02E-09-1. 69-10. 9311q24 19 208864_s_at TXN -2. 37 1.29E-12 2. 96E-09-1. 72-10. 86 9q31 20 203373_at SOCS2 10.36 2. 99E-09 8. 32E-07 2. 09 10. 81 12q 21 41220_at MSF 2.41 1. 25E-10 1.04E-07 1.81 10.74 17q25 22 225703_at KIAA1545 3.31 6.95E-10 3.61 E-07 1. 90 10. 69 12q24. 33 23 211474_s_at SERPINB6 -6.60 4.73E-11 5. 51E-08 -1.82 -10.60 6p25 24 212207_at KIAA1025 3.52 1. 13E-09 5. 02E-07 1.90 10.59 12q24. 22 25 209318_x_at PLAGL1 -5. 51 6. 00E-12 1. 18E-08-1. 70-10. 58 6q24-q25 26 206870_at ELA2 -12.06 5. 60E-11 5. 51E-08-1. 83-10. 5719p13. 3 27 231736_x_at MGST1 -30. 18 1. 73E-10 1.22E-07-2. 02-10.51 12p12. 3-p12. 1 28 217989_at RetSDR2-2. 36 5.37E-13 2. 14E-09-1. 61-10. 46 4q21. 3 29214172xatRYK-3. 30 9.41 E-13 2. 49E-09-1. 61-10. 38 3q22 30 212827_at IGHM 11. 25 1.02E-08 2.01 E-06 2. 12 10. 35 14q32. 33 31 203796_s_at BCL7A 8.32 9. 82E-09 1. 96E-062'1010. 3312q24. 13 32 225637_at FLJ20186 -7.39 5. 07E-11 5. 51 E-08-1. 71-10. 25 16q24. 3 33 224910 at 3. 52 2. 23E-09 6. 82E-07 1. 83 10. 19 34 208702_x_at APLP2 -4. 58 4. 82E-11 5. 51E-08 -1. 68-10. 15 11 q24 35221581satWBSCR515. 98 2. 08E-08 3. 32E-06 2.22 10.09 7q11. 23 36 202887_s_at RTP801 8.21 1.62E-08 2. 84E-06 2.07 10.05 10pter-q26. 12 37 228827_at -85.32 4.66E-10 2.68E-07-1. 98-10. 02 38 203973 s at CEBPD-8. 39 1. 31 E-10 1. 06E-07-1. 66 -9.89 8p11.2-p11. 1 39 211728_s_at HYAL3 -6. 94 1.47E-10 1. 10E-07-1. 65-9. 83 3p21. 3 40 200871_s_at PSAP -3.23 3. 45E-11 4. 57E-08-1. 57-9. 7910q21-q22 41 219463_at C20orf103 91.29 3. 70E-08 5. 23E-06 2.31 9.78 20p12 42 227353_at EVER2 -3. 53 5. 60E-11 5. 51E-08 -1.57 -9.73 17q25. 3 43 235703_at -4. 27 3. 48E-11 4. 57E-08-1. 55-9. 72 44 218486_at -24. 07 9. 26E-10 4.64E-07-1. 84-9.64 45 228894_at -5. 24 2.12E-10 1.43E-07-1. 61-9. 61 46208704xatAPLP2-3. 67 2. 17E-11 3.33E-08 -1.49 -9.50 11q24 47 206940 s at POU4F1-40. 38 1. 44E-09 5.60E-07-1. 84-9. 4513q21. 1-q22 48 226285_at M11S1 2.14 1.97E-09 6. 23E-07 1.60 9.42 11p13 49 239214_at 25. 84 7.01 E-08 8. 40E-06 2. 17 9. 33 50 49111 at-2. 35 1.41 E-11 2. 42E-08-1. 44-9. 32 2. 10 ALL MLL versus CLL # affy id HUGO name fc p q stn t Map Location 1225927at-5. 82 8. 36E-27 2. 00E-22 -2. 92-21.20 2202625atLYN-5. 24 2. 96E-26 3.54E-22-2. 82-20.51 8q13 34210_at CDW52 -24.53 4.26E-22 1.70E-18 -2.98 -20.17 1p36 Table 2.1-2. 78 4 218942at FLJ22055-10. 00 1.76E-23 1. 40E-19-2. 57-18. 49 12q13. 13 5 224838_at FOXP1-3. 81 2. 81E-22 1. 34E-18-2. 53-18. 13 3p14. 1 6 218029_at FLJ13725-5. 24 1.84E-22 1. 10E-18-2. 46-17. 6716q21 7 208091 s at DKFZP564K0822-15. 89 7.98E-19 9. 59E-16-2. 62-16.99 7p14. 1 8204446satALOX5-13. 33 1. 29E-19 2. 20E-16 -2.49 -16.95 10q11. 2 9 228993_s_at PDCD4 -2. 64 5. 18E-22 1. 77E-18-2. 27-16. 49 lOq24 10 223514_at CARD11 -16.46 2.89E-21 6. 90E-18-2. 28-16. 40 7p22 11 204192_at CD37-11. 59 8.17E-19 9.59E-16-2. 44-16. 38 19p13-q13. 4 12 200999_s_at CKAP4 -6.39 1.48E-21 4. 42E-18-2. 25-16. 31 12q24.11 13 204661_at CDW52-25. 76 2. 24E-18 2. 33E-15-2. 45-16. 191p36 14 207616 s at TANK-3. 82 1. 71E-21 4.54E-18-2. 20-15.98 2q24-q31 15 201812_s_at TOM7 -1.90 9. 45E-20 1. 88E-16-2. 21-15.84 7p15. 3 16 225314_at MGC45416-4. 77 2. 78E-20 6. 05E-17 -2.19 -15.72 4p11 17 212593_s_at PDCD4 -5. 73 4.23E-19 5.94E-16-2. 22-15. 57 10q24 18 224709_s_at SPEC2 -3.28 8.42E-19 9. 59E-16 -2.13 -15. 21 5q31. 1 19 44790_s_at C13orf18 -59.06 4. 94E-17 2. 11E-14 -2.43 -15.18 13q14. 11 20236301at-12. 99 9. 17E-18 6. 64E-15-2. 24-15. 15 21 219471_at C13orf18 -46.18 6.14E-17 2.49E-14-2. 42-15. 08 13a14. 11 22 223391_at SGPP1 -13.05 3. 77E-18 3. 47E-15 -2.18 -15.07 14q23. 1 23 201462 at KIAA0193-26. 17 5. 60E-17 2.35E-14-2. 36-15. 01 7p14. 3-p14. 1 24 212313_at MGC29816-5. 8E 3. 92E-19 5. 86E-16-2. 07-14. 80 8p21. 2 25 204798_at MYB 35. 03 8. 02E-11 3.45E-09 3.24 14.78 6q22-q23 26 208296_x_at GG2-1 -5. 17 1. 22E-19 2. 20E-16-1. 99-14. 47 5q23.1 27 204912 at IL10RA-7. 46 2. 56E-17 1.28E-14-2. 11-14. 4311q23 28 232905_s_at NIR3 -6.53 2.72E-17 1.32E-14-2. 10 -14. 37 12q24. 31 29 239287 at-36. 96 2. 86E-16 8.53E-14-2. 30-14. 33 30 204269_at PIM2 -4.55 2. 94E-18 2. 81E-15 -2.01 -14.26 Xp11. 23 31 213309_at PLCL2 -8.62 1. 37E-17 8. 20E-15-2. 05-14. 26 3p24.3 32 210024_s_at UBE2E3 -6. 64 2. 67E-19 4. 26E-16-1. 96-14. 23 2q32.1 33 212386_at -9.76 2. 11 E-17 1.13E-14-2. 04-14. 16 34 220987_s_at SNARK -5. 13 1. 21E-17 7. 67E-15-1. 99-14. 031q32. 1 35 210754 s at LYN-4. 48 8. 40E-18 6. 48E-15 -1.98 -13.99 8q13 36205192atMAP3K14-4. 48 9. 27E-18 6. 64E-15-1. 96-13. 91 17q21 37 236248_x_at -5.73 6. 06E-19 8. 04E-16-1. 91-13.91 38 206337_at CCR7 -12.80 8. 78E-17 3.37E-14-2. 02-13. 8417q12-q21. 2 39 213142_x_at LOC54103 -25.43 6. 09E-16 1. 64E-13-2. 13-13. 77 7q11. 23 40 236280_at -11. 10 1.48E-16 5.06E-14-2. 02-13.77 41 204949_at ICAM3 -8. 77 1. 52E-16 5. 11E-14-2. 01-13. 7219p13. 3-p13. 2 42'228390at-12. 86 3. 26E-17 1. 50E-14 -1.95 -13. 71 43 214172_x_at RYK -4.53 1. 78E-18 1. 93E-15-1. 89-13. 71 3q22 44 204512_at HIVEP1 -7. 62 1. 39E-16 4.82E-14-2. 00-13. 69 6p24-p22.3 45 210425_x_at GOLGIN-67 -12.13 9. 78E-16 2. 49E-13-2. 11-13. 60 15q11. 2 46 229844_at -4.86 1.22E-17 7. 67E-15-1. 90-13. 59 47 202853_s_at RYK -7.55 5.89E-17 2. 43E-14-1. 93-13. 53 3q22 48 202863 at SP100-3. 09 2. 55E-18 2. 54E-15-1. 86-13. 52 2q37. 1 49 218191_s_at FLJ11240 -2.81 1. 62E-17 9. 46E-15-1. 87-13. 45 6q12 Table 2.1-2. 78 50 202524_s_at SPOCK2 -6. 84 1.73E-17 9.82E-15-1. 88-13. 4410pter-q25. 3 2.11 ALL_MLL versus CML # affy id HUGO name fc stn t Map Location 1 206871_at ELA2 -16. 25 2. 58E-38 5.77E-34-3. 61-29. 24 19p13. 3 2 205557_at BPI -13. 59 1.33E-35 1.49E-31-3. 36-27. 06 20q11. 23-q12 3 203949 at MPO-19. 24 3.90E-35 2. 91E-31 -3. 37-26. 99 17q23. 1 4 210254 at MS4A3-10. 27 1.94E-33 1. 09E-29-3. 01-24.36 11 qu 2 5 214575_s_at AZU1 -35. 47 2. 10E-29 3. 62E-26-3. 19-24. 18 19p13. 3 6 225386 s at LOC92906-17. 75 4. 72E-32 1. 76E-28-3. 02-24. 11 2p22. 2 7 211657_at CEACAM6 -14. 13 2.95E-31 9. 41E-28 -2. 91-23. 24 19q13. 2 8 201554_x_at GYG -6. 75 3.62E-29 5. 40E-26-2. 94-22.87 3q24-q25.1 9 206676 at CEACAM8-10. 48 2.50E-32 1. 12E-28-2. 80-22. 73 19q13. 2 10 203948_s_at MPO -33. 56 3.69E-28 3. 75E-25-2. 99-22. 66 17q23.1 11 205653_at CTSG-20. 45 2. 84E-28 3.03E-25-2. 94-22. 4914q11. 2 12 200654_at P4HB -3. 85 5.88E-28 5. 48E-25-2. 83-22. 40 17q25 13 212268 at SERPINB1-3. 45 1. 13E-29 2. 42E-26-2. 79-22. 36 6p25 14 203757_s_at CEACAM6 -18. 56 1. 21E-29 2. 42E-26-2. 81-22. 2419q13. 2 15 201425_at ALDH2-11. 39 1. 43E-28 1.60E-25-2. 75 -21.63 12q24. 2 16 203021_at SLPI-11. 88 1. 19E-28 1. 40E-25-2. 75-21. 63 20q12 17 210140_at CST7 -8. 07 4.40E-30 1.23E-26-2. 63-21. 2620p11. 21 18 204949_at ICAM3-16. 41 1. 95E-26 1. 37E-23-2. 70-20. 6019p13. 3-p13. 2 19 211275_s_at GYG-4. 57 8. 60E-30 2. 14E-26-2. 53-20. 55 3q24-q25. 1 20 205513_at TCN1 -12. 50 5.72E-27 4. 57E-24-2. 61-20. 3911q11-q12 21 204852_s_at PTPN7 -5. 07 1. 30E-29 2. 42E-26-2. 50-20. 331q32. 1 22223423atGPCR1-7. 85 6. 20E-29 8. 15E-26-2. 52-20. 30 3q26.2-q27 23 208308_s_at GPI -4. 58 3. 12E-29 4. 99E-26-2. 49-20. 2319q13. 1 24 205786_s_at ITGAM -10. 19 1.83E-27 1.58E-24-2. 56-20. 22 16p11. 2 25 204971_at CSTA -9. 57 5. 88E-29 8. 15E-26-2. 48-20.09 3q21 26 200871_s_at PSAP -5. 32 9.20E-29 1. 14E-25-2. 47-19. 9710q21-q22 27 224918_x_at MGST1 -35. 76 6.06E-25 3.15E-22-2. 69-19. 76 12p12. 3-p12. 1 28225782atLOC253827-27. 36 2.52E-25 1. 48E-22-2. 58-19. 61 12q14. 1 29 206111_at RNASE2 -7. 47 6.12E-27 4. 72E-24-2.42-19. 4514q24-q31 30217762satRAB31-28. 14 8.55E-25 4.25E-22-2. 58-19. 3218p11. 3 31 223120_at MGC1314 -4. 11 4. 82E-28 4.69E-25-2. 37-19.23 6q24 32200832satSCD-20. 45 1.97E-26 1. 37E-23-2. 41-19. 13 10q23-q24 33 222764_at ASRGL1 -15. 26 1. 46E-26 1.09E-23-2. 40-19. 0711q12. 2 34 208771_s_at LTA4H -5. 28 3.91 E-27 3.24E-24-2. 35-18. 89 12q22 35 207802_at SGP28 -20. 64 9.90E-25 4. 71E-22-2. 44-18.73 6p12. 3 36205863atS100A12-7. 23 1.40E-27 1.25E-24-2. 31-18. 71 1q21 37 217764_s_at RAB31 -16. 98 9.63E-25 4.68E-22-2. 43-18. 68 18p11. 3 38 210244_at CAMP -14. 11 1.64E-25 1. 02E-22-2. 36-18. 62 3p21. 3 39 231736_x_at MGST1 -26. 96 1. 14E-23 3. 81 E-21-2. 50-18. 42 12p12. 3-p12. 1 40 208699_x_at TKT -5.13 6.68E-26 4. 39E-23 -2.24 -18.10 3p14. 3 Table 2. 1-2. 78 41 205237-at FCNI-19. 53 1.06E-23 3.67E-21-2. 38-18. 07 9q34 42 212531_at LCN2-6. 6e 1.46E-23 4. 72E-21-2.27-17. 96 9q34 43 218942_at FLJ22055 -10.48 3.73E-26 2.53E-23-2. 22-17. 92 12q13. 13 44 201012_at ANXA1-4. 29 4.44E-24 1.69E-21-2. 25-17. 92 9q12-q21. 2 45 209772-s-at CD24-11. 66 1. 11E-24 5.07E-22-2. 27-17. 19 6q21 46 208637_x_at ACTN1 -9. 64 3. 61E-24 1. 39E-21-2. 27-17. 7514q24 47 209369_at ANXA3 -18.19 9.70E-24 3. 44E-21-2.30-17. 74 4q13-q22 48201905satHYA22-8. 78 6.02E-25 3.15E-22-2. 21-17. 60 3p21. 3 49 208700_s_at TKT -3. 85 1.68E-23 5. 35E-21-2. 22-17. 59 3p14. 3 50 207269_at DEFA4 -7.43 2.82E-24 1. 15E-21-2. 19-17. 52 8p23 2. 12ALL-MLL versus normal # affy id HUGO name fc p q stn t Map Location 1223280xatMS4A6A-14. 56 3.06E-08 8.88E-06-4. 28-16. 9711q12. 1 2201425atALDH2-10. 01 8. 93E-08 1.72E-05-4. 05-15. 6512q24. 2 3 202382_s_at GNPI -11.48 1.46E-08 5.75E-06-3. 64-15. 58 5q21 4 218257_s_at UGCGL1 -2. 61 2. 17E-13 3.86E-09-3. 03-15. 36 2q14. 3 5 206488_s_at CD36 -9. 24 4.46E-08 1.18E-05-3. 32-14. 14 7q11. 2 6 205051-s-at KIT-7. 11 9.04E-08 1. 73E-05 -3.39 -14.00 4q11-q12 7200832satSCD-11. 72 1.74E-08 6.05E-06-3. 15 -13.94 10q23-q24 8224356xatMS4A6A-13. 84 4.22E-07 4.82E-05-3. 75-13. 7511q12. 1 9 218424_s_at TSAP6 -4. 44 1. 25E-11 1. 10E-07-2. 75-13. 72 2q14. 1 10 226496 at FLJ22611 11. 98 2.34E-10 4. 53E-07 3.03 13.53 9p12 11 201876_at PON2 -5.05 3.69E-10 5.46E-07-2. 73-13. 24 7q21. 3 12 201858_s_at PRG1 -3.56 6. 80E-11 2.98E-07-2. 67-13. 22 10q22.1 13 205624 at CPA3-11. 15 5.30E-07 5. 47E-05-3. 48-13.07 3q21-q25 14 217047_s at FAM13A1-3. 84 6.82E-10 7.56E-07-2. 70-13. 04 4q22.1 15 201988 s at CREBL2-2. 83 2.56E-10 4. 53E-07-2. 65-12. 9512p13 16 200871_s_at PSAP -6.96 7.02E-07 6.48E-05-3. 39-12. 69 10q21-q22 17 219013 at GALNT11-6. 75 1.86E-07 2. 79E-05-3. 03-12. 67 7q34-q36 18 232098_at-6. 2E 4.07E-08 1. 11E-05 -2. 81-12.54 19 223120_at MGC1314 -3.18 5.86E-09 3.15E-06-2. 67-12.53 6q24 20 202443_x_at NOTCH2 -4. 88 1.17E-10 3.46E-07-2. 49-12. 401p13-p11 21 203535_at S100A9 -4. 41 5.76E-09 3.15E-06-2. 54-12. 041q21 22 206871_at ELA2 -15.53 1.38E-06 9.69E-05-3. 17-11. 78 19p13. 3 23 203373_at SOCS2 23.63 2.64E-09 2. 13E-062'7711. 7612q 24226556at-2. 78 8. 39E-11 2.98E-07-2. 26-11. 44 25208146satCPVL-16. 00 2. 15E-06 1.26E-04-3. 18-11. 42 7p15-p14 26 222736_s_at FLJ10493 -2.40 5. 37E-11 2.98E-07-2. 24-11. 38 9q31. 2 27 204852_s_at PTPN7 -3. 70 1. 16E-07 2. 06E-05-2. 54-11. 35 1q32.1 28 225703_at KIAA1545 3.73 4. 04E-10 5.51 E-07 2.27 11.20 12q24. 33 29 225563_at LOC255967 5.07 1.40E-09 1. 37E-06 2.33 11.12 13q12. 13 30 217800_s_at NDFIP1 -9.54 1. 56E-06 1.06E-04-2. 83-11. 06 5q31. 3 31 218486_at -9. 12 2.13E-06 1.26E-04-2. 94-11.05 Table 2. 1-2.78 32 212481sat TPM4 4. 54 1. 52E-09 1.42E-06 2.31 11. 0319p13. 1 33 201417 at 6. 27 3. 85E-09 2. 55E-06 2. 40 11. 00 34 212967_x_at NAP1L1 1.64 1. 97E-10 4. 53E-07 2.18 10.97 12q21.1 35 210547_x_at ICA1 -4.80 6. 80E-07 6. 35E-05-2. 61-10. 95 7p22 36 212989 at MOB-4. 36 8. 75E-08 1.70E-05-2. 38-10. 90 10q 37 201506_at TGFBI-41. 5C 4. 26E-06 1.86E-04-3. 37-10. 89 5q31 38 203645_s_at CD163 -11.08 5.02E-07 5.42E-05-2. 54-10. 89 12p13. 3 39 224975_at NFIA -5. 66 6. 38E-08 1. 44E-05-2. 35-10. 881p31. 3-p31. 2 40 202973_x_at FAM13A1 -4. 36 6. 37E-08 1.44E-05-2. 35-10. 87 4q22.1 41 228716_at -4.10 3. 66E-1 0 5.46E-07-2. 15-10. 85 42 202018 s at LTF-3. 55 2. 46E-10 4.53E-07-2. 13-10. 79 3q21-q23 43 227388 at-3. 91 1. 85E-08 6.21 E-06-2.24-10. 71 44 212207_at KIAA1025 3.90 5. 47E-10 6. 93E-07 2.15 10.69 12q24. 22 45 215537_x_at DDAH2 6. 41 7. 88E-10 8. 22E-07 2. 16 10. 68 6p21. 3 46208690satPDDM1427 1. 82E-09 1. 61E-06 2. 20 10. 6610q22-q26. 3 47 203796_s at BCL7A 11. 67 4. 18E-09 2. 55E-06 2.25 10.60 12q24. 13 48 221969_at PAX5 8.55 7. 33E-09 3. 33E-06 2.26 10.45 9p13 49 214575 s at AZU1-26. 20 5. 57E-06 2.13E-04-3. 08-10. 3919p13. 3 50223168atARHU-6. 94 3. 09E-06 1.54E-04-2. 72-10. 391q42. 11-q42. 3 2. 13 ALL_Ph+ versus ALL T-lineage # affy ld HUGO name fc p q stn t Map Location 1 211990_at HLA-DPA1 7.91 5.76E-20 1. 71 E-15 2. 61 17. 41 6p21. 3 2 209619_at CD74 8.32 2. 98E-16 4. 43E-12 2. 16 14. 17 5q32 3213539atCD3D-32. 29 2. 13E-12 2. 11E-08 -2. 72-13. 8511q23 4 210982_s_at HLA-DRA 19.25 2. 35E-10 7. 94E-07 1.96 10.65 6p21. 3 5 217478_s_at HLA-DMA 11.29 2. 98E-10 8. 36E-07 1. 90 10. 47 6p21. 3 6 208894_at HLA-DRA 19.28 7. 27E-10 1. 44E-06 1.89 10.10 6p21. 3 7 204670_x_at HLA-DRB5 8.44 3. 09E-10 8. 36E-07 1.70 10.00 6p21. 3 8 227584 at 9. 85 9.47E-10 1. 65E-06 1. 86 9. 96 9 202113_s_at SNX2 3.52 2. 41E-10 7. 94E-07 1. 61 9. 78 5q23 10 222895_s_at BCL11B -16.74 1.54E-09 2.17E-06-1. 85 -9.75 14q32. 31 11 202789_at -3. 31 5.19E-11 3.08E-07-1. 52-9.71 12 201137_s_at HLA-DPB1 11. 82 1. 10E-09 1.71 E-06 1.72 9.66 6p21. 3 13 209771_x_at CD24 8.10 4.78E-10 1. 09E-06 1.57 9.50 6q21 14 211991_s_at HLA-DPA1 23.80 2. 54E-09 2. 90E-06 1.79 9.48 6p21. 3 15 225314_at MGC45416 -3. 27 1. 91E-10 7.94E-07-1. 50-9. 42 4p11 16 216379_x_at KIAA1919 8.98 1.09E-09 1. 71E-06 1.58 9.33 6q22 17 208306_x_at HLA-DRB4 10.10 2. 46E-09 2. 90E-06 1.58 9.11 6p21. 3 18 238376_at 2.91 8.49E-10 1. 58E-06 1.48 9.07 19201160satCSDAZ42 2. 50E-11 1. 86E-07 1. 35 9. 0512p13. 1 20 201161_s_at CSDA 3.75 7. 52E-11 3. 72E-07 1.37 9.04 12p13. 1 21209604satGATA3-8. 16 4. 50E-09 4.05E-06-1. 60-8. 9E 10p 15 22 209312_x_at HLA-DRB1 8.50 3.16E-09 3.24E-06 1.52 8. 90 6p21. 3 Table 2.1-2. 78 23 206804_at CD3G-35. 77 1. 26E-08 8. 31E-06-1. 73-8. 7411q23 24 217979 at NET-6 6. 22 2. OOE-09 2. 58E-06 1.42 8.71 7p21. 1 25224772atNAV110. 79 1.37E-08 8. 31E-06 1.66 8.65 26 212998_x_at HLA-DQB1 27. 15 1. 46E-08 8. 32E-06 1.63 8.59 6p21. 3 27 229487_at 10. 71 1. 25E-08 8. 31 E-06 1. 55 8. 55 28203932atHLA-DMB8. 22 1. 57E-08 8. 73E-06 1. 60 8. 54 6p21. 3 29 229280_s_at -4. 99 3.07E-09 3.24E-06-1. 38-8.52 30 210349_at CAMK4-3. 93 8. 10E-09 6.50E-06-1. 45-8.47 5q21. 3 31 241871-at-10. 76 2. 23E-08 1. 05E-05-1. 63-8. 43 32 221969_at PAX5 7. 26 7. 70E-09 6. 35E-06 1.42 8.42 9p13 33 238021_s_at -8. 63 1. 26E-08 8. 31 E-06-1. 47-8.40 34 239081_at -2. 74 4. 49E-09 4. 05E-06-1. 35-8. 34 35 215193 x at HLA-DRB1 13. 69 2. 15E-08 1. 03E-05 1.53 8.34 6p21. 3 36 228988^at ZNF6-15. 56 3. 09E-08 1.28E-05-1. 56-8. 23 Xq13-q21. 1 37 202207 at ARL7-5. 81 6. 56E-09 5.57E-06-1. 34-8. 21 2q37. 2 38 224774_s_at NAV1 12. 21 3.64E-08 1. 44E-05 1. 57 8. 18 39 224833_at ETS1 -6. 62 2.01 E-08 9.97E-06-1. 43-8. 17 11 q23. 3 40 230643_at 4.79 1.68E-08 8. 83E-06 1. 40 8. 16 41 203133_at SEC61B -1. 63 5. 14E-10 1.09E-06-1. 20-8. 07 9q22. 32-q31. 3 42 2-1721_s_at LAPTM5 1.98 4. 58E-10 1. 09E-06 1.18 8.00 1p34 43 209602_s_at GATA3 -10. 67 2. 99E-08 1.27E-05-1. 39-7. 99 10p15 44 226459_at FLJ35564 4.44 2. 09E-08 1. 02E-05 1.31 7.88 10q23. 33 45 223046 at EGLN1 4. 79 1. 03E-08 7. 82E-06 1. 26 7. 881q42. 1 46 229029_at -15. 16 7.55E-08 2.25E-05-1. 57-7.87 47 219528_s_at BCL11B -14.12 7.58E-08 2.25E-05-1. 52 -7.84 14q32. 31 48 224909_s_at PRex1 4.13 1. 69E-08 8. 83E-06 1. 27 7. 83 20q13. 13 49 201720_s_at LAPTM5 2.80 1.87E-09 2. 53E-06 1. 17 7. 81 1p34 50 224773 at NAV1 17. 95 7. 88E-08 2. 27E-05 1. 50 7. 81 2. 4ALLPh+ versus ALL t (8; 14) # affy id HUGO name fc P q stn t Map Location 1 203373 at SOCS2 27. 49 1. 43E-13 2. 82E-09 2.87 15.24 12q 2 201029 s at CD99 4. 68 5. 63E-13 5. 55E-09 2. 05 12. 02 Xp22.32 3 210487_at DNTT 389. 23 8. 47E-11 4. 18E-07 2. 40 11. 53 10q23-q24 4 201540_at FHL1 13. 44 4. 17E-10 9. 72E-07 1.97 10.35 Xq26 5 212012_at 19. 65 2. 63E-09 3. 24E-06 1. 88 9. 52 6 203372_s_at SOCS2 37. 37 2. 86E-09 3. 32E-06 1.89 9.49 12q 7 3218589_at P2RY5 16. 99 2. 16E-09 2. 96E-06 1.80 9.48 13q14 8 223276 at NID67 6. 11 6.91 E-11 4. 18E-07 1.59 9.48 5q33. 1 9234107satHARS2-5. 70 4.47E-07 1.24E-04-2. 13 -9.36 20p11. 23 10 202123_s_at ABL1 3.13 4. 92E-10 9.72E-07 1.63 9.35 9q34. 1 11 206995 x at SCARF1 3. 05 1.13E-10 4. 44E-07 1. 53 9. 15 17p13. 3 12 227584 at 6. 35 2. 25E-09 2. 96E-06 1. 66 9. 14 13 204663_at ME3 3.68 3. 18E-10 8. 96E-07 1.53 9.05 11cen-q22. 3 Table 2.1-2. 78 14 217979 at NET-6 6. 58 2. 18E-09 2. 96E-06 1. 61 9. 01 7p21. 1 15 226869_at 9. 16 2.33E-10 7. 68E-07 1.50 8.94 16 224710_at RAB34 6.63 4. 93E-10 9. 72E-07 1.51 8.90 17q11. 1 17 213056_at KIAA1013 5.45 3.07E-09 3. 36E-06 1.58 8.85 3p14. 1 18 210299_s_at FHL1 14. 46 9. 37E-09 8. 04E-06 1.72 8.83 Xq26 19 215537_x_at DDAH2 5.36 1.14E-09 2. 04E-06 1.48 8.69 6p21. 3 20 223471 at RAB31P-3. 55 4.30E-07 1. 21E-04 -1.75 -8.60 21 228543_at CSRP2BP -2. 06 8.67E-09 7.77E-06-1. 46-8. 43 20p11. 23 22 226545 at 7. 51 1. 04E-08 8. 53E-06 1.49 8.34 23 212013_at D2S448 122. 63 3.25E-08 1. 83E-05 1. 71 8. 29 2pter-p25. 1 24 209530_at CACNB3 4.71 2. 13E-08 1. 36E-05 1.48 8.14 12q13 25 202519 at MONDOA 3. 32 6.94E-09 6. 85E-06 1.40 8.13 12q21. 31 26 217870_s_at UMP-CMPK 1.71 2.09E-09 2. 96E-06 1.35 8.11 27 219506_at FLJ23221 4. 74 1. 88E-08 1. 33E-05 1.45 8.07 1q21. 2 28 214505 s at FHL1 8. 53 3. 46E-08 1. 84E-05 41.50 8.05 Xq26 29 211709_s_at SCGF 6. 74 1. 57E-08 1. 19E-05 1.42 8.04 19q13. 3 30205790atSCAP1-3. 69 2.34E-06 3. 52E-04-1. 80-8. 01 17q21. 32 31 224772_at NAV1 6. 7g 3. 46E-08 1. 84E-05 1.48 8.00 32 210298 x at FHL1 22. 44 5. 47E-08 2. 59E-05 1.56 7.98 Xq26 33 201015_s_at JUP 14.94 3. 54E-08 1. 84E-05 1. 45 7.94 17q21 34 223467_at RASD1 26. 47 6. 28E-08 2. 69E-05 1.55 7.91 17p11.2 35 209691_s_at DOK4 16. 14 7. 32E-08 3. 07E-05 1.53 7.84 16q12. 2 36 211031_s_at CYLN2 15. 47 6. 05E-08 2. 66E-05 1. 47 7. 82 7q11. 23 37 211671_s_at NR3C1 2.93 2. OOE-08 1. 36E-05 1.36 7.81 5q31 38 202600_s_at NRIP1 4.52 5. 81 E-09 6. 03E-06 1.30 7.78 21q11. 2 39 222488_s_at DCTN4 4.33 1. 38E-08 1. 09E-05 1.31 7. 71 5q31-q32 40 238365_s_at 5.99 8.22E-09 7.72E-06 1.29 7.68 41 242051 at 7. 08 8. 77E-08 3. 46E-05 1. 36 7. 48 42 218694_at ALEX1 8.11 8. 24E-08 3. 39E-05 1.34 7.47 Xq21. 33-q22.2 43 202262 x at DDAH2 4. 08 1. 84E-08 1. 33E-05 1.26 7.45 6p21. 3 44 201417 at 3. 68 2. 15E-08 1. 36E-05 1.25 7.41 45 224833_at EST1 -5. 24 4. 00E-06 5.16E-04-1. 55 -7.34 11q23. 3 46 201865_x_at NR3C1 2.50 2. 21E-08 1. 36E-05t2375q31 47 203853_s_at GAB2 3.22 2. 88E-08 1. 67E-05 1.23 7.30 11q13. 3 48 202052 s at RAI14 11. 38 2.19E-07 7. 20E-05 1.40 7.29 5p13.3-p13. 2 49 219686_at HSA250839 48.88 2.78E-07 8. 83E-05 1.49 7.27 4p16. 2 50 218966 at MY05C 4. 17 1.27E-07 4. 56E-05 1.31 7.27 15q21 2.15 ALL_Ph+ versus AML MLL # affy id HUGO name fc p q stn t Map Location 1211404satAPLP2-6. 34 2. 86E-19 5. 76E-15-2. 13-15. 3811q24 2 214651_s_at HOXA9 -63.20 2. 48E-16 1. 67E-12-2. 45-15. 16 7p15-p14 3208702xatAPLP2-7. 29 1. 06E-16 1. 06E-12-1. 96-13. 7711q24 4 214875_x_at APLP2 -7.27 2.70E-15 1.09E-11 -1.86 -12.79 11q24 Table 2.1-2. 78 5 201105_at LGALS1 -10.45 6.63E-16 3. 34E-12-1. 75-12.56 22q13. 1 6 213147 at HOXA10-12.71 3. 47E-14 1. 17E-10-1. 92-12. 44 7p15-p14 7 235753_at -12. 81 1. 55E-13 3.12E-10-1. 89-11. 93 8 210487_at DNTT 512.35 8.37E-11 2. 96E-08 2. 40 11. 5410q23-q24 9 206847_s_at HOXA7 -7.12 1.84E-13 3. 37E-10-1. 68-11. 35 7p15-p14 10 209905_at HOXA9 - 1. 99E-12 2.20E-09-1. 87-11.01 7p15-p14 190.24 11 234107sat HARS2-4. 43 1.02E-12 1. 21 E-09-1. 55-10. 57 20p11. 23 12 229860_x_at -4.41 1.52E-13 3.12E-10-1. 40-10. 22 13 223017_at TLP19 -2.13 1.37E-13 3.12E-10 -1. 37-10.11 1p32. 3 14 213150_at HOXA10-28. 94 1. 87E-11 9.69E-09-1. 64-10.02 7p15-p14 15 218404_at SNX10 -6.89 4.53E-12 3. 81E-09 -1. 47-10.02 7p15. 2 16 227584 at 9. 93 1.02E-09 1. 56E-07 1.89 10. 01 17 202546_at VAMP8-3. 7 2.44E-13 4. 10E-10-1. 36-9.98 2p12-p11. 2 18 217979_at NET-6 11. 37 8. 31E-10 1. 39E-07 1.79 9.97 7p21. 1 19 205639 at AOAH-9. 19 2.53E-12 2.47E-09-1. 41-9.93 7p14-p12 20 200742_s_at CLN2 -3.05 9. 87E-14 2.84E-10-1. 32-9. 90 11 p15 21 203733 at MYLE-3. 78 6.12E-13 8. 51E-10 -1.36 -9.90 16p13. 2 22 209249_s_at GHITM -1.79 2. 69E-13 4. 17E-10-1. 32-9. 8010q23. 1 23209771 xatCD2480 4.78E-10 9. 73E-08 1. 60 9. 79 6q21 24 223732_at SLC23A2 4. 96 7.65E-10 1. 30E-07 1. 64 9. 74 5q31. 2-q31. 3 25 204122 at TYROBP-5. 48 6. 75E-13 8. 51E-10-1. 30-9. 61 19q13. 1 26 212071_s_at SPTBN1 4.01 1. 43E-10 4. 17E-08 1.45 9.60 2p21 27 244084_at FLJ30473 -5.06 9.32E-12 6.49E-09-1. 38-9. 59 22q11. 21 28223703atCDA017-6. 08 2. 68E-11 1.23E-08-1. 45-9. 59 10q23. 1 29200803satTEGT-2. 57 2.08E-12 2.20E-09-1. 32-9. 5712q12-q13 30 216379_x_at KIAA1919 9.96 1.05E-09 1. 58E-07 1. 61 9. 57 6q22 31 202054_s_at ALDH3A2 -4.95 2.57E-12 2.47E-09-1. 31-9. 5017p11. 2 32 200743_s_at CLN2 -2.30 6. 53E-13 8. 51 E-10-1. 27-9. 44 11p15 33 228083_at CACNA2D4 -11.06 1.21E-11 7.61E-09 -1.35 -9.44 12p13. 33 34 217936_at 4.17 1.34E-10 4. 03E-08 1.40 9.43 35 41220_at MSF 2.50 1. 70E-10 4. 89E-08 1.40 9.36 17q25 36208608satSNTB1-4. 98 7. 25E-12 5.42E-09-1. 30-9. 31 8q23-q24 37 233849_s_at ARHGAP5 8.16 4.58E-10 9. 42E-08 1.43 9.30 14q12 38 231887_s_at KIAA1274 3.62 2.18E-09 2.61 E-07 1. 56 9. 23 1 Oq22. 1 39 227108_at STARD9 2.55 8. 29E-10 1. 39E-07 1.42 9.12 15q14 40 225745 at 3. 78 6. 70E-10 1. 22E-07 1.40 9.12 41 222845 x at CGI-119-2. 70 6.78E-12 5.26E-09-1. 23-9. 0512q14. 1-q15 42 201540_at FHL1 6.33 1. 30E-09 1. 77E-07 1.43 9. 05 Xq26 43 212012 at 11. 97 3.68E-09 3. 73E-07 1.55 9.03 44 214430_at GLA -2.42 2. 81 E-12 2.58E-09-1. 21-9. 03 Xq22 45 201968_s_at PGM1 -4.22 6.64E-12 5.26E-09-1. 23-9. 03 1p31 46200886satPGAM1-2. 71 7. 54E-12 5.43E-09-1. 23-9. 00 10q25. 3 47 200661_at PPGB-4. 84 1. 59E-11 9. 18E-09-1. 24-8. 98 20q13. 1 48 227853_at -2.96 3. 25E-12 2. 85E-09-1. 19-8. 93 49 216417_x_at HOXB9 -3.94 1. 34E-11 8.20E-09-1. 22-8. 8917q21. 3 Table 2.1-2. 78 50 213056_at KIAA1013 5. 12 4. 98E-09 4.76E-07 1.52 8. 89 3p14. 1 2.16 ALL_Ph+ versus AML-inv (16) # affy id HUGO name fc p q stn t Map Location 1208702xatAPLP2-6. 18 2. 07E-17 2. 52E-13-2.33-15. 48 11q24 2 203373_at SOCS2 22. 27 1. 47E-13 2. 77E-10 2.68 15.06 12q 3 208248 x at APLP2-4. 47 1. 22E-18 2.98E-14-2. 08-14.41 11 q24 4 231310_at -6. 03 6.70E-14 1. 49E-10-2. 34-14.06 5 211404_s_at APLP2 -5. 87 1.02E-14 5. 28E-11-2. 06-13. 3511q24 6 224918_x_at MGST1 -10. 37 4.17E-14 1. 10E-10-1. 97-12. 7412p12. 3-p12. 1 7 214875_x_at APLP2 -6. 83 3. 12E-13 5. 08E-10-2. 01-12. 55 11q24 8 205382_s_at DF -10. 05 1.45E-14 5. 28E-11-1. 86-12. 40 19p13. 3 9 202746_at ITM2A -10. 49 1. 98E-12 2. 10E-09-2. 11-12. 38 Xq13.3-Xq21. 2 10 202747 s at ITM2A-10. 76 1.87E-12 2. 08E-09-2. 07-12.29 Xq13. 3-Xq21. 2 1208704xatAPLP2-4. 46 7. 98E-15 5. 28E-11-1. 80-12. 1711q24 12 231736_x_at MGST1 -10. 18 1. 18E-12 1. 51E-09 -1. 87-11. 7512p12. 3-p12. 1 13 225510_at-6. 59 4. 14E-13 6. 32E-10-1. 79-11.61 14 202720_at TES -5. 42 1. 11E-12 1. 51 E-09-1. 83-11. 59 7q31. 2 15 204214_s_at RAB32 -4. 20 4.29E-14 1. 10E-10 -1.67 -11.33 6q24. 2 16 200661_at PPGB-4. 07 1. 10E-14 5. 28E-11-1. 62-11. 21 20q13. 1 17 233177_s_at MR-1 -2. 60 1. 51E-14 5. 28E-11-1. 62-11. 19 2q35 18 201497_x_at MYH11 -25. 24 5. 08E-11 2.95E-08-2. 15-11. 1816p13. 13-p13. 12 19 210487_at DNTT 34. 98 1. 14E-10 5. 37E-08 2.08 11.15 10q23-q24 20 201496_x_at MYH11 -10. 52 1. 51E-11 1. 15E-08-1. 87-11. 15 16p13.13-p13. 12 21 207075_at CIAS1 -5.11 2. 58E-13 4. 50E-10-1. 65-11. 06 1q44 22 203973 s at CEBPD-4. 43 4. 51E-14 1. 10E-10-1. 57-10.82 8p11. 2-p11. 1 23219229atSLC21A11-6. 75 1.30E-12 1. 51 E-09-1. 62-10-72 15q26 24 217989_at RetSDR2-2. 19 1. 06E-13 2.16E-10-1. 51-10.43 4q21. 3 25 200872_at S100A10 -6. 57 3. 77E-11 2.36E-08-1. 69-10. 421q21 26 201811_x_at SH3BP5 8.81 2. 27E-10 9. 23E-08 1. 81 10. 39 3p24.3 27 204122_at TYROBP -5. 91 1. 27E-12 1. 51 E-09-1. 54-10. 35 19q13. 1 28201360atCST3-9. 35 1. 33E-11 1. 11E-08 -1.60 -10.27 20p11. 21 29 226611_s_at p30 -2. 79 6. 06E-13 8. 71E-10 -1. 48-10. 13 17p11. 2 30229776atSLC21A11-2. 56 2. 77E-12 2. 71E-09 -1. 49-10. 06 15q26 31 224583_at COTL1 -4. 30 2. 72E-12 2. 71 E-09-1. 41-9. 66 16q23. 3 32 221059_s_at CHST6 -4. 22 5.93E-12 5.57E-09-1. 41-9. 59 16q22 33 227711_at FLJ32942 -4. 79 1. 79E-11 1.32E-08-1. 42 -9.49 12q13. 13 34 208703_s_at APLP2 -5. 68 3. 93E-11 2.40E-08-1. 43-9. 46 11 q24 35 203948_s_at MPO -4. 34 2.81 E-11 1. 91 E-08-1. 41-9. 44 17q23. 1 36 220326 s at FLJ10357-4. 45 3. 77E-10 1.28E-07-1. 52-9. 3614q11. 1 37 218017 s at FLJ22242-4. 09 1. 05E-11 9.52E-09 -1.37 -9. 35 8p11. 1 38 203372 s at SOCS2 25. 58 3.41 E-09 7. 12E-07 1.77 9.34 12q 39 209771 x at CD24 7. 36 5. 42E-10 1. 76E-07 1.48 9.24 6q21 40 212012_at 15.84 2. 48E-09 5. 72E-07 1.63 9.24 Table 2. 1-2.78 41 203949 at MPO-3.39 3. 54E-10 1. 25E-07-1. 46-9. 2317q23. 1 42224724atSULF2-7. 95 1. 22E-09 3. 36E-07-1. 58-9. 21 20q12-13. 2 43 202016_at MEST-5. 68 2. 68E-10 1. 07E-07-1. 44-9. 17 7q32 44 217979 at NET-6 7. 52 1. 19E-09 3.31 E-07 1.50 9.14 7p21. 1 45 202074_s_at OPTN 3. 47 4. 99E-11 2. 95E-08 1.35 9.08 10p14 46 212071_s_at SPTBN1 3. 21 1.36E-09 3. 65E-07 1.49 9.06 2p21 47 225579_at MGC33602 -3. 49 5. 73E-10 1.82E-07-1. 44-9.04 2p25. 1 48 222942_s_at TIAM2 6. 59 2. 92E-09 6. 54E-07 1.55 9.02 6q25 49 216379_x_at KIAA1919 7.87 1.24E-09 3.37E-07 1.46 9.01 6q22 50 215706_x_at ZYX -3.01 1.14E-11 9.98E-09 -1.30 -8.97 7q32 2.17 ALL_Ph+ versus AML_inv(3) # affy id HUGO name fc stn t Map Location 1 210487_at DNTT 11. 52 1. 27E-10 1. 60E-06 1.65 9.68 10q23-q24 2 203373_at SOCS2 4. 03 7. 83E-12 1. 98E-07 1.52 9.72 12q 3217963satNGFRAP1-16. 83 2.47E-08 5.67E-05-1. 94-9. 46 Xq22. 1 4234107satHARS2-5. 90 2.91 E-08 5.67E-05-1. 86 -9.26 20p11. 23 5 230659_at KIAA0212 3.25 8.04E-10 6.78E-06 1.54 9.16 3p26.1 6 201462_at KIAA0193 -9. 36 2.54E-08 5.67E-05-1. 76-9. 14 7p14. 3-p14. 1 7 218094_s_at C20orf35 -5. 88 5. 35E-08 6.54E-05-1. 68-8.71 20q13. 11 8 201243_s_at ATP1B1 -8.09 1.31 E-07 1.07E-04-1. 60 -8.24 1q22-q25 9 229487_at 7.70 2. 65E-08 5. 67E-05 1.53 8.23 10 221969_at PAX5 5. 65 2. 02E-08 5. 67E-05 1.43 8.12 9p13 11 230643_at 4.40 2. 81E-08 5.67E-05 1.44 8.04 12 203372_s_at SOCS2 6.50 2. 33E-08 5. 67E-05 1.39 7.98 12q 13 205645 at REPS2-4. 97 5. OOE-08 6.54E-05-1. 37-7. 93 Xp22.22 14 206295_at IL18-5. 36 1.13E-07 9.66E-05-1. 40-7. 8211q22. 2-q22.3 15 204214-s-at RAB32-2. 66 2. 22E-09 1.40E-05-1. 21-7.75 6q24.2 16 227276 at TEM7R-3. 75 2. 11E-07 1.44E-04-1. 43-7. 7410p12. 1 17 210212_at 6.16 1. 36E-08 5. 67E-05 1. 27 7. 72 18 37408_at MRC2-3. 20 2.44E-07 1.46E-04-1. 41-7. 64 17q23. 3 19202626satLN-2. 97 1. 20E-08 5.67E-05-1. 23-7. 63 8q13 20219229atSLC21A11-4. 52 3.14E-08 5.67E-05-1. 23-7.51 15q26 21 202439_s_at IDS -2.76 2.32E-07 1.46E-04-1. 33-7.44 Xq28 22212223at-2. 72 1. 14E-07 9.66E-05-1. 25-7. 38 23244623at-3. 37 7.77E-08 8. 19E-05-1. 23-7.37 24 207111 at EMR1-3. 48 3.87E-07 1.85E-04-1. 35-7. 35 19p13. 3 25 221558_s_at LEF1 17. 17 2.53E-07 1. 46E-04 1. 45 7. 29 4q23-q25 26226865at-7. 62 7. 26E-07 2. 55E-04-1. 41-7. 29 27 207655_s_at BLNK 11. 17 2. 08E-07 1. 44E-04 1.35 7.27 10q23. 2-q23.33 28 218885_s_at GALNT12 -3. 53 4. 68E-08 6.54E-05-1. 18 -7.26 9q22.33 29227425at-2. 60 2.69E-07 1.46E-04-1. 26-7. 21 30 209710_at MGC2306 -4. 81 7.21 E-07 2.55E-04-1. 36-7.20 3q21. 3 31 229649_at NRXN3 11. 73 2. 68E-07 1. 46E-04 1. 36 7. 2014q31 Table 2. 1-2.78 32 229572at-3. 91 1. 97E-07 1.42E-04-1. 23-7. 19 33 206478_at KIAA0125 -13. 00 1.33E-06 3. 50E-04-1. 48-7. 1514q32. 33 34 230896_at -16. 48 1.34E-06 3. 50E-04-1. 44-7.10 35 230206 at-4. 08 1.14E-07 9.66E-05-1. 16-7. 05 36 202123_s_at ABL1 2. 24 4.02E-08 6.54E-05 1. 12 7. 02 9q34. 1 37 224413_s_at BLP1 -2. 31 1.64E-07 1. 26E-04-1. 16-6. 99 8p11. 21 38 201242_s_at ATP1B1 -9. 60 1.49E-06 3.67E-04-1. 37-6. 971q22-q25 39 232114_at TRALPUSH-4. 92 6.54E-07 2.47E-04-1. 23-6. 94 3q25.1 40225745at2*33 1.12E-07 9. 66E-05 1.14 6.93 41 233955_x_at HSPC195 -2. 96 2.72E-07 1.46E-04-1. 16-6. 91 5q31. 3 42 216379_x_at KIAA1919 4.02 4.53E-08 6. 54E-05 1.09 6.90 6q22 43 227379_at MGC44669 -1. 77 6.40E-08 7.04E-05-1. 10-6. 90 6p22.2 44 202746_at ITM2A -5. 83 1.54E-06 3.67E-04-1. 32-6. 88 Xq13. 3-Xq21. 2 45 222942_s_at TIAM2 3.78 5.56E-08 6. 54E-05 1.09 6.87 6q25 46212221xat-2. 67 4.44E-07 2. 01E-04 -1.17 -6. 86 47 212775_at KIAA0657 -9. 18 1.83E-06 3.97E-04-1. 34-6. 85 2q36. 1 48 205997_at ADAM28 -10. 17 1. 66E-06 3.78E-04-1. 28-6. 79 8p21.1 49209771 xatCD24360 5.69E-08 6. 54E-05 1. 06 6. 77 6q21 50 201030_x_at LDHB -1. 50 1. 01E-07 9.66E-05-1. 08 -6.76 12p12.2-p12. 1 2. 18 ALL_Ph versus AML komplext # affy id HUGO name fc p q stn t Map Location 1 203373_at SOCS2 9. 24 3. 05E-13 1. 92E-09 2. 25 13. 82 12q 2 213147_at HOXA10 -5. 85 3. 31E-14 6. 24E-10-1. 55 -11.14 7p15-p14 3 210487_at DNTT 12. 99 1. 43E-10 1. 50E-07 1.65 10. 26 10q23-q24 4 209619 at CD74 2. 60 6.28E-12 1. 97E-08 1.45 10. 15 5q32 5234107satHARS2-4. 18 3. 08E-12 1. 16E-08-1. 44-10. 01 20p11. 23 6200620atC1orf8-1. 82 1. 38E-13 1.30E-09-1. 31-9.82 1 p36-p31 7 206847_s_at HOXA7 -3. 71 1.63E-12 7.69E-09-1. 28-9. 43 7p15-p14 8205020satARL4-4. 10 1. 46E-11 3.43E-08-1. 26-9. 097p21-p15. 3 9 203372_s_at SOCS2 15. 32 5.49E-09 1. 38E-06 1.68 9.08 12q 10 214651_s_at HOXA9 -34. 12 2.17E-10 2.04E-07-1. 41-8.91 7p15-p14 11 207332satTFRC-2. 88 2.45E-11 5. 13E-08-1. 21-8.82 3q26.2-qter 12 217963_s_at NGFRAP1 -14.01 3.58E-10 2.75E-07 -1.33 -8.65 Xq22.1 13 218718_at PDGFC -14.47 675E-10 3.35E-07 -1.38 -8.53 4q32 14 207157_s at GNG5-1. 87 1. 37E-11 3.43E-08-1. 13-8. 49 1p22 15 225782_at LOC253827 -11.06 1.01E-10 1.35E-07 -1.18 -8.48 12q14.1 16 204671_s_at ANKRD6 -2.76 5.02E-11 9.45E-08 -1.13 -8.38 6q14.2-q16.1 17 222978 at SURF4 -2.251 1.07E-10 1.35E-07-1. 15-8. 36 9q34. 2 18 202746 at ITM2A-6. 82 6. 01E-1 3.23E-07-1. 23-8. 32 Xq13.3-Xq21. 2 19 51192_at SSH-3-3. 34 8. 40E-11 1.22E-07-1. 12-8. 2811q13. 1 20 223276_at NID67 3.00 6. 38E-09 1. 46E-06 1.27 8.22 5q33.1 21 210648_x_at SNX3 -1. 65 5. 59E-11 9. 58E-08-1. 09-8. 20 6q21 22 235753_at -5. 68 8. 67E-10 3.78E-07-1. 21-8. 19 Table 2.1-2. 78 23 205997_at ADAM28-11. 00 8.55E-10 3.78E-07-1. 17-8. 10 8p21. 1 24 222401_s_at SMP1 -1.81 7. 48E-11 1.17E-07-1. 08-8. 091p36. 11 25 222229_x_at 1.50 3. 91E-10 2.83E-07 1.11 8.09 26 218224_at PNMA1 -3. 14 5.04E-10 3. 13E-07-1. 12-8. 04 14q24. 1 27 204214_s_at RAB32-4. 24 4.44E-10 3. 10E-07 -1. 11-8. 02 6q24. 2 28235521atHOXA3-6. 05 1.86E-09 6.13E-07-1. 21-8.01 7p15-p14 29 229487_at 6.95 3. 10E-08 3. 90E-06 1.35 8.00 30 221969_at PAX5 5. 81 1.48E-08 2. 40E-06 1.26 7.99 9p13 31 202747_s_at ITM2A -6. 64 1. 41 E-09 5. 21 E-07-1. 17-7. 97 Xq13. 3-Xq21. 2 32 218364_at LRRFIP2 -2.22 1. 22E-10 1. 35E-07-1. 06-7. 94 3p21. 33 33 224598_at MGAT4B -1.91 1.16E-10 1.35E-07-1. 05 -7.93 5q35 34 222000_at -2.03 3. 66E-10 2.75E-07-1. 07-7.88 35 241706_at LOC144402 -3.69 1. 31E-09 5. 21E-07 -1.12 -7.86 12q11 36 208691_at TFRC -2.65 5.42E-10 3.13E-07-1. 08-7. 86 3q26.2-qter 37 218618_s_at FAD104 -4.25 7.06E-10 3. 41 E-07-1. 09-7. 86 3q26.31 38 207549 x at MCP-1. 72 2. 02E-10 2. 00E-07 -1. 04 -7.83 1q32 39 208702_x_at APLP2 -4.98 1.62E-09 5. 56E-07-1. 12-7. 81 11 q24 40 239328 at 3. 78 2.29E-08 3. 24E-06 1. 22 7. 80 41 225032_at FAD104 -3.39 2. 98E-10 2.44E-07-1. 04-7. 78 3q26.31 42 220248_x_at NSFL1C -1. 91 2. 80E-10 2.40E-07-1. 03 -7.73 20 43 211404_s_at APLP2 -4. 81 2.23E-09 7.23E-07-1. 11 -7.73 11q24 44 225790 at LOC253827-9. 82 7.80E-10 3.58E-07-1. 05 -7.72 12q14. 1 45 226416_at MGC35395 -3. 14 2. 77E-09 8.71 E-07-1.12-7. 72 8p23.1 46 202413_s_at USP1 -1.79 2.67E-10 2.39E-07-1. 02 -7. 71 1p32.1-p31. 3 47 209905_at HOXA9 -76. 74 6.95E-09 1.49E-06-1. 26-7. 70 7p15-p14 48 209804_at DCLRE1A -3.87 4.91E-10 3.13E-07-1. 03-7. 7010q25. 1 49 200023_s_at- EIF3S5 1. 51 1. 29E-09 5.21E-07 1.05 7.68 11p15. 3 HG-U133A 50 202001sat NDUFA6-1. 70 7. 29E-10 3.43E-07-1. 04-7. 68 22q13.2-q13. 31 2.19 ALL_Ph+ versus AML-t (15; 17) # affy id HUGO name fc p q stn t Map Location 1 224918_x_at MGST1 -18.86 5.23E-17 2.67E-13-3. 64-21. 2212p12. 3-p12. 1 2211990atHLA-DPA112. 75 3. 45E-18 3. 51 E-14 3. 55 21.15 6p21. 3 3 231736_x_at MGST1 -19. 37 2.72E-15 6.17E-12-3. 47-19. 4012p12. 3-p12. 1 4 205382sat DF-21.42 7.44E-16 2.53E-12-3. 35-19. 32 19p13. 3 5 214450_at CTSW -30.23 1. 29E-13 1. 55E-10-3. 4-17. 70 11 q13. 1 6 212953_x_at CALR -4.60 1. 29E-14 2. 40E-11-3. 01-17. 21 19p13. 3-p13. 2 7 203948_s_at MPO -7. 81 1. 93E-19 3.94E-15-2. 47-16. 2217q23. 1 8209732atCLECSF236. 12 3. 01E-13 3.07E-10 2.98 15.23 12p13-p12 9 203373_at SOCS2 21. 12 1. 78E-13 1. 91 E-10 2. 76 15. 06 12q 10 205624_at CPA3 -55. 84 5. 74E-12 3.77E-09-3. 23-14.93 3q21-q25 11 221739 at IL27w-2. 38 5.10E-17 2. 67E-13-2. 19-14. 2819p13. 3 12 208689_s_at RPN2 -2. 74 7. 91E-17 3. 23E-13-2. 09-13. 70 20q12-q13. 1 Table 2.1-2. 78 13 38487 at STAB1-6.72 1. 43E-13 1.62E-10-2. 23-13. 55 ep21. 31 14 217716_s_at SEC61A1 -2. 64 3.78E-14 5. 92E-11-2. 15-13. 38 3q21. 3 15 209619_at CD74 5. 93 2. 22E-15 5. 67E-12 2. 08 13.37 5q32 16 238022_at -7. 99 2.31 E-12 1. 89E-09-2. 30-13. 27 17 224839_s_at GPT2 -33.18 4. 95E-11 1. 91 E-08-2. 80-13. 17 16q12. 1 18 210788_s_at retSDR4 -4.68 5. 15E-15 1. 05E-11-2. 01-12.91 14q22.3 19 200654 at P4HB-3. 29 1.83E-15 5.34E-12-1. 94-12. 63 17q25 20 203949_at MPO -4. 47 1.99E-14 3. 38E-11-1. 97-12. 5717q23. 1 21 233072_at KIAA1857 -11. 57 8.06E-11 2. 69E-08-2. 33-12. 24 9q34 22217225xatLOC283820-2. 43 3.77E-13 3. 66E-10-1. 93-12. 0916p13. 13 23 202600_s_at NRIP1 13. 01 8. 31E-12 4. 70E-09 2.06 11.92 21q11. 2 24 220798_x_at FLJ11535 -6. 19 1.54E-12 1.36E-09-1. 88-11. 66 19p13. 3 25221087satAPOL34*63 3.50E-12 2. 55E-09 1.89 11.48 22q13. 1 26 217770_at PIGT-2. 59 2. 24E-12 1.89E-09-1. 84-11. 43 20q12-q13. 12 27 210487_at DNTT 81. 93 9. 68E-11 3. 08E-08 2. 26 11. 4010q23-q24 28 221004_s_at ITM2C-4. 40 5. 95E-14 8. 66E-11 -1.72 -11.26 2q37 29 208675_s_at DDOST -2. 80 6.89E-14 9. 37E-11 -1.72 -11.22 1p36. 1 30205663atPCBP3-4. 29 1.17E-11 6.16E-09-1. 83-11. 15 21q22. 3 31 205771_s_at AKAP7 6. 53 7.28E-12 4. 50E-09 1. 82 11. 10 6q23 32 201666_at TIMP1 -5. 05 1. 69E-11 7.82E-09-1. 81-11. 02 Xp11. 3-p11. 23 33 221253_s_at MGC3178 -3. 67 4. 45E-11 1.79E-08-1. 85 -11.00 6p24. 3 34 213491_x_at RPN2-2. 14 1.22E-13 1. 55E-10-1. 66-10. 88 20q12-q13. 1 35 201596_x_at KRT18-11. 99 3. 44E-10 8.07E-08-1. 96-10. 85 12q13 36200803satTEGT-2. 41 3. 16E-12 2. 39E-09-1. 69-10. 7012q12-q13 37 238376_at 4.16 5. 05E-11 1. 91 E-08 1. 81 10. 69 38 200986_at SERPING1 -11. 43 1. 31E-09 2.12E-07-2. 06-10. 5811q12-q13. 1 39 34210_at CDW52 32. 56 3. 48E-10 8. 07E-08 1.99 10.52 1p32 40 209771_x_at CD24 19. 65 1.28E-10 3. 77E-08 1.82 10.47 6q21 41 212873_at HA-1 3. 33 2.74E-12 2. 15E-09 1.62 10.40 19p13. 3 42 214315_x_at CALR -2. 74 9. 34E-11 3.02E-08-1. 73-10. 3919p13. 3-p13. 2 43 200977_s_at TAX1BP1 -2. 29 7. 72E-12 4.63E-09-1. 63-10. 327p15 44 202599_s_at NRIP1 8. 82 1.14E-10 3. 46E-08 1.75 10. 32 21q11. 2 45 201540 at FHL1 14. 05 3.35E-10 8. 07E-08 1. 87 10. 32 Xq26 46 201553_s_at LAMP1 -1. 58 6.66E-13 6.17E-10-1. 57-10. 31 13q34 47 209831_x_at DNASE2 -3. 29 4. 12E-10 8. 92E-08-1. 79-10. 29 19p13. 2 48 204150_at STAB1 -7. 73 7.44E-10 1.34E-07-1. 82-10. 23 3p21. 31 49 225790_at LOC253827 -14. 52 2. 61 E-10 6.83E-08-1. 71-10. 14 12q14. 1 50 208612_at GRP58 -2. 01 4.34E-12 2. 95E-09-1. 56-10. 08 15q15 2, 20 ALL Ph+ versus AML-t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 203373 at SOCS2 8. 25 1. 28E-13 3. 46E-09 2.09 13.13 12q 2 210487_at DNTT 23. 41 1.56E-10 3. 01E-07 2.07 11.00 10q23-q24 3 218718_at PDGFC -14.86 7.65E-11 1.88E-07 -2.01 -10.88 4q32 Table 2.1-2. 78 4 201811rat SH3BP5 10.27 1.93E-10 3.47E-07 1. 91 10. 66 3p24. 3 5 203949_at MPO -4.10 4.67E-13 4.21E-09 -1. 51-10. 30 17q23. 1 6 224918_x at MGST1-9. 71 2. 67E-11 9.63E-08-1. 62-10. 2412p12. 3-p12. 1 7 203948_s_at MPO -5. 71 3.62E-13 4. 21E-09 -1. 46-10. 08 17q23. 1 8 228827 at-75. 79 4.79E-10 7.19E-07-1. 96-10. 01 9 211084_x_at PRKCN 5.01 1.04E-10 2.35E-07 1.44 9.37 2p21 10 208248_x_at APLP2 -3.24 3.25E-12 2.19E-08-1. 35-9. 36 11 q24 11 231736_x_at MGST1 -9.18 4.35E-10 6. 91 E-07-1. 51-9. 29 12p12. 3-p12. 1 12 208702_x_at APLP2 -4. 13 5. 83E-11 1. 58E-07-1. 39-9. 2411q24 13 205529_s_at CBFA2T1-14. 92 2. 20E-09 2.13E-06-1. 72-9.20 8q22 14 228058_at LOC124220-4. 47 2. 85E-11 9.63E-08-1. 36-9. 17 16p13.3 15 217989_at RetSDR2 -2. 05 7.56E-12 4.09E-08-1. 31-9. 10 4q21. 3 16208704xatAPLP2-3. 47 3. 26E-11 9. 78E-08-1. 33-9. 0411q24 17 229406 at-11. 21 1. 96E-09 2.04E-06-1. 56-9. 03 18 233849_s_at ARHGAP5 6.11 1. 46E-09 1. 72E-06 1.46 8.97 14q12 19201810satSH3BP5663 4.46E-09 2. 82E-06 1. 55 8. 91 3p24.3 20 203372 s_at SOCS2 12. 34 7.28E-09 3. 59E-06 1. 66 8. 91 12q 21 202719_s_at TES -4. 02 2. 10E-11 9.46E-08-1. 28-8. 86 7q31. 2 22209262satNR2F6-7. 53 1. 56E-10 3. 01E-07 -1.33 -8.83 19p13. 1 23221000satFKSG2872 5.90E-09 3. 26E-06 1.55 8.81 10q24. 31 24217936at3. 78 2.78E-10 4. 70E-07 1. 32 8. 75 25 226545 at 9. 50 6.70E-09 3. 48E-06 1. 54 8. 75 26 227584_at 5. 15 4.49E-09 2. 82E-06 1. 45 8. 65 27 200023_s_at - EIF3S5 1.50 1.05E-09 1. 29E-06 1.33 8.60 11p15. 3 HG-U133A 28 221581_s_at WBSCR5 10.83 1. 50E-08 5. 62E-06 1. 60 8.57 7q11. 23 29218237satSLC38A15. 09 9.37E-09 4. 22E-06 1.47 8.50 12q12 30 225240_s_at 5.16 1. 21 E-08 4. 95E-06 1. 49 8. 47 31222942satTfAM250 6.25E-09 3.31 E-06 1. 41 8. 47 6q25 32 202600_s_at NRIP1 3.15 2.57E-09 2. 14E-06 1.34 8.45 21q11. 2 33 223732_at SLC23A2 3.68 2.62E-09 2.14E-6 1.33 8.41 5q31.2-q31.3 34 229487_at 8.40 2.36E-08 7.16E-06 1.61 8.39 35 202123_s_at ABL1 2.60 3.24E-09 2. 44E-06 1. 33 8. 39 9q34. 1 36 203568_s_at TRIM38 2.59 1.91E-09 2.04E-06 1.30 8.36 6p21. 3 37 208091_s_at DKFZP564K0822 3.98 9. 54E-10 1. 23E-06 1.27 8.35 7p14.1 38 230643_at 5.18 1. 13E-08 4.71 E-06 1. 40 8. 31 39 226169_at LOC283105 2. 68 3.89E-09 2. 65E-06 1.31 8.28 11p15. 3 40 223703_at CDA017 -3. 72 3.25E-09 2.44E-06-1. 31-8. 27 10q23. 1 41 205528_s_at CBFA2T1 -24.06 1.56E-08 5.70E-06-1. 53-8.27 8q22 42 204214_s_at RAB32 -4.40 2.32E-09 2. 13E-06-1. 29-8.26 6q24.2 43 41220-at MSF 2. 14 2.47E-09 2. 14E-06 1.28 8.24 17q25 44 208146_s_at CPVL 6.22 7.98E-09 3. 79E-06 1.34 8.21 7p15-p14 45 38269_at PRKD2 3. 66 2.78E-08 7. 84E-061.45 8.13 19q13. 2 46 231887_s_at KIAA1274 2.91 1. 04E-08 4.51 E-06 1. 33 8. 13 1 Oq22. 1 47 217979_at NET-6 4 09 1. 87E-08 6. 35E-06 1. 34 8. 01 7p21. 1 48 224772_at NAV1 6.49 4.20E-08 1.02E-05 1.46 8.01 Table 2.1-2. 78 49 213056_at KIAA1013 3. 96 1.44E-08 5.62E-06 1. 31 8. 003p14. 1 50 227041_at 3.20 3.69E-09 2. 65E-06 1. 23 8. 00 2.21 ALL_Ph+ versus CLL # affy id HUGO name fc p q stn t Map Location 1 225927 at-6. 49 1. 81 E-27 4.30E-23-3. 11-23. 10 2 223514_at CARD11 -20. 32 1.96E-20 5. 83E-17-2 59-18. 00 7p22 3 224838_at FOXP1 -3. 26 1.97E-24 2.34E-20-2. 29-17.57 3p14. 1 4 202625_at LYN-4. 47 9. 93E-24 7.86E-20-2. 23-17. 068q13 5 224833_at ETS1 -7. 54 1.52E-21 5. 14E-18-2. 29-16. 9711q23. 3 6 208091_s_at DKFZP564K0822 -11. 10 2.06E-18 2.57E-15-2. 51-16.50 7p14. 1 7 AFFX-GAPD 2. 14 8.68E-23 5. 15E-19 2.13 16.30 12p13 HUMGAPDH/M33 197_3_at-HG- U133B 8 207616sat TANK-3.73 1.97E-22 9. 36E-19-2. 08-15.91 2q24-q31 9 226454_at LOC92979 -4. 72 4.92E-19 8. 54E-16-2. 24-15. 89 12q13. 13 10 203373_at SOCS2 58. 66 1. 80E-13 2. 20E-11 3.21 15.75 12q 11 218191_s_at FLJ11240 -2. 90 6.96E-22 2.75E-18-2. 02-15.48 6q12 12 212313_at MGC29816 -6. 17 3.48E-19 7. 10E-16 -2. 11-15.36 8p21. 2 13 214615_at P2RY10 -8. 89 9.38E-18 7.91 E-15-2. 21-15.19 Xq21. 1 14 234107_s_at HARS2 -4. 18 1.29E-19 3. 41 E-16-2. 01-14. 95 20p11. 23 15 236280 at-20. 58 9.37E-17 3.97E-14-2. 29-14.75 16 201462_at KIAA0198 -19.72 5. 77E-17 2. 96E-14-2. 20-14.70 7p14. 3-p14. 1 17 223391_at SGPP1 -9. 86 9.67E-18 7. 91E-15-2. 08-14. 70 14q23.1 18 201998 at SIAT1-9. 74 1.27E-17 8. 85E-15-2. 08-14. 64 3q27-q28 19 212590_at RRAS2 -5. 48 1.12E-17 8.59E-15-2. 01-14. 35 11 p15. 2 20 205192_at MAP3K14 -4. 73 4. 71 E-18 4.47E-15-1. 95-14.21 17q21 21 239287 at-27. 28 3. 90E-16 1.27E-13-2. 27-14.19 22204192atCD37-6. 01 2. 42E-18 2. 61E-15 -1. 89-14. 03 19p13-q13. 4 23 206337 at CCR7-11. 65 2. 51E-16 9.02E-14-2. 10-14. 03 17q12-q21.2 24208296xatGG2-1-4. 05 3. 59E-19 7. 10E-16-1. 85-13. 97 5q23. 1 25 219471_at C13orf18 -12. 58 1.88E-16 7.22E-14-2. 05-13. 95 13q14. 11 26225364atLOC200227-3. 16 5. 03E-19 8. 54E-16-1. 84-13. 92 20q13. 11 27 44790_s_at C13orf18 -13. 54 9. 19E-17 3.97E-14-1. 98-13. 88 13q14. 11 28214786atMAP3K1-6. 75 1. 90E-17 1.22E-14-1. 90-13.78 5q11. 2 29 209061 at SULF2-5. 16 5. 54E-17 2.96E-14-1. 93-13. 78 20q12-13. 2 30213309atPLCL2-6. 85 3. 71 E-17 2.20E-14-1. 91-13.73 3p24.3 31 228390_at -12. 05 4. 06E-17 2.24E-14-1. 91-13.73 32 AFFX-GAPD 2. 03 1.74E-18 2. 29E-15 1.82 13.73 12p13 HUMGAPDH/M33 197 3 at-HG- U133A 33 208456sat RRAS2-6. 26 5. 90E-17 2. 96E-14-1. 89-13. 58 11 p15. 2 34 213353_at ABCA5-5. 65 2. 60E-16 9. 12E-14-1. 93-13. 4917q24. 3 Table 2. 1-2.78 35 209075_s_at NIFU -2. 61 2.93E-19 6. 96E-16-1. 75-13. 4512q24. 1 36202524satSPOCK2-5. 37 1.75E-16 6.92E-14-1. 89-13.41 10pter-q25. 3 37 217939_s_at FLJ20080 -2. 21 1. 21E-18 1. 80E-15-1. 76-13.37 2p13. 3 38 227047_x_at KIAA1538 -4. 02 1.09E-18 1. 72E-15-1. 75-13. 37 17p13. 1 39 243780_at-6. 24 4. 31 E-18 4. 27E-15-1. 77-13. 33 40 220987_s_at SNARK -4.55 2. 06E-17 1.29E-14-1. 80-13. 301q32. 1 41 202626_s_at LYN -5.33 5. 63E-18 5. 14E-15-1. 77-13.27 8q13 42 236301_at -8.09 7.59E-18 6. 68E-15-1. 75-13.17 43 203288_at KIAA0355 -3.39 1.52E-18 2.13E-15-1. 71-13. 06 19q13. 11 44 224516_s_at HSPC195 -6. 44 1.99E-16 7.49E-14-1. 79-12.98 5q31. 3 45 229072_at-11. 24 3.65E-16 1. 22E-13-1. 80-12.90 46 50277_at GGA1 -1.93 2.41E-18 2. 61E-15 -1. 68-12. 85 22q 13. 31 47 233955_x_at HSPC 195 -5.40 1.20E-16 4.84E-14-1. 74-12. 80 5q31. 3 48 205484_at SIT -10. 64 3.65E-15 8. 65E-13-1. 90-12. 80 9p13-p12 49 221778 at KIAA1718-3. 62 2.48E-17 1. 51 E-14-1. 70-12.79 7q33-q35 50205105atMAN2A1-3. 60 3.89E-18 4. 01E-15 -1. 67-12.78 5q21-q22 2. 22 ALL Ph+ versus CML # affy id HUGO name fc p q stn t Map Location 1225386satLOC92906-15. 36 1.70E-32 3.87E-28-2. 54-21. 52 2p22. 2 2 205513_at TCN1 -8.30 3. 71E-27 4.23E-23-2. 15-18. 05 11q11-q12 3207802atSGP28-17. 80 9.60E-26 5.47E-22-2. 07-17.32 6p12. 3 4 206440_at LIN7A -11.82 1.04E-24 2.97E-21-2. 06-17. 0012q21 5 206207atCLC-10. 51 7.40E-25 2.78E-21-2. 01-16. 72 19q13. 1 6 204174_at ALOX5AP -6.16 4.38E-26 3.33E-22-1. 97-16. 72 13q12 7 212531_at LCN2 -5.79 5. 86E-24 1.48E-20-2. 01-16.72 9q34 8 210244_at CAMP -9.28 6.62E-25 2.78E-21-1. 88-15.97 3p21. 3 9 205786_s_at ITGAM -5.65 8.54E-25 2.78E-21-1. 86-15.82 16p11. 2 10 209369_at ANXA3-10. 9E 8.80E-24 1.87E-20-1. 84-15. 48 4q13-q22 11 211990_at HLA-DPA1 4.01 2. 00E-18 4. 96E-16 1. 95 15. 26 6p21. 3 12 224918_x_at MGST1 -8.86 9.02E-24 1.87E-20-1. 79-15. 14 12p12. 3-p12. 1 13 226794_at STXBP5-9. 4E 2. 55E-21 2. 15E-18-1. 88-15.14 6q24.3 14 202391_at BASP1-6 5c 3.16E-23 6. 00E-20 -1. 74-14.79 5p15. 1-p14 15 205863 at S100A12-5. 00 2.14E-22 3.05E-19-1. 75-14. 72 1q21 16 200803_s_at TEGT -2.53 4.54E-22 5. 61E-19 -1. 75-14. 65 12q12-q13 17 218857_s_at ASRGL1 -8.29 7. 68E-22 7.62E-19-1. 76-14. 64 11q12. 2 18 203936_s_at MMP9 -7.63 6.08E-23 1.07E-19-1. 72-14.61 20q11. 2-q13. 1 19 228061_at LOC90693-4. 33 9. 21 E-22 8.75E-19-1. 75-14.58 7p15. 3 20 231736_x_at MGST1 -8.20 1.14E-22 1. 86E-19 -1.71 -14.52 12p12.3-p12. 1 21 218454_at FLJ22662 -8. 87 2.12E-22 3.05E-19-1. 72-14.51 12p13. 1 22204669satRNF24-4. 34 5. 05E-22 5.75E-19-1. 72-14.46 20p13-p12. 1 23227769atGPR27-8. 51 7.58E-22 7. 62E-19-1. 72-14.40 3p21-p14 24 208438_s_at FGR -7. 34 2.99E-22 4. 01E-19 -1.71 -14.40 1p36. 2-p36.1 Table 2.1-2. 78 25 222764at ASRGL1-6. 12 4.68E-22 5. 61E-19-1. 67-14. 18 11q12. 2 26 219010_at FLJ10901-4. 50 6.35E-22 6. 90E-19-1. 68-14. 171q31. 3 27206676atCEACAM8-5. 70 4. 08E-18 8. 77E-16-1. 75-13. 97 19q13. 2 28 206851_at RNASE3 -7. 64 3.74E-21 3. 04E-18-1. 65-13. 91 14q24-q31 29201968satPGM1-5. 58 1.05E-21 9.56E-19-1. 64-13. 881p31 30 226789 at-3. 60 4.12E-21 3.24E-18-1. 63-13.77 31 205557_at BPI -5. 31 8. 84E-17 1.21E-14 -1.76 -13.75 20q11.23-q12 32 203373_at SOCS2 8.21 5. 47E-13 1. 98E-11 2. 18 13. 69 12q 33 205237 at FCN1-7. 08 2. 00E-21 1.75E-18-1. 61-13. 66 9q34 34 201029_s_at CD99 5.64 1. 31 E-12 4. 23E-11 2.31 13.65 Xp22. 32 35 225782_at LOC253827 -9. 86 1.84E-20 1.20E-17-1. 62-13. 59 12q14. 1 36 209619_at CD74 4.47 5.03E-14 2. 47E-12 1. 94 13. 56 5q32 37 210648_x_at SNX3 -1.80 1. 34E-19 5. 99E-17-1. 63-13. 52 6q21 38227266sat-7. 36 1. 52E-19 6. 43E-17-1.65-13. 51 39 225639_at SCAP2 -9. 99 4. 35E-19 1.50E-16-1. 67-13.43 7p21-p15 40223423atGPCR1-4. 72 6. 10E-19 1. 93E-16-1. 62-13. 36 3q26.2-q27 41 200625_s_at CAP -2.58 7.62E-21 5. 79E-18-1. 57-13. 31 1 p34. 1 42 226726_at LOCa129642 -4. 34 1.39E-20 9.88E-18-1. 57-13. 27 2p25. 2 43 227236_at TSPAN-2 -12.94 1.56E-18 4. 28E-16-1. 67-13. 26 1p12 44 234978_at FLJ38932-5. 77 4. 94E-19 1. 68E-16-1. 63-13. 24 11 q14. 3 45 211883_x_at CEACAM1 -8. 71 7.83E-19 2.38E-16-1. 63-13. 20 19q13. 2 46 210951 x at RAB27A-4.39 1. 29E-20 9. 45E-18-1. 56-13. 1915q15-q21. 1 47 200983_x_at CD59 -4. 63 5. 39E-20 3. 06E-17-1. 57-13. 17 11 p13 48 223703 at CDA017-4.37 5. 90E-20 3.06E-17 -1. 57-13. 16 10q23. 1 49 231688_at -5. 57 6. 09E-20 3. 06E-17-1. 56-13.14 50224707atORF1-FL49-6. 65 1. 67E-20 1. 12E-17-1. 55-13. 13 5q31. 3 2. 23 ALL_Ph+ versus normal # affy id HUGO name fc p q stn t Map Location 1 203373_at SOCS2 18.81 3.48E-13 2.14E-09 3.04 15.14 12q 2 217988 at HEI10 2. 78 1.79E-14 3. 30E-10 2.47 13.90 14q11. 1 3 218257_s_at UGCGL1 -2. 67 1. 02E-13 9. 41E-10-2. 29-12. 94 2q14. 3 4 204285_s_at PMAIP1 8. 93 6.33E-12 2. 34E-08Z3012. 3218q21. 31 5 218718_at PDGFC -5. 78 3. 75E-07 4. 08E-05-2. 85-12. 21 4q32 6218424satTSAP6-2. 97 1. 20E-10 2. 78E-07-2. 25-12. 14 2qat4'1 7 206488_s_at CD36 -5. 12 2.42E-08 7.60E-06-2. 46-12.03 7q11. 2 8205624atCPA3-6. 57 6.24E-07 5. 64E-05-2. 88-11. 98 3q21-q25 9 224975_at NFIA -5.23 7.05E-07 6. 12E-05-2. 83-11. 79 1p31.3-p31. 2 10 232098_at -5.33 1. 09E-08 4. 08E-06-2. 22-11. 32 11 201029_s_at CD99 3.75 4.98E-12 2. 30E-08 2.01 11.28Xp22. 32 12 223044_at SLC11A3 -9. 84 1.70E-06 1. 11E-04 -2. 73-11. 01 2q32 13 202443_x_at NOTCH2 -3. 08 1.46E-09 1.68E-06-2. 06-10. 991p13-p11 14 203645_s_at CD163 -9.38 8. 92E-07 7. 13E-05-2. 51-10. 8912p13. 3 15 209732_at CLECSF2 4. 21 1. 06E-11 3. 27E-08 1.94 10.87 12p13-p12 Table 2. 1-2. 78 16 210487_at DNTT 18. 51 1. 92E-10 3.55E-07 2. 13 10. 8610q23-q24 17 209806_at HIST1H2BK 4.55 8. 79E-11 2.32E-07 2.02 10.81 6p21. 33 18 226448 at-2. 84 2.53E-08 7.80E-06-2. 10-10. 70 19208690satPDUM15*82 1. 75E-10 3. 55E-07 1.99 10.58 10q22-q26. 3 20 202018_s_at LTF -3. 05 2. 32E-10 3.80E-07-1. 90-10. 47 3q21-q23 21 218262 at FLJ22318-2. 87 1.50E-07 2.34E-05-2. 08-10. 24 5q35.3 22201540atFHL110. 76 7. 06E-10 1. OOE-06 2. 02 10. 20 Xq26 23 223276_at NID67 5.04 2.47E-10 3. 80E-07 1. 88 10. 16 5q33.1 24226806sat-6. 93 3.98E-06 1.84E-04-2. 58-10.14 25 224976 at NFIA-4. 30 2.93E-06 1.52E-04-2. 46-10. 12 1p31.3-p31. 2 26 201988_s_at CREBL2 -2. 20 1.04E-09 1. 38E-06-1. 85-10. 10 12p13 27223502satTNFSF13B-5. 19 8.48E-07 6.99E-05-2. 16-9. 9613q32-34 28 203535_at S100A9-3. 19 7.75E-09 3.67E-06-1. 87 -9.96 1q21 29 206845_s_at RNF40 -2. 26 1.46E-09 1.68E-06-1. 82-9. 95 16p11. 2-p11. 1 30 224608 s at MGC10540-2. 14 1.53E-08 5. 46E-06-1. 89-9. 92 17q21. 2 31 212531_at LCN2-5. 27 2.13E-07 3. 00E-05-2. 00-9. 86 9q34 32223280xatMS4A6A-3. 40 2.07E-09 1. 91 E-06-1. 81-9. 86 11q12. 1 33 227230_s_at KIAA1211 -9. 59 6.57E-06 2.41 E-04-2. 64 -9.85 4q12 34 219013_at GALNT11 -3. 69 1.02E-07 1.82E-05-1. 94-9. 81 7q34-q36 35 234107_s_at HARS2 -3. 95 2. 88E-06 1. 52E-04-2.29-9. 77 20p11. 23 36 234985_at LOC143458-3. 12 1.09E-06 8. 21E-05 -2. 05-9. 54 11p13 37 230988_at -4. 92 7. 55E-06 2. 62E-04-2. 48-9. 53 38 223063_at FLJ14525 -3. 49 1. 23E-06 8.95E-05-2. 04-9. 47 1q42.13-q43 39 205076_s_at CRA -3. 43 2.42E-06 1.36E-04-2. 12-9. 431q12-q21 40 218589_at P2RY5 14. 37 2.73E-09 2. 26E-06 1.82 9.38 13q14 41 205566_at ABHD2 -2. 09 2. 25E-07 3.05E-05 -1.86 -9.35 15q26. 1 42 223223_at ARV1-2. 69 9.92E-09 4.08E-06-1. 73-9. 341q42. 2 43 203372_s_at SOCS2 23. 71 3. 86E-09 2. 55E-06 1. 88 9. 34 12q 44 219505_at CECR1 -3. 47 3. 30E-08 926E-06-1. 76-9. 31 22q11. 2 45 212012_at 13. 95 3.73E-09 2. 55E-06 1.82 9.28 46 212383_at ATP6V0A1 -2. 15 2. 33E-08 7.60E-06-1. 74 -9.26 17q21 47 223515_s_at COQ3 -2.12 1. 82E-09 1. 87E-06-1. 66 -9.20 6q16. 3 48 226751_at DKFZP566K1924 -7. 05 4.27E-06 1.89E-04-2. 13-9. 20 2p13. 2 49 220966_x_at MGC3038 5.05 3.23E-09 2. 30E-06 1. 72 9. 11 9q34. 11 50 236297_at -3. 32 1.25E-07 2. 09E-05-1 77-9. 10 2.24 ALL_T-lineage versus ALL_t (8; 14) affy id HUGO name fc p q stn t Map Location 1 201029 s at CD99 5. 66 7.83E-18 1. 39E-13 2.93 17.39 Xp22. 32 2 213539_at CD3D 14. 40 2. 84E-12 1. 26E-08 2.45 13.12 11q23 3 201028_s_at CD99 7.32 9.33E-12 3. 32E-08 2.24 12.19 Xp22. 32 4 201417_at 6.05 6. 89E-13 6. 13E-09 2. 06 12. 06 5 201416_at SOX4 6.61 2. 05E-12 1. 21 E-08 1. 87 11. 10 6p22. 3 6 220987_s_at SNARK -4.41 1. 15E-07 3. 84E-05-2. 15 -10.05 1q32.1 Table 2. 1-2. 78 7 242051_at 12.17 9.29E-10 2.07E-06 1.84 9.83 8 224861_at 6. 44 4.91 E-11 1. 46E-07 1. 63 9. 68 9 209619_at CD74 -6. 53 1. 31E-08 1.06E-05-1. 78-9.60 5q32 10 224847 at 6. 47 1.78E-09 2. 88E-06 1. 66 9. 20 11 204446 s at ALOX5-7. 10 8.49E-08 3.43E-05-1. 77-9. 10 10q11. 2 12225120at3. 10 5. 96E-10 1. 51E-06 1.54 9.01 13 228007_at 4.17 1.74E-09 2. 88E-06 1.56 8.90 14 204529_s_at TOX 14.92 8.67E-09 7. 83E-06 1.70 8.84 8q11. 23 15 222895_s_at BCL11B 8.78 2.56E-09 3. 80E-06 1. 55 8. 78 14q32. 31 16 204798_at MYB 4.87 1.58E-09 2. 88E-06 1.49 8.69 6q22-q23 17 229838_at NUCB2 6. 75 3.73E-09 5. 11E-06 1.54 8.68 11p15.1-p14 18 209604_s_at GATA3 7.59 4.05E-09 5. 14E-06 1.52 8.62 10p15 19 228174_at 5.05 7.99E-09 7. 83E-06 1.57 8.60 20 235171_at 9.11 6.51 E-09 7. 23E-06 1.54 8.58 21 226878 at-3. 72 4.68E-07 9.14E-05-1. 70 -8.45 22 224848 at 6. 04 2.30E-08 1. 57E-05 1.57 8.30 23 238021_s_at 9.80 7.56E-09 7. 83E-06 1.45 8.27 24 218267_at CINP-1. 73 1. 71E-08 1.22E-05-1. 35-7. 90 14q32. 33 25 235353_at KIAA0746 -3. 96 1.28E-06 1. 81E-04 -1.57 -7.79 4p15. 2 26 37590-a-at 3. 27 1. 71 E-08 1. 22E-05 1.34 7.76 27 212293_at Nback2 2.40 5.33E-09 6. 32E-06 1.29 7.74 1p12 28 217478_s_at HLA-DMA -6. 59 3.02E-06 2. 88E-04-1. 69 -7. 72 6p21. 3 29 209530_at CACNB3 5.85 7.43E-08 3. 22E-05 1.45 7.72 12q13 30 224851_at 10.30 8.92E-08 3. 50E-05 1.49 7.71 31 226048_at 2. 73 9.66E-09 8. 18E-06 1.30 7.70 32 206015 s_at KIAA1041 2. 05 8.80E-09 7.83E-06 1.30 7.70 1pter-q31. 3 33 204639 at ADA 7. 61 7.87E-08 3. 33E-05 1.45 7.69 20q12-q13. 11 34 206804_at CD3G 8.19 5.66E-08 2. 96E-05 1. 40 7. 6911q23 35 212462_at MORF 2.49 1.48E-08 1. 15E-05 1.30 7.65 10q22. 2 36 211990_at HLA-DPA1 -6. 30 1.65E-06 1. 99E-04-1. 54-7. 62 6p21. 3 37 208306_x_at HLA-DRB4 -5. 63 1.05E-06 1.65E-04-1. 47-7. 58 6p21. 3 38 215111_s_at TSC22 7.26 1.16E-07 3. 84E-05 1.44 7.56 13q14 39 219441_s_at FLJ23119 -4. 27 1.60E-06 1. 99E-04-1. 49-7. 5215q26. 3 40 205349_at GNA15 7.54 2.92E-08 1. 73E-05287. 4819p13. 3 41 209312_x_at HLA-DRB1 -5. 25 1. 31E-06 1.83E-04-1. 45-7. 48 6p21. 3 42 218694_at ALEX1 9.86 1.06E-07 3. 84E-05 1.38 7.47 Xq21. 33-q22.2 43 215193_x_at HLA-DRB1-7. 22 3.33E-06 3. 10E-04 -1. 57-7. 46 6p21. 3 44 209602_s_at GATA3 7.21 6.74E-08 3. 22E-05 1.32 7.44 10p15 45 204670_x_at HLA-DRB5 -5. 48 2.44E-06 2.58E-04-1. 50-7. 41 6p21. 3 46220320atFLJ22570-3. 52 1.26E-06 1. 81 E-04-1. 43-7. 40 5q35.3 47 207143_at CDK6 4.18 6.73E-08 3. 22E-05 1.29 7.36 7q21-q22 48 219528_s_at BCL11B 8.45 1.56E-07 4. 66E-05 1.34 7.29 14q32. 31 49 228242_at 3.38 2.73E-08 1. 73E-05 1.22 7.25 50 28046_at LOC152485 3. 22 5.23E-08 2. 96E-05 1.24 7.24 4q31.1 Table 2.1-2. 78 2. 25 ALL T-lineage versus AML MLL # affy id HUGO name fc p q stn t Map Location 1 200743_s_at CLN2 -4. 77 5.67E-21 1. 12E-16-2. 23-16. 30 11p15 2200742satCLN2-7. 00 1.02E-17 4.06E-14-2. 27-15. 50 11p15 3211404satAPLP2-6. 61 1. 34E-19 8. 86E-16 -2. 06-15. 06 11 q24 4 201858_s_at PRG1 -4.82 5.66E-20 5. 62E-16-2. 01-14. 88 10q22. 1 5 206111_at RNASE2 -8. 04 1. 49E-17 4. 94E-14-1. 99-14. 17 14q24-q31 6 222698_s at IMPACT-5. 04 8. 05E-18 4. OOE-14-1. 93-13. 9618q11. 2-q12. 1 7 213539_at CD3D 32.88 1.64E-12 6. 77E-10 2. 51 13. 78 11 q23 8208702xatAPLP2-7. 42 8. 84E-17 2. 51 E-13-1. 95-13. 76 11 q24 9 214651 s at HOXA9-13. 70 1. 41 E-16 2. 79E-13 -1.88 -13.34 7p15-p14 10 227853_at -5.26 1. 41 E-16 2.79E-13-1. 73-12.64 11 203799_at BIMLEC -10. 51 7. 61 E-15 1. 01E-11 -1. 82-12.48 2q24.2 12 204122_at TYROBP -12.79 3. 68E-14 3. 32E-11-1. 91-12. 40 19q13. 1 13 210314 x at TNFSF13-11. 31 1.98E-14 2. 19E-11-1. 85-12. 3717p13. 1 14 214430_at GLA -3. 65 5.96E-16 9. 10E-13-1. 70-12. 33 Xq22 15 201105_at LGALS1 -10.90 4. 58E-16 7. 58E-13 -1.69 -12.28 22q13. 1 16 200663_at CD63 -2. 82 1.07E-16 2. 65E-13-1. 62-12. 0812q12-q13 17 214875_x_at APLP2 -6. 16 3.69E-15 5.23E-12-1. 69-12. 04 11q24 18 201537_s_at DUSP3 -3.76 2.57E-16 4. 63E-13-1. 60-11. 89 17q21 19 223120atMGC1314-4. 76 8.27E-15 1. 03E-11-1. 64-11. 73 6q24 20 202789 at 4. 46 6.38E-12 1. 52E-09 1. 72 11. 21 21 209500_x_at TNFSF13 -7.25 1. 07E-13 8. 20E-11-1. 61-11. 19 17p13. 1 22204971atCSTA-12. 16 3. 91 E-13 2. 22E-10-1. 67-11. 15 3q21 23 231902 at LOC152485 3. 52 4.33E-12 1. 21E-09 1.66 11.04 4q31.1 24205640atALDH3B1-14. 27 6. 25E-13 3. 10E-10-1. 66-11. 0311q13 25 223158_s_at NEK6 -4.80 5. 86E-14 4. 85E-11-1. 53-10. 95 9q33. 3-q34.11 26200764satCTNNA1-3. 53 1. OOE-14 1.17E-11-1. 48-10.89 5q31 27 219013_at GALNT11 -5.92 2. 03E-13 1.27E-10-1. 54-10.80 7q34-q36 28218109satFLJ14153-5. 11 1. 40E-13 1. 03E-10-1. 52-10. 79 3q25. 32 29221841sat-9. 87 2.42E-13 1. 46E-10-1. 53-10.74 30 229215_at ASCL2 -7.82 5. 21E-13 2. 72E-10-1. 56-10. 7311p15. 5 31 202054_s_at ALDH3A2 -9.35 7. 58E-14 6. 02E-11-1. 48-10.71 17p11. 2 32 201029_s_at CD99 2.39 3.12E-14 3. 19E-11 1.44 10.60 Xp22.32 33 216041_x_at GRN -10.15 3.01E-12 1. 02E-09-1. 61-10.51 17q21. 32 34 201416_at SOX4 5.66 1. 25E-12 5. 66E-10 1.48 10.46 6p22. 3 35 41220 at MSF 2. 61 9. 98E-12 2. 06E-09 1.54 10.43 17q25 36223703atCDA017-8. 97 7.50E-12 1. 73E-09-1. 68-10. 37 10q23. 1 37 209905_at HOXA9 -20.72 4.03E-12 1. 21E-09-1. 56-10.32 7p15-p14 38 226438 at-6. 26 2.39E-12 8. 76E-10-1. 51-10.27 39 225314_at MGC45416 3. 9 4. 16E-11 5. 82E-09 1.56 10.24 4p11 40 210844_x_at CTNNA1 -4.54 3.22E-14 3. 19E-11-1. 37-10.22 5q31 41 201200_at CREG -3.15 3.56E-14 3. 32E-11-1. 37-10. 21 1q24 42 238483 at 3. 84 3. 52E-11 5. 10E-09 1.54 10. 19 43 218217_at RISC -12.71 1. 16E-11 2. 37E-09-1. 64-10. 1817q23. 1 Table 2.1-2. 78 44 200736sat GPX1-3. 18 5.25E-14 4. 53E-11-1. 36-10. 16 3p21. 3 45 203555_at PTPN18 -5. 95 4.45E-12 1. 21E-09 -1. 51-10.15 2q21. 1 46 228007_at 6.31 2.97E-10 2. 84E-08 1. 68 10. 12 47 213187_x_at -2. 48 1. 84E-13 1. 22E-10-1. 36-10.06 48 203507_at CD68 -3. 86 1. 70E-13 1. 17E-10-1. 36-10.01 17p13 49 209014_at MAGED1 3. 90 4.70E-10 3. 93E-08 1.67 9.96 Xp11. 23 50 211284_s_at GRN -10.99 1.39E-11 2.72E-09 -1.54 -9.96 17q21.32 2.26 ALL_T-lineage versus AML_inv(16) # affyid HUGO name fe p q stn t Map Location 1 203949_at MPO-15. 39 1.88E-26 4. 18E-22-4. 23-28. 2417q23. 1 2 203948_s at MPO-23. 70 1.67E-19 1.24E-15-3. 54-21. 99 17q23. 1 3 203973_s_at CEBPD -12. 92 2.84E-18 1. 01E-14 -2. 80-18. 05 8p11.2-p11. 1 4211990atHLA-DPA1-7. 98 1.82E-20 2.02E-16-2. 53-17.26 6p21. 3 5 217478_s_at HLA-DMA -10. 46 4.19E-15 4.66E-12-2. 56-15.54 6p21. 3 6 217989_at RetSDR2-3. 68 3. 66E-19 1.63E-15-2. 25-15.46 4q21. 3 7 208702_x_at APLP2-6.28 1. 60E-17 3.97E-14-2. 32-15. 44 11 q24 8205382satDF-67. 41 6.20E-14 3. 20E-11-2. 89-15. 29 19p13. 3 9200742satCLN2-4. 57 1.15E-16 2.32E-13-2. 28-15. 00 11 p15 10 200743_s_at CLN2 -3.42 3. 25E-19 1.63E-15-2. 16-14. 94 11 p15 11 209619_at CD74-7.93 3.17E-18 1. 01E-14 -2 17-14.82 5q32 12215706xatZYX-5. 52 1.96E-15 2. 56E-12-2. 17-14.07 7q32 13 233177_s_at MR-1 -3. 34 9.27E-17 2.06E-13-2. 08-14. 05 2q35 14 224918_x_at MGST1-17. 39 4. 61 E-14 2. 85E-11-2. 25-13. 83 12p12. 3-p12. 1 15 209166_s_at MAN2B1 -3. 49 6. 81 E-15 6.07E-12-2. 15-13. 80 19cen-q13. 1 16200808satZYX-6. 11 2.97E-14 2. 14E-11-2. 21-13.78 7q32 17 204670_x_at HLA-DRB5 -7. 86 6.32E-15 6.07E-12-2. 12-13. 71 6p21. 3 18 213539_at CD3D 23. 12 2.79E-12 7. 13E-10 2.70 13.68 11q23 19 208248_x_at APLP2 -4. 40 8. 32E-18 2. 31 E-14-1. 97-13. 68 11 q24 20 207075_at CIAS1 -10. 22 4.90E-14 2. 94E-11-2. 16-13. 471q44 21 223120_at MGC1314 -3. 95 1.77E-16 3.03E-13-1. 96-13.35 6q24 22209312xatHLA-DRB1-9. 42 4.43E-14 2. 85E-11-2. 10-13.27 6p21. 3 23208306xatHLA-DRB4-10. 58 6.33E-14 3. 20E-11-2. 11-13.25 6p21. 3 24229776atSLC21A11-3. 56 1.45E-16 2. 68E-13-1. 93-13. 23 15q26 25 200665_s_at SPARC -10. 31 5.86E-14 3. 16E-11-2. 10-13.23 5q31. 3-q32 26 204122atTYROBP-13. 81 7. 60E-13 2. 45E-10-2. 29-13. 15 19q13. 1 27211404satAPLP2-6. 13 4. 57E-15 4. 84E-12-1. 98-13. 12 11q24 28210982satHLA-DRA-20. 46 1.02E-12 3.08E-10-2. 27-12.99 6p21. 3 26 204122_at TYROBP -13.81 7.60E-13 2.45E-10 -2.29 -13.15 19q13.1 27 211404_s_at APLP2 -6.13 4.57E-15 4.84E-12 -1.98 -13.12 11q24 28 210982_S_at HLA-DRA -20.46 1.02E-12 3.08E-10 -2.27 -12.99 6p21.3 29 203799_at BIMLEC -10.91 3.15E-13 1.27E-10 -2.10 -12.87 2q24.2 30 38487_at STAB1 -7.03 3.20E-15 3.75E-12 -1.91 -12.83 3p21.31 31 231736_x_at MGST1-17. 87 9.94E-13 3.03E-10-2. 15-12. 7012p12. 3-p12. 1 32 219079_at b5-2.51 5. 30E-16 7. 86E-13-1. 83-12.59 6pter-q22.33 33 200696_s_at GSN -6. 77 1.92E-13 8. 54E-11-1. 97-12.47 9q33 34 224391_s_at CSE-C -4. 40 5. 93E-14 3. 16E-11 -1.91 -12.46 11q24 Table 2.1-2. 78 35 205419_at EBI2 -11. 69 7. 72E-13 2. 45E-10-2. 03-12. 3913q32. 2 36 228058_at LOC124220 -10. 60 5. 85E-13 2. 00E-10 -2.00 -12.38 16p13. 3 37 202789 at 5. 57 6. 05E-12 1. 29E-09 2. 15 12. 37 38 200736_s_at GPX1 -3. 75 3.22E-16 5. 12E-13-1. 79-12.37 3p21. 3 39 217984_at RNASE6PL-3. 08 5. 11 E-14 2. 99E-11-1. 89-12. 37 6q27 40 221841 s at-10. 69 1.96E-13 8. 54E-11-1. 93-12. 32 41 224252_s_at FXYD5 -2. 50 7. 38E-16 1. 03E-12-1. 75-12. 1219q12-q13. 1 42 218217_at RISC-8. 28 3.57E-12 8.55E-10-2. 06-12. 0917q23. 1 43 202241_at C8FW -7. 80 1. 44E-12 4. 11 E-10-1. 95-12. 00 8q24. 13 44 208704_x_at APLP2 -4.51 7.38E-15 6. 32E-12-1. 76-11. 95 11 q24 45 201887_at IL13RA1 -16. 03 1.16E-11 2. 15E-09-2. 17-11. 88 Xq24 46 225510 at-7. 12 3. 44E-13 1. 37E-10-1. 85-11. 88 47 201531_at ZFP36-4. 02 6. 83E-15 6. 07E-12-1. 74-11. 86 19q13. 1 48 214875_x_at APLP2 -5. 79 3.12E-13 1.27E-10-1. 81-11. 74 11q24 49 201360_at CST3 -22. 30 1. 06E-11 2. 05E-09-2. 05-11. 71 20p11. 21 50217983satRNASE6PL-2. 82 3. 51E-14 2.44E-11 -1.74 -11.70 6q27 2. 27 ALL T-lineage versus AML inv (3) # affy id HUGO name fc stn t Map Location 1 213539_at CD3D 25. 77 1.56E-12 2. 99E-08 2. 50 13. 58 11q23 2 211990_at HLA-DPA1 -7. 73 1. 78E-11 7. 54E-08-2. 06-11. 98 6p21. 3 3 209619_at CD74 -6. 38 2.35E-12 2. 99E-08-1. 82-11. 22 5q32 4201200atCREG-3. 83 1. 02E-11 5. 20E-08-1. 83-11. 10 1q24 5 228624 at FLJ 11155-5. 59 3.60E-10 7.04E-07-1. 77-10. 28 4q32.1 6 202789_at 4.14 7.45E-12 4. 74E-08 1. 65 10. 28 7 201888_s_at IL13RA1 -5.36 5. 76E-10 9.76E-07-1. 79-10. 26 Xq24 8 218818 at FHL3-2. 51 3. 77E-11 1.37E-07-1. 62-10. 001p34 9 226694_at AKAP2 14. 72 7. 93E-10 1. 26E-06 1.76 9.79 9q31-q33 10 201029_s_at CD99 2.00 7.35E-12 4. 74E-08 1.53 9.75 Xp22. 32 11 22895_s_at BCL11B 15. 95 1.53E-09 2. 05E-06 1.83 9.69 14q32. 31 12 202626_s_at LYN -4.85 2.60E-10 6.34E-07-1. 60-9. 65 8q13 13 206295_at IL18 -14. 82 2.50E-08 1. 37E-05-1. 88-9. 3611q22. 2-q22.3 14 221558_s_at LEF1 25. 64 5.65E-09 5. 64E-06 1.83 9.15 4q23-q25 15 217989_at RetSDR2 -3. 39 3.93E-09 4.76E-06-1. 58-9. 14 4q21. 3 16 217478_s_at HLA-DMA -8. 47 3. 59E-08 1.43E-05-1. 78-9. 05 6p21. 3 17 221710_x_at FLJ10647 -6. 23 5. 52E-09 5. 64E-06-1. 57-9. 041p34. 3 18 201137_s_at HLA-DPB1 -9. 95 3.13E-08 1.37E-05-1. 74-9. 02 6p21. 3 19 200765_x_at CTNNA1 -3. 82 1.46E-10 4.12E-07-1. 43-9. 00 5q31 20 202759_s_at AKAP2 8.96 4.38E-09 5. 06E-06 1.60 8.91 9q31-q33 21219582atFLJ21079-2. 67 6. 18E-11 1. 97E-07-1. 39-8.91 6q13 22 227853-at-3. 61 1. 21E-09 1. 70E-06-1. 44-8. 82 23 210349_at CAMK4 4.22 5.64E-09 5. 64E-06 1.54 8.71 5q21. 3 24204670xatHLA-DRB5-6. 61 3. 11 E-08 1. 37E-05-1. 58-8. 64 6p21. 3 25206804atCD3G26. 75 1.39E-08 9. 44E-06 1.64 8.61 11q23 Table 2.1-2. 78 26 202625 at LYN-4. 11 5. 43E-10 9. 76E-07-1. 37-8. 61 8q13 27218450atHEBP1-3. 28 2.74E-10 6.34E-07-1. 35-8. 58 12p13. 2 28 227193 at 4. 83 6.83E-09 6. 44E-06 1. 48 8. 50 29 221497_x_at EGLn1 -2. 90 3.48E-10 7.04E-07-1. 33-8. 48 1q42.1 30227276atTEM7R-4. 87 6.47E-08 2. 08E-05-1. 57-8.41 10p12. 1 31 241871_at 10. 30 2.37E-08 1. 34E-05 1. 62 8. 38 32 228058_at LOC124220 -4. 92 7.40E-09 6.72E-06-1. 38-8. 29 16p13. 3 33 209014_at MAGED1 2. 79 5.77E-09 5. 64E-06 1.38 8.24 Xp11. 23 34 201537 s_at DUSP3 3 1.20E-08 8.70E-06-1. 37-8. 1917q21 35 226459_at FLJ35564 -3. 47 1.82E-08 1.16E-05-1. 38-8. 13 10q23. 33 36 202760_s_at AKAP2 13. 26 2.77E-08 1 37E-05 1. 48 8. 13 9q31-q33 37 210844_x_at CTNNA1 -3. 60 9. 89E-10 1.48E-06-1. 28-8. 12 5q31 38 205255 x_at |TCF7 9. 44 4.17E-08 1. 57E-05 1.58 8.12 5q31.1 39 203127_s_at SPTLC2 -2. 61 2.30E-08 1.33E-05-1. 39-8.12 14q24. 3-q31 40209312xatHLA-DRB1-7. 21 1. 01E-07 2.79E-05-1. 50-8. 10 6p21. 3 41 203799_at BIMLEC -6. 76 9. 40E-08 2.69E-05-1. 48-8.07 2q24.2 42239422atDKFZp547M1094. 85 1.45E-08 9. 44E-06 1. 38 8. 07 7q22.1 43 202888_s_at ANPEP -4. 31 1.16E-08 8.70E-06-1. 34-8. 06 15q25-q26 44 235492_at MGC26996 -2. 98 3.72E-08 1.46E-05-1. 39-8.05 6q22.33 45 220134 x at FLJ10647-3. 27 3.37E-08 1.38E-05-1. 38-8. 04 1p34. 3 46 208178_x_at TRIO -4. 54 3.16E-09 4.02E-06-1. 27-7. 98 5p15. 1-p14 47 214032_at ZAP70 11. 00 3.25E-08 1. 38E-05 1.42 7.97 2q12 48 238469 at-3. 26 9.25E-09 7.84E-06-1. 29-7.90 49 229029_at 15.69 7.27E-08 2.25E-05 1.59 7.89 50 219528_s_at BCL11B 14.46 7.40E-08 2.27E-05 1.54 7.85 14q32.31 2.28 ALL T-lineage versus AML komplext # affy id HUGO name fc p q stn t Map Location 1201200atCREG-3. 92 2. 00E-17 3. 58E-13-1. 67-12. 52 1q24 2 213539_at CD3D 10. 37 1.14E-12 1. 20E-09 1.87 12.16 11q23 3 200620_at C1orf8-2. 07 9.09E-16 8. 13E-12-1. 50-11. 281p36-p31 4200742satCLN2-4. 73 5. 41 E-13 6. 91 E-10-1. 51-10. 56 11 p15 5228624atFLJ11155-7. 60 7.45E-13 8.88E-10-1. 51-10.48 4q32.1 6 203837_at MAP3K5 -4.26 5.52E-14 1.77E-10-1. 40-10. 36 6q22. 33 7 224598_at MGAT4B -2. 22 4.96E-14 1.77E-10-1. 38-10.27 5q35 8 202789 at 3. 50 3. 49E-11 1. 49E-08 1. 54 10. 23 9 227853_at -4. 03 6.29E-14 1.77E-10-1. 37-10.21 10 200743_s at CLN2-3 43 1. 41 E-13 2. 80E-10-1. 39-10.21 11 p15 11 226459_at FLJ35564 -4. 28 2.95E-13 5.27E-10-1. 40-10. 19 10q23. 33 12 214430_at GLA -2. 72 6.92E-14 1.77E-10-1. 35-10.11 Xq22 13 210648_x_at SNX3 -2. 00 6.47E-14 1.77E-10-1. 32-9.98 6q21 14 201858_s_at PRG1 -3. 90 9.85E-14 2.20E-10-1. 30-9. 85 10q22. 1 15 200701_at NPC2-3. 06 3. 50E-13 5. 69E-10 -1.30 -9.69 14q24. 3 16 221188_s_at CIDEB -3.21 1.43E-12 1. 34E-09-1. 32-9. 63 14q11. 2 Table 2.1-2. 78 17 223120at MGC1314-3. 28 5. 01E-13 6.89E-10-1. 29-9.61 6q24 18 226694 at AKAP2 10. 47 1. 73E-09 2. 17E-07 1. 73 9. 61 9q31-q33 19 214356_s_at KIAA0368 -3.30 3. 98E-13 5.93E-10-1. 25-9.46 9q32 20 218364_at LRRFIP2-2. 3E 3.93E-12 3.05E-09-1. 30-9.42 3p21. 33 21218109satFLJ14153-3. 65 1.22E-12 1. 21E-09 -1.26 -9.41 3q25.32 22 207809_s_at ATP6IP1 -2.59 1.12E-12 1.20E-09-1. 24-9. 28 Xq28 23 206111 at RNASE2-6. 98 2. 30E-11 1. 21 E-08-1. 33-9. 25 14q24-q31 24 200696_s_at GSN -4. 84 1.14E-11 6.78E-09-1. 27-9.16 9q33 25 201061_s_at STOM -4. 96 6.20E-12 4. 11E-09 -1.25 -9.15 9q34.1 26 200975_at PPT1 -2. 53 5. 11 E-12 3.66E-09-1. 24 -9.13 1p32 27 204249_s_at LMO2 -4. 31 1.69E-12 1.52E-09-1. 20-9. 08 all3 28 226438-at 4. 51 2. 22E-11 1.20E-08 -1.27 -9.04 29 213798_s_at CAP -2.49 5. 53E-12 3. 81E-09 -1.22 -9.02 1p34. 1 30 201443_s_at ATP6IP2 -2. 18 3.39E-12 2.76E-09-1. 20-9. 01 Xq21 31 222895_s_at BCL11B 9.43 2.21 E-09 2. 58E-07 1. 44 8. 96 14q32.31 32 202381_at ADAM9 -5.08 2. 95E-11 1.35E-08-1. 25-8. 94 8p11. 21 33 223158_s_at NEK6 -5. 73 7. 96E-11 2. 91E-08 -1.30 -8.93 9q33. 3-q34.11 34 213187_x_at -2.40 4.44E-12 3. 31 E-09-1. 18-8. 90 35 205418_at FES -8. 59 2. 90E-11 1.35E-08-1. 24-8. 8915q26. 1 36202263atCYB5R1-2. 23 3. 29E-12 2.76E-09-1. 18-8. 8 1 p36. 13-q41 37 201029_s_at CD99 1.92 1.14E-11 6. 78E-09 1.20 8.88 Xp22.32 38 210145_at PLA2G4A -8.10 1. 91E-10 4.79E-08-1. 35-8. 84 1 q25 39 201060_x_at STOM -5. 93 3.71 E-11 1.55E-08-1. 23-8. 84 9q34. 1 40203836satMAP3K5-6. 13 3. 22E-11 1.43E-08-1. 23-8.83 6q22.33 41 225059_at AGTRAP -7. 31 1. 20E-10 3.71 E-08-1.28-8. 80 1p36. 21 42 213066_at KIAA0375 -6.14 2. 37E-10 5.30E-08-1. 31-8. 72 9p13. 1 43 202241_at C8FW-7. 8C 2. 40E-10 5.30E-08-1. 30-8. 69 8q24. 13 44 227185-at-2. 67 8. 80E-11 3.02E-08-1. 22-8. 67 45 203041_s_at LAMP2 -4. 07 9. 10E-11 3.02E-08-1. 22-8.66 Xq24 46 210613_s_at SYNGR1 -7. 61 1. 38E-10 4. 10E-08-1. 24-8. 66 22q13. 1 47 221558_s_at LEF1 12. 45 1. OOE-08 7. 57E-07 1. 52 8. 65 4q23-q25 48 227999 at LOC170394-3. 04 8.41 E-12 5.37E-09-1. 14-8.63 10q26. 3 49 207980_s_at CITED2 -4. 65 1.57E-10 4.53E-08-1. 24-8.62 6q23.3 50 202252_at RAB13 -3.79 2. 19E-11 1. 20E-08-1. 15-8. 591q21. 2 2.29 ALL_T-lineage versus AML_t(15 ; 17) # affy id HUGO name fc p q stn t Map Location 1 203949_at MPO -20.28 1. 41 E-20 2.64E-16-4. 90-28. 93 17q23. 1 2 203948_s_at MPO -42. 61 3. 90E-17 1.46E-13-4. 88-25. 92 17q23.1 3 224918_x_at MGST1 -31. 61 2. 51E-16 5. 87E-13-4. 06-22. 3612p12. 3-p12. 1 4 I205382 s at IDP -I 1.00E-14 1. 11E-11I -4. 55-21. 22 19p13. 3 143.63 5 231736rat MGST1-34.01 6. 64E-15 8. 89E-12-3. 87-20. 2812p12. 3-p12. 1 6 206871_at ELA2 -14. 98 1. 02E-17 4. 80E-14-3. 31-20. 10 19p13. 3 Table 2. 1-2.78 7 206111_at RNASE2 -8. 11 4. 22E-18 2.64E-14-2. 98-18. 6014q24-q31 8 200654_at P4H8 -3. 92 2.83E-19 2. 65E-15-2. 92-18. 60 17q25 9 212953_x_at CALR -5.L70 2.18E-15 4.09E-12-3. 07-17. 91 19p13. 3-p13. 2 10 38487_at STAB1 -55. 71 3. 99E-13 3. 12E-10-3. 58-17.21 3p21. 31 11 214450_at CTSW -15.45 5.37E-14 5. 26E-11-2. 96-16. 63 11q13. 1 12 214575_s_at AZU1 -48.06 9. 33E-13 5. 58E-10-3. 32-16. 29 19p13. 3 13 200663 at CD63-3. 32 1. 45E-16 3. 87E-13-2. 39-15. 20 12q12-q13 14 209215_at TETRAN -6. 30 3.23E-13 2.63E-10-2. 36-13. 96 4p16. 3 15 213854_at SYNGR1 -5.75 7.86E-15 9. 83E-12-2. 22-13.94 22q13. 1 16205624atCPA3-19. 90 1.76E-12 8. 91E-10 -2. 44-13.83 3q21-q25 17 208689_s_at RPN2 -2. 58 5. 45E-17 1.70E-13-2. 10-13. 79 20q12-q13. 1 18 202789 at 8.98 1.45E-12 7. 77E-10 2.44 13.49 19 231902_at LOC152485 5. 52 9. 25E-13 5. 58E-10 2.33 13.34 4q31.1 20 208675_s_at DDOST -3.19 4. 12E-15 7.03E-12-2. 09-13. 341p36. 1 218084_x_at FXYD5 -2.51 3. 51E-16 7. 30E-13-1. 99-13. 07 19q12-q13. 1 22 208612 at GRP58-2. 71 6. 15E-15 8. 87E-12-2. 01-12. 8915q15 23208852satCANX-3. 42 5. 76E-13 4. 00E-10 -2. 12-12.87 5q35 24 221004_s_at ITM2C -4.81 1.01E-14 1. 11 E-11-2. 00-12.83 2q37 25 210613_s_at SYNGR1 -10.53 8.63E-12 3. 30E-09 -2. 25-12. 76 22q13. 1 26 204347_at AK3 -10.69 1. 27E-11 4.50E-09-2. 26-12. 68 1 p31. 3 27 201858_s_at PRG1 -3. 94 4. 88E-15 7. 62E-12-1. 87-12. 22 10q22. 1 28225286at-6. 16 1. 36E-12 7. 52E-10-2. 00-12. 20 29 221253_s_at MGC3178 -4. 90 7.89E-12 3.08E-09-2. 06-12.12 6p24.3 30 220798_x_at FLJ11535 -5.89 4.86E-12 2. 19E-09-2. 03-12. 10 19p13. 3 31 216032_s_at SDBCAG84 -3.01 5. 61 E-14 5. 26E-11-1. 88-12.05 20pter-q12 32201136atPLP2-4. 55 3.03E-12 1.42E-09-1. 99-12. 02 Xp11. 23 33 204150_at STAB1 -58. 82 2. 45E-10 4. 56E-08-2. 57-12.01 3p21. 31 34 225314_at MGC45416 5.49 2.05E-11 6.31E-09 2.15 11.88 4p11 35 203591 s at CSF3R -10. 25 3. 71 E-11 1. 03E-08-2. 10 -11.88 1p35-p34. 3 36201596xatKRT18-23. 28 3. 63E-10 5. 96E-08-2. 42-11. 66 12q13 37 221739_at IL27w -2.05 1.49E-14 1. 56E-11-1. 78-11. 6519p13. 3 38 201360 at CST3-17. 88 1. 64E-10 3. 26E-08-2. 18 -11.63 20p11. 21 39 228625_at CITED4 -3.98 1. 63E-12 8. 51E-10-1. 87-11. 621p34. 1 40 217225_x_at LOC283820 -2.35 5. 76E-13 4. 00E-10-1. 83-11. 58 16p13. 13 41 200714_x_at OS-9 -2.84 2. 08E-12 1. 00E-09-1. 85 -11. 49 12q13 42 200649_at NUCB1 -4.29 2.48E-11 7. 39E-09-1. 95-11. 4619q13. 2-q13. 4 43 228007_at 14. 37 7. 23E-11 1. 83E-08 2. 17 11. 44 44 39854_r_at TTS-2. 2-3. 12 6. 44E-11 1. 68E-08-1. 99-11. 40 11p15. 5 45 201666_at TIMP1 -5.85 7.37E-12 2. 94E-09-1. 86-11. 34 Xp11. 3-p11. 23 46 203471_s_at PLEK -5.03 1. 71 E-11 5.45E-09-1. 88-11.28 2p13. 2 47 209166_s_at MAN2B1 -3.78 1.48E-10 3. 03E-08-2. 00-11. 2019cen-q13. 1 48 211934_x_at G2AN -4.29 3. 41E-11 9. 68E-09-1. 89-11. 19 11q12. 2 49 210788_s_at retSDR4 -2.92 8.10E-13 5. 24E-10-1. 75-11. 1514q22. 3 47 209166_s_at MAN2B1 -3.78 1.48E-10 3.03E-08 -2.00 -11.20 19cen-q13.1 48 211934_x_at G2AN -4.29 3.41E-11 9.68E-09 -1.89 -11.19 11q12.2 49 210788_s_at retSDR4 -2.92 8.10E-13 5.24E-10 -1.75 -11.15 14q22.3 50 210140_at CST7 -16.06 7.10E-10 9.51E-08 -2.25 -11.13 20p11.21 Table 2.1-2. 78 2.30 ALL T-lineage versus AML_t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 203949 at MPO-18. 61 2. 14E-18 4.79E-14-3. 33-20. 4517q23. 1 2 203948 s at MPO-31. 15 2.42E-14 7. 74E-11-2. 70-15. 4017q23. 1 3 217989_at RetSDR2 -3.45 2. 21E-17 2.47E-13 -2.03 -13. 89 4q21. 3 4 213539_at CD3D 23. 17 1. 72E-12 2. 57E-09 2. 44 13. 52 11 q23 5 217478 s at HLA-DMA-7. 27 5. 46E-14 1.53E-10-2. 10-13.23 6p21. 3 6 211990 at HLA-DPA1-7. 06 2. 80E-15 1. 59E-11-1. 93-12. 94 6p21. 3 7 204604_AT PFTK1 -4.19 1.97E-14 7. 35E-11-1. 85-12. 32 7q21-q22 8 228058_at LOC124220 -12. 47 1. 45E-12 2. 31E-09 -2. 05-12. 30 16p13. 3 9 209545_s_at RIPK2 -5. 07 2. 84E-15 1. 59E-11-1. 71-11.81 8q21 10 209619_at CD74 -6. 36 7. 64E-15 3. 42E-11-1. 71-11. 695q32 11 210613 s at SYNGR1-10. 58 3.76E-12 4. 21E-09-1. 91-11.63 22q13. 1 12 200743_s_at CLN2 -3.62 2. 07E-13 4.64E-10 -1.70 -11.31 11p15 13 200696 s at GSN-7. 92 8.43E-12 8.73E-09-1. 86-11. 28 9q33 14 213854_at SYNGR1 -5. 78 9.12E-13 1.70E-09-1. 73-11.24 22q13. 1 15 211991_s_at HLA-DPA1-16. 0 2. 74E-11 1. 91E-08 -1.89 -11.05 6p21. 3 16 224918_x_at MGST1 -16.27 1. 67E-11 1. 40E-08-1. 84-11. 04 12p12. 3-p12. 1 17 210982_s_at HLA-DRA -15. 95 3. 36E-11 2.09E-08-1. 90-10.99 6p21. 3 18 215193_x_at HLA-DRB1 -11.40 2. 47E-11 1. 84E-08-1. 83-10. 91 6p21. 3 19 212268_at SERPINB1 -3.88 2.29E-13 4. 66E-10-1. 61-10. 88 6p25 20 238483 at 4. 25 2. 94E-11 1. 93E-08 1. 78 10. 85 21 223158_s_at NEK6 -3. 71 1. 67E-13 4. 16E-10 -1.59 -10.81 9q33. 3-q34.11 22 200742_s_at CLN2 -4.85 2.07E-11 1. 61E-08 -1.73 -10.66 11p15 23 206871_at ELA2-12. 68 3. 99E-11 2.29E-08-1. 73-10. 50 19p13. 3 24209312xatHLA-DRB1-7. 10 9.36E-12 8. 87E-09-1. 64-10. 49 6p21. 3 25 228007 at 6. 94 3.02E-10 8. 78E-08 1.88 10.45 26 205418_at FES -11.30 2. 69E-11 1. 91E-08-1. 65-10. 35 15q26. 1 27 208894 at HLA-DRA-16. 69 1. 69E-10 6. 41E-08-1. 82-10. 30 6p21. 3 28211728satHYAL3-7. 52 1. 41 E-10 5. 80E-08-1. 70-10. 11 3p21. 3 29 231902_at LOC152485 3.08 1. 34E-11 1. 20E-08 1.54 10.08 4q31.1 30208306xatHLA-DRB4-7. 43 3. 02E-11 1. 93E-08-1. 57-10. 03 6p21. 3 31 231736_x_at MGST1 -16. 11 2. 20E-10 7. 60E-08-1. 72-10. 0312p12. 3-p12. 1 32 226878 at-3. 66 2. 08E-11 1. 61E-08 -1. 54-9.99 33 206106_at MAPK12 -4.12 3.54E-12 4.17E-09 -1.48 -9.97 22q13. 33 34 223553_s_at FLJ22570 -4.5 7. 46E-11 3.71 E-08-1.59-9. 92 5q35.3 35 202241_at C8FW -6. 84 1.42E-10 5. 80E-08-1. 62-9. 88 8q24. 13 36 228827 at-42. 42 5.18E-10 1.28E-07-1. 79-9. 84 37 225120 at 3. 42 2. 61 E-10 8. OOE-08 1. 61 9. 80 38 235843_at -3.56 3.21 E-12 3.99E-09-1. 44-9. 78 39 213572_s_at SERPINB1 -3.23 1. 33E-12 2. 29E-09-1. 41-9. 75 6p25 40 223703_at CDA017 -5.49 5.55E-10 1.34E-07-1. 70-9. 68 10q23. 1 41 227979_at 2.53 3. 76E-11 2. 24E-08 1.48 9.68 42200808satZYX-4. 91 2.13E-10 7. 60E-08-1. 57-9. 63 7q32 226178_at 2.42 8.57E-12 8. 73E-09 1.42 9.62 Table 2.1-2. 78 44 228345at 4. 86 3. 20E-10 9.08E-08 1. 55 9.57 45 221710_x_at FLJ10647 -6.28 6. 12E-11 3. 26E-08-1. 47-9. 531p34. 3 46 218818_at FHL3-2. 52 9.51 E-12 8.87E-09-1. 41-9.51 1 p34 47 218627_at FLJ11259 -3.13 2. 24E-12 3. 14E-09-1. 37-9.50 12q23.3 48 209604_s_at GATA3 12. 98 1.96E-09 3. 46E-07 1.73 9.50 10p15 49 222895_s_at BCL11B 13.16 1.63E-09 3.01 E-07 1.67 9.45 14q32.31 50 215706_x_at ZYX -4.68 1.94E-10 7.24E-08 -1.50 -9.43 7q32 2.31 ALL_T-lineage versus CLL # affy id HUGO name fc p q stn t Map Location 1204670xatHLA-DRB5-11. 20 5.56E-33 1. 18E-28-3. 57-27.19 6p21. 3 2 208306 x at HLA-DRB4-13. 68 2.45E-31 1. 73E-27 -3.45 -26. 06 6p21. 3 3 209619_at CD74 -10. 94 1. 41E-32 1.49E-28-3. 38-25. 90 5q32 4 217478_s_at HLA-DMA -18.42 1.59E-24 3.72E-21-3. 45-23. 77 6p21. 3 5209312xatHLA-DRB1-11. 52 1.32E-28 4.66E-25-3. 05-23. 05 6p21. 3 6 211990_at HLA-DPA1 -8.81 2.82E-30 1.49E-26 -2.99 -22. 92 6p21.3 7 225927 at-7.65 7.71 E-29 3.26E-25-2. 90-22. 14 8 215193_x_at HLA-DRB1 -18.73 2. 34E-22 4. 50E-19-2. 87-20.11 6p21. 3 9 224838_at FOXP1 -4.55 2.67E-27 8. 06E-24-2. 61-20.03 3p14. 1 10 212827_at IGHM -19. 11 3. 49E-22 6. 15E-19-2. 80-19.7214q32. 33 11 202625_at LYN -7.46 7.02E-27 1.85E-23-2. 56-19. 61 8q 13 12 208894 at HLA-DRA-29. 04 2.15E-20 2. 17E-17-2. 82-18. 79 6p21. 3 13 2109823_s_at HLA-DRA -29.63 2.29E-20 2. 20E-17-2. 78-18. 64 6p21. 3 14 203932_at HLA-DMB -17.45 9. 70E-20 7. 32E-17-2. 81-18. 25 6p21.3 15 211991 s at HLA-DPA1-28. 13 3. 42E-19 2.07E-16-2. 55-17. 15 6p21. 3 16 218829_s_at KIAA1416 -5.05 1. 04E-22 2.19E-19-2. 28-17. 15 8q12. 1 17 209374_s_at IGHM -22.46 2. 49E-19 1. 69E-16 -2.42 -16.78 14q32. 33 18 2000999_S_at CKAP4 -5. 61 2.48E-21 3.28E-18-2. 23-16. 60 12q24. 11 19 201137 s at HLA-DPB1-13. 25 8.43E-20 6. 60E-17-2. 32-16.57 6p21. 3 20226123atLOC286180-6. 82 4.35E-22 7. 07E-19-2. 16-16. 37 8q12. 1 21243780at-18. 06 2.55E-19 1.69E-16-2. 27-16.13 22204192atCD37-9. 52 1.22E-18 6.28E-16-2. 30-15. 9619p13-q13. 4 23 220987sat SNARK-7.86 2.99E-18 1.43E-15-2. 32-15. 84 1q32. 1 24 202863_at SP100 -3.99 1.39E-20 1. 60E-17 -2.08 -15.55 2q37.1 25 225658_at-5. 6 5.02E-20 4. 24E-17-2. 10-15. 54 26 209306 s at SWAP70-11. 40 4.66E-18 2.05E-15-2. 24 -15.45 11p15 27207132xatPFDN5-2. 30 8.46E-22 1.28E-18-2. 00-15. 37 12q12 28 201417 at 47. 61 2. 02E-13 1.62E-11 2.83 15.36 29 223287_s_at FOXP1 -5.28 5. 08E-19 2. 83E-16 -2.08 -15.15 3p14.1 30 201029_s_at CD99 2.99 6. 61 E-15 8. 68E-13 2.31 15.09 Xp22.32 31 227167 s at-7. 22 6.90E-19 3. 74E-16-2. 07-15.08 32204446satALOX5-9. 52 3.09E-20 2. 84E-17-2. 01-15. 0810q11. 2 33 212386_at -15. 41 9.05E-18 3. 54E-15-2. 16-15.01 34 229597_s_at KIAA1607 -7.11 1. 61E-19 1.13E-16 -2.02 -14.99 10q11. 21 Table 2. 1-2.78 35 225364at LOC200227-2. 88 2.47E-21 3. 28E-18-1. 95-14. 9720q13. 11 36 202626_s_at LYN -8.70 3.09E-19 1. 93E-16-2. 03-14. 96 8q13 37 204613_at PLCG2 -6.47 1.65E-18 8. 30E-16-2. 04-14. 8016q24. 1 38 214786_at MAP3K1-9. 09 7.59E-18 3.03E-15-2. 07-14. 69 5q11. 2 39 209307 at SWAP70-9. 74 1.34E-17 4. 71E-15 -2.08 -14.63 11p15 40 201416_at SOX4 79.86 7.97E-13 5.21E-11 2.87 14.59 6p22.3 41 218029-at FLJ13725-5. 84 1.78E-20 1.88E-17-1. 90-14.51 16q21 42 209075_s_at NIFU -2.55 1. 44E-20 1. 60E-17-1. 89-14. 46 12q24.1 43 218191 s at FLJ11240-2. 84 1.37E-20 1. 60E-17-1. 87-14.37 6q12 44 206398 s at CD19-23. 31 3.02E-16 6.32E-14-2. 27-14. 30 16p11. 2 45 239287 at-30. 92 3.52E-16 7.23E-14-2. 30-14. 26 46 210754_s_at LYN -6.49 1.28E-19 9.36E-17-1. 88-14. 23 8q13 47 213309_at PLCL2 -8. 56 1. 20E-17 4. 54E-15-1. 98-14.22 3p24.3 48 200998_s_at CKAP4 -3.57 4.28E-20 3. 77E-17-1. 85-14. 1512q24. 11 49 206337_at CCR7 -13.34 1.37E-16 3.26E-14 -2.08 -14.12 17q12-q21. 2 50 214615_at P2RY10-6. 5Z 1.58E-17 5. 22E-15-1. 96-14. 08 Xq21.1 2. 32 ALL T-lineage versus CML # affy id HUGO name fc p q stn t Map Location 1 210254_at MS4A3-19. 46 1.95E-37 1.83E-33-3. 51-29. 04 11q12 2 206871 at ELA2-17. 0'1. 64E-39 3.08E-35-3. 32-28. 11 19p13. 3 3 205557_at BPI -16.63 1. 16E-36 7.24E-33-3. 27-27. 26 20q11.23-q12 4 203949_at MPO-17. 81 1.18E-35 4.47E-32-3. 21-26. 6617q23. 1 5 212268_at SERPINB1 -5.96 2.65E-34 6. 21E-31 -2. 97-24.87 6p25 6206676atCEACAM8-16. 46 4.03E-34 8.39E-31-2. 98-24. 79 19q13. 2 7 214575_s_at AZU1 -58.29 2. 39E-29 2.03E-26-3. 27-24. 60 19p13. 3 8 216379_x_at KIAA1919 -13. 74 1. 13E-34 3.54E-31-2. 91-24. 43 6q22 9209771xatCD24-12. 21 1. 19E-35 4.47E-32-2. 88-24. 42 6q21 10 206111_at RNASE2 -11.53 8.31 E-34 1. 56E-30-2. 86-23. 92 14q24-q31 11 211657_at CEACAM6 -16.60 2.61 E-31 3.50E-28-2. 94-23. 86 19q13. 2 12 212531_at LCN2 -12. 34 2.61 E-34 6. 21 E-31-2. 83-23.85 9q34 13 210140_at CST7 -13. 66 1.50E-30 1.76E-27-2. 96-23. 73 20p11. 21 14 203757_s_at CEACAM6 -23.78 2.49E-29 2.03E-26-2. 90-22. 99 19q13. 2 15 211275_s_at GYG -5. 82 1. 16E-31 1. 67E-28-2. 76-22. 85 3q24-q25. 1 16 205653_at CTSG -23. 29 1.03E-28 6.88E-26-2. 84-22. 46 14q11. 2 17 204971_at CSTA-18. 18 8.76E-30 8. 21E-27 -2.76 -22.40 3q21 18 201554_x_at GYG -7. 44 8.37E-31 1.05E-27-2. 71-22.34 3q24-q25.1 19 208308_s_at GPI -5. 21 1.15E-32 1.96E-29-2. 64-22. 27 19q13. 1 20 203948_s_at MPO -28. 41 8.93E-29 6.20E-26-2. 77-22.12 17q23.1 21 203021_at SLPI -13. 40 5.09E-29 3.82E-26-2. 70-21. 82 20q12 22 204351_at S100P -12. 62 1.36E-29 1. 21 E-26-2. 64-21. 59 4p16 23 204174_at ALOX5AP -10.76 6. 79E-29 4.89E-26-2. 62-21. 31 13q12 24201061satSTOM-8. 18 4.98E-32 7.78E-29-2. 49 -21.09 9q34.1 25 205513_at TCN1-17. 05 2. 26E-27 1. 21 E-24-2. 64-20. 95 11 q 11-q 12 Table 2.1-2. 78 26 208650sat CD24-21. 33 2.54E-27 1.32E-24-2. 57-20. 58 6q21 27 206851_at RNASE3 -27. 15 5.05E-26 1. 93E-23-2. 67-20. 43 14q24-q31 28 219281_at MSRA -6.49 6. 01 E-30 6. 26E-27 -2.41 -20.23 8p23. 1 29 201858_s_at PRG1 -6.09 8. 67E-27 3.87E-24-2. 46 -20.18 10q22. 1 30 201029_s_at CD99 6.82 1.81E-16 6. 14E-15 3.30 20.14 Xp22. 32 31 266-s-at CD24-16. 69 4.09E-27 2.02E-24-2. 47-19.94 6q21 32 205786 s at ITGAM-9. 7g 9. 43E-28 5.70E-25-2. 42-19. 87 16p11. 2 33 209772_s_at CD24 -39.25 5. 08E-25 1.46E-22-2. 65-19. 77 6q21 34 223423_at GPCR1-8. 7a 8. 39E-30 8.21 E-27-2.34-19. 74 3q26.2-q27 35 210244 at CAMP-26. 08 1. 21E-25 4.19E-23-2. 54-19. 73 3p21. 3 36200742satCLN2-6. 32 2.46E-28 1.59E-25-2. 37-19. 67 11p15 37 223120_at MGC1314 -5.00 4. 45E-30 4.90E-27-2. 32-19. 64 6q24 38 200654_at P4HB-3. 26 1. 21E-26 5. 27E-24-2. 36-19. 50 17q25 29 207802_at SGP28 -37. 32 6.83E-25 1.88E-22-2. 53-19.34 6p12. 3 40 206207_at CLC -30.16 7. 93E-25 2.09E-22-2. 53 -19.28 19q13. 1 41 221766_s_at C6orf37 -9.43 6.55E-28 4.09E-25-2. 32-19. 27 6q14 42205863atS100A12-8. 76 4. 55E-29 3. 56E-26-2. 28-19. 26 1q21 43 208158_s_at OSBPL1A -7.11 2.62E-27 1.33E-24-2. 30-19. 0218q11. 1 44 217762_s_at RAB31 -25.5 3. 83E-25 1. 16E-22-2. 42-19. 0018p11. 3 45 217764_s_at RAB31 -16.13 1. 12E-24 2.83E-22-2. 38-18. 64 18p11. 3 46 206440_at LIN7A -21.03 1. 39E-24 3.47E-22-2. 38-18. 5812q21 47 208636 at ACTN1-7. 90 3. 49E-26 1. 42E-23-2. 26-18. 5314q24 48 202391_at BASP1 -12.43 1.44E-25 4. 91E-23 -2.28 -18.45 5p15.1-p14 49 209369_at ANXA3-26. 2C 1. 18E-23 2. 48E-21-2. 45-18. 34 4q13-q22 50203936satMMP9-13. 04 6. 50E-25 1. 82E-22-2. 28-18. 27 20q11. 2-q13. 1 2.33 ALL T-lineage versus normal # affy id HUGO name fc p q stn t Map Location 201029_s_at CD99 4.54 1. 49E-16 2.37E-12 2.94 16.60 Xp22. 32 2 201858_s_at PRG1 -5. 80 4. 79E-12 1.52E-08-2. 93-15. 58 10q22. 1 3218424satTSAP6-4. 96 1. 82E-11 2. 88E-08-2. 94-15. 46 2q14. 1 4223280xatMS4A6A-10. 91 2. 82E-09 1.06E-06-3. 21-15.41 11q12. 1 5 218257_s_at UGCGL1 -2.58 2.90E-14 2.30E-10-2. 69-14. 99 2qu4. 3 6 226190 at-5. 38 3. 04E-08 4.91 E-06-3. 25-14. 63 7 210613_s_at SYNGR1 -6.69 2. 88E-10 2.28E-07-2. 78-14. 29 22q13. 1 8 202018_s_at LTF -5.32 2. 64E-11 3.80E-08-2. 66-14. 15 3q21-q23 9 201416 at SOX4 14. 82 2. 35E-12 9. 30E-09 2. 75 13. 75 6p22. 3 10 203535_at S100A9 -6. 04 4.61 E-09 1.36E-06-2. 73 -13.50 1q21 1 1 201417_at 7. 32 1. 84E-12 9. 30E-09 2.55 13. 41 '12 226556 at-3. 16 9. 38E-12 1.86E-08-2. 46-13. 37 13 206488_s_at CD36 -7. 81 1.68E-08 3.28E-06-2. 78-13.30 7q11. 2 14 223120_at MGC1314 -3. 87 7. 67E-10 4. 49E-07-2. 55-13. 15 6q24 15 224356_x_at MS4A6A -11.05 1.24E-07 1.17E-05-2. 88-12. 86 11q12. 1 16 222698_s_at IMPACT -3. 79 1. 21E-09 6. 59E-07-2. 47-12. 72 18q11.2-q12. 1 Table 2. 1-2.78 17 212531atLCN2-11. 23 5. 71E-07 3.14E-05-2. 95-12. 19 9q34 18 221188_s_at CIDEB -4.98 3.85E-07 2.49E-05 -2.84 -12.17 14q11.2 19 219013_at GALNT11 -5.93 1.26E-07 1.18E-05 -2.63 -12.10 7q34-q36 20208908satCAST-6. 58 5.78E-08 7.71 E-06-2. 49 -11.90 5q15-q21 21 206845_s_at RNF40 -2. 57 6. 50E-10 4.12E-07-2. 21-11. 75 16p11. 2-p11. 1 22 206871_at ELA2 -16.33 1.P9E-06 4.78E-05 -2. 94-11. 72 19p13. 3 23 200701_at NPC2 -2.98 2. 66E-10 2.22E-07-2. 16-11. 62 14q24. 3 24 226448_at -2.79 1.90E-07 1. 54E-05-2. 50-11. 52 25 201028_s_at CD99 5.66 1. 68E-11 2. 88E-08 2. 09 11. 40 Xp22. 32 26204776atTHBS4-5. 40 1.05E-06 4.65E-05-2. 75-11. 36 5q13 27 213539_at CD3D 6.56 7.50E-12 1. 86E-08 2.02 11.24 11q23 28 200631_s_at SET 2.04 8. 28E-12 1. 86E-08 2. 00 11. 17 9q34 29 203645_s_at CD163 -10.25 1.15E-06 4.93E-05-2. 68-11. 16 12p13. 3 30 224975_at NFIA-4. 4 6.27E-07 3.28E-05-2. 51-11. 061p31. 3-p31. 2 31 204393 s at ACPP-4. 08 1.19E-07 1.14E-05-2. 28-10.99 3q21-q23 32 218394_at FLJ22386 -3. 92 1.44E-08 3.04E-06-2. 12-10. 88 16p13. 3 33 218739_at CGI-58 -3.16 6.03E-07 3.20E-05-2. 40-10. 79 3p25.3-p24. 3 34 201486at RCN2 4.84 1.26E-10 1. 27E-07 2. 03 10. 75 15q23 35237444at-3. 98 2. 38E-10 2. 10E-07-1. 96-10.75 36223664xatBCL2L13-1. 95 1. 82E-08 3.50E-06-2. 10-10. 75 22q11 37 223553 s at FLJ22570-5. 65 1.71 E-06 6. 42E-05-2. 59-10. 72 5q35. 3 38 214575_s_at AZU1 -43.05 5.19E-06 1.27E-04-3. 18-10. 58 19p13. 3 39 228499_at PFKFB4-3. 05 5.97E-07 3.20E-05-2. 31-10.53 3p21-p22 40201425atALDH2-4. 03 2. 91 E-09 1.07E-06-1. 97-10. 51 12q24.2 41 236297_at -3.63 3.70E-07 2.43E-05-2. 19-10.32 42 208651_x_at CD24 -8. 81 2. 41 E-06 7.82E-05-2. 49-10.31 6q21 43 219304_s_at SCDGF-B -2. 41 3.55E-08 5.46E-06-1. 99-10. 1811q22. 3 44 201988_s_at CREBL2 -2.70 9. 25E-11 1.05E-07-1. 81-10.16 12p13 45 228624_at FLJ11155 -8.45 3. 11 E-06 9.33E-05-2. 49-10.14 4q32.1 46 216041_x_at GRN -8. 03 3.50E-06 1. 01E-04 -2. 52-10. 12 17q21. 32 47 212414_s_at SEPT6 4.38 4.81 E-10 3. 17E-07 1. 90 10. 07 Xq24 48 228716_at -3.45 4.16E-10 3.14E-07-1. 81-10.03 49 205076 s at CRA-3. 69 3.51 E-06 1. 01 E-04-2. 46-10.01 1q12-q21 50 230988_at-6. 14 4.78E-06 1. 22E-04-2. 56-9. 98 2.34 ALL_t(8;14) versus AML_MLL # affy id HUGO name fc p q stn t Map Location 1 213737 x at -6. 52 2.80E-19 4. 69E-15-2. 31-15.60 2 214651_s at HOXA9-41. 49 3.25E-16 2. 73E-12-2. 48-15.04 7p15-p14 3 201163_s_at IGFBP7 -5.53 2.04E-14 8. 56E-11-1. 75-11. 75 4q12 4201105atLGALS1-7. 18 1.37E-14 7. 66E-11-1. 67-11. 32 22q13. 1 5 235753_at -9. 89 1. 73E-13 5. 80E-10-1. 74-11.31 6 209905 at HOXA9 1. 97E-12 3. 67E-09-1. 90-11. 02 7p15-p14 225.42 Table 2.1-2. 78 7 201162 at IGFBP7-12. 89 7.82E-13 1.64E-09-1. 67-10.80 4q12 8 213147_at HOXA1 -5.90 3.63E-13 1. 01E-09 -1. 57-10. 50 7p15-p14 9 228083_at CACNA2D4 -22. 80 6.43E-12 8.04E-09-1. 74-10. 46 12p13. 33 10 211709satSCGF-11. 81 3.27E-12 5.32E-09-1. 64-10. 41 19q13. 3 11 214430_at GLA-2. 65 4. 59E-13 1. 10E-09-1. 50-10. 13 Xq22 12 202265_at BMI1 -4. 44 6. 71E-12 8.04E-09-1. 48-9. 7510p11. 23 13 206847_s_at HOXA7 -4. 83 3.49E-12 5.32E-09-1. 40-9. 50 7p15-p14 14 213150_at HOXA10-11. 25 6. 79E-11 6.15E-08-1. 50 -9.37 7p15-p14 15 221581_s_at WBSCR5 -3. 67 4.92E-12 6.88E-09-1. 38-9. 36 7q11. 23 16 204082_at PBX3 -5. 23 2. 40E-11 2.37E-08 -1.40 -9.24 9q33-q34 17 204798_at MYB -4. 22 7.87E-12 8.81 E-09-1. 36-9.23 6q22-q23 18 214875 x_at APLP2-3. 57 1. 00E-11 1.05E-08-1. 35-9. 1711q24 19 203373_at SOCS2 -16.27 1.78E-10 1.36E-07-1. 43-8. 99 12q 20208702xatAPLP2-3. 53 1.28E-10 1.02E-07-1. 33-8. 83 11 q24 21 215785_s_at CYFIP2 6.20 4.75E-07 4. 09E-05 1. 68 8. 63 5q34 22211404satAPLP2-3. 17 2.78E-09 8.80E-07-1. 34-8. 56 11 q24 23 203733_at MYLE -3.10 6. 96E-11 6.15E-08-1. 26 -8.54 16p13. 2 24 204168at MGST2-4. 41 1. 96E-10 1. 39E-07-1. 29-8. 53 4q28. 3 25203372satSOCS2-20. 78 7.83E-10 3.30E-07-1. 39-8.53 12q 26 201944_at HEXB-3. 67 1.14E-10 9.58E-08-1. 24-8.39 5q 13 27 212174_at AK2 -4.10 5.89E-10 2.67E-07-1. 30-8. 38 1 p34 28 202546_at VAMP8-3. 23 2.17E-10 1.46E-07-1. 24-8. 37 2p12-p11. 2 29 41220_at MSF 2.15 1.09E-07 1. 35E-05 1.40 8.24 17q25 30 58780_s_at FLJ10357 -7.09 9.87E-10 3.74E-07-1. 28-8. 23 14q11. 1 31 202012 s_at EXT2-1. 9 1.99E-10 1.39E-07-1. 21-8. 22 11 p12-p11 32223703at CDA017-4.67 2.42E-10 1.46E-07-1. 21-8. 2010q23. 1 33213908at-6. 06 2.43E-10 1.46E-07-1. 21-8.19 34 209360_s_at RUNX1-5. 50 2.31 E-10 1.46E-07-1. 20-8. 17 21 q22. 3 35 209605_at TST-5. 22 4. 45E-10 2.34E-07-1. 22-8. 15 22q13. 1 36204069atMEISI-12. 06 1.86E-09 6.42E-07-1. 31 -8.14 2p14-p13 37 224699_s_at KIAA1228 -3.19 2.82E-10 1.63E-07 -1.20 -8.11 7q36. 3 38 219889_at FRAT1 -2. 95 2. 98E-10 1.67E-07-1. 20-8. 10 1 Oq24. 1 39 206674_at FLT3 -23. 84 2.87E-09 8.93E-07-1. 35-8. 09 13q12 40 213491_x_at RPN2 -2.29 4.96E-10 2.44E-07-1. 19-8. 01 20q12-q13. 1 41 218048_at BUP -3. 26 1. OOE-09 3.74E-07-1. 21-8.01 10pter-q22. 1 42226676atEHZF-11. 62 2. 69E-09 8.67E-07-1. 28-8. 00 18q11. 1 43 212465_at FLJ23027 -2. 17 4.33E-10 2.34E-07-1. 18-7. 9814q32. 31 44 229838_at NUCB2 -3.69 5. 08E-10 2.44E-07-1. 18 -7.97 11p15.1-p14 45 212442_s_at LOC253782 -3. 72 4. 85E-10 2.44E-07-1. 17-7. 96 2q31. 1 46 205418_at FES -6. 91 5. 57E-10 2.60E-07 -1.17 -7.92 15q26. 1 47 218109_s_at FLJ14153 -3. 05 6. 05E-10 2.67E-07-1. 17-7.91 3q25.32 48 205382_s_at DF -9. 94 2.02E-09 6.80E-07-1. 21-7. 90 19p13. 3 49 225245_x_at H2AFJ -3. 28 8.26E-10 3.30E-07-1. 17 -7.87 12p12 50 211200_s_at FGR-3. 87 7.88E-10 3.30E-07-1. 15-7.81 1 p36. 2-p36.1 Table 2.1-2. 78 2.35 ALL-t (8; 14) versus AML_inv (16) # affy id HUGO name fc p q stn t Map Location 1 201029 s at CD99-4. 38 3. 33E-18 4.82E-14-3. 36-20. 10 Xp22. 32 2200665satSPARC-25. 46 5.73E-14 1.66E-10-2. 62-14.63 5q31. 3-q32 3 224710_at RAB34 -7. 91 4. 29E-15 3. 10E-11-2. 11-13. 00 17q11. 1 4 203585_at ZNF185 -3. 46 1.45E-14 6. 98E-11-2. 12-12.97 Xq28 5205382satDF-10. 80 3. 41 E-14 1. 23E-10-2. 14-12.92 19p13. 3 6211709satSCGF-9. 72 2. 06E-13 4.96E-10-2. 18-12.80 19q13. 3 7 202747_s_at ITM2A -15. 81 1. 00E-12 1.80E-09-2. 25-12.73 Xq13. 3-Xq21. 2 8 202746_at ITM2A-9. 69 1. 66E-12 2. 41E-09 -2. 10-12.10 Xq13. 3-Xq21. 2 9 231982_at -18. 86 1. 13E-11 1.18E-08-2. 03-11.44 10 215111 s at TSC22-9. 09 1. 74E-11 1.40E-08-2. 06-11.42 13q14 11 217989_at RetSDR2 -3. 96 5. 65E-11 4.09E-08-1. 93-11. 23 4q21. 3 12209365satECM1-4. 48 1.02E-12 1.80E-09-1. 76-10. 79 1q21 13 215116 s at DNM1-13. 20 8. 05E-11 5. 21E-08 -2. 00-10.78 9q34 14 231310_at -4. 90 1. 12E-12 1.80E-09-1. 74-10. 73 15 223471_at RAB3IP 7.29 9. 13E-08 8. 36E-06 2. 38 10. 67 16 38671_at KIAA0620 -3. 05 2.05E-12 2.70E-09-1. 74-10.66 3q21. 3 17 201497_x_at MYH11 -11. 98 6. 27E-11 4.32E-08-1. 78-10. 3016p13. 13-p13. 12 '18201564satFSCN1-13. 17 1. 10E-10 5.66E-08-1. 81-10.25 7p22 19 212667_at SPARC-11. 41 1. 16E-10 5.79E-08-1. 79-10.19 5q31. 3-q32 20 223276_at NID67 -5. 17 7.96E-12 9. 61E-09 -1. 65-10.10 5q33. 1 21 207075_at CIAS1 -5. 61 1. 14E-11 1. 18E-08-1. 61-9. 89 1q44 22 203948_s_at MPO -4.29 1.74E-09 4.85E-07-1. 72-9. 86 17q23.1 23 220974_x_at BA108L7. 2-8.57 1. 60E-11 1.38E-08-1. 61 -9.85 10q24. 31 24 201162_at IGFBP7 -6. 55 1. 52E-11 1.38E-08-1. 61-9. 84 4q12 25 203949_at MPO-3. 54 2. 36E-08 3.13E-06-1. 85-9. 83 17q23. 1 26201596xatKRT18-6. 80 9. 87E-11 5. 36E-08-1. 67-9. 83 12q 13 27 225510_at -4. 52 1. 62E-11 1.38E-08-1. 57-9. 65 28217865atGP-4. 38 1. 76E-10 7. 29E-08-1. 61-9.64 5q35.3 29 201887_at IL13RA1 -5. 22 1. 00E-10 5.36E-08-1. 58-9.48 Xq24 30212442satLOC253782-4. 39 3. 92E-11 2.98E-08-1. 53-9. 38 2q31. 1 31 208891_at DUSP6 -5. 27 1. 21E-10 5.86E-08-1. 53-9. 32 12q22-q23 32205330atMN1-16. 88 1. 53E-09 4. 35E-07-1. 71 -9.28 22q12. 1 33 38487_at STAB1 -3. 60 8. 75E-11 5. 21 E-08-1. 50-9.21 3p21. 31 34 201496_x_at MYH11 -6. 02 8. 99E-11 5. 21E-08 -1.48 -9. 11 16p13. 13-p13. 12 35 201417 at-3. 29 1.27E-10 5.91 E-08-1.48-9. 09 36 204044_at QPRT-3. 86 8. 84E-11 5. 21 E-08-1. 47-9.06 16p12. 1 37 58780_s_at FLJ10357 -4. 92 3. 11E-10 1. 12E-07-1. 50-9. 0314q11. 1 38 204900_x_at SAP30 -3. 90 2.82E-10 1.05E-07-1. 49-8.98 4q34.1 39 210613_s_at SYNGR1 -4. 52 1. 34E-10 5.95E-08-1. 45-8.92 22q13. 1 40 225831_at LOC 148894-4. 05 1. 36E-10 5.95E-08-1. 44-8. 891p36. 11 41 205131_x_at SCGF -12. 79 2. 39E-09 6. 28E-07-1. 56-8. 84 19q13. 3 42 201389_at ITGA5-3. 99 1. 73E-10 7.29E-08-1. 43 -8.83 12q11-q13 43 202007_at NID -8. 75 1. 25E-09 3. 70E-07-1. 51-8. 82 1 q43 Table 2.1-2. 78 44 201739 at SGK-4.63 2.55E-10 9. 98E-08-1. 43-8.76 6q23 45 214875_x_at APLP2 -3.35 2.04E-10 8. 18E-08-1. 42-8.74 11 q24 46 223095_at MGC4415 -4. 05 2.66E-10 1. 01 E-07-1. 40-8. 64 1 Oq24. 1 47 201015_s_at JUP -9. 77 9.79E-10 3.15E-07-1. 44-8. 6417q21 48 206674_at FLT3 -12. 76 5.62E-09 1. 13E-06-1. 57-8. 62 13q12 49 208818_s_at COMT -3. 27 3.98E-10 1.40E-07-1. 40-8. 59 22q11. 21 50 209190_s_at DIAPH1 -2. 61 3.63E-09 8.73E-07-1. 44-8.56 5q31 2. 36 ALL t (8; 14) versus AML inv (3) # affy id HUGO name fc p q stn t Map Location 1 215111_s_at TSC22 -8. 61 1.87E-08 5. 11E-05 -2. 03-9. 60 13q14 2 38671_at KIAA0620 -3. 21 6.09E-10 1. 06E-05-1.69-9. 30 3q21. 3 3217226satBA108L7. 2-4.72 5.47E-09 3. 18E-05-1. 74-9. 19 10q24. 31 4 203746 s at HCCS 1. 62 1.33E-07 1. 13E-04 1.83 8.99 Xp22.3 5 217963_s_at NGFRAP1 -10. 15 3.73E-08 5. 11 E-05-1. 82-8. 95 Xq22. 1 6 201829 at NET1-3. 60 3.66E-08 5. 11E-05-1. 75-8. 78 10p15 7 206295_at IL18 -8. 27 4.38E-08 5. 11 E-05-1. 71-8. 63 11q22. 2-q22.3 8 201029_s_at CD99 -2.82 2.44E-09 2. 13E-05-1. 53-8.52 Xp22.32 9 224710_at RAB34 -7. 11 2.43E-08 5. 11 E-05-1. 57-8. 34 17q11. 1 10 235199_at -4. 90 2.26E-08 5. 11 E-05-1. 56-8.32 11 229307_at -5. 52 4.26E-08 5. 11 E-05-1. 60-8.32 12 208998_at UCP2 2. 6E 1.78E-07 1. 24E-04 1.61 8.21 11q13 13 215537_x_at DDAH2 -6.74 7.77E-08 7.52E-05-1. 59-8. 17 6p21. 3 14 217667_at-3. 1 1.68E-08 5. 11 E-05-1. 43-7.87 15 226025_at KIAA0379 -3.79 2.79E-07 1.67E-04-1. 61-7.85 3p25. 1 16 217989_at RetSDR2 -3. 65 1. 16E-08 5. 07E-05-1. 41-7. 85 4q21. 3 17 226528_at 4.20 5.72E-07 2. 65E-04 1. 57 7. 85 18 202262_x_at DDAH2 -4.68 6.77E-08 6. 93E-05-1. 45-7. 74 6p21. 3 19 231982_at -26. 73 5.80E-07 2.65E-04-1. 68-7.66 20206267satMATK-4. 19 4.07E-08 5. 11 E-05-1. 38-7. 60 19p13. 3 21 221773_at -4.69 5.73E-08 6. 23E-05-1. 37-7. 51 22 225799_at MGC4677-3. 33 4.40E-08 5. 11 E-05-1. 36-7.51 2p11. 1 23 202371 at FLJ21174-5. 1 E 2.50E-07 1.56E-04-1. 44-7. 46 Xq22.1 24218806satVAV3-2. 88 4.31 E-08 5. 11 E-05-1. 32-7. 35 1 pu 3. 2 25 213504_at COPS6 2. 3C 9.52E-07 3.51 E-04 1. 44 7. 34 7q22. 1 26 205349_at GNA15 -6. 67 1.39E-07 1. 13E-04-1. 35-7. 2919p13. 3 27 212775_at KIAA0657 -15.19 1. 11E-06 3. 67E-04-1.58-7. 28 2q36.1 28214909satDDAH2-5. 11 7.13E-07 2.95E-04-1. 46-7. 24 6p21. 3 29 210473_s_at GRP125 -5.49 1. 66E-07 1.24E-04-1. 34-7.22 4p15. 31 30 36711_at MAFF-9. 2 1.09E-06 3.67E-04-1. 51-7. 20 22q13. 1 31 225567_at -5. 42 5.93E-07 2.65E-04-1. 40-7. 16 32 223471_at RAB3IP 2.62 1. 96E-06 4. 80E-04 1. 43 7. 14 33 226869_at-7. 73 1.74E-07 1. 24E-04-1. 28-7. 03 34 220974_x_at BA108L7.2 -6.98 3. 13E-07 1.70E-04-1. 30-7. 01 10q24. 31 Table 2.1-2. 78 35 202747_s_at ITM2A -9. 26 1.29E-06 4.08E-04-1. 43-7. 01Xq13. 3-Xq21. 2 36217870satUMP-CMPK-1. 89 2.97E-07 1.67E-04-1. 30-6. 99 37 220668_s_at DNMT3B -4. 04 6.99E-07 2.95E-04-1. 35-6. 99 20q11. 2 38 201938_at CDK2AP1 -2. 01 1.36E-07 1.13E-04-1. 26-6. 97 12q24. 31 39 206995_x_at SCARF1 -3. 46 5.92E-07 2. 65E-04-1. 32-6. 96 17p13. 3 40 228252_at PIF1 4.11 9.45E-06 1.14E-03 1.57 6.94 15q22. 1 41 218899_s_at BAALC -14. 83 2.21 E-06 5.03E-04-1. 52-6.93 8q22.3 42 206478_at KIAA0125 -9. 64 1. 90E-06 4.73E-04-1. 45-6.91 14q32.33 43 204897_at PTGER4-2. 97 1. 43E-07 1.13E-04-1. 24-6. 90 5p13. 1 44 38340_at H IP1 R 2. 64 3.89E-06 6. 72E-04 1. 39 6. 86 12q24 45 211181_x_at -3. 62 2.97E-07 1.67E-04-1. 25-6.86 46225306satC14orf69-3. 90 3.51 E-07 1. 80E-04-1. 25-6. 83 14q32. 32 47 204446_s_at ALOX5 3.52 7.09E-07 2. 95E-04 1. 26 6. 79 10q11. 2 48 223708_at C1QTNF4 -47. 84 3.17E-06 5.82E-04-1. 55-6. 78 11q11 49 212235 at KIAA0620-3. 58 2. 01 E-07 1.35E-04-1. 22-6. 78 3q21. 3 50 217975_at LOC51186 -7.72 2.52E-06 5.28E-04 -1.39 -6.73 Xq22.1 2.37 ALL_t(8;14) versus AML_komplext # affy id HUGO name fc p q stn t Map Location 1 212293_at Nbak2-2. 65 2. 17E-12 6. 91 E-08-1. 43-9. 72 1p12 2 201548_s_at PLU-1 -3. 44 3.81 E-11 1.73E-07-1. 45-9.62 1q32. 1 3 213737_x_at -4. 14 7.58E-12 8.05E-08-1. 38-9.37 4 212397_at RDX-3. 33 5. 30E-12 8.05E-08-1. 37-9. 36 11 q23 5219201satTWSG1-9. 58 3. 02E-11 1.60E-07-1. 43-9. 34 18p11. 3 6 202265_at BMI1-4. 19 1.52E-11 9.67E-08-1. 40-9. 3210p11. 23 7 206015_s_at KIAA1041 -2. 30 1. 30E-11 9.67E-08-1. 32-9. 03 1 pter-q3i. 3 8 214651_s_at HOXA9 -22. 40 3.19E-10 5.09E-07-1. 42-8. 77 7p15-p14 9201807atVPS26-2. 44 3.71 E-10 5.60E-07-1. 32-8. 73 10q21. 1 10 201829_at NET1 -3. 31 2. 02E-10 4.95E-07-1. 30 -8.58 10p15 11 215111_s_at TSC22 -7.00 4.76E-10 5. 71E-07 -1.34 -8.53 13q14 12 205791_x_at ZNF230 -4. 47 8. 54E-11 3.40E-07-1. 24-8. 47 1913. 31 13 202747_s_at ITM2A -9. 76 3. 87E-10 5.60E-07-1. 30-8. 45 Xq13. 3-Xq21. 2 14 222182_s_at CNOT2 -2. 14 1.68E-10 4.86E-07-1. 25-8. 43 12q14. 3 15 201994_at MORF4L2 -1. 74 9.95E-10 7. 93E-07-1. 26-8.35 Xq22 16201029satCD99-2. 95 1.19E-10 3. 80E-07-1. 22-8.33 Xp22.32 17 203519_s_at UPF2 -2. 12 1. 19E-10 3.80E-07-1. 21-8. 3210p14-p13 18 218649_x_at SDCCAG1 -2. 04 4.04E-10 5.60E-07-1. 23-8.31 14q22 19 206175_x_at ZNF222 -6. 74 3. 17E-10 5. 09E-07-1. 24-8. 28 19q13. 2 20201196satAMD1-1. 94 3. 05E-10 5.09E-07-1. 21-8.25 6q21-q22 21 218280_x_at HIST2H2AA -4. 51 2.55E-10 5.09E-07-1. 21-8.21 1q21. 2 22226869at-13. 19 4.50E-10 5. 71 E-07-1. 23-8.20 23 45687 at MGC3121-2. 08 1. 94E-10 4.95E-07-1. 19-8. 17 16p11. 2 24207643satTNFRSF1A-5. 26 2. 39E-10 5. 09E-07-1. 18-8. 12 12p13. 2 25 214290_s_at HIST2H2AA -3.83 2. 64E-10 5. 09E-07-1. 18-8. 11 1q21. 2 Table 2.1-2. 78 26 200677_at PTTG1IP -3. 00 2. 82E-10 5.09E-07-1. 18-8. 0921q22. 3 27217963satNGFRAP1-8. 45 1.17E-09 9.06E-07-1. 24-8. 09 Xq22. 1 28 202746 at ITM2A-6. 30 8. 80E-10 7.38E-07-1. 22-8. 06 Xq13.3-Xq21.2 29 38671_at KIAA0620 -2.68 4.62E-10 5. 71 E-07-1. 18-8. 03 3q21. 3 30 218618_s_at FAD104 -4. 31 6. 84E-10 6. 60E-07-1. 19-8.01 3q26.31 31 219793_at SNX16-2. 98 6. 74E-10 6.60E-07-1. 19-8. 00 8q21. 12 32 208634_s_at MACF1 -3. 96 7.71 E-10 7.06E-07-1. 19-7. 98 1p32-p31 33 213074_at-2. 98 8.01 E-10 7.06E-07-1. 19-7.97 34 201263_at TARS -2.29 5. 51 E-10 6. 22E-07-1. 16-7. 95 5p13. 2 35 201325_s_at EMP1 -25.32 3.24E-09 1.62E-06-1. 29-7. 94 12p12. 3 36 218718_at PDGFC-8 17 2.42E-09 1.38E-06-1. 24-7.93 4q32 37 201920_at SLC20A1 -2.21 4. 84E-10 5. 71 E-07-1. 16-7. 92 2q11-q14 38 201324_at EMP1 -15. 80 3.59E-09 1.74E-06-1. 28 -7.90 12p12. 3 39 204798_at MYB -3. 91 6. 05E-10 6. 22E-07-1. 15-7.86 6q22-q23 40 227481_at FLJ31349 -4. 17 6.03E-10 6.22E-07-1. 15-7.85 6q25.2 41 201830 s at NET9-3. 93 5. 89E-10 6.22E-07-1. 15-7. 8510p15 42200929atTMP21-2. 13 1.20E-09 9. 11 E-07-1. 15-7. 79 14q24. 3 43 214700_x_at DKFZP434D193 -2.83 7. 94E-10 7. 06E-07-1. 13-7. 77 2q23. 3 44 217523_at CD44-4. 18 8. 20E-10 7.06E-07-1. 13-7. 76 11 pu 3 45 209160_at AKR1 C3-14. 63 5.61 E-09 2.35E-06-1. 25-7. 74 10p15-p14 46 202797_at SACM1L -2. 78 9. 05E-10 7. 39E-07-1. 13-7. 73 3p21. 3 47 209905_at HOXA9 -90. 93 6.69E-09 2.56E-06-1. 30-7. 72 7p15-p14 48 226545_at -6. 01 2.60E-09 1.38E-06-1. 15-7.65 49 201604_s_at PPP1R12A -2. 28 1.53E-09 1. 12E-06-1. 12-7. 64 12q15-q21 50 210613_s_at SYNGR1 -5. 32 1.54E-09 1.12E-06-1. 12-7.61 22q13. 1 2.38 ALL_t (8; 14) versus AML_t(15 ; 17) # affy id HUGO name fc p q stn t Map Location 1201029sat CD99-5. 10 1. 50E-19 2.05E-15-3. 57-20. 49 Xp22. 32 2205382satDF-23. 02 1.94E-15 5. 31E-12 -3. 72-19. 6919p13. 3 3 221004_s_at ITM2C -23. 37 1. 41 E-14 2. 42E-11-3. 48-18.24 2q37 4214450atCTSW-28. 11 7.12E-14 1.08E-10-3. 39-17. 43 11q13. 1 5 212953_x_at CALR -4.79 1.17E-14 2. 28E-11-3. 24-17. 3919p13. 3-p13. 2 6 38387_at STAB1 -28. 53 4. 42E-13 5.03E-10-3. 47-16. 84 3p21. 31 7 203948_s_at MPO -7. 72 1. 26E-16 8. 64E-13-2. 93-16. 7417q23. 1 8 224918_x_at MGST1 -5. 83 3.58E-16 1.63E-12-2. 70-15. 5312p12. 3-p12. 1 9 211709_s_at SCGF -14. 81 7.77E-13 7.59E-10-2. 92-15. 16 19q13. 3 10231736xatMGST1-6. 39 1.68E-15 5. 31 E-12-2. 65-15. 13 12p12.3-p12. 1 11 208689_s at RPN2-2. 72 2.65E-15 6.03E-12-2. 61-14.94 20q12-q13. 1 12 205624_at CPA3 -22. 18 5. 59E-12 3.49E-09-2. 88-14. 35 3q21-q25 13 201825_s_at CGI-49 -5. 55 2.72E-12 2.06E-09-2. 61-13.81 1 q44 14 203949_at MPO -4. 67 1. 52E-11 8. 01E-09 -2. 46-13. 25 17q23. 1 15 200654_at P4HB -3. 40 9.86E-13 8. 42E-10-2. 33-13. 0417q25 16 208852_s_at CANX -3.48 5. 36E-13 5. 63E-10-2. 20-12. 46 5q35 Table 2. 1-2.78 17 212509_s_at -12. 77 6. 52E-11 2. 55E-08-2. 48-12. 45 18 219869_s_at BIGM103 -4. 34 3.24E-12 2. 33E-09-2. 25-12. 41 4q22-q24 19 213854_at SYNGR1 -4. 61 2.03E-13 2. 78E-10-2. 14-12. 30 22q13. 1 20 205349_at GNA15 -8. 27 3.03E-13 3. 77E-10-2. 12-12. 13 19p13. 3 21238365sat-12. 76 1. 66E-11 8.41 E-09-2. 21-12. 00 22238022at-7. 91 8.42E-13 7.67E-10-2. 11-11. 99 23 204150_at STAB1 -31. 21 3. 01E-10 8. 75E-08-2. 50-11. 803p21. 31 24201028satCD99-8. 53 2. 61E-10 7. 93E-08-2. 31-11. 54 Xp22. 32 25201596xat KRT18-17.74 3.94E-10 1. 06E-07-2. 34-11.44 12q13 26 210613_s_at SYNGR1 -7. 36 8.22E-12 4. 88E-09-2. 04-11. 43 22q13. 1 27 213491_x_at RPN2 -2. 41 1. 42E-11 7. 75E-09-2. 03-11. 40 20q12-q13. 1 28217716satSEC61A1-2. 53 2.15E-12 1. 73E-09-1. 95-11. 22 3q21. 3 29231982at-19. 65 3.57E-10 1.02E-07-2. 20-11. 18 30 221739 at IL27w-2. 27 2. 69E-11 1. 23E-08-2. 00-11. 1819p13. 3 31 222477_s_at TM7SF3 -5.40 2.15E-10 7.01E-08 -2. 11-11. 08 12q11-q12 32 204347 at AK3-7. 50 9.46E-12 5. 39E-09-1. 95-11. 05 1p31. 3 33217225xatLOC283820-2. 34 4. 91E-12 3.36E-09-1. 88-10. 82 16p13. 13 34 228543 at CSRP2BP 2. 66 3.98E-10 1. 06E-07 1. 99 10. 81 20p11. 23 35 209215_at TETRAN-4. 32 5. 61E-12 3. 49E-09-1. 87-10. 75 4p16. 3 36 215116_s_at DNM1 -13. 38 1. 31 E-09 2. 57E-07-2. 20-10.70 9q34 37242520sat-15. 81 4.04E-10 1.06E-07-1. 97-10.51 38 208675_s_at DDOST -2. 73 2. 23E-11 1. 09E-08-1. 83-10. 441p36. 1 39 45687_at MGC3121 -2.54 4.98E-11 2.00E-08 -1. 86-10. 43 16p11. 2 40 200986_at SERPING1-12. 30 7.27E-10 1.69E-07-1. 99-10. 43 11q12-q13. 1 41 202012_s_at EXT2-3. 31 6. 81E-10 1.60E-07-1. 98-10. 4011p12-p11 42 06761 _at TACTILE-13. 70 1.87E-09 3.39E-07-2. 09-10. 37 3q13. 13 43 202262_x_at DDAH2 -5. 99 1.48E-10 5. 18E-08-1. 85-10.25 6p21. 3 44 214575_s_at AZU1 -6. 54 2. 62E-11 1. 23E-08-1. 79-10. 2419p13. 3 45 213399_x_at RPN2 -2.25 3. 55E-11 1.57E-08-1. 78-10.19 20q12-q13. 1 46 201826_s_at CGI-49 -3. 82 1.08E-09 2.20E-07-1. 94-10. 18 1q44 47 201162_at IGFBP7 -9. 47 6. 34E-10 1. 52E-07-1.86-10. 04 4q12 48 220987_s_at SNARK 4.66 6.39E-08 5. 74E-06 2. 09 10. 03 1q32. 1 49 210788_s_at retSDR4 -3. 07 4. 49E-11 1. 86E-08-1. 74-9. 9814q22. 3 50200656satP4HB-5. 21 5. 45E-10 1. 38E-07-1. 83-9. 9717q25 2. 39 ALL t (8; 14) versus AML_t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 211709_s_at SCGF -11. 39 6.95E-14 1. 15E-09-2. 35-13. 68 19q13. 3 2209160atAKR1C3-12. 54 1. 29E-11 4. 28E-08-2. 05-11. 47 10p15-p14 3 203949_at MPO -4. 28 2. 82E-11 5.85E-08-1. 82-10. 80 17q23. 1 4 210613_s_at SYNGR1 -7. 40 6. 49E-12 2. 70E-08-1. 75-10.54 22q13. 1 5 203948_s_at MPO -5. 64 3. 20E-12 2. 65E-08-1. 68-10. 32 17q23. 1 6 217989_at RetSDR2 -3.72 2.87E-10 2.97E-07 -1.75 -10.21 4q21.3 7 213854_at SYNGR1 -4.63 6.53E-12 2.70E-08 -1.66 -10.16 22q13. 1 Table 2. 1-2. 78 8 218718 at PDGFC-8.39 1. 59E-10 1.76E-07-1. 77-10.05 4q32 9 201825_s_at CGI-49 -4. 35 1.05E-10 1.58E-07-1. 74-10. 041q44 10201029satCD99-3. 99 2. 17E-11 5.14E-08-1. 64-9.93 Xp22.32 11 38671_at KIAA0620 -2. 85 2. 11 E-11 5.14E-08-1. 61 -9.82 3q21.3 12 228827_at -29.89 6. 68E-10 5.34E-07-1. 85-9.77 13 209122 at ADFP-3. 27 4. 96E-11 9.12E-08-1. 54-9.42 9p21. 3 14 206940 s at POU4F1-32. 15 1. 62E-09 1. 03E-06-1. 82-9. 3813q21. 1-q22 15 212133_at MGC5466 2. 43 4.32E-08 1.04E-05 1. 71 9.20 15q11. 2 16 228058 at LOC124220-5. 47 5. 51E-11 9.12E-08-1. 49-9. 2016p13. 3 17 212229_s_at FBXO21 3. 50 7.06E-10 5. 34E-07 1.54 9.16 12q24.22 18 232232_s_at CT2 -4. 04 1.34E-10 1. 71 E-07-1. 47-9.00 6q22.1 19 209318_x_at PLAGL1 -3. 96 1.30E-10 1. 71E-07-1. 46-8.95 6q24-q25 20 201015_s_at JUP -11. 06 7. 40E-10 5.34E-07-1. 50-8. 90 17q21 21202012satEXT2-1. 91 1. 54E-10 1.76E-07-1. 43-8. 8411p12-p11 22 220987 s at SNARK 3. 24 3.05E-07 4. 21E-05 1.76 8.80 1q32.1 23 224710_at RAB34 -7. 15 5. 01 E-10 4.61 E-07-1.46-8. 78 17q11.1 24 222477_s at TM7SF3-3. 98 1.40E-09 9.26E-07-1. 49-8. 76 12q11-q12 25 215537_x_at DDAH2 -5.24 4. 30E-10 4.19E-07-1. 44-8. 75 6p21. 3 26212442satLOC253782-4. 56 7. 41 E-10 5.34E-07-1. 39-8. 49 2q31. 1 27 211341_at POU4F1 -83. 12 1.12E-08 4.30E-06-1. 66 -8.47 13q21.1-q22 28 235353_at KIAA0746 4. 67 1. 10E-06 1. 06E-04 1.83 8.44 4p15. 2 29 219869_s_at BIGM103 -2. 34 7. 21 E-10 5.34E-07-1. 37-8.41 4q22-q24 30 201826_s at CGI-49-3. 67 6.17E-09 2.76E-06-1. 48-8. 40 1q44 31 231982_at-20. 00 1.07E-08 4.30E-06-1. 53-8.35 32 205528_s_at CBFA2T1 -23. 20 1.58E-08 5.44E-06-1. 54-8.24 8q22 33 221004_s_at ITM2C -6. 92 2.18E-09 1.24E-06-1. 35-8.16 2q37 34 202262_x_at DDAH2 -3. 60 1.18E-09 8.17E-07-1. 32-8. 15 6p21. 3 35 210473_s_at GPR125 -6.10 2.18E-09 1.24E-06-1. 34-8. 12 4p15. 31 36 212231_at FBX021 3. 26 1.95E-07 3. 02E-05 1.47 8.05 12q24. 22 37 205382_s_at DF -12. 14 1.53E-08 5.44E-06-1. 41-8.02 19p13. 3 38 201723_s_at GALNT1 -1. 81 1.75E-09 1.07E-06-1. 30-7. 99 18q12. 1 39 211728_s_at HYAL3 -3. 62 5.14E-09 2.57E-06-1. 31-7. 91 3p21. 3 40 206761_at TACTILE-9. 40 3.47E-08 9.36E-06-1. 41-7. 79 3q13. 13 41 204548_at STAR -17. 83 4.39E-08 1.04E-05-1. 44-7.76 8p11. 2 42 213355_at ST3GALVI-4. 80 3.92E-09 2.16E-06-1. 26-7.75 3q12. 1 43 225306_s_at C14orf69 -6. 91 2.28E-08 7.34E-06-1. 34-7. 7414q32. 32 44 203859_s_at PALM -4.37 5.27E-09 2.57E-06-1. 27-7. 73 19p13. 3 45 205529_s_at CBFA2T1-6. 28 1. 11 E-08 4.30E-06-1. 29-7.72 8q22 46 224833_at ETS1 6. 68 2.27E-06 1. 83E-04 1.61 7.71 11q23.3 47 201564_s_at FSCN1 -11. 83 3.96E-08 1. 01 E-05-1. 38-7.69 7p22 48 211474_s_at SERPINB6 -3. 41 4. 54E-09 2.42E-06-1. 25-7.69 6p25 49 204798_at MYB -3. 76 5.92E-09 2.76E-06-1. 26-7.68 6q22-q23 50201028satCD99-5. 30 4.12E-08 1.03E-05-1. 37-7.66 Xp22.32 2.40 ALL_t (8; 14) versus CLL Table 2.1-2. 78 # affy id HUGO name fc p q stn t Map Location 1 225927_at -2.74 3.75E-18 5. 46E-14-2. 12-14.68 2 239287_at-11. 04 9.76E-16 2.03E-12-1. 96-13.08 3 218191_s_at FLJ11240 -2. 41 2.75E-16 1. 00E-12 -1. 87-12.96 6q12 4 227670 at ZNF75A-4. 28 9.20E-17 6. 69E-13-1. 81-12. 69 16p13. 11 5217906atKLHDC2-2. 06 3. 98E-15 4.82E-12-1. 84-12. 59 14q21. 3 6 225629_s_at KIAA1538 -4.65 2. 18E-16 1. OOE-12-1. 79-12. 48 17p13. 1 7205105atMAN2A1-2. 74 7. 99E-16 2.03E-12-1. 77-12. 29 5q21-q22 8 212589_at RRAS2 -5. 94 8.38E-16 2.03E-12-1. 70-11. 9311p15. 2 9 214615_at P2RY10 -4. 21 1. 37E-15 2. 50E-12-1. 69-11.78 Xq21.1 10 217478_s_at HLA-DMA -2. 79 6.67E-14 3. 88E-11-1. 73-11. 75 6p21. 3 11 226508_at -3. 07 1. 83E-15 2. 95E-12-1. 67-11.71 12 213295_at -3.01 3.34E-15 4. 65E-12-1. 68-11. 70 13 224709-s-at SPEC2-2. 40 4. 03E-12 8. 03E-10-1. 75-11.47 5q31. 1 14 206337_at CCR7 -6. 16 3. 52E-15 4.65E-12-1. 64-11. 4617q12-q21. 2 15 39582_at -3. 38 5. 11 E-14 3. 23E-11-1. 66-11.38 16208306xatHLA-DRB4-2. 43 9.66E-12 1. 43E-09-1. 75-11.37 6p21. 3 17 205997_at ADAM28 -28. 23 8.14E-14 4. 08E-11-1. 71-11. 36 8p21. 1 18 218149_s_at DKFZp434K1210 -3. 46 1.09E-14 1. 21E-11-1. 62-11.30 8p21. 1 19 230689 at-9. 61 7.93E-14 4. 08E-11-1. 66-11.19 20 224838_at FOXP1-3. 09 5. 53E-10 3. 68E-08-1. 85-11. 17 3p14. 1 21 221718_s_at AKAP13-2. 20 7.28E-14 4. 07E-11-1. 62-11. 16 15q24-q25 22236280at-4. 68 1.70E-14 1. 76E-11-1. 58-11.02 23 226538_at -2. 97 3.16E-14 2. 56E-11-1. 57-10.95 24 213034_at KIAA0999 -3. 12 2.20E-14 1. 89E-11-1. 57-10. 94 11 q23. 3 25 205933_at SETBP1 -7. 67 3.86E-14 2. 86E-11-1. 58-10. 9418q21. 1 26 205788_s_at KIAA0663 -1. 81 2.19E-14 1. 89E-11-1. 56-10. 89 1q32. 1 27207700satNCOA3-4. 18 2. 20E-14 1. 89E-11-1. 56-10.89 20q12 28 207132_x_at PFDN5 -2. 18 1.74E-10 1.47E-08-1. 71-10. 78 12q12 29 217952_x_at PHF3 -2. 18 1. 76E-13 7. 37E-11-1. 55-10.73 30213142xatLOC54103-5. 50 4.82E-14 3. 19E-11-1. 54-10. 72 7q11. 23 31 212959_s_at MGC4170 -4. 15 4.23E-14 2. 93E-11-1. 53-10. 6912q23. 3 32 203057_s_at PRDM2 -3. 21 3.94E-14 2. 86E-11 -1. 53-10. 68 1 p36 33 202880_s_at PSCD1-2. 64 4. 19E-12 8. 24E-10 -1.59 -10.67 17q25 34 209061_at SULF2 -3. 66 5.92E-14 3. 59E-11-1. 52-10.63 20q12-13. 2 35 212590_at RRAS2 -4. 05 2.24E-13 8. 59E-11 -1. 53-10. 60 11 p15. 2 36 208456_s_at RRAS2 -5. 30 2. 08E-13 8. 19E-11-1. 53-10. 59 11p15. 2 37 41660_at CELSR1 -10. 17 3.14E-13 1. 06E-10-1. 54-10.50 22q13. 3 38 202254_at KIAA0440 -8. 20 5.16E-13 1. 53E-10-1. 56-10.49 14q24.1 39 212914_at PKP4-10. 57 4.16E-13 1. 32E-10-1. 55-10.49 2q23-q31 40213567at-2. 79 1. 28E-13 6. 01E-11 -1. 51-10.48 41 226869 at-10. 28 8.06E-14 4. 08E-11-1. 50-10.47 42 229844_at -3. 51 1.96E-13 7. 92E-11-1. 51-10. 46 43 212569_at KIAA0650 -3. 18 1.39E-13 6. 14E-11 -1. 49-10. 41 18p11. 31 44209236atSLC23A1-4. 55 9.73E-14 4. 72E-11-1. 48-10. 39 20p13 Table 2.1-2. 78 45 205192 at MAP3K14-3. 14 2.97E-13 1.03E-10-1. 48-10.31 17q21 46 212614_at MRF2 -5.02 4.76E-13 1. 44E-10-1. 51-10.31 10q22. 1 47 236226 at-6. 96 1.33E-13 6. 03E-11-1. 48-10.31 48 230245_s_at LOC283663 -15.22 3. 00E-12 6.33E-10-1. 62-10. 30 15q21. 2 49 204882_at KIAA0053 -7. 94 9.56E-13 2.48E-10-1. 52-10. 25 2p13. 2 50 AFFX-GAPD 1. 91 2. 46E-10 1. 95E-08 1.60 10.22 12p13 HUMGAPDH/M33 197 3 at-HG- U133B 2.41 ALL_t (8; 14) versus CML # affy id HUGO name fc p q stn t Map Location 1231982at-15. 81 5.94E-23 1.12E-18-2. 05-16. 03 2 214575_s_at AZU1 -7.93 3. 75E-15 5.07E-12-1. 95-14. 19 19p13. 3 3 208158_s_at OSBPL1A -4.40 2. 89E-16 6.82E-13-1. 76-13. 26 18q11. 1 4 205653_at CTSG -5. 64 2.09E-14 1. 88E-11-1. 78-13. 0014q11. 2 5 209485_s_at OSBPL1A -8. 61 1. 81 E-18 1. 71 E-14-1. 63-12. 77 18q11. 1 6 210140 at CST7-4. 40 3.97E-13 1.63E-10-1. 76-12. 60 20p11. 21 7204669satRNF24-7. 19 5. 55E-15 6. 56E-12-1. 68-12. 56 20p13-p12. 1 8201904satHYA22-8. 42 3. 20E-17 1. 51 E-13-1. 61-12. 51 3p21. 3 9225386satLOC92906-5. 00 4. 00E-12 9. 32E-10-1. 78-12. 38 2p22. 2 10 207949_s_at ICA1 -5. 20 2. 66E-16 6.82E-13-1. 60-12. 30 7p22 11 228497_at FLIPT1 -5. 91 4. 78E-18 3. 01E-14 -1. 56-12. 301p13. 1 12 202794_at INPP1 -3.18 2.53E-15 3. 98E-12-1. 55-11. 83 2q32 13 203948_s_at MPO -5.15 3.07E-12 8.16E-10-1. 63-11. 6417q23. 1 14 213572_s_at SERPINB1 -3. 87 1. 16E-09 9.03E-08-1. 87-11. 62 6p25 15 213541_s_at ERG -5.55 5.94E-17 2.24E-13 -1.47 -11.59 21q22. 3 16 200654-at P4HB-2. 85 1. 11E-09 8.71 E-08-1.85-11. 54 17q25 17 211709_s_at SCGF -7.05 8.05E-17 2. 54E-13-1. 47-11. 54 19q13. 3 18 201825_s_at CGI-49 -2.70 8.44E-16 1.59E-12-1. 49-11. 531q44 19 226869 at-8. 85 5.19E-14 3. 63E-11-1. 52-11. 44 20 225782 at LOC253827-5. 40 2. 54E-13 1.12E-10-1. 54-11.41 12q14. 1 21 217989_at RetSDR2 -4. 11 5.20E-12 1.18E-09-1. 60-11. 40 4q21. 3 22 203949 at MPO-4. 10 2.75E-10 2.87E-08-1. 73 -11.38 17q23. 1 23 205769_at SLC27A2 -4.79 4.23E-16 8.87E-13-1. 45-11. 3315q21. 2 24219010atFLJ 10901-4. 29 1.27E-13 7. 08E-11-1. 50-11.21 1 q31. 3 25 201905_s_at HYA22 -5.12 9.89E-13 3.49E-10 -1. 53-11.19 3p21.3 26222692satFAD104-4. 20 7.67E-15 8.05E-12-1. 45-11. 17 3q26. 31 27 210613_s_at SYNGR1 -4. 39 1. 75E-11 3.12E-09-1. 58-11. 11 22q13. 1 28214430atGLA-2. 20 1.22E-12 4.03E-10-1. 52-11.11 Xq22 29228726at-4. 69 4.55E-14 3. 30E-11-1. 43-10. 91 30 213737_x_at -3. 56 9.17E-10 7. 46E-08-1. 65-10.79 31 219890_at CLECSF5 -6.04 1. 96E-15 3. 36E-12-1. 36-10. 71 7q33 32 202441_at KEO4 -3. 16 3. 58E-11 5. 52E-09-1. 52-10. 7010q21-q22 33 208636_at ACTN1 -4.82 3. 14E-11 4. 99E-09-1. 51-10. 6914q24 Table 2. 1-2.78 34 204798_at MYB-4. 11 8. 56E-15 8.51 E-12-1. 37-10. 64 6q22-q23 35 218618_s_at FAD104 -3. 81 4.77E-15 6. 00E-12 -1. 35-10. 58 3q26. 31 36 206207 at CLC-4. 67 3.39E-12 8. 55E-10-1. 44-10. 56 19q13. 1 37 209215_at TETRAN -3.99 1.83E-13 8. 41E-11 -1. 39-10.56 4p16. 3 38 211728_s_at HYAL3 -4. 14 2.90E-15 4. 21 E-12-1. 34-10. 53 3p21. 3 39 207341 at PRTN3-8. 55 6.24E-15 6. 93E-12-1. 35-10.51 19p13. 3 40 205768_s_at SLC27A2 -4.51 3.47E-14 2. 63E-11-1. 34-10.41 15q21. 2 41 203675_at NUCB2 -4. 04 3.36E-10 3.35E-08-1. 51-10. 36 11p15.1-p14 42 226794_at STXBP5 -4. 13 8.68E-14 5. 47E-11-1. 34-10.33 6q24. 3 43 217963_s_at NGFRAP1 -5. 76 1.58E-14 1. 49E-11-1. 28-10.08 Xq22.1 44 239213 at SERPINB1-5. 74 3. 21E-14 2.58E-11 -1. 28-10.05 6p25 45 208637_x_at ACTN1 -5. 34 1. 04E-10 1. 29E-08-1. 41-10. 0514q24 46 218251_at STRAIT11499 -3. 47 1.12E-13 6. 41 E-11-1. 30-10. 05 up11. 4 47 202871_at ELA2 -3.91 1.89E-08 8. 88E-07-1. 66-10. 04 19p13. 3 48 204381_at LRP3 -6. 49 3. 96E-11 5.90E-09-1. 39-10. 20 19q13. 11 49 212268 at SERPINB1-4. 01 5.05E-08 1.97E-06-1. 76-10.01 6p25 50 205471_s_at DACH -4. 66 1.66E-13 8. 06E-11-1. 29-10. 00 13q22 2. 42 ALL_t (8; 14) versus normalBM # affy id HUGO name fc p q stn t Map Location 1209160atAKR1C3-9. 54 1.37E-06 3. 29E-03-2. 94-11. 1610p15-p14 2 210613_s_at SYNGR1-4. 68 9.89E-10 3.16E-05-2. 32-10.86 22q13. 1 3 218718_at PDGFC-3. 27 2.04E-07 1.64E-03-1. 85-8.48 4q32 4 226751_at DKFZP566K1924 -5. 01 5.51 E-06 5.40E-03-2. 03-8.36 2p13. 2 5 217047 s at FAM13A1-2. 86 7.28E-08 1. 16E-03-1. 77-8. 29 4q22.1 6232232satCT2-4. 92 2.30E-06 3.87E-03-1. 90-8. 24 6q22. 1 7226806sat-3. 83 3.82E-06 4.91 E-03-1.88-8. 04 8 223437_at MGC2452 -3. 69 6.53E-07 2.08E-03-1. 72-7. 87 22q13. 31 9 205051_s_at KIT -3. 79 2.06E-07 1.64E-03-1. 65-7. 72 4q11-q12 10 203645 s at CD163-4. 45 5.86E-07 2.08E-03-1. 66-7. 66 12p13. 3 11 222078_at HCN3 -5. 52 2.99E-05 1.02E-02-1. 99-7. 621q21. 3 12 206488 s at CD36-3. 06 3.02E-07 1. 93E-03-1.61-7. 53 7q11. 2 13 218424_s_at TSAP6 -2. 56 5.25E-07 2.08E-03-1. 62-7.48 2q14. 1 14 202973_x_at FAM13A1 -2. 99 3.98E-07 2.08E-03-1. 60-7. 47 4q22.1 15 214575_s_at AZU1 -5. 85 2.07E-06 3. 87E-03-1. 64-7. 40 19p13. 3 16 227627_at SGKL -3. 18 5.78E-07 2.08E-03-1. 57-7. 34 8q12. 3-8q13. 1 17 223044_at SLC11A3 -4. 21 9.69E-07 2.81 E-03-1. 58-7.31 2q32 18 209605_at TST -3. 60 2.84E-06 4.12E-03-1. 63-7.31 22q13. 1 9223769xatHT036-2. 62 1.42E-06 3.29E-03-1. 59-7.24 1 p34. 1 20 226608_at SAS10 2.81 4. 94E-06 5. 12E-03 1.67 7.18 4q13. 3 21 230988_at -3. 45 3.35E-06 4.65E-03-1. 57-7.09 22 209048_s_at PRKCBP1 -2. 10 1.15E-05 7.30E-03-1. 61 -7.00 20q13. 12 23 206871_at ELA2 -3. 74 1.60E-06 3. 29E-03-1. 49-6. 92 19p13. 3 24 208152_s_at DDX21 1.66 2.26E-06 3. 87E-03 1.50 6.89 10q21 Table 2.1-2. 78 25 213056_at KIAA1013 -2.36 1. 60E-06 3. 29E-03 -1.47 -6.84 3p14.1 26 204976_s_at AMMECR1-2. 47 7.48E-06 6. 29E-03-1. 53-6. 82 Xq22.3 27213292satSNX13-1. 97 2.71 E-06 4.12E-03-1. 48 -6.82 7p21. 1 28 208158_s_at OSBPL1A -3. 32 1. 13E-05 7. 30E-03-1. 52-6. 72 18q11. 1 29226590atLOC286334-2. 76 1.65E-06 3.29E-03-1. 43-6.69 9q32 30 222624 s at LOC51193 2. 36 2.82E-06 4. 12E-03 1.45 6.69 3q27. 1 31 202616_s_at MECP2 -3. 12 4.43E-06 5.05E-03-1. 42-6. 56 Xq28 32 218247_s_at LOC51320 2.79 7. 37E-06 6. 29E-03 1.45 6.50 18q21.1 33 227230 s at KIAA1211-4. 05 5.57E-06 5.40E-03-1. 39-6.42 4q12 34 213012_at NEDD4-3 2c 1.62E-05 8.46E-03-1. 44 -6.41 15q 35 210140_at CST7 -3.93 3.02E-05 1.02E-02-1. 47 -6.38 20p11. 21 36205927satCTSE-3. 69 2.18E-05 9.52E-03-1. 45-6.38 1 q31 37225437satMGC229162*34 8.17E-06 6. 52E-03 1. 40 6. 34 7p22.3 38 218729_at LXN -2.87 7.14E-05 1.44E-02-1. 55-6.34 3q25.32 39 213541 s at ERG-5. 93 1.48E-04 2.05E-02-1. 70 -6.33 21q22. 3 40223166xatFLJ101011. 66 3. 87E-06 4.91 E-03 1. 35 6. 33 9q34.3 41 226869_at -6.29 1. 24E-05 7.50E-03-1. 39-6.31 42204776atTHBS4-2. 69 4. 31 E-06 5.05E-03-1. 35-6. 30 5q13 43 217963_s_at NGFRAP1 -4.26 5.10E-05 1. 31 E-02-1. 49-6. 30 Xq22. 1 44 202061_s_at SEL1L -2.06 4.70E-06 5.12E-03-1. 35-6.29 14q24. 3-q31 45 201432_at CAT -2. 21 4. 00E-06 4.91 E-03-1.34-6. 27 all3 46 219714_s_at CACNA2D3 -5.89 3. 01 E-05 1.02E-02-1. 41-6. 20 3p21. 1 47 203506_s_at TNRC11 -1. 81 4.97E-06 5.12E-03-1. 32-6.20 Xq 13 48 212628_at -2.29 6. 43E-05 1.40E-02-1. 47-6.18 49 203100_s_at CDYL -2. 57 1.30E-05 7.66E-03-1. 35-6.16 6p25.1 50 225202_at RHOBTB3 -2.04 9.34E-06 6.78E-03 -1.34 -6.14 5q14.3 2.43 AML_MLL versus AML_inv(16) # affy id HUGO name fc p q stn t Map Location 1 213737_x_at 3.65 1.30E-18 3. 71E-14 2. 17 15. 48 2 214651_s_at HOXA9 22.10 4.22E-16 6. 01 E-12 2. 26 14. 60 7p15-p14 3 200665 s at SPARC-14. 82 7. 41 E-14 3. 52E-10-2. 27-14.07 5q31. 3-q32 4 200953_s_at CCND2 -4. 16 1. 61E-15 1. 53E-11-1. 86-13. 20 12p13 5 202746_at ITM2A-16. 0¢ 9. 80E-13 2.15E-09-2. 15-12.88 Xq13. 3-Xq21. 2 6 202747_s_at ITM2A -16.65 8.69E-13 2.06E-09-2. 09-12.76 Xq13.3-Xq21. 2 7 235753_at 14.15 1. 49E-13 6. 06E-10 1. 98 12. 10 8 227567_at 5.31 5.68E-15 4. 05E-11 1. 66 11. 93 9 229215_at ASCL2 11.42 2. 22E-13 6. 34E-10 1. 73 11. 48 11 p15. 5 10 206847_s_at HOXA7 7.10 2. 07E-13 6. 34E-10 1. 70 11. 41 7p15-p14 11 231310_at -4.40 2.33E-14 1.33E-10-1. 54-11.24 12 201497_x_at MYH11 -27.86 4. 74E-11 4.22E-08-2. 16-11. 2316p13. 13-p13. 12 13 200951_s_at CCND2 -4.96 2. 30E-12 4.22E-09-1. 60-10. 90 12p13 14 209905_at HOXA9 70.38 2. 46E-12 4. 22E-09 1. 82 10. 90 7p15-p14 15 224049_at KCNK17 4. 3 2. 74E-11 2.70E-08-1. 66-10. 60 6p21. 1 Table 2. 1-2.78 16 213147_at HOXA10 5. 72 2.97E-13 7. 68E-10 1.48 10.56 7p15-p14 17 203949_at MPO -3. 36 1. 91 E-13 6. 34E-10-1.41-10. 32 17q23. 1 18 213908 at 15. 52 8.76E-12 9. 99E-09 1.66 10.30 19 201496_x_at MYH11 -6. 20 5. 40E-11 4.67E-08-1. 56-10. 1416p13. 13-p13. 12 20 202370_s_at CBFB 3.09 3. 66E-12 5. 22E-09 1. 46 10. 07 16q22. 1 21 202931_x_at BIN1 -3. 16 1. 41E-12 2.87E-09-1. 39-10. 05 2q14 22 226517_at BCAT1 -10. 55 1. 85E-10 1.15E-07-1. 66-10. 0512pter-q12 23 204082_at PBX3 5. 42 2. 57E-11 2. 61E-08 1. 52 9. 76 9q33-q34 24212667atSPARC-7. 96 2.45E-10 1.42E-07-1. 54-9. 70 5q31. 3-q32 25 225831_at LCO148894 -3. 79 5. 89E-11 4.89E-08-1. 41-9. 59 1p36. 11 26 203733_at MYLE 3.27 3.18E-12 5. 03E-09 1.30 9.50 16p13. 2 27 223385 at CYP2S1-2. 38 1. 24E-10 8.39E-08-1. 38 -9.34 19q13. 1 28205330atMN1-16. 74 1.73E-09 5.37E-07-1. 75-9.33 22q12. 1 29 223471 at RAB31P 3. 58 7. 10E-12 8. 43E-09 1.28 9.29 30201830satNET1-4. 44 3.73E-10 2. 00E-07 -1. 42-9. 26 1 Op 15 31 202551_s_at CRIM1 -4. 62 2. 91 E-10 1.63E-07-1. 39-9. 23 2p21 32 210139_s_at PMP22 -9. 69 1.47E-09 4. 81E-07 -1.55 -9.18 17p12-p11. 2 33 224772_at NAV1 -2. 82 3. 27E-10 1.79E-07-1. 37-9. 12 34 211012 s_at PML-2. 69 1. 13E-11 1.24E-08-1. 24-9. 09 15q22 35 228058_at LOC124220 -5. 16 4.73E-12 6.12E-09-1. 22-9. 0916p13. 3 36 223299_at LOC90701 2.79 4. 18E-12 5.67E-09 1.20 9.00 18q21. 31 37 214452_at BCAT1 -4.30 3.97E-10 2. 02E-07-1. 34-8. 99 12pter-q12 38 228497 at FLIPT1 7.80 2. 17E-10 1.29E-07 1. 41 8.98 1p13. 1 39 225102_at LOC152009 5.25 84.41E-11 6.48E-08 1.30 8.95 3q21.3 40 201828_x_at CXX1 2.85 2.52E-12 4.22E-09 1.17 8.91 Xq26 41 203948 s at IMPO -3. 51 6. 09E-12 7.55E-09-1. 19-8.91 17q23.1 42 200602 at APP-6. 96 1. 09E-10 7. 70E-08-1. 26-8. 90 21q21. 3 43 218041_x_at SLC38A2 -1. 65 3.59E-12 5. 22E-09-1. 17-8. 9012q 44 225285_at -9. 24 1.04E-09 3.97E-07-1. 35-8. 82 45 203373 at SOCS2 13. 18 2. 48E-10 1. 42E-07 1.34 8.82 12q 46201029satCD99-1. 85 1. 78E-11 1. 88E-08-1. 18-8. 75 Xp22. 32 47 213150_at HOXA10 8.63 1.06E-10 7. 70E-08 1.25 8.74 7p15-p14 48 228496_s_at CRIM1 -2. 68 8. 74E-11 6.56E-08-1. 20-8. 70 2p21 49 221581_s_at WBSCR5 2.78 3. 22E-11 3. 06E-08 1.19 8.70 7q11. 23 50 205453_at HOXB2 -6.83 3.79E-10 2.00E-07 -1.25 -8.69 17q21-q22 2.44 AML_MLL versus AML_inv(3) # affy id HUGO name fc stn t Map Location 1 204082_at PBX3 8.60 2. 88E-12 2. 35E-08 1.63 10.50 9q33-q34 2 226789_at 3.28 1. 48E-13 1. 81E-09 1.47 10.39 3 214651_s_at HOXA9 4.67 9.43E-14 1. 81E-09 1.45 10. 29 7p15-p14 4 235753 at 4. 92 3.97E-12 2. 43E-08 1. 42 9. 76 5 228083_at CACNA2D4 11. 16 1. 43E-11 5. 83E-08 1.46 9.66 12p13. 33 6 214643_x_at BIN1 -4.56 2. 50E-09 1. 64E-06-1. 59-9. 58 2q14 Table 2. 1-2.78 7 209905at HOXA9 7. 7c 3. 17E-11 1. 11E-07 1.34 9. 13 7p15-p14 8 202054_s_at ALDH3A2 5.02 6.40E-12 3. 14E-08 1.27 9.05 17p11. 2 9208116satMAN1A1-4. 86 2. 19E-08 6. 38E-06 -1.59 -8. 95 6q22 10 236398_s_at 5.77 7. 08E-11 1. 58E-07 1.31 8.88 11 201829_at NET1 -3.59 3. 90E-08 9.18E-06-1. 61-8.81 10p15 12 203733_at MYLE 2.69 6. 75E-11 1. 58E-07 1.23 8.59 16p13. 2 13 212318_at TRN-SR 2. 53 8. 52E-11 1.67E-07 1.23 8. 55 7q32.2 14 233955_x_at HSPC195 -4.61 1.78E-08 5.60E-06-1. 41-8. 54 5q31. 3 15 213893_x_at PMS2L5 2.24 3.81 E-11 1. 17E-07 1. 19 8. 49 7q11-q22 16208702xatAPLP2Z83 4. 39E-11 1. 19E-07 1. 19 8. 45 11 q24 17 231431_s_at -2. 62 7.32E-08 1.39E-05-1. 54-8.45 18 202605_at GUSB 3.28 9. 55E-11 1. 67E-07 1.20 8.44 7q21.11 19 210006_at DKFZP564O243 2.17 1.66E-10 2.71 E-07 1. 21 8. 40 3p21. 1 20 210201_x_at BIN1 -2.98 1.82E-08 5.64E-06-1. 35-8.34 2q14 21 214439_x_at BIN1 -3. 31 1.27E-08 4. 55E-06-1. 31-8. 27 2q14 22212782xatPOLR2J2. 38 3. 41 E-10 4. 29E-07 1.18 8.24 7q11. 2 23200602atAPP-10. 57 8.51 E-08 1.58E-05-1. 47-8. 24 21 q21. 3 24 214875_x_at APLP2 2. 72 9. 39E-11 1. 67E-07 1.15 8.23 11q24 25 219551 at TRAITS 3. 35 3. 68E-10 4. 29E-07 1.19 8.19 3q13. 33 26 206847_s_at HOXA7 2.98 2.37E-10 3. 23E-07 1. 16 8. 15 7p15-p14 27 218217_at RISC 4.10 1.13E-09 9. 89E-07 1.23 8.14 17q23. 1 28 223703_at CDA017 3.49 1.23E-09 1. OOE-06 1. 22 8. 0910q23. 1 29 201186_at LRPAP1 3.21 7. 48E-10 7. 89E-07 1.18 8.07 4p16. 3 30 201105_at LGALS1 2.91 1.88E-10 2. 88E-07 1.12 8.00 22q13. 1 31 203725 at GADD45A-3. 08 1. 71 E-09 1.27E-06-1. 16-7. 99 1 p31. 2-p31. 1 32 214430_at GLA 2.03 2. 27E-10 3. 23E-07 1. 12 7. 97 Xq22 33 206440_at LIN7A 8.55 1. 13E-09 9. 89E-07 1.17 7.97 12q21 34 211709_s_at SCGF 4.44 4.41 E-10 4.91 E-07 1.11 7.86 19q13. 3 35 219033_at FLJ21308 3.62 1.20E-09 1. 00E-06 1.14 7.85 5q11. 1 365 219126_at XAP135 1.85 3.53E-10 4. 29E-07 1. 10 7. 84 6q27 37 208967_s_at AK2 3.68 3.22E-09 1. 84E-06 1.20 7.83 1p34 38 212174_at Ak2 3.63 1. 63E-09 1. 24E-06 1. 15 7. 83 1 p34 39 202053_s_at ALDH3A2 2.61 9.28E-10 8.75E-07 1.11 7.78 17p11. 2 40 202961_s_at ATP5J2 2.16 8.60E-10 8. 43E-07 1. 10 7. 77 7q22. 1 41 201830_s_at NET1 -5.62 3.42E-07 3.90E-05-1. 47-7. 7510p15 42 231300_at LOC90835 4.14 2. 74E-09 1. 68E-06 1.15 7.74 16p11. 2 43 204951_at ARHH -3.59 3. 51 E-08 8.51 E-06-1.21-7. 71 4p13 44 211404_s_at APLP2 2.23 1.44E-09 1. 14E-06 1. 09 7. 65 11 q24 45 219991_at SLC2A9 2.29 2.55E-09 1. 64E-06 1.12 7.64 4p16-p15. 3 46 223328_at MGC3195 2.12 7.73E-10 7. 89E-07 1. 07 7. 61 7q22.1 47 213908 at 3. 56 4.03E-09 2. 10E-06 1. 12 7. 58 48 228652_at FLJ38288-2. 21 6.80E-08 1.32E-05-1. 21-7. 58 19q13. 43 49 214953_s_at APP -5.50 1.23E-07 1.99E-05-1. 23-7. 52 21q21. 3 50 202931_x_at BIN1 -3.09 1. 11 E-07 1.89E-05-1. 21-7.50 2q14 Table 2.1-2. 78 2.45 AML MLL versus AML komplext # affy id HUGO name fc p q stn t Map Location 1 201377 at NICE-4 -2. 72 3. 69E-15 2. 46E-11-1. 51-11. 56 1q21. 3 2201105atLGALS14. 52 6.07E-14 2. 57E-101'3610. 55 22q13. 1 3200608satRAD21-1. 86 3. 88E-15 2. 46E-11 -1.28 -10.40 8q24 4 228083 at CACNA2D4 11. 81 1. 68E-11 9. 93E-09 1.53 9.94 12p13.33 5201830satNET1-5. 21 6.70E-12 6. 55E-09-1. 37-9. 77 10p15 6 201225 s at SRRM1-1. 72 1. 39E-13 4.42E-10-1. 18-9. 52 1p36. 11 7208886atH1FO-7. 16 2. 03E-11 9.93E-09-1. 32-9. 40 22q13. 1 8 214700_x_at DKFZP434D193 -3. 12 1. 37E-11 9.65E-09-1. 27-9. 33 2q23.3 9 209022 at STAG2-1. 98 3. 31 E-12 5.25E-09-1. 17-9. 17 Xq25 10 218041_x_at SLC38A2 -1. 84 3. 42E-13 8.70E-10-1. 12-9. 13 12q 11 203544_s_at STAM -4.39 3. 49E-11 1.48E-08-1. 26-9. 11 10p14-p13 12 218823 s at FLJ20038-2. 77 3. 12E-11 1. 41E-08-1. 25-9. 098p21. 1 13 201196 s at AMD1-1. 93 1.72E-12 3.49E-09-1. 14-9. 09 6q21-q22 14 201560_at CLIC4-4. 16 4.61 E-12 5.33E-09-1. 16-9. 07 1p36.11 15 202746_at ITM2A -10. 44 1.47E-10 3.83E-08-1. 28 -8.85 Xq13.3-Xq21. 2 16 209705_at -2.03 1.78E-11 9.93E-09-1. 14-8. 80 17 205788_s_at KIAA06634 -1.79 1. 87E-11 9. 93E-09-1. 14-8. 78 1q32. 1 18 203519_s_at UPF2 -2.09 1. 91 E-11 9.93E-09-1. 13 -8.75 10p14-p13 19 222902 s at FLJ21144-1. 92 1.92E-12 3.49E-09-1. 08-8. 75 1 p34. 1 20 233168 s at IMAGE3510317-1. 73 4.52E-12 5.33E-09-1. 09-8. 75 22q13. 33 21 209362 at SURB7-2. 15 1. 91 E-11 9.93E-09-1. 11-8. 67 12p11. 23 22204082atPBX34*49 5. 32E-11 2. 05E-08 1.l14 8.66 9q33-q34 23 201585_s_at SFPQ -1. 91 9.60E-12 8. 21E-09 -1.09 -8.65 1p34. 3 24 200997_at RBM4 -1. 92 1.18E-11 8. 79E-09 -1. 09-8. 6411q13 25 201829 at NET1-3. 30 1.95E-10 4. 21 E-08-1. 21-8. 62 10p15 26 239071_at -1.83 3.72E-12 5. 25E-09-1. 04-8.51 27203725atGADD45A-4. 33 6. 08E-11 2.21 E-08-1.11-8. 51 1p31.2-p31. 1 28 211137_s_at ATP2C1 -3. 12 4.82E-10 7.28E-08-1. 26-8. 50 3q21-q24 29 202747 s at ITM2A-10. 27 3.18E-10 5. 61 E-08-1. 20-8. 49 Xq13. 3-Xq21. 2 30201166satPUM1-1. 86 3. 89E-11 1. 60E-08-1. 09-8. 491p35. 2 31 212232_at FNBP4 -1. 77 1.15E-11 8.79E-09-1. 05 -8.43 11p11. 12 32 200086 s at- ICOX4 1 1.64 5.17E-12 5. 47E-09 1.03 8.43 16q22-qter HG-U133B 33 223318 s at MGC10974 3.61 2.44E-10 4.77E-08 1. 14 8. 38 19p13. 3 34 212463 at-4. 10 1.52E-10 3. 83E-08-1. 11-8.35 35 213549_at PRO2730 -4.66 6.44E-10 8. 52E-08-1. 21-8. 33 3p21.31 36 201358_s_at COPB -1.65 1. 96E-11 9. 93E-09-1. 04-8. 33 11 p15. 2 37 212031_at S164 -2.00 1. 55E-11 9.93E-09 -1.03 -8.32 14q24. 3 38 228974_at -4. 54 1.70E-10 4. 01E-08 -1.10 -8.31 39 2054849_s_at UQCRB 1.52 9.70E-12 8.21 E-09 1.02 8.31 8q22 40201061satSTOM-3. 25 2.69E-10 5. 17E-08-1. 12-8. 31 9q34. 1 41 205639_at AOAH 3. 94 2.96E-10 5. 43E-08 1.12 8.29 7p14-p12 42 218331_s_at FLJ20360 -2.05 6. 54E-11 2.31 E-08-1. 06I2810p15. 1 Table 2. 1-2.78 43 223592sat MGC13061 2.62 2.99E-10 5. 43E-08 1.12 8. 28 17q11. 2 44 217887_s_at ESP15 -2. 10 5. 29E-11 2.05E-08-1. 05-8. 26 1 p32 45 200985_s_at CD59 -4. 95 1. 95E-10 4. 21E-08-1. 09-8. 2511p13 46 214439_x_at BIN1 -3. 72 2. 41E-10 4.77E-08-1. 09-8.21 2q14 47 200071_at-HG-SPF30-1 89 7. 53E-11 2.52E-08-1. 04-8. 19 10q23 U133A 48 202413_s_at USP1 -1. 73 3. 43E-11 1.48E-08-1. 01-8. 161p32. 1-p31. 3 49 218846_at CRSP3-2. 57 3.67E-10 6. 13E-08-1. 09-8. 15 6q22. 33-q24.1 50 202659_at PSMB10 3.04 1.05E-10 3.27E-08 1.04 8.15 16q22. 1 2. 46 AML MLL versus AML_t(15 ; 17) # affy id HUGO name fc p q stn t Map Location 1 221004_s_at ITM2c -9. 69 6. 96E-15 2. 78E-11-2. 63-16.45 2q37 2 38487_at STAB1 -16. 22 3. 38E-13 4.51E-10-2. 90-16. 13 3p21. 31 3 203948_s_at MPO -6. 32 8. 76E-21 2. 10E-16 -2. 19-15. 8317q23. 1 4 214651_s_at HOXA9 237. 17 2. 30E-16 1. 84E-12 2. 66 15. 41 7p15-p14 5 205624_at CPA3 -36. 02 6. 17E-12 3.79E-09-3. 01-14. 75 3q21-q25 6 212953_x_at CALR -3. 21 2.50E-14 6. 66E-11 -2.22 -14. 41 19p13. 3-p13. 2 7 214450_at CTSW-6. 11 7.04E-14 1. 41 E-10-2. 21-14. 15 11q13. 1 8 203949_at MPO -4. 43 9.42E-19 1.13E-14-1. 91-13. 8717q23. 1 9 200953_s_at CCND2 -6. 10 3.06E-12 2.45E-09-2. 26-13. 42 12p13 10 213147_at HOXA10 23. 93 1.62E-14 4. 85E-11 2.12 13. 06 7p15-p14 11 238022_at -5.73 4.14E-12 3. OOE-09-1. 96-12.30 12 235753_at 16. 83 1.12E-13 1. 79E-10 2. 04 12. 26 13 233072_at KIAA1857 -11. 75 7. 57E-11 2.44E-08-2. 24-12.25 9q34 14 205771_s_at AKAP7 10. 25 3.35E-14 8. 02E-11 1.82 12.10 6q23 15 206871_at ELA2 -3. 69 4.90E-16 2. 94E-12-1. 64-11. 89 19p13. 3 16 206847_s_at HOXA7 9. 48 6. 90E-14 1.41E-10 1.80 11. 89 7p15-p14 17 209448_at HTATIP2 10. 38 2.48E-13 3. 64E-10 1.79 11.54 11p15. 1 18 204150_at STAB1 -19. 25 3.63E-10 8.30E-08-2. 23-11. 50 3p21. 31 19 213587_s_at LOC155066 7.64 6. 58E-13 7. 88E-10 1.79 11.29 7q36. 1 20205663atPCBP3-3. 93 3. 63E-11 1.36E-08-1. 79-11. 19 21 q22. 3 21 201522_x_at SNRPN 4.63 2. 51E-15 1. 20E-11 1. 54 11. 19 15q12 22212509sat-6. 33 1. 53E-10 4. 37E-08-1. 87-11.08 23 209905_at HOXA9 720. 22 1. 83E-12 1. 75E-09 1.92 11.06 7p15-p14 24 205349_at GNA15 -4. 14 1.47E-12 1. 53E-09-1. 62-11. 03 19p13. 3 25 200951_s_at CCND2 -6. 76 2. 21 E-10 5.88E-08-1. 88-10. 98 12p13 26 206761_at TACTILE -28. 74 1. 21E-09 2. 02E-07-2.29-10. 90 3q13. 13 27 201029_s_at CD99 -2. 16 1. 80E-14 3. 69E-11-1. 48-10. 74 Xp22. 32 28 217848_s_at PP 3.89 1.09E-13 1. 79E-10 1.49 10.59 10q11.1-q24 29225532atLOC91768-5. 64 9.02E-10 1.64E-07-1. 92-10. 5918q11. 1 30 200952 s at CCND2-4. 07 2. 77E-10 6.83E-08-1. 76-10. 57 12p13 31 204425_at ARHGAP4 15. 58 4. 11 E-12 3. 00E-09 1.65 10. 49 Xq28 32 204082_at PBX3 8. 50 2. 90E-12 2. 40E-09 1. 61 10. 47 9q33-q34 Tabie 2. 1-2. 78 33 231736xat MGST1-2. 80 2.58E-13 3.64E-10-1. 46-10. 42 12p12. 3-p12. 1 34 210788_s_at retSDR4 -2. 38 2. 11E-11 9. 75E-09-1. 57-10.41 14q22.3 35 224918_x_at MGST1 -2. 62 9.12E-14 1. 68E-10-1. 42-10. 3012p12. 3-p12. 1 36201596xatKRT18-8. 14 5.16E-10 1.08E-07-1. 69-10. 20 12q13 37 213150_at HOXA10 45. 69 1. 41 E-11 7. 20E-09 1.71 10.17 7p15-p14 38 218404_at XNX10 6.77 5.71 E-12 3. 60E-09 1.53 10.09 7p15. 2 39 225386_s_at LOC92906 34. 47 1. 65E-11 8. 20E-09 1.66 10.08 2p22.2 40 211474_s_at SERPINB6 4. 55 2.77E-12 2. 40E-09 1.47 10. 04 6p25 41 221253-s-at MGC3178-2. 99 2.44E-10 6. 44E-08-1. 59-10. 03 6p24.3 42 228083_at CACNA2D4 11. 77 1. 68E-11 8. 20E-09 1.57 9.93 12p13. 33 43 213571_s_at EIF4EL3 2.54 6. 08E-13 7. 67E-10 1.37 9. 84 2q37.1 4 208852_s_at CANX -2. 26 6. 45E-11 2. 18E-08-1. 46 -9.78 5q35 45 227999_at LOC170394 3.11 7.06E-13 8. 06E-10 1. 36 9. 76 10q26. 3 46217716satSEC61A1-1. 93 1. 04E-11 5. 68E-09-1. 40-9. 72 3q21. 3 47 202265_at BMI1 4.29 8. 23E-12 4. 70E-09 1.43 9. 71 10p11. 23 48 217853_at TEM6 6. 43 1.19E-11 6.31 E-09 1.43 9.66 7p15. 1 49 223663_at FLJ37970 6.99 2.35E-12 2. 17E-09 1.37 9.66 11q12. 3 50228263atGRASP-2. 66 3.59E-12 2. 77E-09-1. 36-9. 63 12q13. 13 2.47 AML_MLL versus AML_t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 214651_s_at HOXA9 207. 35 2. 33E-16 6. 38E-12 2. 65 15. 40 7p15-p14 2 221581_s_at wbscr5 10. 61 3. 46E-15 2. 36E-11 2.04 13.41 7q11. 23 3 213147_at HOXA10 17. 19 2. 21E-14 1. 01E-10 2.00 12.78 7p15-p14 4 235753_at 15. 72 1. 24E-13 4. 83E-10 2. 01 12. 20 5 201105_at LGALS1 7.06 3. 40E-15 2. 36E-11 1. 63 11. 87 22q13. 1 6 206847_s_at HOXA7 7.80 1.77E-13 6. 06E-10 1.79 11.69 7p15-p14 7 227853_at 3.59 7.38E-15 4. 04E-11 1.54 11.33 8 203949_at MPO -4. 06 7.26E-16 9.92E-12-1. 47-11. 1617q23. 1 9 209905 at HOXA9 687. 57 1.83E-12 4. 55E-09 1.92 11. 06 7p15-p14 10213908at16. 07 8. 41 E-12 1. 53E-08 1.68 10.33 11 213150_at HOXA10 58. 80 1. 26E-11 2. 16E-08 1.73 10.23 7p15-p14 12 210314_x_at TNFSF13 4.81 5.81e-13 1. 59e09 1.42 10.22 17p13. 1 13 228827 at 4. 44E-10 2.89E-07-1. 99-10. 05 110. 08 14 228083 at CACNA2D4 12.77 1. 51 E-11 2. 29E-08 1. 60 10. 05 12p13. 33 15 209500_x_at TNFSF13 4. 18 3. 77E-12 7. 93E-09 1.39 9.82 17p13. 1 16 204082_at PBX3 6.63 5.42E-12 1. 06E-08 1.39 9. 77 9q33-q34 17 228058_at LOC124220-6. 07 2.57E-12 5. 84E-09-1. 33-9. 70 16p13. 3 18 203948_s_at MPO -4. 62 4. 25E-13 1. 29E-09-1. 28-9. 66 17q23. 1 19 206940_s_at POU4F1 -41. 89 1.43E-09 6.02E-07-1. 86-9. 46 13q21. 1-q22 20 212423_at FLJ90798 5. 26 1. 45E-11 2. 29E-08 1.34 9.42 10q22. 3 21 201944 at HEXB 3. 49 5. 23E-11 5. 29E-08 1.44 9.41 5q13 22223562atPARVG3. 11 2. 14E-11 2. 67E-08 1.34 9.35 22q13.2-q13 Table 2. 1-2.78 23 229406 at-12. 04 2. 06E-09 7. 54E-07-1. 65-9.19 24 205639_at AOAH 5.75 2. 05E-11 2. 67E-08 1.29 9.18 7p14-p12 25 204202_at KIAA1023 3.45 2. 15E-11 2. 67E-08 1.28 9.13 7p22. 3 26205529satCBFA2T1-12. 90 2. 76E-09 8.88E-07-1. 70-9. 10 8q22 27230650at-5. 19 2.41 E-09 8.23E-07-1. 55-9. 01 28 206009_at ITGA9-3. 49 2. 03E-10 1. 50E-07-1. 30-8. 95 3p21. 3 29 203859_s_at PALM -5. 31 1. 28E-09 5.66E-07-1. 39-8. 88 19p13. 3 30 217853 at TEM6 5. 32 2. 90E-11 3. 44E-08 1.22 8.87 7p15.1 31 201850_at CAPG 8.40 4. 01E-10 2.67E-07 1.37 8.73 2cen-q24 32 224415_s_at HINT2 1.98 1. 84E-11 2. 65E-08 1.16 8.66 9p13. 1 33 216417_x_at HOXB9 3. 56 3. 49E-11 3.81 E-08 1.17 8.64 17q21. 3 34 203733_at MYLE 2.65 6. 93E-11 6. 53E-08 1.18 8.59 16p13. 2 35 211341 at POU4F1 - 9.63E-09 2.23E-06-1. 69-8. 5413q21. 1-q22 266. 20 36 225245_x_at H2AFJ 4.56 3. 12E-11 3.55E-08 1.15 8. 54 12p12 37 204069 at MEIS1 20. 28 8. 95E-10 4. 51E-07 1.42 8.54 2p14-P13 38 205528_s_at CBFA2T1 -41. 63 1. 17E-08 2.56E-06-1. 63-8. 45 8q22 39 206761_at TABCTILE -19. 71 1. 31 E-08 2.72E-06-1. 57-8. 38 3q13. 13 40204880atMGMT-2. 31 1. 57E-10 1.26E-07-1. 14-8. q26 41 225386_s_at LOC92906 7.38 1. 95E-10 1. 48E-07 1. 15 8. 31 2p22. 2 42 225009_at CKLFSF4 4.99 6. 86E-10 3. 83E-07 1.22 8.29 16q21 43 202746_at ITM2A -6.60 3. 24E-09 9. 84E-07-1. 25-8. 28Xq13. 3-Xq21. 2 44 218217_at RISC 4.76 3. 65E-10 2. 49E-07 1.17 8.28 17q23. 1 45232227at-11. 48 1. 52E-08 2.99E-06-1. 50-8. 27 46 238756 at 3. 91 6. 11E-10 3. 55E-07 1.20 8.26 47 224301_x_at H2AFJ 3.97 1. 00E-10 8. 64E-08 1.11 8.24 12p12 48 212459 x at SUCLG2 3. 21 4. 89E-11 5. 14E-08 1. 09 8. 21 3p14. 2 49 241706_at LOC144402 6.44 1.09E-09 5. 31E-07 1.19 81.3 12q11 50 225344_at ERAP140 -4.28 9.94E-09 2.25E-06-1. 30-8. 13 6q22. 33 2. 48 AML MLL versus CLL # affy id HUGO name fc p q stn t Map Location 1 224838_at FOXP1-6. 07 8.36E-29 6.94E-25-3. 56-26.98 3p14. 1 2 41220_at MSF -3. 19 8.08E-33 1.34E-28-2. 71-22. 48 17q25 3202880satPSCD1-6. 55 4.92E-24 1.36E-20-2. 70-20. 46 17q25 4225927at-4. 22 6.07E-27 3.36E-23-2. 41-19.51 5 212827_at IGHM -17. 91 8.69E-23 1. 23E-19 -2.55 -19.23 14q32. 33 6 223514_at CARD11 -41.15 3. 94E-20 1. 87E-17-2. 91-18.90 7p22 7 224837_at FOXP1 -.388 9. 76E-22 8. 11 E-19-2. 51-18.62 3pu4. 1 8 201163_s_at IGFBP7 35. 15 9. 25E-19 2. 36E-16 2. 92 18. 36 4q12 9 207168_s_at H2AFY 3.01 1.91E-24 6. 35E-21 2.23 17.97 5q31. 3-q32 10 226905_at 7.02 3.02E-25 1. 25E-21 2. 21 17. 94 11 204215_at MGC4175-5. 22 2.93E-22 2. 72E-19-2. 30-17. 78 7q21. 1-q21. 2 12 224833_at ETS 1-10. 03 2.95E-22 2.72E-19-2. 29-17. 73 11q23. 3 Table 2. 1-2.78 13 204951_at ARHH-14.78 6.87E-20 2. 85E-17-2. 53-17. 71 4p13 14 243780 at-37. 44 6. 73E-19 1. 93E-16-2. 63-17.23 15 208657_s_at MSF -6. 86 1.07E-19 4. 13E-17-2. 32-16. 86 17q25 16 206111_at RNASE2 31. 57 9.90E-18 1. 55E-15 2. 60 16. 7714q24-q31 17 209374_s_at IGHM -20. 50 2.26E-19 7.67E-17-2. 31-16. 6414q32. 33 18 21373_x_at 4.04 1. 90E-18 4. 34E-16 2. 37 16. 63 19 209075-s-at NIFU-3. 01 2.08E-23 4.94E-20-2. 05-16. 5812q24. 1 20212590atRRAS2-11. 91 8.40E-19 2.27E-16-2. 38-16. 56 11p15. 2 21 39582_at -4. 91 4.97E-20 2. 23E-17-2. 19-16.44 22 215785_s_at CYFIP2 -9.58 2.53E-20 1. 31 E-17-2. 16-16. 42 5q34 23 208944_at TGFBR2-4. 11 1.74E-22 2. 01E-19-2. 02-16.25 3p22 24 41577_at PPP1R16B -9. 45 7.42E-21 5. 14E-18-2. 09-16. 22 20q11. 23 25 212589_at RRAS2 -25. 69 4. 92E-18 8. 79E-16-2. 42-16. 09 11p15. 2 26212750atPPP1R16B-7. 28 8.90E-23 1.23E-19-1. 98-16. 06 20q11. 23 27 212313_at MGC29816-6. 02 1.93E-18 4.34E-16-2. 24-15.87 8p21. 2 28208456satRRAS2-16. 84 7.02E-18 1.19E-15-2. 35-15. 83 11p15. 2 29 214615_at P2RY10 -11. 66 4. 87E-18 8. 79E-16-2. 28-15. 75 Xq21. 1 30 201648_at -2. 80 1. 31 E-21 9.91 E-19-1. 95-15. 62 31 229844_at -6. 66 7.08E-18 1.19E-15-2. 25-15.56 32 223391_at SGPP1-17. 31 2.66E-18 5.52E-16-2. 17-15. 5414q23. 1 33 226508 at-4. 47 1. 20E-18 2.98E-16-2. 11-15.49 34 214651_s_at HOXA9 199. 29 2.35E-16 2. 10E-14 2.66 15.40 7p15-p14 35 224482 s at RAB11-FIP4-7. 81 2. 08E-20 1.24E-17-1. 96-15.39 36 211404_s_at APLP2 5.26 2. 79E-18 5. 72E-16 2. 07 15. 33 11 q24 37 AFFX-GAPD 2. 28 1. 21E-22 1. 54E-19 1. 87 15. 33 12p13 HUMGAPDH/M33 197_3_at - HG- U133B 38 228390at-46. 90 2. 89E-17 3.78E-15-2. 35-15.33 39 208091_s_at DKFZP564K0822 -7.35 3.43E-18 6.62E-16-2. 12-15.31 7p14. 1 40 223287_s_at FOXP1 -4.95 1. 93E-18 4.34E-16 -2. 08-15.27 3p14. 1 41207000satPPP3CC-5. 93 7.39E-19 2. 08E-16-2. 04-15. 27 8p21. 2 42 202863_at SP100 -3. 35 4. 98E-19 1. 48E-16-2. 02-15. 26 2q37. 1 43 224709_s_at SPEC2 -2 68 2.88E-23 5. 99E-20 -1. 84-15.25 5q31. 1 44 234734 s at TNRC6-2. 60 1.06E-21 8.34E-19-1. 88-15. 25 16p11. 2 45 213295 at-4. 06 1.42E-19 5. 23E-17-1. 98-15.23 46 227670_at ZNF75A-5. 65 4. 99E-19 1.48E-16-2. 00-15. 18 16p13. 11 47 226331_at -3. 59 3.76E-23 6.94E-20-1. 83-15.16 48 233849_s_at ARHGAP5 -12. 51 3. 55E-19 1.13E-16-1. 98-15. 14 14q12 49 AFFX-GAPD 2. 19 1. 81 E-22 2. 01 E-19 1. 84 15. 11 12p13 HUMGAPDH/M33 197_3_at-HG- U133A 50 212386_at -17. 35 6.03E-18 1. 05E-15-2. 09-15.09 2.49 AML_MLL versus CML = I Table 2. 1-2.78 # affy id HUGO name fc p q stn t Map Location 1 206676_at CEACAM8-27. 77 7. 07E-33 2. 11E-29-3. 29-26. 8819q13. 2 2 212531_at LCN2 -22.72 2. 13E-34 9. 55E-31-3. 09-26. 28 9q34 3 209771_x_at CD24 -13.42 1. 81 E-36 1.62E-32-2. 94-25. 80 6q21 4 216379_x_at KIAA1919 -15. 24 1.45E-34 8. 63E-31-2. 96-25. 51 6q22 5 205557_at BPI -10. 70 1.66E-37 2.97E-33-2. 69-24. 22 20q11. 23-q12 6 211657_at CEACAM6 -17. 83 1.18E-32 3.02E-29-2. 68-23. 2019q13. 2 7 203757_s_at CEACAM6 -28.13 9. 61 E-30 1. 91 E-26-2. 80-23. 02 19q132 8208650satCD24-29. 40 6.44E-27 8.63E-24-2. 71-21.27 6q21 9 205513_at TCN1 -19. 93 1. 70E-27 2. 76E-24-2. 62-21. 1911q11-q12 10 203021 at SLPI-9. 07 5.59E-28 1. OOE-24-2. 57-21.15 20q12 11 201061_s_at STOM -5. 35 3.04E-31 6.79E-28-2. 40-21. 10 9q34. 1 12 202018_s_at LTF -9. 14 6.96E-34 2.49E-30-2. 31-20. 89 3q21-q23 13 266_s at CD24-20. 66 9. 11 E-27 1.09E-23-2. 56-20. 61 6q21 14 210224_at CAMP -31. 74 1.46E-25 1. 13E-22-2. 57-20. 00 3p21. 3 15 209772_s_at CD24 -42. 41 4.50E-25 3. 22E-22-2. 61-19.80 6q21 16 207802_at SGP28 -54. 67 4.75E-25 3.27E-22-2. 51-19.51 6p12. 3 17 209396_s_at CHI3L1 -31. 25 3.93E-24 2.20E-21-2. 44-18. 74 1q32.1 18 208651 x at CD24 -11. 30 3.48E-26 3.67E-23-2. 09-18.01 6q21 19 203936_s_at MMP9 -13.29 1. 23E-25 1. OOE-22-2. 08-17. 79 20q11.2-q13. 1 20201060xatSTOM-5. 38 6.78E-26 6.07E-23-2. 03-17. 58 9q34. 1 21209369atANXA3-18. 37 4.42E-24 2.27E-21-2. 13-17. 55 4q13-q22 22 224967_at UGCG -6. 19 1.42E-26 1. 59E-23-1. 97-17. 32 9q31 23 230006_s_at DKFZ33A2432 -6. 65 4.44E-24 2.27E-21-1. 99-16. 83 11 p14. 2 24 201554_x_at GYG -3. 92 3.30E-27 4.92E-24-1. 81-16. 38 3q24-q25.1 25 226278_at DKFZp313A2432 -5.99 3. 11 E-24 1.79E-21-1. 90-16. 37 11 p14. 2 26210140atCST7-5. 33 6.75E-27 8.63E-24-1. 79-16. 19 20p11. 21 27 231688_at -8. 54 4.12E-26 3.88E-23-1. 79-16. 09 28219281atMSRA-3. 01 1.06E-24 6.54E-22-1. 83-16. 07 8p23.1 29 207269_at DEFA4 -7.80 8.84E-26 7.53E-23-1. 77-15. 94 8p23 30 230285_at DKFZp313A2432-6. 50 2.57E-22 1. 05E-19-1. 90-15. 8411p14. 2 31 236979 at-4. 55 5.45E-22 2. 07E-19 -1. 92-15.81 32 206871_at ELA2-4. 21 1.20E-23 5.94E-21-1. 79-15. 73 19p13. 3 33 211275_s_at GYG -3. 02 3.90E-26 3. 88E-23-1. 74-15.71 3q24-q25.1 34 201905_s_at HYA22 -6. 24 1.34E-24 8. 00E-22 -1. 77-15.67 3p21. 3 35 206207_at CLC -9 87 5.37E-25 3. 56E-22-1. 72-15. 44 19q13. 1 36 200985_s_at CD59 -7.59 2. 00E-23 9. 41E-21-1. 75-15. 3311p13 37 214953_s_at APP -8. 96 1.23E-23 5.94E-21-1. 73-15.27 21q21. 3 38 202252_at RAB13 -3. 03 3.48E-25 2.59E-22-1. 68-15. 221q21. 2 39 234317_s_at DKFZp762K222 -5. 51 2.70E-21 9. 30E-19-1. 84-15. 20 4q35. 1 40206656satC20orf3-3. 26 4.13E-24 2.24E-21-1. 70-15. 16 20p11. 22-p11. 21 41 09447 at SYNE1-8. 48 6.26E-21 1. 96E-18 -1.86 -15.13 6q25 42223423atGPCR1-3. 50 8.78E-25 5. 61E-22 -1.68 -15. 12 3q26.2-q27 43 225829_at LOC118987 -6. 43 1.25E-21 4. 39E-19-1. 79-15. 0610q26. 12 44 204881_s_at UGCG -8. 18 4. 33E-21 1. 41 E-18-1. 80-14. 95 9q31 45 209395_at CHI3L1 -72. 69 1. 00E-19 2. 72E-17-2. 03-14. 91 1q32. 1 Table 2. 1-2. 78 46 224707_at ORF1-FL49 -5.25 3.25E-21 1. 10E-18-1. 78-14. 89 5q31. 3 47 201904 s_at HYA22-10. 51 2.35E-22 9.78E-20-1. 70-14.79 3p21. 3 48 202119_s_at CPNE3 -6.86 8.93E-22 3. 33E-19-1. 72-14. 78 8q21. 13 49 204411 at KIAA0449-8. 27 7. 46E-23 3.18E-20-1. 66-14. 70 1 pter-q31. 3 50217762satRAB31-5. 79 2.92E-23 1. 31 E-20-1. 65-14. 67 18p11. 3 2. 50 AML MLL versus normal # affy id HUGO name fc p q stn t Map Location 1 202018_s_at LTF -9. 66 2. 68E-10 1.20E-07-3. 31-17.59 3q21-q23 2 214651_s_at HOXA9 30. 37 4.97E-16 6.89E-12 2.54 14.95 7p15-p14 3 235733_at 04 3. 20E-11 2.46E-08-2. 38-13.93 4228716at-4. 24 2.87E-09 7.95E-07-2. 49-13.53 5 227041_at -2.61 8.52E-12 9.84E-09-2. 14-12.98 6 212531_at LCN2-20. 69 6.47E-07 3.79E-05-3. 25-12.96 9q34 7 214109_at LRBA -1.95 6. 29E-15 4. 35E-11-1. 93-12. 44 4q31. 22-q31. 23 8 213737_x_at 2.56 3. 00E-14 1. 38E-10 1. 82 11. 73 9225792at-4. 45 7.07E-07 3.89E-05-2. 43-11. 20 10 201105_at LGALS1 5. 54 9. 84E-14 3. 41E-10 1.71 11.06 22q13. 1 11 209905_at HOXA9 156. 33 2. 07E-12 3. 19E-09 1. 90 11. 00 7p15-p14 12 213147_at HOXA10 6.85 2. 03E-13 5. 48E-10 1.71 11. 00 7p15-p14 13 235753 at 6. 91 9.30E-13 1. 84E-09 1. 76 10. 95 14 206847_s_at HOXA7 7.31 2. 37E-13 5. 48E-10 1. 67 10. 79 7p15-p14 15 225923 at-2. 10 6.23E-10 2.40E-07-1. 78-10.69 16 205849_s_at UQCRB 1.98 6. 58E-10 2. 46E-07 1. 74 10. 50 8q22 17 217979_at NET-6 -3. 89 2.16E-08 3.48E-06-1. 85-10. 42 7p21. 1 18 210192_at ATP8A1 -2. 79 5.95E-08 6.99E-06-1. 86-10. 26 4p14-p12 19 202265_at BMI1 5.04 3. 15E-12 4. 36E-09 1.62 10.25 10p11. 23 20 208651_x_at CD24 -8. 71 2. 18E-06 8. 71 E-05-2. 30-10. 256q21 21229860xat3. 92 1. 24E-12 2. 15E-09 1. 57 10. 18 22 228083_at CACNA2D4 12. 06 1. 69E-11 1. 46E-08 1.64 9.99 12p13. 33 23 217047_s_at FAM13A1 -2. 90 2.62E-10 1.20E-07-1. 60-9. 91 4q22. 1 24 237444 at-2. 68 7.69E-09 1.64E-06-1. 68-9.89 25 224767_at 5.87 8. 27E-12 9. 84E-09 1. 55 9. 84 26 209771_x_at CD24 -10. 88 5.64E-06 1.65E-04-2. 38-9.75 6q21 27 200631 s at SET 1. 63 1. 08E-11 1.15E-08 1.48 9.57 9q34 28 216379_x_at KIAA1919 -12. 73 8. 00E-06 2.08E-04-2. 44-9.56 6q22 29 205624_at CPA3 -4. 24 1.04E-07 1.06E-05-1. 70-9.49 3q21-q25 30 221030_s_at DKFZP564B1162 -2. 62 7.20E-08 8. 24E-06-1. 67-9.46 4q21. 3 31 202561_at TNKS -2. 22 6.05E-10 2.40E-07-1. 51-9. 40 8p23.1 32 201268_at NME2 2.34 1. 47E-10 8. 17E-08 1.48 9.38 17q21. 3 33 209066_x_at UQCRB 2.48 1. 23E-11 1. 21 E-08 1. 45 9. 37 8q22 34 201162_at GFBP7 5.03 3. 56E-11 2. 59E-08 1. 48 9. 37 4q12 35 201135_at ECHS1 2. 33 1. 65E-11 1. 46E-08 1.44 9.29 10q26. 2-q26.3 36227812at-3. 41 4.97E-06 1. 53E-04-2. 06-9. 26 Table 2. 1-2.78 37 214785_at CHAC-2. 05 5. 14E-08 6. 36E-06-1. 61-9.25 9q21 38 205033_s_at DEFA1 -4.06 1.08E-07 1.08E-05-1. 64-9. 24 8p23. 2-p23. 1 39225464atC14orf31-2. 82 3. 87E-09 9. 59E-07-1. 51-9.21 14q21. 3 40 209329 x at MGC2198 1. 93 2. 29E-11 1.86E-08 1.42 9.18 5q35.3 41 225700_at GLCCI1 -3.81 8. 54E-06 2. 14E-04-2. 16 -9.11 7p22.1 42 211404_s_at APLP2 2.19 5.47E-11 3. 61 E-08 1.41 9.08 11q24 43 226301_at dJ55C23. 6-4. 12 4. 34E-09 1. 06E-06-1. 49-9.06 6q22. 3-q23.3 44 213150 at HOXA10 8. 08 1. 86E-10 9.53E-08 1.49 9.05 7p15-p14 45 209036_s_at MDH2 1.92 8. 33E-11 5. 25E-08 1.41 9.04 7p12.3-q11. 2 46 40189_at SET 1.69 4. 19E-11 2.90E-08 1.40 9.03 9q34 47 211662_s_at VDAC2 1.83 1.58E-10 8. 43E-08 1.41 9.01 10q22 48 227448 at-2. 18 1.26E-07 1. 22E-05-1. 58-8. 98 49 203734_at FHX -1.79 9.97E-08 1. 03E-05-1. 56-8. 93 12p13. 31 50 227545_at -2.13 2.15E-06. 8.63E-05 -1.77 -8.88 2.51 AML_inv(16) versus AML_inv (3) # affy id HUGO name fc p q stn t Map Location 1 203949_at MPO 4.50 1.34E-17 3. 70E-13 2.52 16.16 17q23. 1 2 203948_s_at MPO 5.13 3. 61 E-16 4. 97E-12 2.05 13.37 17q23. 1 3 205382_s_at DF 5.63 3. 26E-13 2. 99E-09 1.85 11.66 19p13. 3 4 201497 x at MYH11 19. 05 6. 47E-11 3. 56E-07 2.09 11.02 16p13.13-p13. 12 5 209365 s at ECM1 3. 55 3.80E-12 2. 62E-08 1.68 10.58 1q21 6 210755_at HGF 6.55 1. 77E-10 6. 09E-07 1.70 9.96 7q21.1 7217963satNGFRAP1-22. 83 1. 95E-08 1. 45E-05-1. 97-9. 62 Xq22. 1 8 205718_at ITGB7 3.13 8.99E-11 4. 12E-07 1.41 9.03 12q13. 13 9 208248 x at APLP2 2. 15 1.31 E-10 5. 17E-07 1.35 8.78 11q24 10 202605_at GUSB 2.31 2. 30E-10 7.03E-07 1.35 8.72 7q21. 11 11 224841_x_at -1.65 4. 68E-09 5. 86E-06-1. 42-8.60 12 224741_x_at -1.65 4.37E-09 5. 73E-06-1. 41-8. 57 13200985 s at CD59-7. 88 6.95E-08 3. 10E-05 -1. 58-8.43 11p13 14 223136_at AIG-1 -5. 64 1. 52E-08 1. 25E-05-1. 40-8. 33 6q24. 1 15 222862_s_at AK5 27.90 1. 73E-08 1. 36E-05 1.54 82.3 1p31 16 201496_x_at MYH11 3.43 1. 98E-09 4. 53E-06 1.31 8.22 16p13.13-p13. 12 17 211709_s_at SCGF 3.66 3. 59E-10 9.87E-07 1.25 8.20 19q13. 3 18 212358_at CLIPR-59 18. 74 2. 53E-08 1. 66E-05 1.56 8.09 19q13. 12 19 226197-at 2. 63 3. 14E-09 4. 93E-06 1.25 7.94 20 200985_s_at CD59 -3.23 8. 03E-08 3. 39E-05-1. 39-7. p13 21 218217_at RISC 2.67 3.47E-09 4. 93E-06 1.24 7.88 17q23. 1 22 201462 at KIAA0193-5. 53 4.85E-08 2. 30E-05-1. 33-7. 86 7p14. 3-p14. 1 23 210997_at HGF 22.58 4.15E-08 2. 12E-05 1.46 7.82 7q21.1 24 226121_at MGC23280 -2. 43 3.57E-08 1. 91 E-05-1. 30-7. 81 17q11. 1 25 228497_at FLIPT1 -3. 42 1. 25E-07 4. 52E-05-1. 39 -7.80 1p13.1 26208702xatAPLP2240 2. 97E-09 4.93E-06 1.20 7.78 11q24 27220668satDNMT3B-5. 06 3. 67E-07 9. 36E-05-1. 54-7. 76 20q11. 2 Table 2.1-2. 78 28 214875_x_at APLP2 2.55 1. 88E-09 4.53E-06 1. 19 7. 75 11q24 29207961xatMYH1113. 58 5.40E-08 2. 52E-05 1.43 7.71 16p13.13-p13. 12 30 204198_s_at RUNX3 -5. 88 2.49E-07 7.54E-05-1. 42 -7.69 1p36 31201029satCD991*55 1. 51 E-08 1. 25E-05 1. 23 7. 67 Xp22. 32 32 205076_s_at CRA 4.58 4. 39E-08 2. 16E-05 1.35 7.66 1q12-q21 33 231736_x_at MGST1 3.21 2. 85E-09 4. 93E-06 1. 16 7. 5612p12. 3-p12. 1 34 223640_at PIK3AP 2.38 3. 34E-09 4. 93E-06 1.15 7.53 19q13. 1 35 I200078 s at- IATP6V0B # 2.01# 3.17E-09 4. 93E-06 1. 15 7. 51 1 p32. 3 HG-U 133B 36 209975_at CYP2E1 3. 78 2. 34E-08 1. 61E-05 1.22 7. 50 10q24. 3-qter 37 224918_x_at MGST1 2.97 3. 48E-09 4. 93E-06 1. 14 7. 49 12p12. 3-p12. 1 38 202185_at PLOD3 1.83 3. 58E-09 4. 93E-06 1. 14 7. 49 7q22 39 200872_at S100A10 3. 0C 7. 76E-09 7. 90E-06 1.16 7.47 1q21 40 241525_at LOC200772 37.93 9.78E-08 3. 74E-05 1. 41 7. 47 2q37.3 41 230896 at-41. 32 9. 11 E-07 1. 71 E-04-1. 70-7. 47 42208704xatAPLP22*39 4. 96E-09 5. 93E-06 1.14 7.44 11q24 43 243244_at 3 0c 6. 78E-09 7. 47E-06 1. 14 7. 41 44 212463 at-4. 59 5.24E-07 1. 13E-04-1. 39 -7.39 45 202283_at SERPINF1 4.66 2. 32E-08 1. 61E-05 1.17 7.33 17p13. 1 46 205859_at LY86 3.57 7. 41 E-09 7. 84E-06 1. 12 7. 32 6p24.3 47 204122 at TYROBP 2. 73 6. 45E-09 7. 40E-06 1.12 7.31 19q13. 1 48 223091_x_at GL004 -1. 53 1. 84E-08 1. 41 E-05-1. 14-7. 30 2q36.3 49 205131_x_at SCGF 4.95 3. 38E-08 1. 90E-05 1.17 7.29 19q13. 3 50 238151_at 2.68 3.62E-08 1.91E-05 1.16 7.27 2.52 AML_inv(16) versus AML_komplext # affy id HUGO name fc p q stn t Map Location 1 209190_s_at DIAPH1 2.58 2.08E-14 1. 34E-10 1. 64 11. 80 5q31 2 201497_x_at MYH11 20. 34 5. 66E-11 2. 80E-08 2.00 11.03 16p13.13-p13. 12 3 201496_x_at MYH11 8.16 1. 93E-11 1.38E-08 1.63 10. 61 16p13. 13-p13. 12 4 200984_s_at CD59 -5.61 1. 78E-12 3. 27E-09-1. 54-10. 44 11 p13 5212463at-8. 87 3.40E-12 4.96E-09-1. 59-10.41 6 209619 at CD74 2. 48 3.74E-13 9. 64E-10 1. 42 10. 41 5q32 7 222229_x_at 1.45 1.28E-14 1. 34E-10 1.35 10. 37 8 200985_s_at CD59 -13. 21 5. 81E-12 6. 02E-09-1.54-10. 16 11p13 9 200093_s_at HINT1 1.79 8.03E-14 3. 45E-10 1.28 9.82 5q31. 2 HG-U133B 10 205382sat DF 3. 68 3. 91E-12 5.04E-09 1.31 9. 62 19p13. 3 11 206847_s_at HOXA7 -3. 70 1.36E-12 2.91 E-09-1. 30 -9.60 7p15-p14 12 217846 at QARS 1. 68 3. 05E-13 9. 64E-10 1. 24 9. 52 3p21. 3-p21. 1 13 232247_at FLJ14855 -2. 34 1.13E-11 9.74E-09-1. 26-9. 18 3p21. 31 14 204198_s_at RUNX3 -7. 48 5. 36E-11 2.76E-08-1. 33 -9.13 1p36 15 208886_at H1F0 -5.94 4.78E-11 2.56E-08 -1. 28-9. 01 22q13. 1 16 207332_s_at TFRC -2.71 6. 34E-11 2. 90E-08-1. 29-8. 98 3q26. 2-qter Table 2. 1-2. 78 17 201360_at CST3 4. 32 4. 84E-10 1.18E-07 1.34 8. 97 20p11.21 18 241706_at LOC144402 -5.96 4. 36E-11 2.56E-08-1. 26-8. 9612q11 19 202413_s at USP1-1. 86 3.47E-12 4.96E-09-1. 16-8. 851p32. 1-p31. 3 20 223276_at NID67 2.53 9.44E-11 3. 80E-08 1.23 8.85 5q33.1 21217963satNGFRAP1-19. 01 2.22E-10 6. 97E-08-1. 35-8. 83 Xq22. 1 22 200675 at CD81-3. 56 6.30E-12 6. 02E-09-1. 16-8. 82 11 p15. 5 23 218040_at FLJ 10330-2. 2 6.54E-12 6.02E-09 -1.16 -8.82 1p13. 2 24 210715_s_at SPINT2 -3.66 1. 37E-11 1. 10E-08 -1. 17-8. 7619q13. 1 25209523atTAF2-2. 75 5. 20E-12 6.02E-09-1. 14-8. 74 8q24. 12 26 244552_at -4.00 6. 01E-11 2.86E-08-1. 19-8. 64 27 200983_x_at CD59 -8.23 3. 32E-10 9.44E-08-1. 29-8. 61 11p13 28 244741_s_at -6.23 3.17E-10 9. 29E-08-1. 27-8.58 29 235753 at-6. 27 5. 94E-10 1. 32E-07-1. 32-8.50 30200665satSPARC3*15 4.51 E-11 2. 56E-08 1.13 8.49 5q31. 3-q32 31 202406_s_at TIAL1 -1.66 1. 81E-11 1. 37E-08-1. 11-8. 4710q 32 213779_at LOC129080 -3. 29 1. 78E-10 5.89E-08-1. 19-8.46 22q12. 1 33 212066 s at KIAA0570-1. 86 4. 63E-11 2.56E-08-1. 12 -8.39 2p14 34 208033_s_at ATBF1 3.73 1. 09E-09 1. 97E-07 1.20 8.35 16q22. 3-q23.1 35224724atSULF25'32 3.98E-09 4. 79E-07 1.29 8.35 20q12-13. 2 36 214651_s_at HOXA9 -11.93 7.94E-10 1.57E-07-1. 26-8. 34 7p15-p14 37 225383_at ZNF275 -1.92 8. 65E-11 3.59E-08-1. 12-8.32 Xq28 38 213737 x at-2. 31 1. 73E-10 5. 89E-08 -1.14 -8. 30 39 201663_s_at SMC4L1 -2.67 2. 46E-10 7.54E-08-1. 14-8.26 3q26.1 40 203965 at USP20-2. 20 3. 14E-11 2. 13E-08-1. 07-8. 21 9q34. 13 41 205718_at ITGB7 3.46 6. 54E-11 2. 90E-08 1.08 8.20 12q13. 13 42 218414_s_at NUDE1 -2.89 7.27E-10 1. 49E-07-1. 19-8. 19 16p13. 11 43 201377_at NICE-4 -1.89 8. 01E-11 3.44E-08-1. 08-8. 161q21. 3 44 212826_s_at SLC25A6 1.63 3. 95E-11 2. 54E-08 1.06 8.15 Xp22.32 and Yp 45 223769 x at HT036-2. 28 3. 80E-10 1. 01E-07-1. 13-8. 131p34. 1 46 202265_at BMI1 -2.97 4.98E-10 1.18E-07-1. 13-8. 1010p11. 23 47 230219 at NUDE1-2. 08 1.63E-10 5.82E-08-1. 08-8. 10 16p13. 11 48 207992_s_at AMPD3 -2. 91 3. 85E-10 1. 01E-07 -1.11 -8.08 11p15 49 200620_at C1orf8 -1.54 1.23E-10 4.67E-08-1. 07-8. 05 1p36-p31 50 208691_at TFRC -2.54 8.50E-10 1.63E-07-1. 14-8. 04 3q26. 2-qter 2.53 AML_inv(16) versus AML_t (15 ; 17) # affy id HUGO name fc p q stn t Map Location 1 211990atHLA-DPA112. 87 6.59E-19 1. 76E-14 3. 40 20. 83 6p21. 3 2214450atCTSW-7. 68 6. 17E-13 5. 50E-10-2. 95-15. 78 11q13. 1 3 204661_at CDW52 33.90 2.84E-14 7. 34E-11 2. 75 15. 391p36 4 38487_at STAB1-7. 9= 2.48E-12 1. 89E-09-3. 00-15. 22 3p21.31 5209732atCLECSF230. 41 1.19E-13 1. 77E-10 2. 75 14. 7612p13-p12 6 217478_s_at HLA-DMA 7.72 5. 11E-15 2. 13E-11 2. 38 14. 68 6p21. 3 7 221004_s_at ITM2C -4.93 9. 59E-14 1. 51E-10-2. 43-14. 58 2q37 Table 2. 1-2. 78 8 34210 at CDW52 43. 95 1. 36E-13 1.92E-10 2.64 14. 51 1p36 9200654atP4HB-2. 26 2. 17E-15 1.16E-11-2. 24-14. 34 17q25 10 203535_at S100A9 8.87 5.77E-16 5. 14E-12 2.17 14.08 1q21 11 209619_at CD74 5.65 4. 69E-17 6. 26E-13 2. 09 13. 92 5q32 12 238022_at -8. 04 2. 75E-12 2. 00E-09 -2. 31-13. 37 13 200931_s_at VCL 3.99 1.89 1.89E-15 1. 16E-11 2. 04 13. 2910q22. 1-q23 14 201923_at PRDX4 7.40 5.83E-14 1. 11 E-10 2. 12 13. 18 Xp22. 13 15 209312_x_at HLA-DRB1 8.91 4. 83E-14 9. 92E-11 2. 10 13. 11 6p21. 3 16 208306_x_at HLA-DRB4 9.68 8.26E-14 1. 47E-10 2. 12 13. 11 6p21. 3 17 205624_at CPA3 -8.88 1.01E-11 5. 61E-09 -2. 34-13.07 3q21-q25 18 204563_at SELL 9.19 5. 06E-13 5.01 E-10 2. 18 12. 90 1 q23-q25 19 204670_x_at HLA-DRB5 6.82 5. 58E-15 2. 13E-11 1. 94 12. 69 6p21. 3 20 231310_at 4.86 4. 39E-14 9. 77E-11 1.98 12. 63 21 208891_at DUSP6 7.87 1.16E-14 3. 88E-11 1. 92 12. 52 12q22-q23 22 212953_x_at CALR -2.83 3. 00E-14 7. 34E-11-1. 93-12. 4919p13. 3-p13. 2 23238365sat-10. 18 1.04E-10 3.05E-08-2. 44-12.36 24 207375_s_at IL15RA 4. 86 3.02E-14 7. 34E-11 1.86 12.14 10p15-p14 25 221059_s_at CHST6 6.79 8.00E-13 6. 89E-10 1.98 12. 11 16q22 26 208982_at PECAM1 4.84 3.84E-13 4. 22E-10 1.91 11.99 17q23 27 205718_at ITGB7 6. 51 4.60E-13 4. 72E-10 1.91 11.97 12q13. 13 28205663atPCBP3-4. 82 1. 21 E-11 6. 17E-09-2. 01-11. 95 21 q22. 3 29229168atDKFZp434K0621-6. 66 3. 87E-10 8.47E-08-2. 35-11. 57 5q35. 3 30 233072_at KIAA1857 -7.11 2.16E-10 5.54E-08-2. 13-11. 47 9q34 31 211991_s_at HLA-DLA1 25.47 2. 35E-11 1. 07E-08 2. 09 11. 45 6p21. 3 32 224583_at COTL1 5.47 3. 94E-13 4. 23E-10 1.78 11.44 16q23. 3 33 232617_at CTSS 8.68 2. 07E-11 9.71 E-09 2. 05 11. 43 1 q21 34 224839_s_at GPT2 -8. 67 4. 98E-11 1.73E-08-1. 95-11. 38 16q12. 1 35 201497_x_at MYH11 29.05 4. 61 E-11 1. 65E-08 2.19 11.25 16p13.13-p13. 12 36 241742_at PRAM-1 11.62 2. 96E-11 1. 22E-08 2.01 11.23 19p13. 2 37 226878_at 4.23 4.00E-12 2.61 E-09 1. 81 11. 18 38 201137_s_at HLA-DPB1 15. 27 5. 30E-11 1. 81E-08 1.99 10. 99 6p21. 3 39208689_s_at RPN2 -1. 74 1. 74E-13 2.32E-10-1. 65-10. 96 20q12-q13. 1 40 201496_x_at MYH11 10.95 8.48E-12 5. 03E-09 1.78 10.95 16.p13.13-p13. 12 41 202803_s_at ITGB2 5.33 5. 45E-13 5. 20E-10 1. 66 10. 86 21q22. 3 42 204150 at STAB1-9. 25 1.13E-09 2. 11E-07-2. 20-10. 85 3p21. 31 43 238376_at 3.13 1.34E-12 1. 11E-09 1.68 10. 82 44 202820_at AHR 7.11 2.91 E-12 2. 05E-09 1. 69 10. 77 7p15 45 202644_s_at TNFAIP3 2.63 9.42E-14 1. 51 E-10 1. 60 10. 76 6q23 46223280xatMS4A6A24. 32 1. 17E-10 3. 37E-08 2.00 10.68 11q12. 1 47 228046 at LOC152485 3. 11 5.33E-12 3. 39E-09 1.69 10.68 4q31.1 48 228113_at STAT3 3.41 2. 65E-13 3.31 E-10 1. 60 10. 63 17q21 49 213779 at LOC129080-6 48 1.04E-09 1.96E-07-2. 02-10.63 22q12. 1 50 210982_s_at HLA-DRA 7.45 1.37E-12 1.11E-09 1.63 10.60 6p21.3 2.54 AML_inv (16) versus AML_t (8;21) Table 2. 1-2.78 # affy id HUGO name fc p q stn t Map Location 1 207075 at CIAS1 6. 20 6. 53E-13 4.40E-09 2.14 12.84 1q44 2 205718 at ITGB7 7. 97 2. 06E-13 2.37E-09 1.94 12.42 12q13. 13 3 208890_s_at PLXNB2 5.47 2. 82E-13 2. 37E-09 1.95 12.41 22q13. 33 4 224764 at ARHGAP10 9. 78 6.18E-12 1. 89E-08 2. 04 11. 8810 5 205419_at EBI2 7.28 3. 55E-12 1. 52E-08 1.93 11.76 13q32. 2 6 218795_at ACP6 -4.43 2.56E-13 2.37E-09 -1. 71-11.41 1 q21 7 224049_at KCNK17 4.96 2. 15E-11 5. 57E-08 1.93 11.23 6p21. 1 8 201497_x_at MYH11 27.72 4. 77E-11 7. 64E-08 2.18 11.23 16p13.13-p13. 12 9 218236_s_at PRKCN 5. 61 2. 01 E-12 1. 13E-08 1. 65 10. 88 2p21 10 238604_at 3.46 2.13E-13 2. 37E-09 1.50 10. 47 11 205453_at HOXB2 15.78 1. 65E-10 1.74E-07 1.88 10.41 17q21-q22 12201596xatKRT189TF 3. 90E-11 6.91 E-08 1. 67 10. 37 12q13 13 224724_at SULF2 26.58 2.51E-10 2.26e-07 1.96 10. 31 20q12-13. 2 14 209365_s_at ECM1 3.32 5.67E-12 1. 89E-08 1.52 10.17 1q21 15 228827_at - 4. 49E-10 3.22E-07-1. 97-10.04 100.56 16 201496xat MYH11 6. 61 2. 98E-11 6. 14E-08 1. 55 10. 02 16p13.13-p13.12 17 200665 s at SPARC 3. 67 6. OOE-12 1. 89E-08 1.49 10.02 5q31. 3-q32 18 201739_at SGK 4. 55 3.60E-12 1. 52E-08 1. 46 9. 97 6q23 19201944atHEXB126 3. 09E-11 6. 14E-08 1.52 9.92 5q13 20 209500 x at TNFSF13 4. 26 1. 51E-10 1. 70E-07 1.52 9.61 17p13. 1 21 235359_at 3. 06 5. 86E-11 8. 57E-08 1. 46 9. 56 22 203320 at LNK 2. 89 7. 98E-11 1. 12E-07 1. 47 9. 56 12q24 23 208683_at CAPN2 3. 25 1. 30E-11 3. 66E-08 1.39 9.47 1q41-q42 24 211084_x_at PRKCN 4.90 2.81 E-11 6. 14E-08409'462p21 25 217849_s_at CDC42BPB 5.22 3.31 E-11 6. 19E-08 1.41 9.46 14q32. 3 26 210314 x at TNFSF13 5. 02 1. 80E-10 1. 80E-07 1.48 9.45 17p13. 1 27206940satPOU4F1-37. 07 1. 50E-09 8.29E-07-1. 82 -9.42 13q21.1-q22 28 201887_at IL13RA1 4.32 3. 65E-10 2. 73E-07 1.52 9.40 Xq24 29 223249_at CLDN12 3. 44 5. 41 E-11 8. 27E-08 1.41 9.40 7q21 30 240572_s_at 3.50 3. 10E-11 6. 14E-08 1. 391 9. 40 31 220974_x_at BA108L7.2 4.98 1. 02E-10 1. 33E-07 1.39 9.22 10q24. 31 32205529satCBFA2T1-14. 03 2. 39E-09 1. 17E-06 -1.70 -9.16 8q22 33 236738_at 7. 02 4.91 E-10 3. 38E-07 1.44 9.10 34 201005_at CD9 7. 50 3. 32E-10 2. 65E-07 1.40 9.04 12p13. 3 35 201360_at CST3 4.55 3. 35E-10 2. 65E-07 1 3c 902 20p11. 21 36 225102_at LOC152009-3. 87 3. 38E-10 2.65E-07-1. 34-8. 83 3q21. 3 37 218236_s_at SLC38A1 3.46 4. 08E-10 2. 98E-07 1.35 8.82 12q12 38 205330_at MN1 9.47 3.99E-09 1. 74E-06 1. 56 8. 81 22q12. 1 39225602atC9orf192'74 4. 53E-11 7. 63E-08 1.26 8.75 9p13-p12 40 220591_s_at FLJ22843 3.10 7. 60E-10 4. 74E-07 1.35 8.72 Xp11. 3 41 229309_at 10. 85 4.42E-09 1. 91 E-06 1. 52 8. 71 42 229383_at 5.16 3. 78E-09 1. 67E-06 1. 46 8. 66 43 201425_at ALDH2 6.54 3. 46E-10 2. 65E-07 1.29 8.64 12q24. 2 Table 2.1-2. 78 44 229406at-8. 50 3. 12E-09 1. 48E-06-1. 43-8. 63 45 208033_s_at ATBF1 4.00 6.81 E-10 4.41 E-07 1.30 8.57 16q22. 3-q23.1 46 205859_at LY86 3. 64 2. 66E-09 1. 28E-06 1.38 8.57 6p24.3 47 211341 at POU4F1 - 1.10E-08 3.29E-06-1. 68-8. 52 13q21.1-q22 162. 01 48 224579 at 3. 69 1. 71 E-09 9.28E-07 1. 33 8. 52 49 202283_at SERPINF1 8. 1C 2. 29E-09 1. 15E-06 1.35 8.51 17p13. 1 50 226818_at LOC219972 10.78 6. 29E-09 2. 38E-06 1.45 8.48 11q12. 1 2.55 AML-inv (16) versus CLL # affy id HUGO name fc p q stn t Map Location 1 203949_at MPO 140. 69 6.50E-22 8. 85E-19 6.40 34.02 17q23. 1 2 224838 at FOXP1-5. 75 4. 76E-28 8.42E-24-3. 73-26. 98 3p14. 1 3 203948_s_at MPO 228.28 2. 74E-18 9. 63E-16 4. 62 23. 95 17q23. 1 4 207168_s_at H2AFY 3.02 4.10E-27 3. 63E-23 2. 81 21. 50 5q31. 3-q32 5 212827 at IGHM-22. 96 2.32E-21 2.74E-18-3. 15-20. 4914q32. 33 6 223514_at CARD11 -42. 77 5. 00E-20 3.54E-17-3. 10-18. 99 7p22 7 201029_s_at CD99 2.32 1. 78E-23 4. 49E-20 2.37 18. 11 Xp22.32 8 AFFX-GAPD 2. 23 1. 84E-25 1. 08E-21 2.30 17.95 12p13 HUMGAPDH/M33 197 3 at-HG- U133B 9 201811_x_at SH3BP5 -11.14 9.30E-21 9. 14E-18-2. 48-17. 75 3p24. 3 10 224837_at FOXP1 -3.53 1. 38E-21 1. 74E-18-2. 39-17. 61 3pu4. 1 11 41220_at MSF -2.10 4. 06E-25 1.80E-21-2. 25-17. 57 17q25 12 201012_at ANXA1 5. 40 2. 01 E-22 3. 24E-19 2.29 17.38 9q12-q21.2 13 243780_at -36. 28 8. 86E-19 3. 91E-16-2. 76-17. 28 14 200650_s_at LDHA 2.62 2.64E-24 9. 35E-21 2.18 17.03 11p15. 4 15 209374_s_at IGHM -19.86 9. 06E-19 3. 91E-16 -2.60 -16.99 14q32. 33 16 209075_s_at NIFU -3. 14 2.52E-23 5. 58E-20-2. 18-16. 8412q24. 1 17 227670_at ZNF75A -8.18 2. 91E-19 1. 51E-16 -2. 42-16. 78 16p13. 11 18 AFFX-GAPD 2. 88 1.83E-22 3. 24E-19 2.18 16.74 12p13 HUMGAPDH/M33 197 M at-HG- U133A 19 AFFX-GAPD 2.83 2. 01 E-22 3. 24E-19 2.17 16. 67 12pu3 HUMGAPDH/M33 197_M_at - HG- U133B 20 208864sat TXN 5. 66 1. 15E-16 1. 63E-14 2.46 16. 56 9q31 21 201417_at 25. 91 2. 14E-15 1. 76E-13 2.66 16. 45 22 211787_s_at EIF4A1 2.68 2. 52E-20 2. 03E-17 2.20 16.44 17p13 23 AFFX-GAPD 2. 09 1. 65E-23 4. 49E-20 2.10 16.40 12p13 HUMGAPDH/M33 197 3 at-HG- U133A 24 204215_at MGC4175 -4. 08 2. 78E-21 3. 07E-18-2. 13-16. 15 7q21. 1-q21. 2 25 233177_s_at MR-1 4.18 1. 49E-17 3. 26E-15 2.28 16.10 2q35 Table 2. 1-2.78 26 215785 s at CYFIP2-7. 76 1.13E-19 6. 90E-17-2. 21-16. 09 5q34 27 224833 at ETS1-5. 86 6.34E-21 6. 60E-18-2. 14-16. 0711q23. 3 28 226454_at LOC92979 -4. 48 2. 31 E-18 8. 34E-16-2. 34-16. 02 12q13. 13 29 224710_at RAB34 15. 28 2. 65E-15 2. 12E-13 2. 53 15. 96 17q11.1 30 227261 at KLF12-9. 62 4. 26E-18 1. 24E-15-2. 36-15. 8913q22 31 201200_at CREG 5.69 3. 07E-17 5. 43E-15 2.25 15.85 1q24 32 223287_s_at FOXP1 -5. 32 2. 77E-18 9. 63E-16 -2.31 -15.84 3p14.1 33 226611_s_at p30 6.26 2. 95E-15 2. 29E-13 2. 50 15. 83 17p11. 2 34 202252_at RAB13 5.39 4.13E-16 4. 63E-14 2.34 15.76 1q21. 2 35 213572_s_at SERPINB1 4. 44 6. 35E-16 6. 47E-14 2. 34 15. 65 6p25 36236301at-17. 09 7.24E-18 1. 89E-15 -2.31 -15.59 37 229844 at-6. 47 8.95E-18 2. 17E-15-2. 29-15. 50 38 223276_at NID67 17. 02 1.93E-14 1. 03E-12 2.59 15. 43 5q33. 1 39 225927_at -2. 96 2.95E-22 4. 35E-19-1. 96-15. 34 40 212268_at SERPINB1 5.56 1. 27E-15 1. 13E-13 2.30 15. 32 6p25 41 212590_at RRAS2 -7. 07 3. 09E-18 1. 01E-15-2. 15-15. 25 11p15. 2 42 214615 at P2RY10-8. 82 1.02E-17 2. 39E-15-2. 21-15. 19 Xq21.1 43 226905_at 5. 91 1. 01 E-19 6.41 E-17 2.01 15. 18 44 44790_s_at C13orf18 -53. 54 5. 66E-17 8. 79E-15-2. 48-15. 1813q14. 11 45 228390_at -30. 85 4. 40E-17 7. 09E-15-2. 38-15. 17 46212386at-14. 55 1.99E-17 3. 91E-15 -2.25 -15.16 47 212313_at MGC29816 -6. 00 2. 99E-19 1. 51E-16 -2. 04-15.13 8p21. 2 48 231310_at 8.50 3. 71E-14 1. 78E-12 2.57 15.11 49 204198_s_at RUNX3 -9. 42 2. 17E-18 8.01 E-16-2. 08-15.01 1p36 50 219471_at C13orf18 -36.72 7.61E-17 1.12E-14 -2.42 -15.01 13q14.11 2.56 AML_inv(16) versus CML # affy id HUGO name fc p q stn t Map Location 1 201029_s_at CD99 5.28 8.31 E-26 6. 27E-23 4. 05 29.96 Xp22.32 2 206676_at CEACAM8 -18. 41 7. 91 E-34 3. 73E-30-3. 07-25. 48 19q13. 2 3 209771_x_at CD24 -11. 10 2. 71 E-35 5.12E-31-2. 72-23. 39 6q21 4 216379_x_at KIAA1919 -12. 05 1.34E-34 1.26E-30-2. 69-23. 09 6q22 5 212531_at LCN2 -13. 18 2.99E-34 1.88E-30-2. 62-22.54 9q34 6 211657_at CEACAM6-10. 24 1.70E-31 6. 40E-28-2. 60-21. 92 19q13. 2 7 203021_at SLPI -12. 91 7.17E-29 1.50E-25-2. 69-21. 82 20q12 8 205513_at TCN1 -17. 23 6.44E-27 7. 95E-24-2. 74-21. 2411q11-q12 9 203757_s_at CEACAM6 -13. 09 5.93E-30 1. 60E-26-2.52-21. 12 19q13. 2 10 205653_at CTSG -12. 07 3.88E-29 9.15E-26-2. 46-20. 5514q11. 2 11 201061_s_at STOM -3. 93 8.07E-28 1.52E-24-2. 50-20. 42 9q34. 1 12 1207802 at ISGP28 - 6. 12E-25 3.04E-22-2. 81-20. 00 6p12. 3 234.23 13 205557at BP)-5. 69 1.57E-30 4. 93E-27-2. 33-19. 94 20q11.23-q12 14 231688_at -20. 27 2. 81 E-26 2. 78E-23-2. 50-19. 88 15 210244_at CAMP-28. 02 5. 79E-26 4. 98E-23-2. 47-19. 62 3p21. 3 Table 2. 1-2.78 16 209772sat CD24-26.63 2. 57E-25 1.67E-22-2. 44-19. 22 6q21 17 266_s_at CD24 -13. 20 1.62E-27 2. 78E-24-2. 25-18.85 6q21 18 201669_s_at MARCKS -28.00 2.72E-24 1.28E-21-2. 48-18.85 6q22.2 19 200832_s_at SCD -11. 33 4. 02E-25 2.26E-22-2. 36-18. 7610q23-q24 20203936satMMP9-16. 59 2. 47E-25 1.67E-22-2. 30-18. 56 20q11. 2-q13. 1 21 200985_s at CD59-20. 26 5.19E-24 2.33E-21-2. 32-18. 13 11 p13 22 209369_at ANXA3-21. 05 8. 29E-24 3. 55E-21-2. 30-17.96 4q13-q22 23 211275_s_at GYG -3. 09 2. 71 E-27 4.27E-24-2. 11-17. 95 3q24-q25. 1 24224967atUGCG-6. 04 7. 71 E-26 6.06E-23-2. 15-17.91 9q31 25 206440_at LIN7A -13.71 1.26E-24 6.10E-22 -2. 17-17. 66 12q21 26 219281_at MSRA-3. 32 4.19E-25 2.26E-22-2. 13-17.60 8p23.1 27 210638_s_at FBXO9 -3. 69 1.04E-25 7.52E-23-2. 08-17. 45 6p12. 3-p11. 2 28 201554_x_at GYG -3. 51 8.80E-27 9.23E-24-2. 04-17.37 3q24-q25.1 29 200983_x_at CD59 -18. 36 6.37E-23 2.07E-20-2. 25-17. 36 11 p13 30207269atDEFA4-7. 01 5.39E-27 7.27E-24-2. 02-17. 35 8p23 31 226726_at LOC129642-9. 24 3.65E-23 1.35E-20-2. 21-17.34 2p25.2 32204430satSLC2A5-7. 99 1.63E-23 6. 67E-21-2. 18-17. 33 1p36. 2 33 202018 s at LTF-5. 86 7. 67E-26 6.06E-23-2. 02-17.16 3q21-q23 34 221952_x_at KIAA1393 -2. 02 4.80E-27 6.97E-24-1. 99-17. 09 14q23. 1 35 223423_at GPCR1-4. 99 6.74E-27 7.95E-24-1. 98-17. 04 3q26. 2-q27 36 227019_at -4. 83 7.23E-27 8.03E-24-1. 98-17.01 37 204411_at KIAA0449-14. 85 4.39E-23 1.52E-20-2. 13-16. 96 1 pter-q31. 3 38 210254_at MS4A3 -3.79 4. 13E-25 2.26E-22-2. 00-16. 9311q12 39 218795_at ACP6 -7. 90 8.05E-24 3.53E-21-2. 03-16.69 1q21 40 208651_x_at CD24 -8. 67 1. 47E-25 1.02E-22-1. 94-16.56 6q21 41 208650 s at CD24-12. 15 3. 52E-26 3.32E-23-1. 92-16.52 6q21 42 205863_at S100A12-4. 78 5. 81E-26 4.98E-23-1. 91-16. 44 1q21 43 223471_at RAB31P-5. 01 3. 24E-25 1. 91 E-22-1. 93-16.42 44 230006_s_at DKFZp313A2432 -5. 11 2.19E-22 6.66E-20-2. 06-16. 3911p14. 2 45 201060_x_at STOM-3. 85 1.75E-23 6. 90E-21-1. 96-16. 21 9q34.1 46 205786_s_at ITGAM -4.80 2.93E-25 1.84E-22-1. 89-16. 20 16p11. 2 47 224707_at ORF1-FL49-8. 23 6.32E-23 2.07E-20-1. 95-16.02 5q31. 3 48 227567_at -5. 08 3.13E-25 1. 90E-22-1. 87-16. 01 49 204174_at ALOX5AP -3. 90 6.06E-25 3.04E-22-1. 87-15. 97 13q12 50215806xatTRGC2-6. 37 1. 71 E-23 6.87E-21-1. 90-15.87 7p15 2.57 AML inv (16) versus normalBM # affy id HUGO name fc p q stn t Map Location 1 201029_s_at CD99 3.51 1.24E-14 1. 69E-10 3.43 19.01 Xp22. 32 2 202018_s_at LTF -6. 20 3. 78E-11 2. 00E-08 -2. 84-15.16 3q21-q23 3226326at-2. 99 3. 81E-11 2. 00E-08 -2. 70-14.53 4 224975_at NFIA -10. 75 4.86E-07 2.26E-05-3. 53-13. 501p31. 3-p31. 2 5223769xatHT036-2. 42 1.50E-09 3. 01 E-07-2. 60-13. 44 1 p34. 1 6 200832_s_at SCD -6.49 1. 27E-07 8. 06E-06-3. 05-13. 4410q23-q24 Table 2. 1-2.78 7 200665sat SPARC 8.11 4. 31E-13 9.82E-10 2.42 13.31 5q31. 3-q32 8 205382_s_at DF 6. 51 7. 01 E-13 1. 13E-09 2.30 12.79 19p13. 3 9 235733_at -2. 92 1. 74E-11 1. 40E-08 -2. 29-12. 77 10 228716_at -3. 91 1. 75E-09 3. 31 E-07-2. 44-12. 75 11 214109_at LRBA -1.76 3.03E-13 9. 82E-10-2. 17-12. 52 4q31. 22-q31. 23 12 224710_at RAB34 5.38 8.67E-14 5. 31E-10 2.13 12.43 17q11. 1 13 201417 at 3. 98 4. 08E-13 9. 82E-102512. 33 14 225923_at -2.35 4. 67E-10 1.25E-07-2. 28-12. 31 15 231310_at 5. 26 1. 17E-13 5. 31E-10 2.11 12.30 16204285satPMA) P1M6 5. 69E-13 1. 11E-09 2.13 12.17 18q21. 31 17 212531 at LCN2-12. 00 3.08E-07 1. 59E-05-2. 69-12. 01 9q34 18 227041_at -3.26 8. 30E-13 1.13E-09 -2.06 -11. 91 19 202561 at TNKS-2. 60 3. 52E-10 1.04E-07-2. 18-11. 88 8p23. 1 20 223276_at NID67 4.27 8.10E-13 1. 13E-09 2. 06 11. 84 5q33. 1 21 203582_s_at RAB4A 2. 77 3. 35E-12 3.81 E-09 2.05 11.79 1q42-q43 22 223044_at SLC11A3 -18. 63 1. 59E-06 5. 04E-05-3. 12-11. 76 2q32 23 219304 s at SCDGF-B-2. 75 4. 36E-08 3. 79E-06-2. 38-11. 7611q22. 3 24 225346_at LOC80298-2. 75 1. 28E-07 8.06E-06-2. 42-11. 5712q24. 1 25 218262_at FLJ22318 -3. 50 9. 78E-08 6.68E-06-2. 39-11. 54 5q35. 3 26 228983_at -2. 04 3. 51 E-08 3. 39E-06-2. 29-11. 49 27 201496 x at MYH11 13. 8C 9. 16E-12 8. 94E-09 2.05 11. 41 16p13. 13-p13. 12 28204976satAMMECR1-6. 54 1. 67E-06 5. 22E-05-2. 82-11. 26 Xq22. 3 29 215111 s_at TSC22 7. 76 3. 20E-11 1. 90E-08 2.10 11.24 13q14 30226726atLOC 129642-5. 98 1. 82E-06 5. 58E-05-2. 83-11. 20 2p25. 2 31 235359_at 4.69 2.65E-12 3.30E-09 1.93 11.16 32 202747 s at ITM2A 5.89 1.23E-11 1. 05E-08 1.99 11.16 Xq13.3-Xq21. 2 33 202746_at ITM2A 5.36 1.86E-11 1. 42E-08 1.98 11.05 Xq13.3-Xq21. 2 34 226806_s_at -11. 61 3. 29E-06 8. 53E-05-3. 06-10. 99 35204900xatSAP306'58 2. 72E-11 1. 77E-08 1.99 10.99 4q34. 1 36 212967_x_at NAP1L1 1.48 4. 93E-12 5. 18E-09 1.89 10.97 12q21.1 37 201497_x_at MYH11 18. 74 5. 42E-11 2. 64E-08 2.04 10.93 16p13.13-p13. 12 38 224976_at NFIA -5.30 2. 48E-06 6. 89E-05-2. 76-10. 851p31. 3-p31. 2 39 226301_at dJ55C23. 6-3.71 1. 62E-07 9. 68E-06-2. 18-10. 68 6q22.3-q23. 3 40 226120_at TTC8 -3. 02 4. 46E-08 3.84E-06-2. 08 -10.65 14q31. 3 41 226190_at -3.22 4. 64E-09 7.12E-07-1. 97-10. 62 42 217846 at QARS 1. 72 2. 69E-11 1. 77E-08 1.83 10.57 3p21. 3-p21.1 43 217988 at HEI10 2. 54 1. 09E-11 9.93E-09 1.82 10.51 14q11. 1 44 232098_at -3. 60 1. 10E-07 7.28E-06-2. 09-10.49 45 208668 x at HMGN2-1. 52 1. 44E-08 1. 69E-06-1. 98-10. 471p36. 1 46225792at-4. 61 8. 15E-08 5. 80E-06 -2. 03-10. 32 47 230988_at -6. 92 5-13E-06 1. 15E-04-2. 83-10. 31 48 213908_at -3. 71 4.03E-08 3.68E-06-1. 98-10.30 49 238389_s_at 4.02 3. 20E-11 1. 90E-08 1.75 10.11 50 209045_at XPNPEP1 1.91 6.75E-11 3.08E-08 1.75 10.11 10q25.3 Table 2. 1-2.78 2.58 AML_inv(3) versus AML_komplext # affy id HUGO name fc p q stn t Map Location 1 222229 x at 1. 59 1.43E-12 2. 58E-08 1. 49 10.36 2 206781_at DNAJC4 2. 26 7. 27E-11 4. 54E-07 1.37 9.35 11q13 3 208730_x_at RAB2 2. 22 1.23E-09 1. 71 E-06 1. 38 9. 00 8q12. 1 4 200093 s at- HINT1 1.88 6. 67E-10 1.71E-06 1.21 8.35 5q31. 2 HG-U133B 5 213682 at NUP50-1. 96 7. 52E-11 4. 54E-07-1. 14-8. 23 22q13. 31 6 227708_at EEF1A1 2. 34 1.67E-08 8. 16E-06 1. 30 8. 20 6q14. 1 7 208826_x_at HINT1 1.52 5. 20E-10 1. 64E-06 1.14 8.05 5q31. 2 8201202atPCNA-2. 84 2. 31E-10 1.05E-06-1. 10-7.93 20pter-p12 9209122atADFP-4. 15 1.08E-09 1. 71 E-06-1. 12-7. 82 9p21. 3 10200700satKDELR2-2. 80 1. 13E-09 1. 71 E-06-1. 09-7. 67 7p22. 2 11 201377_at NICE-4-1. 90 5. 46E-10 1. 64E-06-1. 06 -7.67 1q21. 3 12 203538_at CAMLG 2. 07 4.91 E-08 1. 51 E-05 1. 20 7. 65 5q23 13 205436 s_at H2AFX-3. 79 2.79E-09 2. 71 E-06-1. 12-7. 6411q23. 2-q23.3 14 218883_s_at FLJ23468 -2. 56 8. 92E-10 1. 71 E-06-1. 07-7. 63 4q35. 1 15 200094 s at- EEF2 1.41 4.93E-09 3. 72E-06 1.09 7.56 19pter-q12 HG-U133A 16 201663 s at SMC4L1 -2. 49 1.36E-09 1.76E-06-1. 06-7. 55 3q26. 1 17 201386_s_at DDX15 -1. 79 9.01 E-10 1. 71E-06 -1.05 -7.53 4p15. 3 18 222047 s at ARS2-1. 55 1.08E-09 1. 71E-06 -1.04 -7.50 7q21 19 212491_s_at DNAJC8 -1. 75 2.35E-09 2. 61 E-06-1. 05-7. 47 1p35. 2 20206550satNUP155-2. 08 2.18E-09 2. 61E-06 -1.04 -7.40 5p13.1 21 203421_at PIG11 -6. 24 1.66E-08 8.16E-06-1. 14-7. 30 11p11. 2 22 212031_at S164-1. 92 2. 84E-09 2. 71 E-06-1. 02-7. 28 14q24. 3 23213008atFLJ10719-2. 96 2.45E-09 2. 61E-06-1. 01-7. 2515q25-q26 24202580xatFOXM1-3. 95 7. 57E-09 4.72E-06-1. 05-7. 25 12p13 25 218115_at ASF1B -2. 62 4.20E-09 3.55E-06-1. 02-7. 24 19p13. 12 26 213088_s_at DNAJC9 -2.44 7. 48E-09 4. 72E-06-1. 03-7. 18 10q22. 2 27213292satSNX13-2. 17 6.26E-09 4. 35E-06-1. 01-7. 16 7p21. 1 28 204695_at CDC25A-4. 38 1.11 E-08 6.26E-06-1. 03-7.14 3p21 29 218585 s at RAMP-3. 20 1.41 E-08 7. 48E-06-1. 04-7.12 30 208715_at LOC54499 -2. 21 4.16E-09 3.55E-06-0. 99 -7.11 1q22-q25 31 201457_x_at BUB3 -1. 73 4.55E-09 3.57E-06-0. 99-7. 10 10q26 32222680satRAMP-2. 06 4. 32E-09 3.55E-06-0. 98-7. 10 33 211950_at RBAF600-2. 14 6. 18E-09 4.35E-06-0. 99-7. 08 1 p36. 13 34 223157_at MGC3232 2.00 4.48E-07 5. 23E-05 1.18 7.07 4q12 35 215123 at-3. 06 7. 02E-09 4.70E-06-0. 97-6.98 36227165atC13orf3-2. 41 1.84E-08 8. 51E-06 -1.01 -6.98 13q11 37 218350_s_at GMNN -2. 41 1.04E-08 6.07E-06-0. 97-6.93 6p22.1 38 202954_at UBE2C -3. 17 3.02E-08 1. 21 E-05-1. 02-6.91 20q13. 11 39 232247_at FLJ 14855-2. 01 8.55E-09 5.15E-06-0. 96-6. 91 3p21. 31 40 214141_x_at SFRS7 -1.77 1.72E-08 8.17E-06-0. 98-6. 90 2p22. 1 41201680xatARS2-1. 59 1. 17E-08 6.43E-06-0. 95-6. 82 7q21 Table 2. 1-2.78 42 202413_s_at USP1 -1.82 3.54E-08 1. 31E-05-0. 97-6. 821p32. 1-p31. 3 43 209619_at CD74 2.00 1.60E-07 2. 89E-05 1.03 6.82 5q32 44 200094 s at-EEF2 1. 39 4.08E-08 1. 44E-05 0.98 6.81 19pter-q12 HG-U 133B 45 226123_at LOC286180-3.56 2.20E-08 9.47E-06-0. 96 -6.80 8q12. 1 46 204709_s_at KIF23 -4.17 6.32E-08 1.77E-05-1. 03-6. 8015q22. 31 47 210140_at CST7-4. 76 5.60E-08 1. 66E-05-1. 01-6. 78 20p11. 21 48 210178_x_at FUSIP1 -1.97 1.54E-08 7.94E-06-0. 94-6. 77 1p36. 11 49 227056_at 3.40 1. 85E-06 1. 23E-04 1.20 6.72 50204023atRFC4-2. 23 1.88E-08 8.51 E-06-0.93-6. 70 3q27 2. 59 AML inv (3) versus AML-t (15; 17) # affy id HUGO name fc p q stn t Map Location 1 203948_s_at MPO -9. 22 7.85E-20 8.48E-16-3. 33-20. 1817q23. 1 2 203949_at MPO -5. 92 7.32E-21 1.58E-16-3. 19-19. 69 17q23. 1 3205382satDF-12. 00 3. 95E-15 1. 07E-11-3. 44-18. 83 19p13. 3 4 212953_x_at CALR -4. 97 5.32E-16 2.30E-12-2. 76-16. 36 19p13. 3-p13. 2 5 200654 at P4HB-3. 54 5.30E-18 3. 81E-14-2. 62-16. 1317q25 6 224918_x_at MGST1 -5. 40 5. 25E-17 2.83E-13-2. 49-15. 2912p12. 3-p12. 1 7231736xatMGST1-6. 11 7.03E-16 2.53E-12-2. 51-15. 14 12p12.3-p12. 1 8214450atCTSW-6. 80 4.70E-14 1.02E-10-2. 44-14. 2911q13. 1 9205624atCPA3-18. 38 6. 13E-12 5. 51E-09 -2. 76-14. 18 3q21-q25 10 206871_at ELA2 -5. 26 1. 18E-15 3.64E-12-2. 20-13. 53 19p13. 3 11 211990_at HLA-DPa1 12. 46 4. 97E-11 2. 98E-08 2. 67 13. 52 6p21. 3 12 38487_at STAB1-5. 47 4. 81 E-13 6.92E-10-2. 24-13. 06 3p21. 31 13 217716_s_at SEC61A1 -2. 52 1. OOE-13 1.65E-10-2. 15-12. 88 3q21. 3 14 214575_s_at AZU1 -8. 67 1. OOE-13 1.65E-10-2. 12-12. 7319p13. 3 15 238022_at -7.63 7.53E-13 9. 07E-10-2. 12-12. 49 16208852satCANX-3. 04 3.58E-12 3. 68E-09-2. 18-12. 48 5q35 17 221739_at IL27w-2. 20 1.28E-14 3. 06E-11-2. 02-12. 4719p13. 3 18 208689_s_at RPN2 -2.59 1.07E-13 1.65E-10 -2. 02-12. 26 20q12-q13. 1 19 221004_s_at ITM2C -4. 37 5.63E-14 1. 11E-10 -1. 99-12. 16 2q37 20 233072_at KIAA1857 -9. 87 1.26E-10 6.35E-08-2. 39-12. 10 9q34 21 210788_s_at retSDR4 -2. 78 4.14E-12 4.06E-09-2. 00-11.71 14q22.3 22 206914_at CRTAM 6. 73 2. 22E-11 1. 60E-08 2. 03 11. 62 11 q22-q23 23211709satSCGF-5. 57 6.43E-13 8.68E-10-1. 91-11. 55 19q13. 3 24213716satSECTM110. 56 1.74E-09 5. 54E-07 2. 25 11. 11 17q25 25 227353_at EVER2 5. 13 2.92E-10 1. 24E-07 2.00 11.00 17q25. 3 26 209021 x_at KIM0652-5. 31 1. 35E-11 1.12E-08-1. 84-10. 90 11p11. 12 27 214797_s_at PCTK3 5.81 2. 43E-10 1. 05E-07 1.95 10. 87 1q31-q32 28 208730_x_at RAB2 2. 63 4.23E-10 1. 72e-07 1.98 10.86 8q12. 1 29 202487_s_at H2AV -2. 35 7.56E-13 9. 07E-10-1. 76-10. 82 7p13 30 203675_at NUCB2-3. 45 1. 59E-11 1. 27E-08-1. 83-10. 81 11p15. 1-p14 31 217225_x_at LOC283820 -2.26 2. 10E-12 2.26E-09-1. 77-10. 77 16p13. 13 Table 2.1-2. 78 32 200652at SSR2-1. 99 1. 05E-12 1.19E-09-1. 73-10. 681q21-q23 33 209215 at TETRAN-3. 46 4. 99E-12 4.68E-09-1. 75-10.63 4p16. 3 34 229168_at DKFZp434K0621 -4. 90 5.86E-10 2. 30E-07-1. 95-10. 53 5q35. 3 35 209619_at CD74 4.55 1.98E-11 1. 47E-08 1.72 10.36 5q32 36 221253_s_at MGC3178 -3. 26 1.04E-10 5.78E-08-1. 78-10. 33 6p24. 3 37 210140_at CST7-8. 32 1. 51E-09 5. 06E-07-1. 98-10. 31 20p11. 21 38 224839_s_at GPT2 -6. 24 6. 83E-11 3. 88E-08-1. 74-10. 23 16q12. 1 39 217770 at PIGT-2. 32 1. 69E-11 1.30E-08-1. 68-10. 17 20q12-q13. 12 40 205614_x_at MST1 -9.35 3. 11 E-09 8.56E-07-2. 03-10. 12 3p21 41 209732_at CLECSF2 29.15 1.41E-08 2. 74E-06 2. 22 10. 0212p13-p12 42201004atSSR4-2. 56 2. 78E-11 1. 82E-08-1. 64-9. 95 Xq28 43 204897_at PTGER4 5.27 1. 51E-10 7. 41E-08 1.68 9.90 5p13. 1 44 201029_s_at CD99 -1. 81 1. 13E-11 9.73E-09-1. 61-9. 89 Xp22. 32 45 241696 at 3. 13 3. 64E-11 2. 25E-08 1.62 9.81 46 214789_x_at SRP46 4.12 8. 67E-10 3. 28E-07 1. 71 9. 76 11 q22 47 201825 s at CGI-49-3. 27 2. 66E-11 1.79E-08-1. 57-9.61 1q44 48 204150_at STAB1 -5.48 2.26E-09 6.96E-07 -1.74 -9.57 3p21.31 49 241383_at -4.21 2.75E-09 7.92E-07 -1.75 -9.55 50200068sat-CANX-1. 65 2.98E-11 1.89E-08-1. 55-9. 52 5q35 HG-U 133B 2. 60 AML inv (3) versus AML_t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 203949_at MPO -5.44 5.57E-18 1. 52E-13-2. 29-14. 9617q23. 1 203948_s at MPO-6. 74 3.58E-14 4. 89E-10-1. 89-12. 11 17q23.1 3 209122_at ADFP -3.38 1.03E-12 9. 42E-09-1. 55-10. 15 9p21. 3 4228827at-92. 61 4.57E-10 2. 08E-06-1. 97-10. 03 5 217963_s_at NGFRAP1 34.31 1.80E-08 2. 47E-05 2.15 9.83 Xq22. 1 6211709satSCGF-4. 29 8. 01 E-12 5. 47E-08-1.44-9. 45 19q13. 3 7 211084_x_at PRKCN 5.66 3.98E-09 9 88E-06 1.59 9.24 2p21 8 205529_s_at CBFA2T1 -14.76 2.25E-09 6.83E-06-1. 74-9. 20 8q22 9 233955_x_at HSPC195 5.01 2. 80E-08 3. 47E-05 1.80 9.19 5q31. 3 10 207839_s_at LOC51754 3.06 2.36E-10 1. 29E-06 1.45 9.13 9p13. 1 11 213716satSECTM14*93 3.75E-09 9.88E-06 1.55 9.11 17q25 12229406at-12. 12 1.70E-09 6. 39E-06-1. 60-9. 09 13 202887_s_at RTP801 4.18 5.07E-08 4. 62E-05 1.52 8.39 10pter-q26. 12 14 205528_s_at CBFA2T1 -27.75 1. 41 E-08 2. 15E-05-1. 56-8. 32 8q22 15 212895_s_at ABR 2.87 3.10E-08 3. 53E-05 1.36 8.06 17p13. 3 16 212423 at FLJ90798 3. 77 4. 04E-08 4. 42E-05 1.34 7.93 10q22. 3 17 206871_at ELA2 -4.45 1.87E-09 6. 39E-06-1. 22-7. 88 19p13. 3 18 217226_s_at BA108L7.2 3.17 4.71 E-08 4. 62E-05 1.31 7.79 10q24. 31 19 204494_s at DKFZP434H 132 4. 61 3. 95E-07 1. 37E-04 1.56 7.76 15q22. 33 20 225010_at D10S170 2.54 1. 04E-08 1. 77E-05 1.23 7.75 10q21 21 210150_s_at LAMA5 -3.67 7.23E-09 1. 52E-05-1. 23-7. 73 20q13. 2-q13. 3 Table 2.1-2. 78 22 226865_at 9.73 5.70E-07 1.64E-04 1.64 7. 68 23211728satHYAL3-3. 34 8.95E-09 1.75E-05-1. 22-7.67 3p21. 3 24 228058 at LOC124220-2. 54 9.74E-09 1.77E-05-1. 20-7. 5916p13. 3 25 210613_s_at SYNGR1-2. 97 4. 40E-09 1. OOE-05-1. 17-7.58 22q13. 1 26 233467_s_at PHEMX 2.46 6. 91 E-08 5. 05E-05 1.26 7.56 11p15. 5 27 227276_at TEM7R 3.51 3.09E-07 1. 23E-04 1.39 7.55 10p12. 1 28 233072_at KIAA1857 -4. 59 5.06E-08 4.62E-05-1. 28-7.49 9q34 29 206478_at KIAA0125 22. 61 9. 17E-07 1. 95E-04 1.71 7.46 14q32. 33 30 222996_s_at HSPC195 4.19 7. 29E-07 1. 77E-04 1. 52 7. 46 5q31. 3 31 235468_at -6. 55 8. 20E-08 5.47E-05-1. 32-7.42 32 201243_s_at ATP1 B1 5. 00 4.26E-07 1. 42E-04 1.37 7.42 1q22-q25 33 204495_s_at DKFZP434H132 5.13 9.12E-07 1. 95E-04 1.53 7.37 15q22. 33 34 205382_s_at DF -6. 33 7.39E-08 5. 05E-05-1. 26-7. 35 19p13. 3 35 201281_at ADRM1-2. 12 1. 71E-08 2. 45E-05-1.16-7. 35 20q13. 33 36 227853 at 2. 46 5. 80E-08 4. 96E-05 1. 18 7. 30 37 213908 at 4. 51 5. 12E-07 1. 57E-04 1.34 7.30 38 219183 s at PSCD4 2. 35 2.77E-07 1. 16E-04 1. 26 7. 27 22q12. 3-q13. 1 39 217975 at LOC51186 14. 36 1.13E-06 2. 26E-04 1. 51 7. 26 Xq22. 1 40 221773 at 3. 52 2.17E-07 1. 02E-04 1. 24 7. 24 41 215051_x_at AIF1 2.45 9. 99E-08 6. 07E-05 1.19 7.23 6p21. 3 42 242845_at -4. 10 4. 98E-08 4.62E-05-1. 17-7.21 43 218854_at SART2 6.30 1.20E-06 2. 34E-04 1. 48 7. 20 6q22 44 222955 s at HT011-2. 24 6.72E-08 5.05E-05-1. 19-7. 19 Xq26. 1 45 201811_x_at SH3BP5 8. 59 1.30E-06 2.41 E-04 1. 46 7. 15 3p24. 3 46 203820_s_at KOC1 3.81 9. 22E-07 1. 95E-04 1.36 7.15 7p11 47 201288_at ARHGDIB -1. 41 1.29E-08 2. 07E-05-1. 10-7. 1512p12. 3 48 210115_at RPL39L -8. 57 2. 10E-07 1. 02E-04-1. 33-7. 12 3q27 49 204548_at STAR -7. 93 1.56E-07 8. 38E-05-1. 23-7.08 8p11. 2 50 202759_s_at AKAP2 -3. 83 2.73E-08 3.47E-05-1. 10-7. 08 9q31-q33 2.61 ALM_inv(3) versus CLL # affy id HUGO name fc p q stn t Map Location 1 224838_at FOXP1 -4. 02 6.58E-27 1.18E-22-2. 84-20.86 3p14. 1 2 225927_at -4. 93 3. 18E-26 2.84E-22-2. 77-20.35 3 218829_s_at KIAA1416 -5. 60 2.78E-22 1. 66E-18-2. 62-18.58 8q12.1 4 223514_at CARD11-23. 95 4.73E-20 9. 41 E-17-2. 83-18.46 7p22 5 226123_at LOC286180-8. 20 5. 40E-22 2.26E-18-2. 48-17.74 8q12.1 6243780at-36. 23 6.53E-19 8. 98E-16-2. 67-17. 20 7 201030 x at LDHB 2. 37 1.03E-21 3. 06E-18 2. 34 17. 0212p12. 2-p12. 1 8 218191_s_at FLJ11240 -2. 92 6. 31E-22 2. 26E-18-2. 30-16.74 6q12 9 208091_s_at DKFZP564K0822 -12. 30 8.45E-19 1. 08E-15-2. 46-16.48 7pu4. 1 10 204215_at MGC4175 -4. 44 1.89E-21 4. 82E-18-2. 23-16.26 7q21. 1-q21. 2 11 226454_at LOC92979 -4. 79 2.68E-19 4. 35E-16-2. 23-15. 72 12q13.13 12 212827 at IGHM-6. 32 4. 29E-21 9. 59E-18-2. 14-15. 6914q32. 33 Table 2. 1-2. 78 13 214615_at P2RY10-8. 85 1. 09E-17 7. 53E-15-2. 27-15. 22 Xq21.1 14 44790 s at C13orf18-62. 00 5.14E-17 2.24E-14-2. 48-15. 21 13q14. 11 15 212590_at RRAS2 -7.29 1. 95E-18 2. 18E-15-2. 18-15. 17 11p15. 2 16 219471_at C13orf18 -48.59 6.33E-17 2.46E-14-2. 47-15. 12 13q14. 11 17 213564 x at LDHB 1. 87 8. 69E-18 6. 22E-15 2. 08 14. 7812p12. 2-p12. 1 18 228390_at -19. 22 5.90E-17 2.34E-14-2. 25-14. 76 19 212313_at MGC29816 -5. 53 6. 06E-19 8. 98E-16-2. 04-14. 65 8p21. 2 20202880satPSCD1-3. 89 8.68E-20 1. 55E-16-2. 00-14. 64 17q25 21208456satRRAS2-10. 56 4. 70E-18 4. 42E-15-2. 08-14.61 11p15. 2 22236280at-16. 23 1. 34E-16 4.52E-14-2. 26-14.53 23 211984 at-3. 69 2. 88E-18 3.03E-15-2. 01 -14.33 24 239287_at -32. 35 3. 46E-16 9.36E-14-2. 34-14. 29 25 201200_at CREG 7.14 5. 74E-12 3. OOE-10 2. 47 14. 281q24 26 206337_at CCR7 -15. 17 8. 46E-17 3.03E-14-2. 10-14. 1917q12-q21. 2 27 244261 at IL28RA-57. 53 4. 73E-16 1.21E-13-2. 28-14. 12 1p36. 11 28 223287_s_at FOXP1 -4. 31 3. 08E-18 3. 06E-15-1. 94-14. 00 3p14. 1 29 236301_at -12. 56 1. 83E-18 2.18E-15-1. 93-13. 99 30 229844_at -4. 57 4. 68E-17 2.13E-14-2. 02-13. 98 31 204674 at LRMP-6. 49 4. 58E-17 2.13E-14-2. 01-13. 96 12p12. 1 32 226989_at LOC285705 -5. 23 1. 57E-16 5.19E-14-2. 05-13. 89 5qu5 33 229072_at -18. 08 3. 66E-16 9.64E-14-2. 11-13.87 34 221778_at KIAA1718 -4. 22 5.36E-18 4. 79E-15-1. 91-13. 76 7q33-q35 35 223391 at SGPP1-8. 22 8. 35E-18 6.22E-15-1. 91-13. 72 14q23. 1 36 204951 at ARHH-4. 12 1.66E-17 1.03E-14-1. 91-13. 654p13 37 202524_s_at SPOCK2 -6. 30 4.13E-17 2. 11 E-14-1. 94-13. 6510pter-q25. 3 38 206398_s_at CD19 -12. 84 5. 18E-16 1.29E-13-2. 03-13. 57 16p11. 2 39 41220_at MSF -2. 09 1. 30E-15 2.86E-13-1. 94-13. 56 17q25 40 205484_at SIT -17. 73 1. 69E-15 3. 60E-13-2. 15-13.49 9p13-p12 41 216095_x_at MTMR1 -3. 15 1.27E-17 8.45E-15-1. 85-13. 35 Xq28 42 201998_at SIAT1 -6. 44 4.75E-17 2.13E-14-1. 87-13. 33 3q27-q28 43 212579_at KIAA0650 -4. 10 4.42E-17 2.13E-14-1. 87-13.31 18p11. 31 44 209374_s_at IGHM -6. 10 6. 84E-18 5. 82E-15-1. 80-13. 1714q32. 33 45 213309_at PLCL2-6. 14 5. 59E-17 2. 29E-14-1. 84-13. 15 3p24.3 46 227193_at -4. 88 3.14E-17 1.70E-14-1. 82-13.11 47 227670_at ZNF75A -4.28 8.42E-18 6. 22E-15-1. 79-13. 07 16p13. 11 48 214786_at MAP3K1-5. 45 8. 29E-17 3.03E-14-1. 83-13. 06 5q11. 2 49 236226_at -25. 93 4. 17E-15 8. 12E-13-2.01-12. 96 50 224837_at FOXP1 -2. 61 7. 45E-18 6. 06E-15-1. 76-12.94 3p14. 1 2. 62 AML inv (3) versus CML # aKy id HUGO name fc stn t Map Location 1 212531_at LCN2 -11. 33 3. 93E-33 7.80E-29-2. 84-23.24 9q34 2 205557_at BPI -8. 11 3.76E-29 2.49E-25-2. 63-21. 30 20q11.23-q12 3 204174_at ALOX5AP-9. 82 6. 03E-29 2.99E-25-2. 55-20. 60 13q12 Table 2. 1-2.78 4 203021 at SLPI-9. 44 9.41 E-29 3.73E-25 -2. 53-20.43 20q12 5210140atCST7-7. 08 1.29E-29 1. 28E-25 -2.49 -20.33 20p 11. 21 6 206676 at CEACAM8-8. 54 3. 10E-28 8. 78E-25-2. 45-19. 93 19q13. 2 7 205513_at TCN1 -12.10 1.81E-27 4. 48E-24-2. 48-19. 8411q11-q12 8 203757 s at CEACAM6-9. 79 1. 39E-28 4. 62E-25-2. 36-19. 3019q 13. 2 207802_at SGP28-29. 32 7.15E-25 7. 89E-22-2. 50-19. 11 6p12. 3 10 209772_s_at CD24 -17.79 .07E-25 5.38E-22 -2.39 -18.69 6q21 11 226789_at -5.45 3.02E27 5.99E-24 -2.29 -18.64 12 214575_s at AZU1-10. 51 7. 41E-27 1.34E-23 -2. 25-18. 3719p13. 3 13 201554_x_at GYG -4. 44 2.14E-27 4.73E-24-2. 24-18. 34 3q24-q25. 1 14 210244_at CAMP -15.15 4.36E-26 7. 22E-23-2. 21-17. 94 3p21. 3 15 206871 at ELA2-6. 00 3. 94E-20 1.50E-17 -2. 32-17. 7019p13. 3 16225386satLOC92906-8. 21 5. 64E-24 5. 60E-21-2. 19-17.55 2p22.2 17 206440_at LIN7A -16.13 5.02E-25 6. 23E-22-2. 18-17.52 12q21 18 203949_at MPO -5. 20 9. 71 E-23 622E-20-2. 19-17. 37 17q23. 1 19 203467 at PMM1-5. 5 7. 71E-26 1. 18E-22-2. 10-17. 21 22q13. 2 20 208308_s_at GPI -3. 87 8.43E-24 7. 6E-21 -2. 13-17. 1619q13. 1 21223423atGPCR1-5. 39 6.93E-25 7.89E-22-2. 06-16.77 3q26.2-q27 22 212318 at TRN-SR-3. 30 3.44E-25 4. 88E-22-2. 04-16.70 7q32.2 23 209369_at ANXA3-10. 45 2.02E-23 1. 67E-20-2. 05-16. 41 4q13-q22 24 217762_s_at RAB31 -7.89 6. 78E-24 6. 41E-21-2. 02-16. 3618p11. 3 25 416378_x_at KIAA1919 -6.15 1. 94E-20 7. 69E-18-2. 09-16. 33 6q22 26 204351_at S100P -5. 29 3. 11 E-24 3.25E-21-2. 00-16. 314p16 27 211657_at CEACAM6 -6. 01 3.17E-22 1. 91E-19 -2. 02-16. 20 19q13. 2 28 204411_at KIAA0449 -11.88 3.63E-23 2. 67E-20-2. 00-16. 04 1pter-q31. 3 29205863atS100A12-5. 50 3.22E-23 2. 46E-20-1. 95-15. 85 1q21 30 205653_at CTSG -6.59 7.74E-23 5. 30E-20-1. 95-15. 79 14q11. 2 31 209771_x_at CD24 -5.43 8.91E-19 2.21E-16 -2.05 -15.75 6q21 32 221952 x at KIAA1393-2. 40 2. 83E-19 8. 78E-17-2. 02-15. 69 14q23. 1 33 219281_at MSRA -3.15 8. 82E-24 7.62E-21-1. 92-15. 69 8p23.1 34 202487_s_at H2AV -2.86 3.79E-21 1. 75E-18-1. 96-15.64 7p13 35 208650_s_at CD24 -7. 56 2.92E-23 2.32E-20-1. 92-15. 62 6q21 36 200654_at P4HB-2. 97 4.41 E-17 6. 29E-15-2. 09-15. 60 17q25 37 206656_s_at C20orf3 -3.26 5.73E-23 4. 06E-20-1. 85-15. 14 20p11. 22-p11. 21 38 207269 at DEFA4-6. 47 1.92E-19 6. 15E-17-1. 93-15.14 8p23 39 210254_at MS4A3 -4.96 7.30e-17 9.23E-15 2.02 015.10 11q12 40 219010_at FLJ10901 -5.45 9.27E-23 6.14E-20 -1.85 -15.10 1q31.3 41 203948_s_at MPO -6.15 1.66E-21 8.91E-19 -1. 86-15. 03 17q23.1 42 224707_at ORF1-fl49 -6.35 4. 75E-22 2. 77E-19-1. 86-15. 00 5q31. 3 43 204301 at KIAA0711-11. 17 1.46E-20 6.06E-18-1. 94-14.99 8p23.2 44 211275_s_at GYG -3. 21 1. 68E-20 6.83E-18-1. 86-14. 86 3q24-q25.1 45 236979_at -4 04 1.79E-21 9. 33E-19 -1.85 -14.83 46 208651_x_at CD24 -5.58 1.75E-22 1.09E-19-1. 81-14. 80 6q21 47 206851_at RNASE3 -6. 81 4.88E-22 2.77E-19-1. 81-14. 7614q24-q31 48 218660_at DYSF -5.36 3.54E-21 1. 67E-18 -1. 82 -14. 59 2p13. 3-p13. 1 49 217763_s_at PAB31 -8.22 4.59E-21 2. 07E-18-1. 82 -14.57 18p11. 3 Table 2.1-2. 78 50 203936 sat MMP9-9.33 2.43E-21 1. 24E-18 -1.78 -14.45 20q11.2-q13. 1 2.63 AML_inv(3) versus normaIBM # affyid HUGO name fc p q stn t Map Location 1 225923 at-2. 50 2. 61E-10 6.95E-07-2. 52-12.56 2 212531 at LCN2-10. 31 5. 31E-07 6. 23E-05-2. 96-12.01 9q34 3 202018_s_at LTF -4. 47 3. 71E-11 5.12E-07-2. 33-11.96 3q21-q23 4 232098_at -6. 49 4. 46E-09 4. 79E-06-2. 34-11. 45 5 218662_s_at HCAP-G -3.13 1.86E-08 8. 49E-06-2. 37-11. 29 4p16-p15 6 223545_at FANCD2-2. 57 5. 47E-08 1. 87E-05-2. 39-11. 13 3p26 7 226556_at -2.92 7.16E-11 5. 12E-07-2.11-10. 96 82l3292satSNX13-2. 90 3.38E-07 4. 93E-05-2. 46-10.85 7p21. 1 9 225788_at LOC88745-1. 50 1.22E-10 5. 12E-07-2. 10-10. 85 6p21. 1 10 209054_s_at WHSCl -2.56 6.09E-08 1. 95E-05-2. 27-10. 71 4p16. 3 11 218257 s at UGCGL1-1. 94 1. 36E-10 5. 12E-07-2. 01-10. 4 2q14. 3 12 203535_at S100A9 -3. 26 1. 39E-08 7. 27E-06-2. 13-10. 431q21 13 208668_x_at HMGN2 -1.66 6.58E-10 1.24E-06 -2. 02-10. 34 1p36. 1 14 212967_x_at NAP1L1 1.53 2. 78E-10 6. 95E-07 1. 97 10. 19 12q21. 1 15 228983_at -2. 03 5.91 E-09 5. 13E-06-1. 97-9. 92 16 227708_at EEF1A1 3.15 1. 26E-09 1. 81E-06 1.94 9.89 6q14. 1 17 222430_s_at HGRG8 2.23 4.23E-10 9.08E-07 1.90 9.86 14q12-21 18 203538 at CAMLG 2.88 1. 32E-09 1. 81E-06 1.88 9.65 5q23 19 228566_at-2. 75 1.78E-06 1.39E-04-2. 22-9. 57 20 219588_s_at FLJ20311 -3.83 2.19E-06 1.53E-04 -2.23 -9.53 7q36.3 21 206871_at ELA2 -5.73 5.98E-07 6.71 E-05-2. 07-9. 46 19p13. 3 22 235733_at -2. 62 1. 05E-09 1. 75E-06-1. 82-9.43 23 201988_s_at CREBL2-2. 10 4.18E-09 4.79E-06-1. 84-9. 43 12p13 24 215111_s_at TSC22 7.35 2. 88E-08 1. 14E-05 2.07 9.43 13q14 25222606atFLJ10036-1. 77 2. 46E-08 1. 04E-05-1. 87-9. 3315q22. 2 26 218829_s_at KIAA1416 -3. 84 5. 12E-06 2.40E-04-2. 28-9. 26 8q12. 1 27 203755_at BUB1B -2.71 1.28E-06 1.09E-04-2. 05-9. 21 15q15 28 230988_at -4.72 5.08E-06 2.40E-04-2. 24-9.18 29 225619_at FLJ30046-7. 68 6. 46E-06 2.71 E-04-2. 30-9. 18 13q21. 33 30204976satAMMECR1-3. 62 2. 33E-06 1. 58E-04-2. 10-9. 14 Xq22.3 31 203746_s at HCCS-1. 77 4. 91 E-06 2.38E-04-2. 21-9. 12 Xp22. 3 32 221030_s_at DKFZP564B1162 -2. 47 1. 58E-07 3. 31E-05 -1.88 -9.11 4q21.3 33 230044_at -5. 51 6. 19E-06 2.66E-04-2. 25-9. 10 34 227554_at -2. 51 4.95E-06 2.39E-04 -2.20 -9.09 35 233701_at -2. 19 5.17E-07 6. 12E-05-1. 94-9.08 36 203073_at GOG2 -1.99 7.77E-09 5.56E-06 -1.77 -9.07 1q42.13 37 203221_at TLE1 -2.29 1.40E-08 7.27E-06 -1.78 -9.05 9q21.32 38204767satFEN1-2. 16 6. 84E-09 5. 41E-06 -1.76 -9.04 11q12 39 219471_at C13orf18 -6.25 1.45E-05 4. 10E-04-2. 51-8. 9713q14. 11 40 203582_s_at RAB4A 2.63 2.82E-09 3.53-06 1.73 8.97 1q42-q43 Table 2.1-2. 78 41 235158-at FLJ14803-2. 08 5.08E-09 4.93E-06-1. 75-8. 97 7q32. 3 42 206845 s at RNF40-2.14 7.49E-09 5.56E-06-1. 73-8. 92 16p11.2-p11. 1 43 201859_s_at PRG1 -2. 04 1. 62E-08 8.09E-06-1. 74-8. 87 10q22. 1 44 214813_at ZNF75 -2. 32 2.97E-07 4.50E-05-1. 84-8.84 Xq26.3 45 226190_at -3.55 5.24E-09 4.93E-06-1. 70-8.81 46 226089_at MGC23920 -2.09 6. 08E-08 1.95E-05-1. 76-8. 79 3q13. 33 47 205909_at POLE2-2. 45 8.69E-07 8. 65E-05-1.88-8. 7614q21-q22 48 228252_at PIF1 -3. 51 5.39E-06 2.45E-04-2. 05-8. 6915q22. 1 49 214575_s at AZU1-7. 76 2.88E-06 1.79E-04-1. 96-8. 6919p13. 3 50 210192_at ATP8A1 -2.38 1.34E-07 2.96E-05-1. 76 -8.66 4p14-p12 2.64 AML_komplext versus AML_t(15 ; 17) # affyid HUGO name fc p q stn t Map Location 1205382satDF-7. 84 1.62E-15 2.79E-12-2. 74-17. 32 19p13. 3 2 212953_x_at CALR -3. 21 1. 30E-13 9. 18E-11-2. 45-15. 0319p13. 3-p13. 2 3 203948_s_at MPO -4. 01 3. 68E-19 4.69E-15-2. 02-14. 64 17q23. 1 4214450atCTSW-6. 67 6.70E-14 6. 09E-11-2. 28-14. 52 11q13. 1 5 38487_at STAB1 -5. 91 5. 67E-13 2. 67E-10-2. 18-13. 64 3p21. 31 6 216032_s_at SDBCAG84 -3. 37 2.16E-14 2. 29E-11-2. 03-13. 59 20pter-q12 7 208826_x_at HINT1 -1. 69 7. 49E-18 4.77E-14-1. 76-12.96 5q31. 2 8238022at-7. 84 7.82E-13 3.55E-10-1. 99-12. 81 9 213147_at HOXA10 11. 01 4. 54E-15 5. 75E-12 1.91 12.80 7p15-p14 10 200931_s_at VCL 4. 91 6. 72E-16 1.71E-12 1.82 12. 74 10q22. 1-q23 11 209732_at CLECSF2 35. 32 4. 46E-14 4. 37E-11 2. 04 12. 46 12p13-p12 12 200654_at P4HB -2. 34 2. 10E-16 8. 89E-13-1. 70-12. 3617q25 13 207721_x_at HINT1 -1. 89 6. 21E-16 1. 71E-12 -1. 57-11.54 5q31. 2 14200047sat-YY1132 1. 07E-15 2. 27E-12 1. 55 11. 37 14q HG-U133A 15 203949_at MPO-2.48 1. 75E-15 2.79E-12-1. 53-11. 2317q23. 1 16 200093 s at-HINTI-1. 89 2. 93E-15 4. 15E-12-1.50-11. 06 5q31. 2 HG-U133B 17 201923 at PRDX4 8.38 3. 10E-13 1. 80E-10 1.63 11. 02 Xp22. 13 18 204897_at PTGER4 5.03 4. 97E-15 5. 75E-12 1.48 10.91 5p13. 1 19 217225_x_at LOC283820 -2. 07 6.98E-12 1.85E-09-1. 59-10. 73 16p13. 13 20 227353_at EVER2 4.55 1. 06E-13 7. 94E-11 1.51 10. 6917q25. 3 21 206847_s_at HOXA7 4.94 9. 60E-14 7. 94E-11 1. 47 10. 53 7p15-p14 22 227999_at LOC170394 3. 30 1. 56E-13 1. 04E-10 1.41 10.21 10q26. 3 23 202600_s_at NRIP1 12. 57 3.27E-12 9. 68E-10 1. 52 10. 19 21q11. 2 24 207375_s at IL15RA 5. 82 1.33E-12 5. 36E-10 1. 46 10. 16 10p15-p14 25 214789_x_at SRP46 3.86 1. 77E-13 1. 13E-10 1.40 10.14 11q22 26 221004_s_at ITM2C -3. 41 2.27E-13 1. 38E-10-1. 40-10.14 2q37 27 204150_at STAB1 -6. 71 1. 26E-09 8.02E-08-1. 73-10. 06 3p21. 31 28 200934_at DEK 2.41 1.06E-13 7. 94E-11 1. 36 10. 01 6p23 29 208892_s_at DUSP6 6.46 1. 35E-12 5.36E-10 1.39 9.84 12q22-q23 Table 2.1-2. 78 30 202413_s_at USP1 2. 49 4. 61 E-13 2. 37E-10 1. 35 9. 84 1 p32. 1-p31. 3 31 217848 s at PP 3. 96 1. 63E-12 6. 11E-10 1.389 9.78 10q11. 1-q24 32208891atDUSP66*82 9.06E-13 3. 98E-10 1.36 9.77 12q22-q23 33 220798_x_at FLJ11535 -3.676 2. 63E-11 5.28E-09-1. 42-9. 75 19p13. 3 34 224473 x at KIAA1813 2. 33 9. 97E-13 4. 23E-10 1.36 9. 75 10q24 35 225547_at 1.73 3.36E-13 1. 86E-10 1.33 9.75 36 200008 s at-GD12-2. 39 1. 53E-11 3. 41E-091 -1. 40-9. 74 10p15 HG-U 133A 37 238949 at FLJ31951 8. 00 5.50E-12 1. 49E-09 1.41 9.71 5q33.3 38 203535_at S100A9 7.92 3.22E-12 9. 68E-10 1.38 9.68 1q21 39 210788_s at retSDR4-2. 19 8. 24E-11 1. 17E-08-1. 44-9. 6714q22. 3 40 226460_at KIAA1450 3. 63 1.79E-12 6. 33E-10 1.35 9.66 4q32. 1 41 200093 s at-HINT1-1. 69 5.55E-13 2. 67E-10-1. 32-9. 63 5q31. 2 Hug-USA 42 225172 at CRAMP1 L 2.61 4. 65E-13 2. 37E-10 1.31 9. 60 16p13. 3 43 229693_at-2. 78 1. 07E-10 1. 42E-08-1. 42-9. 56 44 203302_at DCK 4. 08 4.56E-12 1. 30E-09 1.33 9.44 4q13.3-q21. 1 45 200656 s_at P4HB-4. 16 1. 53E-09 9. 31E-08 -1. 51-9. 39 17q25 46 205033_s_at DEFA1 5.34 2.50E-12 8. 36E-10 1.30 9.37 8p23.2-p23. 1 47 227308_x_at SCYL1 4.60 1. 47E-11 3. 34E-09 1.35 9.36 48 205663_at PCBP3 -3. 06 1. 14E-10 1. 44E-08-1. 37-9. 35 21 q22. 3 49 202599 s at NRIP1 8. 20 2. 13E-11 4. 38E-09 1.36 9.31 21q11. 2 50 221087_s_at APOL3 3.50 4.58E-12 1.30E-09 1.29 9.29 22q13.1 2.65 AML_komplext versus AML_t(8;21) # affyid HUGO name fc p q stn t Map Location 1 213147 at HOXA10 7.91 8.54E-15 1. 20E-10 1.70 12.02 7p15-p14 2 201920_at SLC20A1 3. 17 3.09E-14 2. 18E-10 1. 46 10. 83 2q11-q14 3206847satHOXA7406 5. 19E-13 1. 46E-09 1.43 10.29 7p15-p14 4222229xat-1. 45 5.56E-14 2. 61 E-10-1. 29-9.90 5 200833_s_at RAP1B 2.26 3. 79E-13 1. 33E-09 1.27 9.62 12q14 6228827at-24. 12 6. 82E-10 1. 35E-07-1. 66-9.62 7 209523_at TAF2 3.00 6. 58E-13 1. 55E-09 1.23 9.37 8q24. 12 8206940satPOU4F1-26. 63 1.75E-09 2. 40E-07-1. 69-9. 2913q21. 1-q22 9 224481_s_at HECTD1 1.84 8.52E-13 1. 72E-09 1.20 9.20 14q12 10 214651_s_at HOXA9 111. 95 1. 42E-10 4. 64E-08 1.55 9.15 7p15-p14 11 211423_s_at SC5DL 2.73 2.78E-12 3. 64E-09 1.21 9.12 11q23. 3 12217963satNGFRAP128. 57 1. 56E-10 4 76E-08 1.46 9.07 Xq22. 1 13 209022_at STAG2 2. 17 1.59E-12 2. 50E-09 1.18 9.04 Xq25 14 201807_at VPS26 2. 21 1. 60E-12 2. 50E-09 1.17 8.99 10q21.1 15 241706_at LOC144402 =97 4. 36E-11 2.06E-08 1.27 8.98 12q11 16 206003_at KIAA0635 2.44 2. 87E-12 3. 64E-09 1.16 8.90 4q12 17 212232_at FNBP4 1.87 3. 36E-12 3. 64E-09 1.16 8.85 11p11.12 18 202406_s_at TIAL1 1.77 3. 16E-12 3. 64E-09 1.15 8.84 10q Table 2.1-2. 78 19 203079sat CUL2 2.44 3.64E-12 3. 66E-09 1. 15 8. 83 10p11. 21 20 212585 at OSBPL8 2. 34 5.76E-12 4. 77E-09 1.16 8.80 12q14 21201663satSMC4L13. 00 4.61 E-11 2. 06E-08 1.22 8.78 3q26.1 22 218577 at FLJ20331 2. 34 4.62E-12 4.21 E-09 1.15 8.77 1p31. 1 23 227853_at 2.75 1.14E-11 8. 46E-09 1. 15 8. 72 24 222902_s_at FLJ21144 1.96 4.78E-12 4. 21E-09 1.13 8.70 1p34. 1 25 211061_s_at MGAT2 1.93 4. 68E-11 2. 06E-08 1.19 8.69 14q21 26 235753_at 6.97 3. 87E-10 9. 05E-08 1.36 8.68 27 203949_at MPO -2. 28 6.50E-12 5. 09E-09-1. 13-8. 6417q23. 1 28 205529_s_at CBFA2T1 -8. 73 4. 85E-09 4.90E-07-1. 44-8.61 8q22 29 218236_s_at PRKCN 7. 50 2. 70E-10 7. 68E-08 1.26 8.60 2p21 30 201972_at ATP6V1 A1 2. 49 3. 96E-11 2. 06E-08 1. 16 8.57 3q13. 2 31 226460_at KIAA1450 2.94 3.24E-11 1. 90E-08 1.14 8.53 4q32. 1 32 212397_at RDX 2.69 6. 23E-11 2. 58E-08 1.15 8.47 11q23 33 203320_at LNK 2.62 1. 00E-10 3. 76E-08 1.16 8.45 12q24 34 211341_at POU4F1 -72. 39 1. 11E-08 8.38E-07-1. 57-8. 44 13q21. 1-q22 35 218754_at FLJ23323 1.87 4. 40E-11 2. 06E-08 1.12 8.42 1p36. 23 36 235521 _at HOXA3 7. 65 7.60E-10 1. 44E-07 1.31 8.42 7p15-p14 37 211746_x_at PSMA1 1. 68 1. 55E-11 1. 09E-08 1.09 8.39 11p15. 1 38 203948_s_at MPO -2. 93 5.41 E-11 2.31 E-08-1. 11-8. 36 17q23. 1 39 212463_at 4.11 1.59E-10 4. 76E-08 1.15 8.36 40 218040-at FLJ10330 2.14 2. 71E-11 1. 73E-08 1.10 8.36 1p13. 2 41 201425_at ALDH2 10. 22 4. 43E-10 9. 67E-08 1.21 8.35 12q24. 2 42 201377_at NICE-4 2.04 2. 58E-11 1. 73E-08 1.09 8.31 1q21. 3 43 215051_x at AIF1 2. 38 3. 60E-11 2. 03E-08 8.25 6p21. 3 44 217846_at QARS -1. 58 3. 17E-11 1. 90E-08-1. 08-8. 25 3p21. 3-p21.1 45 214700_x at DKFZP434D 193 2. 73 1. 20E-10 4. 22E-08 1.11 8. 22 2q23.3 46 220936_s_at H2AFJ 4.97 1. 58E-10 4. 76E-08 1.11 8.21 12p12 47 201994_at MORF4L2 1.68 4.03E-11 2. 06E-08 1.07 8.18 Xq22 48 202775_s_at SFRS8 1.86 1. 01E-10 3. 76E-08 1.09 8.16 12q24. 33 49 226545 at 7. 60 8. 73E-10 1. 56E-07 1. 19 8. 16 50 200934_at DEK 1.96 4. 59E-11 2. 06E-08 1.06 8.13 6p23 2.66 AML komplext versus CLL # affy id HUGO name fc stn t Map Location 1 224838_at FOXP1 -4. 30 3.70E-29 2.44E-25-2. 95-23.50 3pu4. 1 2 209619_at CD74-3. 42 2.95E-31 3.90E-27-2. 52-21. 05 5q32 3 212827_at IGHM -7. 31 1.48E-21 2. 98E-18-2. 26-17. 3814q32. 33 4 223514_at CAPD11 -14. 56 1. 18E-20 1.20E-17-2. 31-17.28 7p22 5 243780_at -24. 21 3. 92E-19 2. 46E-16-2. 35-16.68 6 224837_at FOXP1 -3. 19 3.42E-21 4. 51 E-18-2. 15-16.67 3p14.1 7 201200_at CREG 7. 30 1. 82E-19 1. 38E-16 2. 21 16. 41 1q24 8225927at-3. 37 3.61 E-24 1. 59E-20-1. 87-15. 65 9 208091_s_at DKFZP564K0822-8. 37 1. 25E-18 6. 60E-16-2. 10-15. 49 7p14. 1 Table 2.1-2. 78 10 208864sat TXN 5. 94 5.76E-18 2. 11E-15 2.08 15.19 9q31 11 213911_s_at H2AFZ 2.50 5. 00E-19 3. 00E-16 1.98 15.27 4q24 12208456satRRAS2-11. 00 9.43E-18 2. 89E-15-2. 11-15. 05 11p15. 2 13 222680 s_at RAMP 7. 27 1. 92E-16 3. 20E-14 2. 30 14. 90 14 212590_at RRAS2 -6. 68 2. 26E-18 1.06E-15-1. 99-14. 89 11p15. 2 15 217478_s_at HLA-DMA -3. 42 4.04E-22 1.33E-18-1. 79-14.80 6p21. 3 16 AFFX-GAPD 2. 43 1. 37E-20 1. 29E-17 1.81 14.65 12p13 HUMGAPDH/M33 197 3 at-HG- U133B 17 203932_at HLA-DMB-5.71 1. 88E-19 1.38E-16-1. 86-14.64 6p21. 3 18 223391_at SGPP1 -9. 69 7. 57E-1 2.44E-15-1. 97-14. 5814q23. 1 19 229844 at-5. 13 2. 40E-17 6. 08E-15-2. 03-14. 57 20 228390_at -18. 70 3.07E-17 7.35E-15-2. 03-14.51 21 41220 at MSF-2. 30 2. 04E-21 3. 37E-18-1. 76-14.51 17q25 22 223287_s_at FOXP1 -3. 96 2. 15E-17 5.80E-15-1. 97-14.37 3p14. 1 23 209374_s_at IGHM -6. 15 7. 84E-18 2.46E-15-1. 92-14. 3714q32. 33 24 44790_s_at C13orf18 -19. 84 5.16E-17 1.06E-14-2. 01-14. 34 13q14. 11 25204670xatHLA-DRB5-2. 82 9.35E-22 2. 47E-18-1. 72-14. 30 6p21. 3 26 201998_at SIAT1 -7. 78 4. 13E-17 8.94E-15-1. 99-14.30 3q27-q28 27 219471_at C13orf18 -16. 08 9. 61E-17 1.74E-14-2. 01-14. 18 13q14. 11 28 212313_at MGC29816 -4. 21 1.16E-17 3. 25E-15-1. 87-14. 09 8p21. 2 29 239287 at-23. 28 4. 46E-16 6.68E-14-2. 19-14.08 30 226538 at-4. 00 8. 19E-19 4. 70E-16-1. 78-14.06 31 205105_at MAN2A1 -2. 98 6. 57E-20 5. 77E-17-1. 73-14. 02 5q21-q22 32202880satPSCD1-3. 50 1.58E-21 2. 98E-18-1. 68-14. 0017q25 33 225246_at STIM2 -4. 88 2. 80E-17 6. 97E-15-1. 88-13.97 4p15. 2 34 AFFX-GAPD 2. 13 8. 11E-21 8.91E-18 1.68 13.93 12p13 HUMGAPDH/M33 197 3 at-HG- U133A 35 208306xat HLA-DRB4-2. 93 3. 14E-21 4. 51E-18-1. 66-13.85 6p21. 3 36 229072 at-19. 60 2. 31E-16 3. 77E-14-1. 97-13.83 37 213309_at PLCL2 -6. 43 8.19E-17 1.52E-14-1. 89-13.79 3p24.3 38 214615_at P2RY10 -6. 31 1.04E-17 2. 98E-15-1. 79-13.76 Xq21. 1 39 201263_at TARS 4.89 9. 13E-16 1. 22E-13 2. 01 13. 75 5p13. 2 40 209061 at SULF2-5. 23 3.32E-17 7. 64E-15-1. 82-13.68 20q12-13. 2 41 236301 at-9. 65 1. 98E-18 9. 68E-16-1. 71-13.59 42 224578_at TD-60 2.90 2.39E-16 3. 85E-14 1. 86 13. 59 1 p36. 13 43 204192 at CD37-4.73 2.24E-17 5. 91E-15 -1. 77-13. 5419p13-q13. 4 44 226635_at-4. 13 1.62E-16 2.78E-14-1. 84-13.49 45 206398_s_at CD19 -13. 04 3. 63E-16 5.57E-14-1. 89-13. 48 16p11. 2 46236280at-10. 91 7. 32E-17 1. 41E-14 -1. 80-13.48 47 200853_at H2AFZ 3.32 6. 45E-17 1. 27E-14 1. 78 13. 47 4q24 48 209312_x_at HLA-DRB1 -3. 04 7.56E-21 8. 91E-18 -1. 61-13.47 6p21. 3 49 202503_s_at KIAA0101 29.94 5.71 E-15 5. 98E-13 2. 21 13. 45 15q22. 1 50 212589_at RRAS2 -7. 40 1. 02E-17 2. 98E-15-1. 72-13. 44 11 p15. 2 Table 2. 1-2.78 2.67 AML_komplext versus CML # affy id HUGO name fc stn t Map Location 1 210244 at CAMP-14. 07 5.78E-26 4.95E-22-2. 17-18.39 3p21. 3 2 212531_at LCN2 -5. 21 9.13E-27 1.56E-22-1. 81-16.35 9q34 3 203936_s_at MMP9 -9.17 2. 25E-25 1. 21E-21-1. 82-16.22 20q11. 2-q13. 1 4209772satCD24-7. 30 1.76E-24 6. 01 E-21-1. 79-15. 83 6q21 5207802atSGP28-11. 06 2.83E-25 1. 21E-21 -1.73 -15.58 6p12. 3 6 205557_at BPI-3. 43 6.31 E-24 1. 80E-20 -1.65 -14.88 20q11.23-q12 7 206676_at CEACAM8 -3.92 2.68E-23 6.55E-20-1. 60-14. 41 19q13. 2 8 203021 at SLPI-4. 25 4.98E-23 1.07E-19-1. 53-13.88 20q12 9 214575_s_at AZU1 -4.15 7.83E-21 1. 22E-17-1. 43-12. 94 19p13. 3 10 204971 at CSTA-3. 29 2.59E-21 4.93E-18-1. 42-12. 91 3q21 11 219281 at MSRA-2. 58 6.56E-21 1.12E-17-1. 39-12. 67 8p23.1 12 208699_x_at TKT -2.69 1. 40E-20 1. 99E-17 -1. 39-12. 62 3p14. 3 13 206440_at LIN7A -4.02 2.43E-20 2. 97E-17-1. 39-12. 5812q21 14 208650_s at CD24-3. 98 1.86E-20 2. 45E-17-1. 37-12. 45 6q21 15 266_s_at CD24 -3. 78 3.52E-20 4.02E-17-1. 35-12. 29 6q21 16 207384 at PGLYRP-10. 11 2.89E-17 1. 98E-14 -1.46 -12.16 19q13.2-q13. 3 17 216379_x_at KIAA1919 -3. 20 2.34E-18 2. 00E-15 -1. 36-12. 07 6q22 18 208651_x_at CD24 -3. 50 1.20E-19 1.29E-16-1. 32-12. 02 6q21 19 218454_at FLJ22662 -4. 49 3.53E-19 3. 56E-16-1. 31-11. 8512p13. 1 20 208645_s_at RPS14 -1.46 9.23E-19 8. 31E-16-1. 31-11.81 5q31-q33 21 206697_s_at HP-4. 56 2.66E-18 2. 16E-15-1. 31-11. 7016q22. 1 22223423atGPCR1-2. 95 8. 62E-19 8.19E-16-1. 29-11. 70 3q26.2-q27 23207269atDEFA4-3. 21 6.18E-18 4. 81E-15 -1.29 -11.57 8p23 24 209771_x_at CD24 -3. 01 5.56E-17 3.66E-14-1. 32-11. 53 6q21 25 203079_s_at CUL2 2. 94 1.33E-14 3. 05E-12 1.38 11.18 10p11. 21 26227929at-5. 70 1.44E-16 6.68E-14-1. 27-11. 11 27 236979_at -2. 76 1. 06E-17 7.88E-15-1. 22-11. 09 28 224573_at MGC49942-2. 08 1. 12E-17 7.96E-15-1. 22-11. 08 17p13. 2 29211890xatCAPN3-7. 57 2. 59E-16 1.08E-13-1. 27-11. 04 15q15.1-q21.1 30 205627_at CDA -5. 33 1.09E-16 5.69E-14-1. 25-11. 02 1 p36. 2-p35 31 203757_s_at CEACAM6 -3.41 6.36E-17 3.75E-14-1. 23-11. 01 19q13. 2 32 212586_at APTS-1 -2.88 1.29E-16 6. 28E-14 -1.24 -11.00 5q14. 3 33 208700 s at TKT-2. 15 5.99E-17 3.74E-14-1. 23-10. 99 3p14. 3 34 224818 at-3. 33 6.12E-17 3. 74E-14-1. 21-10. 85 35 200654_at P4HB -1.96 1.54E-15 5.50E-13 -1.25 -10.83 17q25 36 205863 at S10OA12-3. 12 9. 34E-17 5. 18E-14-1. 21-10. 821q21 37 208470_s_at HPR -9.27 3.83E-15 1.18E-12-1. 31-10. 7916q22. 1 38 223894_s_at FTS -3.10 1. 11E-16 5.69E-14-1. 20-10. 77 16q12. 1 39 218251_at STRAIT11499-2. 90 6.36E-16 2. 47E-13-1.23-10. 71 Xp11.4 40 206515_at CYP4F3-6. 88 1.87E-16 8.20E-14-1. 19-10. 65 19p13. 2 41 205653_at CTSG -2. 96 1.54E-16 6.94E-14-1. 18-10. 62 14q11. 2 42 220001_at PADI4 -5. 66 9. 87E-16 3. 67E-13 -1. 20-10. 561p36. 13 Table 2. 1-2.78 43 201904_s_at HYA22 -3. 37 1. 40E-16 6.63E-14-1. 17-10. 55 3p21. 3 44 201029 s at CD99 3. 55 1.08E-12 1. 08E-10 1. 44 10. 54 Xp22.32 45 214523_at CEBPE -4. 50 2.13E-15 7. 13E-13-1. 22-10. 53 14q11. 2 46 205538_at CORO2A -3.25 2. 48E-16 1. 06E-13-1. 17-10.52 9q22.3 47 219010_at FLJ10901-2. 61 1.13E-16 5.69E-14-1. 16-10. 521q31. 3 48 202442_at AP3S1-2. 09 9.38E-17 5.18E-14-1. 15-10. 51 5q22 49 206871 at ELA2-2. 76 2.09E-14 4. 40E-12-1.24-10. 4819p13. 3 50 212783_at RBBP6 2. 67 1. 91E-13 2. 70E-11 1.31 10.46 16p12-p11. 2 2.68 AML komplext versus norma ! BM # affyid HUGO name fc p q stn t Map Location 1 201595_s_at HT010 2.39 1. 81 E-14 4. 80E-10 1. 86 11. 99 2q32. 1 2 201437 s at EIF4E 3. 61 6. 14E-13 8. 17E-09 1.58 10.32 4q21-q25 3 201830_s_at NET1 5.96 4.48E-12 1. 52E-08 1. 66 10. 31 10p15 4 217812_aT HGRG8 2.09 5.57E-12 1. 52E-08 1.56 10.08 14q12-21 5 210396_s_at 2. 70 2.53E-12 1. 35E-08 1. 55 10. 03 6216652satZ30 2.24E-12 1. 35E-08 1.53 9.99 7 202265 at BM11 4. 75 6.27E-12 1. 52E-08 1.53 9.85 10p11. 23 8 200040-at-HG-KHDRBSI 1. 63 2.38E-12 1. 35E-08 1.50 9.84 1p32 U133A 9 200071_at - HG- SPF30 2.31 3. 41E-12 1. 51E-08 1.49 9. 78 10q23 U133A 10 201560_at CLIC4 4.23 6. 02E-12 1.52E-08 1.51 9. 74 1 p36. 11 11 218649_x_at SDCCAG1 2. 12 7. 76E-12 1. 57E-08 1. 49 9. 69 14q22 12 201994 at MORF4L2 1. 69 8.49E-12 1. 57E-08 1. 48 9. 66 Xq22 13 222035_s_at PAPOLA 2.26 8.37E-12 1. 57E-08 1.48 9.66 14q32. 31 14 212531 at LCN2-4. 74 2.67E-07 1.94E-05-1. 78-9. 61 9q34 15 201263_at TARS 2.47 5. 20E-12 1. 52E-08 1.47 9.60 5p13. 2 16 201699_at PSMC6 2.37 2. 61 E-11 3. 16E-08 1. 46 9. 44 14q22. 1 17 209388_at PAPOLA 2. 53 8.83E-12 1. 57E-08 1.44 9.44 14q32. 31 18 209806_at HIST1H2BK 4.07 2.52E-11 3.16E-08 1.48 9.44 6p21. 33 19 202018_s_at LTF -2. 61 4.60E-10 1. 97E-07-1. 50-9. 42 3q21-q23 20 208645_s_at RPS14 -1. 41 4.18E-09 8.99E-07-1. 54-9. 39 5q31-q33 21 214290_s_at HIST2H2AA 5.84 1.36E-11 2.27E-08 1.43 9.37 1q21. 2 22 211069_s_at UBL1 2.06 2. 21 E-11 3. 16E-08 1.44 9.31 2q33 23 201593 s at HT010 2. 54 1.80E-10 1. 09E-07 1. 44 9. 21 2q32.1 24218224atPNMA13. 91 6. 10E-11 5. 21E-08 1.46 9.21 14q24.1 25 200047 s at-YY1 1. 89 1.23E-10 8. 17E-08 1. 42 9. 13 14q HG-U133A 26 222430sat HGRG8 2.43 1. 98E-11 3. 11 E-08 1.39 9. 13 14q12-21 27 201548_s_at PLU-1 2.34 8.25E-11 6. 25E-08 1.40 9.10 1q32. 1 28 201077_s_at NHP2L1 1.62 2. 32E-11 3. 16E-08 1.39 9.09 22q13.2-q13. 31 29 218280_x_at HIST2H2AA 6.41 2. 92E-11 3. 36E-08 1.39 9.09 1q21. 2 30 209732 at CLECSF2 4. 12 3. 03E-11 3. 36E-08 1.39 9.07 12p13-p12 31 208843_s_at GORASP2 2.16 2. 55E-11 3. 16E-08 1. 38 9. 05 2p24. 3-q21. 3 32 201196sat AMD1 2.10 2.68E-10 1. 43E-07 1.40 8. 96 6q21-q22 33 218823 s at FLJ20038 2. 63 8. 45E-11 6. 25E-08 1.39 8.94 8p21. 1 34 218582_at FLJ20445 2. 37 4. 28E-11 4. 25E-08 1. 37 8. 93 10q23. 32 35 201917 s at FLJ10618 3. 25 4. 02E-11 4. 25E-08 1. 36 8. 90 3q23 36 202824_s_at TCEB1 2.12 4. 31E-11 4. 25E-08 1.35 8.88 8q13. 3 37 218478_s_at DKFZp434E2220 2.76 5. 50E-11 4. 88E-08 1.35 8.86 12q24. 31 38 229269_x_at ISYNA1 3. 54 5. 27E-11 4. 88E-08 1.35 8.85 19p13. 11 39 204299_at FUSIP1 3.12 5. 39E-11 4. 88E-08 1.35 8.83 1p36.11 40 202467_s_at TRIP15 1.95 5. 60E-10 2. 13E-07 1.38 8.82 15q21. 2 41209122atADFP5. 68 1.40E-10 8. 87-08 1.38 8.81 9p21. 3 42 209186_at ATP2A2 1.86 6. 44E-11 5.21 E-08 1. 34 8. 77 12q23-q24. 1 43 203582_s_at PAB4A 2.83 6. 47E-11 5.21 E-08 1.34 8.76 1q42-q43 44 203177_x_at TFAM 2.72 6. 85E-11 5. 36E-08 1.33 8. 73 10q21 45 208546_x_at HIST1H2BH 5.44 1.04E-10 7. 48E-08 1.34 8.72 6p21. 3 46214651satHOXA916. 40 4.99E-10 2.01 E-07 1. 45 8. 66 7p15-p14 47 204203_at CEBPG 2. 89 1.39E-10 8. 87E-08 1.33 8.63 19q13. 11 48 215009_s_at 3.30 1.23E-10 8. 17E-08 1.31 8.58 49 218936 s at HSPC128 2. 01 1.89E-10 1. 10E-07 1.31 8.56 12q21. 31 50 222000_at 2. 21 1. 21 E-10 8. 17E-08 1.30 8.54 2. 69 AML_t (15 ; 17) VERSUS AML-t (8; 21) # affy id HUGO name fc p q stn t Map Location 1 209732_at CLECSF2-31. 87 6. 61 E-16 1. 83E-11-3. 41-18. 50 12p13-p12 2 214450_at CTSW 32. 70 1. 75E-13 8. 07E-10 3.62 17.85 11q13. 1 3 38487_at STAB1 23. 73 4. 75E-13 1. 20E-09 3. 30 16. 70 3p21. 31 4211990atHLA-DPA1-11. 38 8. 43E-15 1. 17E-10-2. 54-15. 15 6p21. 3 5212509sat10. 56 1.02E-10 8. 07E-08 2. 39 1228 6 221004_s_at ITM2C 3.38 3. 94E-13 1. 20E-09 1.92 12.13 2q37 7 217478_s_at HLA-DMA -5. 37 1. 31 E-13 8. 07E-10-1. 90-12.10 6p21. 3 8 212953_x_at CALR 2.46 4. 33E-13 1. 20E-09 1.86 11.84 19p13.3-p13. 2 9 224839_s_at GRT2 9.84 6. 52E-11 6. 28E-08 2. 10 11. 80 16q12. 1 10 204150_at STAB1 26. 03 3.22E-10 1. 88E-07 2. 39 11. 71 3p21. 31 11 226878_at -5. 22 3.86E-12 7. 65E-09-1. 95-11.66 12 205663_at PCBP3 4.49 1. 54E-11 2. 38E-08 1.95 11.65 21q22. 3 13 201596_x_at KRT18 23. 76 3.19E-10 1. 88E-07 2. 32 11. 6312q13 14 204316 at RGS10-2. 58 2. 53E-13 8. 78E-10-1. 78-11. 47 10q25 15 205349_at GNA15 3. 44 3. 85E-11 4. 45E-08 1. 90 11. 2719p13. 3 16 211991 s at HLA-DPA1-17. 13 2. 84E-11 3. 58E-08-1. 96-11. 15 6p21. 3 17 208689_s_at RPN2 1.81 1. 12E-13 8. 07E-10t611080 20q12-q13. 1 18 209619_at CD74 -4. 53 1.48E-13 8. 07E-10-1. 62-10. 79 5q32 19 200986_at SERPING1 10. 67 1.48E-09 6. 06E-07 2.04 10.51 11q12-q13. 1 20 208826_x_aT HINT1 1.43 2. 32E-13 8. 78E-10 1.56 10. 48 5q31. 2 21227326at5. 21 3. 26E-10 1. 88E-07 1. 81 10. 47 22204319satRGS10-5. 48 8. 04E-11 7. 19E-08-1. 76-10. 3410q25 Table 2. 1-2.78 23 209312at HLA-DRB1-6. 71 1. 16E-11 1. 89E-08-1. 63-10. 33 6p21. 3 24201522xatSNRPN-3. 69 5.83E-13 1. 35E-09-1. 55-10.31 15q12 25 211474_s_at SERPINB6 -5.66 8. 59E-11 7.28E-08-1. 73-10.26 6p25 26 217716_s_at SEC61A1 1.98 7.38E-12 1. 36E-08 1.57 10.18 3q21. 3 27 228113_at STAT3-4. 67 2. 42E-11 3. 20E-08-1. 62-10. 1717q21 28 200953 s_at CCND2 2. 76 4. 76E-10 2. 49E-07 1. 73 10. 1 a 12p13 29 228827_at - 4. 47E-10 2. 43E-07-1. 98-10.04 103. 40 30 207721_x_at HINT1 1. 57 1.19E-12 2. 54E-09 1. 48 9. 94 5q31. 2 31 208306_x_at HLA-DRB4 -6. 81 4.41 E-11 4. 89E-08-1. 57-9. 88 6p21. 3 32 227353_at EVER2 -3. 90 1. 85E-11 2. 70E-08-1. 53-9. 8317q25. 3 33 201137_s_at HLA-DPB1 -12. 31 4.76E-10 2. 49E-07-1. 76-9. 82 6p21. 3 34 208852 s at CANX 2. 25 8. 79E-11 7. 28E-08 1.55 9.79 5q35 35 238022_at 4.12 1.01 E-11 1. 76E-08 1. 47 9. 70 36201923atPRDX4-6. 62 1.94E-10 1. 38E-07-1. 60-9. 69 up22. 13 37 218795 at ACP6-2. 77 4. 94E-11 5. 27E-08-1. 50-9. 561q21 38 206940_s_at 0POU44F1 -45.36 1.38E-09 5. 89E-07-1. 87-9. 4813q21. 1-q22 39 205614_x_at MST1 6.64 5.11E-09 1.56E-06 1.73 9.46 3p21 40 223321_s_at FGFRL1 4.08 3. 37E-09 1. 17E-06 1.65 9.40 4p16 41 205771_s_at AKAP7 -5. 88 1.70E-10 1.28E-07-1. 50-9.39 6q23 42 215193_x_at HLA-DRB1 -6. 64 5. 32E-11 5. 46E-08-1. 45-9. 35 6p21. 3 43 222307_at LOC282997-2. 74 3. 08E-11 3. 71 E-08-1. 43-9. 34 lOq25. 2 44 55093_at CSClcA-T 1.90 3.36E-10 1. 90E-07 1.49 9. 33 7q36.1 45 201952_at ALCAM 4.60 2.47E-09 9. 13E-07 1.58 9.27 3q13. 1 46 201136_at PLP2 2.92 7. 82E-11 7. 19E-08 1.42 9.25 Xp11. 23 47 221865_at DKFZp547P234-3. 09 8. 93E-11 7. 28E-08-1. 43-9.21 9q33.1 48 205529_s_at CBFA2T1 -14. 51 2.28E-09 8.69E-07-1. 73-9. 18 8q22 49 224356_x_at MS4A6A -6. 39 9. 01 E-10 4.23E-07-1. 55-9. 18 11 q12. 1 50 202732_at PKIG 2. 71 2.63E-09 9. 36E-07 1.55 9.17 20q12-q13. 1 2. 70 AML_t(15 ; 17) versus CLL # affyid HUGO name fc p q stn t Map Location 1 203949 at MPO 185. 37 3. 80E-18 5. 71E-16 6.90 32.46 17q23. 1 2 211990_at HLA-DPA1 -14. 20 1.95E-31 3.19E-27-4. 06-29. 46 6p21. 3 3 224838_at FOXP1 -8. 40 7.79E-29 2. 55E-25-4. 12-28.94 3p14. 1 4 203948_s_at MPO 410. 53 1.27E-16 1. 07-14 5.898 26.98 17q23. 1 5208306xatHLA-DRB4-12. 53 7.83E-31 5.38E-27-3. 49-25.84 6p21. 3 6 209619_at CD74 -7. 79 6.21 E-30 2.54E-26-3. 33-24.77 5q32 7 204670_x_at HLA-DRB5 -9. 72 9.86E-31 5. 38E-27-3. 26-24. 39 6p21. 3 8 200654 at P4HB 5. 99 3.09E-17 3. 24E-154. 07 24. 0317q25 9226905at8. 10 1. 11 E-26 2. 27E-23 3.30 23.99 10 206871_at ELA2 210. 99 1. 41 E-15 8. 83E-14 4.95 23.57 19p13. 3 11 206111_at RNASE2 31. 85 4. 97E-16 3. 48E-14 4.26 23.20 14q24-q31 12 224918_x_at MGST1 44.95 9. 91 E-16 6. 44E-14 4. 40 23. 0712p12. 3-p12. 1 Table 2.1-2. 78 13 217478_s_at HLA-DMA-13. 59 1.09E-24 1.99E-21-3. 30-22.98 6p21. 3 14 209312_x at HLA-DRB1-10. 89 2.87E-28 7.83E-25-3. 06-22.70 6p21. 3 15 41220_at MSF -2. 94 3.87E-27 9.05E-24-2. 86-21. 25 17q25 16 34210 at CDW52-66. 18 7.63E-22 6.25E-19-3. 26-21.11 1p36 17 212827_at IGHM-44. 65 1.50E-21 1.07E-18-3. 34-21. 0214q32. 33 18 208689_s_at RPN2 3.43 2. 19E-19 5. 96E-17 3. 08 20. 83 20q12-q13. 1 19 231736_x_at MGST1 44.46 1.11E-14 5. 11E-13 4.05 20. 6312p12. 3-p12. 1 20207168satH2AFY3. 54 2. 09E-19 5. 90E-17 3. 03 20.56 5q31. 3-q32 21 205382_s_at DF 33.58 4.18E-15 2. 26E-13 3. 65 20. 3419p13. 3 22 224833_at ETS1 -22.25 2.82E-21 1.77E-18-3. 08-20. 1411q23. 3 23 200650_s_at LDHA 3.22 1.52E-24 2. 49E-21 2.70 19.86 11p15. 4 24 224837_at FOXP1 -4.89 2. 41 E-23 3.59E-20-2. 71-19.48 3p14. 1 25 AFFX-GAPD 3. 56 3.26E-20 1. 41E-17 2.77 19.41 12p13 HUMGAPDH/M33 197 M at-HG- U133A 26 221004_s_at ITM2C 54.89 4.37E-14 1.58E-12 3.82 19.24 2q37 27 223514_at CARD11-52. 2E 4. 33E-20 1.77E-17-3. 11-19.07 7p22 28 212953 x at CALR 5. 80 3.56E-14 1. 34E-12 3. 56 18. 91 19p13. 3-p13. 2 29 200999_s_at CKAP4 -9. 47 4.73E-22 4.30E-19-2. 65-18. 7812q24. 11 30 221739 at IL27w 2. 89 4. 22E-18 6. 17E-16 2. 72 18. 50 19p13. 3 31 224482_s_at RAP11-FIP4 -24.78 4.58E-20 1.82E-17-2. 82-18.47 32 201029 s at CD99 2. 70 4.12E-18 6. 08E-16 2.69 18.34 Xp22. 32 33 202880_s_at PSCD1 -4. 54 3.63E-23 4. 95E-20-2. 40-17. 75 17q25 34 202863_at SP100 -5. 41 2.35E-21 1. 54E-18-2. 48-17. 72 2q37.1 35 212400 at-6. 06 1.26E-21 9. 34E-19-2. 46-17.71 36 203932_at HLA-DMB -12.97 1.01E-19 3. 11E-17-2. 64 -17.69 6p21. 3 37 243780 at 5. 14E-19 1. 14E-16-2. 86-17. 62 111. 12 38 204215 at MGC4175-5. 59 1. 43E-22 1. 67E-19-2. 40-17. 62 7q21. 1-q21. 2 39 AFFX-GAPD 3. 68 3.99E-17 4.01 E-15 2. 61 17. 58 12p13 HUMGAPDH/M33 197_M-at- HG- U133B 40 215193_x_at HLA-DRB1 -10.91 4.12E-23 5.18E-20-2. 37-17.54 6p21. 3 41 208091_s_at DKFZP564K0822 -26. 27 4. 79E-19 1. 07E-16-2. 76-17.53 7p14. 1 42 209374_s_at IGHM -37. 97 5.69E-19 1.22E-16-2. 80-17. 51 14q32.33 43 201137_s_at HLA-DPB1 -18.09 2.10E-19 5. 90E-17-2. 63-17. 45 6p21. 3 44 214450_at CTSW 21.74 1. 51 E-13 4. 37E-12 3. 25 17. 43 11 q 13. 1 45 AFFX-GAPD 5. 3 4. 11E-15 2. 25E-13 2.79 17.35 12p13 HUMGAPDH/M33 197 5 at-HG- U133A 46 236248_x_at -10.95 1.89E-20 9. 11E-18 -2. 46-17.31 47 211991_s_at HLA-DPA1 -30.06 3. 96E-19 9.39E-17-2. 62-17.26 6p21. 3 48 200663_at CD63 4.20 1.68E-17 2.01 E-15 2. 52 17. 25 12q12-q13 49 201012_at ANXA1 5.38 5.68E-20 2. 11E-17 2.40 17.23 9q12-q21. 2 50 215785_s_at CYFIP2 -11. 35 6. 61 E-20 2. 26E-17-2. 49-17. 21 5q34 Table 2.1-2. 78 2.71 AML-t (15; 17) versus CML affy id HUGO name fc p q stn t Map Location 1 212531_at LCN2 -60. 22 2. 31 E-32 7.69E-29-3. 79-28. 44 9q34 2 206676_at CEACAM8 6. 58E-32 1.82E-28-3. 87-28. 38#19q13. 2 107.43 3 205557_at BPI -34.93 1.91E-37 3. 18E-33-3. 35-27.65 20q11. 23-q12 4 209771_x_at CD24-29. 62 1.53E-36 1.28E-32-3. 28-26.99 6q21 5 201029_s_at CD99 6. 14 1.18E-18 1. 16E-16 4. 19 26. 60 Xp22.32 6 225386_s_at LOC92906 -57. 53 7.50E-31 1.56E-27-3. 55-26.52 2p22.2 7 216379_x_at KIAA1919-29. 35 5. 11 E-35 2.83E-31-3. 20-26.20 6q22 8207269atDEFA4-56. 93 3.35E-30 4.64E-27-3. 55-26.03 8p23 9 211657_at CEACAM6 -49. 93 3.31 E-30 4.64E-27-3. 54-26.01 19q13. 2 0202018satLTF-23. 29 5.42E-34 2.25E-30-3. 21-25.99 3q21-q23 11 203757_s_at CEACAM6 -62. 24 1. 01 E-28 1.05E-25-3. 33-24. 23 19q13. 2 12 205863_at S100A12-37. 30 5.83E-29 6.46E-26-3. 10-23. 651q21 13 204174_at ALOX5AP -22. 45 1. 10E-28 1.08E-25-3. 05-23. 228 13q12 14 201061_s_at STOM -6. 06 1.29E-30 2.15E-27-2. 78-22.52 9q34.1 15 203535_at S100A9 -14. 41 6.51 E-31 1.55E-27-2. 65-21. 73 1 q21 16 208650_s_at CD24 -62. 73 3.66E-27 3.08E-24-2. 87-21.73 6q21 17 266_s_at CD24 -50.68 4.56E-27 3.61 E-24-2. 79-21. 39 6q21 18 205786_s_at ITGAM -13. 53 3.18E-27 2.93E-24-2. 77-21. 36 16p11. 2 19 231688_at-72. 42 3.70E-26 2.46E-23-2. 87-21.11 20 200931_s_at VCL -7. 34 2.83E-29 3. 61 E-26-2. 59-21.04 10q22. 1-q23 21 223423_at GPCR1 -13. 88 1. 19E-30 2.15E-27-2. 52-20.86 3q26.2-q27 22 210244_at CAMP-65, 83 9.06E-26 5. 79E-23-2.71-20. 40 3p21. 3 23 208771_s_at LTA4H -6. 03 3.70E-27 3.08E-24-2. 57-20. 3712q22 24 207802 at SGP28 6. 05E-25 2.96E-22-2. 79-19.98 6p12. 3 202. 73 25 209772sat CD24-55. 58 2.07E-25 1. 19E-22-2. 60-19. 79 6q21 26203467atPMM1-9. 53 3.22E-29 3.82E-26-2. 37-19.65 22q13. 2 27 203936_s_at MMP9 -27. 67 5.03E-25 2.53E-22-2. 59-19.56 20q11.2-q13. 1 28201669satMARCKS-81. 40 1.88E-24 8.43E-22-2. 73-19.47 6q22.2 29 209396_s_at CHI3L1 -29. 06 5. 71E-24 2.16E-21-2. 54-18. 76 1q32. 1 30 205382_s_at DF 8. 73 3.25E-14 1. 02E-12 3.31 18.64 19p13. 3 31 209369_at ANXA3 -41.03 6.42E-24 2.37E-21-2. 49-18.61 4q13-q22 32 201060_x_at STOM -5. 63 3.46E-25 1.85E-22-2. 33-18.49 9q34. 1 33 208651_x_at CD24 -21. 00 5.26E-27 3.97E-24-2. 22-18.30 6q21 34 217762_s_at RAB31 -19. 66 1.80E-25 1. 07E-22-2. 28-18. 29 18p11. 3 35 218454_at FLJ22662 -56. 46 3.33E-23 1.06E-20-2. 54-18. 19 12p13. 1 36 208700_s_at TKT -3. 61 1.57E-26 1.13E-23-2. 19-18. 07 3p14. 3 37 230006_s_at DKFZp313A2432 -7.51 1. 37E-23 4.95E-21-2. 32-17. 8311p14. 2 38 204411 at KIAA0449-29. 07 2. 11E-23 7.06E-21-2. 33-17. 801pter-q31. 3 39 226278_at DKFZp313A2432-6. 55 2. 30E-23 7.50E-21-2. 30-17. 6611p14. 2 40 226726_at LOC129642-9. 79 1. 89E-23 6. 70E-21-2. 22-17. 33 2p25. 2 Table 2.1-2. 78 41 205033_s_at DEFA1 -8.45 3.34E-26 2.31 E-23-2.08-17. 24 8p23.2-p23. 1 42 38487_at STAB1 42.93 4.97E-13 1.15E-11 3. 68 17. 15 3p21. 31 43 221004_s_at ITM2C 8.10 1.98E-13 5. 06E-12 3. 03 17. 00 2q37 44 217764_s_at RAB31 -12.08 3.65E-25 1. 90E-22-2. 07-16. 98 18P11. 3 45 227353_aT EVER2 -5.69 1. 19E-25 7.34E-23-2. 05-16. 9817q25. 3 46 208438_s_at FGR-22. 54 2.05E-24 8.97E-22-2. 09-16. 95 1p36. 2-p36.1 47 205237_at FCN1-10. 52 2.12E-23 7. 06E-21-2. 10-16. 76 9q34 48 219938_s_at PSTPIP2 -6.40 2.97E-24 1.23E-21-2. 06-16. 75 18q12 49 223663 at FLJ37970-10. 56 3.42E-25 1.85E-22-2. 03-16. 7511q12. 3 50 211275_s_at GYG -3.80 2.79E-24 1. 19E-21 -2. 02-16.59 3q24-q25.1 2.72 AML_t (15; 17) versus normal # affy id HUGO name fc p q stn t Map Location 1 202018_s_at LTF-24. 63 5. 91 E-09 1.27E-06-5. 08-20.53 3q21-q23 2 205382_s_at DF 13.86 1.72E-14 9. 80E-11 4. 02 19. 61 19p13. 3 3 201029_s_at CD99 4.09 5.79E-17 7.53E-13 3.64 19.53 Xp22.32 4 221004_s_at ITM2C 11. 07 7.35E-14 1. 91 E-10 3. 51 17. 53 2q37 5 223280_x_at MS4A6A -16. 24 5.22E-08 4.75E-06-4. 57-17. 3811q12. 1 6 205771_s_at AKAP7 -10.87 1.54E-08 2.25E-06-3. 98-16. 87 6q23 7 203535_at S100A9 -15.49 2.66E-08 3.20E-06-3. 97-16. 53 1q21 8 38487 at STAB1 13. 31 6.68E-13 1. 09E-09 3.26 16.02 3p21. 31 9 212953 x at CALR 3. 79 2.26E-14 9. 80E-11 2.91 15.45 19p13.3-p13. 2 10 214450_at CTSW 9.27 5.15E-14 1. 67E-10 2.86 15.15 11q13. 1 11 207721_x_at HINT1 2.10 1. 06E-13 2. 29E-10 2. 83 15. 05 5q31. 2 12 238022 at 13. 68 2. 66E-12 3. 14E-09 2. 91 14. 53 13 224356_x_at MS4A6A -16. 43 4.75E-07 2. 31E-05-3. 96-14.02 11q12. 1 14 217047_s_at FAM13A1 -4.12 1.03E-09 3. 28E-07-2. 83-13.89 4q22.1 15 212531_at LCN2-54. 83 7. 71 E-07 3. 13E-05-4. 12-13. 56 9q34 16205624atCPA38. 50 2. 87E-11 2. 33E-08 2.77 13.33 3q21-q25 17 204393_s_at ACPP -6. 05 3.22E-07 1. 71 E-05-3. 25-13. 1 C 3q21-q23 18 205349_at GNA15 7. 54 5.94E-13 1. 09E-09 2.43 13.00 13p13. 3 19 210192_at ATP8A1 -4. 38 2.28E-08 2.94E-06-2. 78-12.93 4p14-p12 20226301atdJ55C23. 6-6. 71 8.32E-08 6.40E-06-2. 91-12. 89 6q22.3-q23. 3 21226326at-3. 43 2. 55E-12 3 14E-09-2. 39-12. 76 22 208826_x_at HINT1 1.78 3.47E-09 8. 35E-07 2.61 12.75 5q31. 2 23225792at-7. 31 3.87E-07 1. 96E-05-3.10-12. 64 24 205033 s at DEFA1-10. 12 2.95E-07 1. 60E-05-3.02-12. 60 8p23.2-p23. 1 25 231736_x_at MGST1 3.44 1.16E-12 1. 68E-09 2.31 12.42 12p12.3-p12. 1 26 218262 at FLJ22318-3. 72 2.46E-07 1. 40E-05-2.88-12. 33 5q35.3 27 224975_at NFIA-7. 37 1. 88E-07 1. 18E-05-2.81-12. 251p31. 3-p31. 2 28 239278 at-3. 94 4.24E-08 4. 20E-06-2.63-12. 23 29 224918_x_at MGST1 3. 04 4.25E-12 4.28E-09 2.28 12. 21 12p12. 3-p12. 1 30 202917_s_at S100A8 -5. 02 2. 03E-08 2. 69E-06-2. 53-12. 06 1 q21 131 1206488 s at CD36-6. 23 4. 60E-09 1.07E-06 -2.41 -1.92 7q11. 2 Table 2.1-2. 78 32 204057 at ICSBP1-4. 98 7. 91 E-07 3. 19E-05-2. 94-11. 84 16q24. 1 33 203645 s at CD163-15. 20 1.58E-06 5. 14E-05-3. 23-11. 83 12p13. 3 34 208612_at GRP58 2. 22 4.28E-12 4. 28E-09 2.18 11.73 15q15 35 200093_s_at- HINT1 1.93 8. 15E-11 5. 64E-08 2.21 11.62 5q31. 2 HG-U133A 36 204150at STAB1 17. 25 4. 75E-10 1. 93E-07 2. 45 11. 48 3p21. 31 37 228056_s_at NAP1L -30. 30 2. 37E-06 6. 72E-05-3. 26-11. 4719q13. 33 38 212989_at MOB -5. 21 4.76E-08 4. 42E-06-2. 41-11. 43 10q 39 201596_x_at KRT18 16. 21 4. 24E-10 1. 80E-072*3511. 3612q13 40 212509_s_at 8.35 5. 37E-11 4. 11E-08 2.16 11.32 41 217225_x_at LOC283820 2.26 1. 09E-11 1. 01 E-08 2. 10 11. 27 16p13. 13 42 224839_s_at GPT2 10. 99 2. 68E-11 2. 33E-08 2. 12 11. 2716q12. 1 43 226726 at LOC129642-6. 34 1.37E-06 4. 67E-05-2. 82-11. 23 2p25. 2 44 202443_x_at NOTCH2 -3.60 3. 78E-10 1. 75E-07-2. 15-11. 19 1 p13-p11 45 202973_x_at FAM13A1 -4.50 8.08E-08 6. 25E-06-2. 38-11.19 4q22. 1 46 238365_s_at 6.97 8. 25E-11 5. 64E-08 2.13 11. 13 47 238949 at FLJ31951-8. 08 5.54E-07 2. 57E-05-2. 55-11. 06 5q33. 3 48 225923_at -2. 35 2. 04E-10 1.20E-07-2. 08-10.99 49 201028_s_at CD99 6.61 3.88E-10 1. 75E-07 2. 17 10. 95 Xp22. 32 50 221030_s_at DKFZP564B1162 -3.11 7.11E-08 5.92E-06 -2.30 -10.94 4q21.3 2.73 AML_T(8;21) versus CLL # affy id HUGO name fc p q stn t Map Location 1 224838_at FOXP1 -5.50 3. 08E-29 5. 98E-25-3. 45-25.79 3p14. 1 2 203949_at MPO 170. 08 1. 32E-17 2. 65E-15 4. 32 22. 3717q23. 1 3 212827_at IGHM -24. 48 1. 51 E-21 1. 63E-18-3. 08-20. 47 14q32. 33 4 41220_at MSF -2. 73 4. 89E-28 4.76E-24-2. 60-20. 27 17q25 5202880satPSCD1-6. 98 2. 81 E-25 1.36E-21-2. 56-19. 54 17q25 6225927at-3. 79 1.38E-25 8.96E-22-2. 43-18.79 7 201811 x at SH3BP5-12. 98 1. 33E-20 9.55E-18-2. 62-18.25 3p24.3 8 223514_at CARD11 -23. 71 7.87E-21 6. 38E-18-2. 52-17. 94 7p22 9 208091_s_at DKFZP564K0822 -44.18 3. 04E-19 1. 21E-16 -2. 81-17. 82 7p14. 1 10 211962_s_at ZFP36L1-7. 08 9.25E-23 2. 00E-19 -2. 33-17. 63 14q22-q24 11 224833_at ETS1 -9. 61 3.53E-22 5. 28E-19-2. 34-17.51 11q23. 3 12-224837_at FOXP1-3. 36 2.83E-21 2. 76E-18-2. 33-17. 22 3p14. 1 13 243780 at-33. 46 7. 68E-19 2.62E-16-2. 66-17.18 14 218191_s_at FLJ11240 -3. 53 4.54E-24 1.77E-20-2. 21-17.18 6q12 15 212590_at RRAS2-12. 74 1.37E-18 4.16E-16-2. 60-16. 8511p15. 2 16 227979_at -3. 31 3. 35E-23 9. 31 E-20-2. 17-16.74 17 208864_s_at TXN 6.14 2. 09E-16 2. 58E-14 2.53 16. 69 9q31 18 218029_at FLJ13725 -4. 76 1. 12E-22 2. 17E-19-2. 16-16. 59 16q21 19 205105_at MAN2A1 -4. 18 4.78E-22 6. 64E-19-2. 16-16. 46 5q21-q22 20208456satRRAS2-32. 68 3. 36E-18 8. 61 E-16-2. 52-16. 37 11 p15. 2 21 226454_at LOC92979 -5. 08 4. 03E-19 1. 45E-16-2. 33-16. 36 12q13. 13 Table 2.1-2. 78 22 209075_s at NIFU-3. 12 3.87E-23 9.40E-20-2. 11-16. 3612q24. 1 23 234734 s at TNRC6-3. 21 3.05E-23 9. 31E-20-2. 10-16. 34 16p11. 2 24 212589_at RRAS2 -28.79 5. 46E-18 1.29E-15-2. 54-16. 23 11p15. 2 25 216095_x_at MTMR1 -5. 27 1.77E-20 1. 11 E-17-2. 18-16. 21 Xq28 26 224579_at -6. 33 7.92E-20 4. 05E-17-2. 22-16.20 27 204118_at CD48 -5. 82 1. 09E-20 8. 18E-18-2. 15-16. 121q21. 3-q22 28 203948 s at MPO 300. 08 2.40E-14 1. 25E-12 3.15 16. 0617q23. 1 29 212313_at MGC29816 -7.09 2. 74E-19 1. 11E-16 -2. 23-16.03 8p21. 2 30 219869_s_at BIGM103 6. 2g 5. 31E-15 3. 60E-13 2.62 16.01 4q22-q24 31 221718 s at AKAP13-3. 37 1. 39E-22 2. 45E-19-2. 04-15. 88 15q24-q25 32 226538 at-5. 38 1. 12E-19 4. 82E-17-2. 14-15. 75 33 218237_s_at SLC38A1 -5. 76 9.56E-20 4. 43E-17-2. 12-15. 65 12qu2 34 39582 at-5. 14 5.89E-21 5. 20E-18-2. 06-15.65 35 208657 s at MSF-5. 47 1. 38E-19 5.83E-17 -2. 12-15. 63 17q25 36212386at-20. 38 1. 59E-17 3. 10E-15-2. 42-15.62 37 213151_s at CDC10-2. 15 2. 85E-22 4.62E-19-2. 00-15. 59 7p14. 3-p14. 1 38 204951_aT ARHH -6.59 3. 36E-19 1.26E-16-2. 14-15. 56 4p13 39 234140_s_at STIM2 -6. 45 5. 25E-18 1. 28E-15-2. 24-15.45 4p15. 2 40 225246_aT STIM2 -7. 51 2. 32E-18 6.09E-16-2. 17-15.40 4p15. 2 41 211084_x_at PRKCN -8.56 1. 08E-19 4. 80E-17 -2.06 -15.32 2p21 42207000satPPP3CC-5. 62 1. 81E-18 5. 02E-16-2. 13-15. 25 8p21. 2 43 211709_s_at SCGF 39. 67 7.60E-14 3. 21E-12 2.92 15. 22 19q13. 3 44 228390_at -32. 75 4. 33E-17 7.20E-15-2. 40-15. 22 45 44790_s_at C13orf18 -46.55 6. 00E-17 9. 41 E-15-2. 44-15. 12 13q14. 11 46227261atKLF12-8. 19 2. 09E-18 5. 56E-16-2. 10-15. 10 13q22 47 214615_at P2RY10 -9.48 3. 73E-18 9.42E-16-2. 12-15.08 Xq21. 1 48 217941 s at ERBB21P-2. 81 7. 24E-22 9. 39E-19-1. 93-15. 06 5q12. 2 49 218236 s at PRKCN-12. 62 1. 05E-17 2.17E-15-2. 16-15. 04 2p21 50 223287_s_at FOXP1 -4.70 3.02E-18 7.82E-16 -2.10 -15.04 3p14.1 2.74 AML_t(8;21) versus CML # affy id HUGO name fc p q stn t Map Location 1225386satLOC92906-12. 32 3.21 E-32 6.78E-28-2. 43-20.92 2p22.2 2 207802 at SGP28 - 5.80 E-25 2.04E-21-2. 78-19. 99 6p12. 3 239.28 3 201425at ALDH2-12. 66 2. 95E-30 3. 11 E-26-2. 33-19.91 12q24.2 4203936satMMP9-11. 57 2. 49E-25 1.05E-21-2. 10-17. 48 20q11. 2-q13. 1 5 210244_at CAMP-10. 52 8. 63E-26 6.07E-22-1. 98-16. 83 3p21. 3 6 202391_at BASP1-9. 03 1. 64E-25 8. 66E-22-1. 97-16. 72 5p15. 1-p14 7 218454_at FLJ22662-12. 67 2. 58E-23 5.45E-20 -1.92 -15.96 12p13. 1 8 205653_at CTSG -6.90 7. 36E-25 2.22E-21-1. 85-15. 83 14q11. 2 9 208091_s_at DKFZPS564K0822 -6. 86 3.77E-24 9.95E-21-1. 85-15.70 7p14. 1 10 201700 at CCND3-3. 45 8. 94E-24 2. 09E-20-1. 77-15.16 6p21 11 200985_s_at CD59 -6.92 7. 39E-23 1. 30E-19 -1.76 -14.92 11p13 Table 2. 1-2.78 12 208438_s_at FGR -5. 53 2.74E-21 3. 21E-18-1. 75-14. 54 1p36. 2-p36.1 13 224595 at CDW92-6.63 6.18E-23 1. 18E-19-1. 68-14. 44 9q31. 2 14 224596_at CDW92 -6. 23 1.70E-22 2.77E-19-1. 67-14.35 9q31. 2 15 230006_s_at DKFZp313A2432 -4. 72 1.99E-22 2.99E-19-1. 67-14. 3211p14. 2 16 220558_x_at PHEMX -2. 68 3. 10E-22 4.35E-19-1. 66-14.21 11 p15. 5 17 213908 at-566 2.96E-21 3. 21E-18 -1. 68-14.16 18 212531_at LCN2 -4.85 1. 90E-19 1.25E-16-1. 72-14.15 9q34 19 202119_s_at CPNE3 -6.40 2.54E-21 3. 21E-18-1. 61-13. 72 8q21. 13 20 200983_x_at CD59 -6. 13 3.03E-21 3. 21E-18 -1. 60-13. 65 11p13 21 233467_s_at PHEMX -2. 93 3.05E-21 3. 21E-18-1. 56-13. 40 11p15. 5 22 230285_at DKFZp313A2432 -4. 48 9.77E-21 8.96E-18-1. 57-13. 39 11 p14. 2 23 205237_at FCN1 -6. 12 3.38E-21 3.39E-18-1. 56-13.38 9q34 24 227019_at -3.17 7. 45E-21 7.14E-18-1. 56-13.34 25 221581_s_at WBSCR5 -6.46 3. 65E-19 2.14E-16-1. 61-13. 22 7q11. 23 26 209395_at CHI3L1 -13.40 2.63E-19 1. 63E-16-1. 58-13.11 1q32. 1 27 219010_at FLJ10901-3. 67 1. 81 E-20 1.53E-17-1. 53-13.11 1 q31. 3 28 210254_at MS4A3 -2. 64 1.68E-18 7. 70E-16-1. 57-13. 05 llql2 29 226278 at DKFZp313A2432-3 9E 1.79E-20 1. 53E-17 -1.50 -12.94 11p14. 2 30217963satNGFRAP1-19. 46 1.63E-17 5. 14E-15-1. 66-12.81 Xq22.1 31 235044_at CYYR1 -7. 78 1.63E-18 7.66E-16-1. 56-12. 80 21q21. 2 32 200984_s_at CD59-4. 56 8. 10E-19 4.40E-16-1. 54-12. 80 11p13 33 211178_s_at PSTPIP1 -3. 95 4.37E-20 3. 54E-17-1. 49-12. 79 15q24-q25. 1 34 213353_at ABCA5-3. 37 5.16E-20 4. 03E-17-1. 49-12.75 17q24.3 35 210146_x_at LILRB2 -7. 53 1.73E-18 7.76E-16-1. 53-12. 67 19q13. 4 36 206515_at CYP4F3 -12. 82 6.16E-18 2. 17E-15-1. 57-12. 67 19p13. 2 37 209396_s_at CHI3L1 -7.09 1.23E-19 8. 91E-17-1. 48-12. 64 1q32. 1 38 236979 at-3. 19 1. 41 E-19 9. 59E-17-1. 48-12.64 39 205627_at CDA -9.39 1.94E-18 8.53E-16-1. 52-12.58 1p36. 2-p35 40 207814_at DEFA6 -5.20 1.39E-19 9.59E-17-1. 46-12. 54 8pter-p21 41 229373_at -2. 95 1.12E-19 8. 45E-17 -1.45 -12. 48 42227236atTSPAN-2-10. 33 2.22E-18 9. 57E-16 -1.49 -12.46 1p12 43 212463_at -4.90 8. 39E-19 4. 43E-16-1. 46-12.36 44 219014_at PLAC8 -2.98 2.34E-19 1.49E-16-1. 44-12.34 4q21. 3 45 225009_at CKLFSF4-3. 8 3.56E-19 2.14E-16-1. 43-12. 2616q21 46212828atSYNJ2-3. 60 1. 42E-18 6. 80E-16 -1.44 -12.22 6q25.3 47 208771_s_at LTA4H -2. 59 7.30E-19 4. 16E-16-1. 41-12.08 12q22 48 206440_at LIN7A -5. 17 1.19E-18 5. 98E-16-1. 41-12. 0712q21 49 202006_at PTPN12 -3. 03 8.14E-19 4. 40E-16-1. 40-12. 04 7qu 1. 23 50 203922_s_at CYBB -7. 48 6. 11 E-17 1.59E-14-1. 50-12.04 Xp21. 1 2.75 AML_t (8; 21) versus normalBM # affy id HUGO name fc p q stn t Map Location 1 227041_at -3.68 4. 06E-13 2.02E-09-2. 67-14.96 2 201425_at ALDH2-11. 12 8. 11E-09 2. 88E-06-3. 09-14. 81 12q24. 2 Table 2.1-2. 78 3 206488_s_at CD36 -6.91 7. 14E-08 1. 17E-05-3. 00-13. 60 7q11. 2 4 212828 at SYNJ2-3. 49 5.73E-09 2.31 E-06-2. 59-13. 09 6q25. 3 5 227388 at-4. 89 1.16E-07 1.65E-05-2. 84-12. 89 6 209122 at ADFP 4. 63 5.55E-14 8. 28E-10 2.19 12.73 9p21. 3 7 208690_s_at PDLIM1 5.84 2.48E-12 9. 26E-09 2.18 12.12 10q22-q26. 3 8 225923_at -2.49 6.95E-11 1.29E-07-2. 15-11. 96 209732 at CLECSF2 3. 71 3.76E-13 2. 02E-09 2. 03 11. 81 12p13-p12 10225792at-5. 22 5.78E-07 4. 74E-05-2. 73-11. 77 11 224975_at NFIA -5. 91 1.88E-07 2.16E-05-2. 48-11. 62 1p31.3-p31. 2 12228056satNAP1L-32. 93 2.60E-06 1. 16E-04-3. 43 -11.56 19q13. 33 13 208146_s_at CPVL -17. 78 2.12E-06 1.03E-04-3. 14-11.51 7p15-p14 14 204767-s-at FEN1-2. 47 9. 17E-10 7.19E-07-2. 06-11. 25 11q12 15 226301_at dJ55C23. 6-4.23 6. 80E-08 1. 15E-05-2. 20-10.98 6q22.3-q23. 3 16 218262 at FLJ22318-3. 19 7.77E-08 1.22E-05-2. 14-10.76 5q35.3 17 213908_at -3. 85 5.90E-08 1. 04E-05-2. 12-10. 72 18 240572_s_at -4. 51 6. 69E-07 5. 23E-05-2. 26-10. 45 19 208091_s_at DKFZP564K0822 -7. 91 2.35E-06 1. 08E-04-2. 49 -10.38 7p14.1 20 201506_at TGFBI -15. 58 4.90E-06 1.70E-04-2. 83-10. 36 5q31 21 217815_aT SUPT16H -1. 91 2. 54E-11 6. 32E-08 -1. 79-10. 35 14q11. 1 22 226806_s_at -7.79 3.36E-06 1. 37E-04-2. 59-10. 32 23 212419_at FLJ90798 -3.25 1. 44E-08 3.91 E-06-1. 92-10. 22 10q22. 3 24 224976_at NFIA-4. 62 1.64E-06 8. 85E-05-2. 30-10. 161p31. 3-p31. 2 25 238756_at -4. 87 2.98E-06 1.26E-04-2. 42-10. 09 26 207243_s_at CALM2 -1.89 1. 39E-10 2.30E-07-1. 76-10. 08 2p21 27 217047_s_at FAM13A1 -2.45 6.67E-09 2. 62E-06-1. 84-10. 03 4q22. 1 28 209545_s_at RIPK2 2.56 2. 29E-11 6. 32E-08 1.72 10.01 8q21 29 228827_at 67. 21 4. 96E-10 5. 28E-07 1.98 9.99 30 239278_at -3.07 1.75E-08 4.29E-06-1. 87 -9.98 31 223044 at SLC11A3-6. 37 1.29E-06 7.57E-05-2. 18-9. 95 2q32 32 200833_s_at RAP1B -2.05 3.87E-09 1.98E-06-1. 80 -9.90 12q14 33 226326_at-2. 61 5.16E-11 1. 10E-07-1. 70-9. 89 34 202443_x_aT NOTCH2 -2.59 5. 05E-09 2. 09E-06-1. 78-9. 821p13-p11 35 201015_s_at JUP 19. 68 5. 54E-10 5. 50E-07 1.83 9.78 17q21 36 213624_aT ASM3A -5. 01 3.32E-06 1.36E-04-2. 30 -9.77 6 37 236297 at-3. 05 9.94E-07 6.42E-05-2. 05-9. 68 38 208908_s_at CAST -3. 55 1.54E-07 1. 93E-05-1. 89-9.66 5q15-q21 39 223515_s_at COQ3 -2.13 1.17E-09 8.28E-07-1. 69-9. 54 6q16. 3 40236305atLOC317671-4. 66 3.60E-06 1.45E-04-2. 18-9. 47 41 202018_s_at LTF -3. 03 2.95E-10 3.66E-07-1. 64-9.45 3q21-q23 42223256atFLJ20333-2. 34 7.40E-08 1. 19E-05 -1.79 -9.45 14q12 43 202561_at TNKS -2. 21 1.26E-09 8.56E-07-1. 66-9.40 8p23.1 44 206940_s_at POU4F1 29.25 1.70E-09 1. 08E-06 1. 81 9. 3513q21. 1-q22 45 204057_at ICSBP1 -2. 97 1.33E-06 7. 73E-05-1. 96-9. 3016q24. 1 46 226460_at KIAA1450 -2. 86 1.73E-07 2.06E-05-1. 79 -9.27 4q32.1 47 201988_s_at CREBL2 -1. 93 9.37E-09 3.12E-06-1. 67-9.23 12p13 48217846atQARS1*62 6. 59E-10 5. 78E-07 1.61 9.22 3p21.3-p21. 1 Table 2. 1-2.78 49 209054sat WHSC1-2. 25 6.35E-08 1. 10E-05 -1. 72-9. 17 4p16. 3 50 201029_s_at CD99 3.20 2. 46E-10 3. 39E-07 1. 58 9. 17 Xp22. 32 2. 76 CLL versus CML # affy id HUGO name fc p q stn t Map Location 1 206871 at ELA2 - 1.06E-35 1.75E-32-4. 68-34. 4519p13. 3 240.77 2 212268_at SERPINB1 -9. 53 2.70E-42 3.99E-38-3. 87-33. 91 6p25 3 210254_at MS4A3 -56. 91 2. 43E-35 3.59E-32-4. 01-31. 87 11q12 4 205557 at BPI-83. 16 4.03E-34 3.73E-31-4. 04-31.07 20q11. 23-q12 5 203949_aT MPO - 4. 55E-33 3. 21 E-30-4. 19-30. 37 17q23. 1 162.81 6 200654_at P4HB-5. 02 1. 63E-40 1.20E-36-3. 42-30. 3217q25 7 213572_s_at SERPINB1 -6. 93 3. 67E-38 1. 81E-34-3. 42-29. 68 6p25 8 202503_s_at KIAA0101 -37.72 6.41 E-32 3.06E-29-3. 84-28. 46 15q22. 1 9 224838_at FOXP1 6.62 1.88E-27 3. 30E-25 3.84 28.37 3pu4. 1 10206676atCEACAM8-72. 60 2. 86E-32 1. 51E-29 -3.60 -28.04 19q13. 2 11 206111_at RNASE2 -45.25 3. 07E-32 1. 57E-29-3. 59-27. 9814q24-q31 12 209619_aT CD74 5.87 4. 99E-36 1.21 E-32 3. 16 27.73 5q32 13 212531 at LCN2-45. 41 1. 94E-33 1.43E-30-3. 37-27. 72 9q34 14204670xatHLA-DRB56*98 4.97E-31 1. 99E-28 3. 28 27. 25 6p21. 3 15 211657_at CEACAM6 -50. 24 2.89E-30 8. 53E-28-3. 45-25. 9919q13. 2 16 207269 at DEFA4-48. 94 9.09E-31 3.05E-28-3. 24-25. 65 8p23 17 208306_x_at HLA-DRB4 7.48 3.61 E-29 8. 75E-27 3. 13 25. 65 6p21. 3 18 201061_s_at STOM -14.74 5.26E-33 3.53E-30-3. 00-25.47 9q34.1 19 214575_s_at AZU1 - 2.96E-29 7.53E-27-3. 53-25. 09 19p13. 3 236. 51 20 202018sat LTF-22. 71 1. 05E-35 1.75E-32-2. 82-25. 02 3q21-q23 21 202252_at RAB13 -11. 58 6. 31 E-31 2.39E-28-3. 06-24. 97 1q21. 2 22208864satTXN-7. 21 2.75E-34 2.71 E-31-2.85-24. 92 9q31 23208700satTKT-8. 05 4.28E-37 1.26E-33-2. 76-24. 87 3p14. 3 24 202589_at TYMS -40. 46 6.71 E-29 1.50E-26-3. 32-24. 47 18p11. 32 25 203675_at NUCB2 -40.18 4.55E-29 1. 05E-26-3. 24-24. 45 11p15.1-p14 26 203757_s_at CEACAM6 -93.21 8. 45E-29 1. 81 E-26-3. 32-24. 37 19q13. 2 27 211275_s_at GYG -6. 92 1. 10E-31 4.95E-29-2. 88-24. 33 3q24-q25.1 28 201554_x_at GYG -10.43 5. 72E-31 2.23E-28-2. 88-24. 03 3q24-q25. 1 29 205653 at CTSG - 2. 60E-28 5.19E-26-3. 34-23. 88 14q11. 2 125.96 30 201432at CAT-5. 01 1.40E-37 5.19E-34-2. 60-23. 77 11p13 31 208308_s_at GPI -5.19 6.27E-32 3. 06E-29-2. 76-23. 69 19q13. 1 32 203948_s_at MPO - 4. 50E-28 8.76E-26-3. 30-23. 5917q23. 1 273.73 33 202487sat H2AV-4. 05 1. 26E-32 7. 46E-30 -2.70 -23.56 7p13 34 203021_at SLPI-24. 64 2. 43E-28 4. 93E-26-3. 08-23 46 20q12 35 202441_at KEO4 -10.82 3. 95E-29 9. 42E-27-2.93-23. 4310q21-q22 36 210140_at CST7 -11.66 1. 41 E-30 4.50E-28-2. 76-23. 28 20p11. 21 Table 2. 1-2. 78 37 226905_at -11. 36 1. 49E-33 1. 16E-30-2.60-23. 08 38 208699_x_at TKT -10. 41 8.12E-34 7. 06E-31-2. 58-22.99 3p14. 3 39 41220_at MSF 2.59 1. 85E-31 7. 97E-29 2. 59 22.78 17q25 40 210613_s_at SYNGR1-22. 2S 6.96E-29 1.54E-26-2. 77-22.63 22q13. 1 41 225927 at 4. 67 8.70E-25 8. 46E-23 2. 92 22.56 42201012atANXA1-7. 02 5. 73E-36 1. 21E-32-2. 43-22.30 9q12-q21. 2 43 205513_at TCN1 -40.38 3.43E-27 5.58E-25-2. 94-22.21 11q11-q12 44 204351_at S100P -18. 25 1.49E-30 4. 60E-28-2. 55-22.06 4p16 45 209312_x_at HLA-DRB1 6. 36 6.49E-27 1. 01 E-24 2. 65 22. 01 6p21. 3 46 201663_s_at SMC4L1 -4. 55 7.78E-31 2.74E-28-2. 50-21. 78 3q26. 1 47 219076_s_at PXMP2 -6.65 3.14E-30 8.98E-28-2. 51-21.71 12q24.33 48 201060_x_at STOM -17. 56 3.08E-27 5. 11 E-25-2. 76-21.71 9q34.1 49 221952_x_at KIAA1393 -2.49 1. 13E-33 9.24E-31-2. 38-21. 56 14q23. 1 50 AFFX-GAPD-3. 70 6. 01E-35 8.08E-32-2. 35-21. 51 12p13 HUMGAPDH/M33 197 M at-HG- U133A 2. 77 CLL versus normal # affy id HUGO name fc p q stn t Map Location 1 202018_s_at LTF-24. 0 2.31 E-09 6.07E-08-4. 21-20.09 3q21-q23 2 210613_s_at SYNGR1 -23. 75 2. 96E-08 5.29E-07-4. 74-18. 95 22q13. 1 3 204285_s_at PMAIP1 11. 02 2.58E-21 3. 52E-17 2. 84 18. 74 18q21. 31 4 224838_at FOXP1 4.00 2. 81E-17 3. 20E-14 2. 91 18. 66 3p14. 1 5 218424_s_at TSAP6 -5.59 7. 11E-10 2.26E-08-3. 39-17.84 2q14. 1 6218662satHCAP-G-12. 98 5.93E-08 9.56E-07-4. 53-17.71 4p16-p15 7 218257_s_at UGCGL1 -2.50 6.15E-14 1. 17E-11-2. 67-16.60 2q14. 3 8 204215_at MGC4175 3.99 7.21 E-20 4. 92eut 16.16 7q21. 1-q21. 2 9 217478_s_at HLA-DMA 3.53 1. 45E-19 6. 59E-16 2. 40 16. 06 6p21. 3 10 208456_s_at RRAS2 19.73 4.25E-18 8. 28E-15 2. 48 15. 89 11 p15. 2 11 201200_at CREG -4.15 3.27E-12 2. 70E-10-2. 60-15.70 1q24 12204767satFEN1-3. 38 6. 31E-09 1. 44E-07-3. 04-15. 6011q12 13 243780 at 9. 48 3.09E-18 8. 28E-15 2. 34 15. 36 14 201858_s_at PRG1 -3.95 2.54E-10 9. 80E-09-2. 71-15. 33 10q22. 1 15 AFFX-GAPD-2. 16 2.35E-13 3. 11E-11-2. 44-15. 22 12p13 HUMGAPDH/M33 197 3 at-HG- U133B 16 212589_at RRAS2 15. 19 3.80E-18 8. 28E-15 2.28 15. 1011p15. 2 17 204286_s_at PMAIP1 18.90 4.77E-17 4. 65E-14 2. 36 14. 9418q21. 31 18 212590_at RRAS2 6.88 3.72E-18 8. 28E-15 2.21 14.74 11p15. 2 19 208091_s_at DKFZP564K0822 5.58 2. 32E-17 2. 88E-14 2. 21 14. 50 7p14. 1 20 209306_s_at SWAP70 7.91 1.36E-17 2. 06E-14 2.18 14.43 11p15 21 205051_s_at KIT -8.06 1.02E-07 1.50E-06 -3. 17-14.42 4q11-q12 22 229872_s_at FLJ23790 3.69 5. 60E-18 9. 55E-15 2.14 14.37 8q24. 13 23 202165_at PPP1R2 3.38 1. 51 E-15 5. 07E-13 2.17 14. 22 3q29 Table 2.1-2. 78 24 226043_at AGS3 -2. 57 2. 15E-11 1. 31 E-09-2. 36-14. 21 9q34.3 25225927at 2. 75 1.23E-14 3. 11E-12 2. 18 14.12 26 223391 at SGPP1 6. 71 9.88E-17 8. 42E-14 2.15 14.05 14q23. 1 27 207000_s_at PPP3CC 5.68 1.53E-17 2. 08E-14 2.09 14.01 8p21. 2 28 239287_at 20.36 5. 19E-16 2. 72E-13 2.24 13.97 29 44790_s_at C13orf18 11.58 3.09E-16 1. 76E-13 2.19 13.97 13q14. 11 30 212386 at 7. 60 1. 28E-16 1. 03E-13 2.14 13.96 31 212827 at IGHM 4. 93 2. 29E-16 1. 42E-13 2.11 13.96 14q32. 33 32 235733_at -2. 97 4. 50E-11 2. 46E-09-2. 32-13. 89 33 228390_at 9. 09 3. 63E-16 1. 98E-13 2.15 13.79 34 206845 s at RNF40-2. 60 2.19E-08 4.13E-07-2. 67-13.76 16p11. 2-p11. 1 35 227388_at -5.25 3.46E-07 4. 17E-06-3. 29-13. 69 36 203194_s_at NUP98 -2.20 1.46E-13 2. 17E-11-2. 14-13. 6811p15. 5 37 202503 s at KIAA0101-32. 35 7.79E-07 8.02E-06-4. 21-13. 6415q22. 1 38 209374 s at IGHM 5. 52 4.61 E-17 4. 65E-14 2. 02 13.54 14q32.33 39 224975_at NFIA -11. 22 4.28E-07 4. 91 E-06-3. 31-13. 52 1p31.3-p31. 2 40 225230 at 2. 90 1. 59E-16 1. 14E-13 2. 03 13. 46 41 212531_at LCN2 -41.35 6.83E-07 7.21 E-06-3. 59-13. 40 9q34 42 201432_at CAT -4. 57 7.50E-08 1.17E-06-2. 73-13. 39 11 p13 43 223253_at UCC1 -5.10 4.82E-07 5. 41E-06 -3.28 -13. 35 7p14. 1 44 223287_s_at FOXP1 4.29 9.34E-17 8. 42E-14 1.99 13. 34 3p14. 1 45 205909_at POLE2 -5.29 3.54E-07 4.22E-06-3. 10-13. 31 14q21-q22 46 219471_at C13orf18 7.78 1. 21E-15 4. 33E-13 2.05 13.23 13q14. 11 47 213113_s_at EEG1 -3. 71 2.87E-07 3. 55E-06-2. 97-13. 2011q11 48 204674 at LRMP 4. 68 8. 59E-16 3. 55E-13 2. 02 13. 1712p12. 1 49 203057_s_at PRDM2 4.43 1.36E-16 1. 03E-13 1.96 13. 15 1p36 50 228249_at LOC119710 -7.89 5.06E-07 5. 64E-06-3. 18-13. 14 11 p12 2. 78 CML versus normaIBM # affy id HUGO name fc p q stn t Map Location 1 218184_at TUSP -3. 12 8. 20E-11 3. 85E-08-2. 62-16.24 6q25-q26 2 203725_at GADD45A 3. 6 6. 10E-20 1. 15E-15 1.91 14.45 1p31.2-p31. 1 3 204805_s_at TGM2 4.50 1.70E-19 1. 60E-151'8414. 00 20q12 4 206206_at LY64-3. 3 2.54E-09 4.54E-07-2. 22-13. 46 5q12 5 223280 x at MS4A6A-2. 98 2.05E-07 1. 25E-05-2. 16-11. 63 11q12. 1 6 209357_at CITED2 3.51 3. 63E-16 1. 54E-12 1. 53 11. 59 6q23. 3 7 207980_s_at CITED2 4.26 4.09E-16 1. 54E-12 1.53 11.57 6q23. 3 8 225829 at LOC118987 3. 29 4.01 E-16 1. 54E-12 1. 52 11. 53llOq26. 12 9202561atTNKS-2. 17 7.65E-09 9.98E-07-1. 77-11. 16 8p23. 1 10 203073_at COG2-1. 9 4.84E-08 4.03E-06-1. 86-11. 081q42. 13 11 228056_s_at NAP1L -12.92 2.64E-06 9. 29E-05-2. 53-10. 83 19q13. 33 12 226326 at-2. 11 1.79E-10 6. 18E-0E-1. 53-10. 61 13 201917 s_at FLJ10618 2. 9 1.48E-12 2. 32E-09 1.38 10.15 3q23 14 218251 at STRAIT11499 3. 28 4.28E-13 8. 04E-101610. 15Xp11. 4 Table 2.1-2. 78 15 201186at LRPAP1 2. 84 2. 37E-13 6.36E-10 1.34 10.05 4p16. 3 16 214109_at LRBA -1. 61 5. 25E-13 8. 97E-10-1. 34-10. 02 4q31. 22-q31. 23 17 225923 at-1. 83 2.03E-08 2. 01 E-06-1. 56-10.01 18 208909_at UQCRFS1 1. 48 2. 97E-12 3. 28E-09 1.35 0.93 19q12-q13.1 19 203645_s at CD163-5. 60 1.47E-06 5.97E-05-1. 90-9. 90 12p13. 3 20 202070_s_at IDH3A -2. 11 1.14E-07 7.92E-06-1. 62-9. 8915q25. 1-q25.2 21 204057_at ICSBP1-3. 19 1.50E-06 6. 04E-05-1. 89-9. 87 16q24. 1 22 205633 s at ALAS1 2. 74 2.91 E-13 6. 83E-10 1.31 9.85 3p21. 1 23 206200_s_at ANXA11 2.17 1. 74E-13 5. 46E-10 1.30 9.82 10q23 24 224356_x_at MS4A6A -3. 10 3.02E-06 1.03E-04-2. 02-9. 78 11 q12. 1 25208499satDNAJC33*52 3. 14E-11 2. 27E-08 1.31 9. 53 13q32 26 225830 at LOC118987 2. 91 4. 10E-13 8. 04E-11 1.24 9.41 10q26. 12 27 209893_s_at FUT4 3.16 3. 90E-11 2. 72E-08 1.28 9.36 11q21 28 237209_s_at NFRKB 2. 34 6. 73E-12 6. 03E-09 1.25 9.28 11q24-q25 29 227388 at-2. 40 1.35E-06 5.65E-05-1. 66 -9.23 30 226301_at dJ55C23. 6-2.79 4.01 E-07 2.07E-05-1. 53-9.16 6q22.3-q23. 3 31 217047_s_at FAM13A1 -2. 01 1.30E-07 8.65E-06-1. 45 -9.12 4q22.1 32 214882_s_at SFRS2 1. 67 1.35E-10 5. 19E-08 1.25 9.10 17q25. 3 33 239105_aT 2.57 2.77E-12 3. 27E-091'2009 34 226713_at C3orf6 -2. 96 3.18E-06 1. 07E-04-1. 74-9. 08 3q29 35 224572_s_at 2.50 1. 54E-10 5. 66E-08 1.25 9.04 36 212420_at ELF1 2. 70 3. 30E-12 3. 44E-09 1.19 9.03 13q13 37 218472 s at PELO 2. 94 2.05E-12 2. 97E-09 1.18 8.97 5q11.2 38 204011_at SPRY2 4.43 2. 30E-12 3. 09E-09 1. 18 8. 96 13q22. 1 39 214108_at MAX 4.28 2. 78E-12 3. 27E-09 1.18 8.94 14q23 40 208864_s_at TXN 1. 93 4.83E-08 4. 03E-06 1.36 8.93 9q31 41 213503_x_at ANXA2 -3. 38 1.02E-05 2.74E-04-1. 98-8. 9015q21-q22 42 208683 at CAPN2-3. 43 1.02E-05 2.73E-04-1. 95-8. 86 1q41-q42 43 204039_at CEBPA 2.56 4.80E-10 1.30E-07 1.23 8.85 19q13. 1 44 216652_s_at 1.81 6. 64E-12 6. 03E-09 1. 16 8. 82 45 226835_s_at 1.73 1. 88E-10 6. 18E-08 1.21 8.81 46 218036_x at CGI-07 2. 35 6. 95E-11 3. 62E-08 1.18 8.76 3q26. 1 47 205681_aT BCL2A1 3.41 7.37E-12 6. 30E-09 1.16 8.76 15q24. 3 48 232098 at-2. 74 1.74E-07 1. 09E-05-1. 37-8. 74 49 201918_at FLJ10618 2.30 5. 58E-11 3. 35E-08 1. 17 8.72 3q23 50 217815_at SUPT16H -1.62 2. 77E-10 8. 02E-08-1. 20-8. 7214q11. 1